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Abstract	
The	primary	goal	of	systems	biology	is	to	integrate	complex	omics	data,	and	data	
obtained	from	traditional	experimental	studies	in	order	to	provide	a	holistic	
understanding	of	organismal	function.	One	way	of	achieving	this	aim	is	to	generate	
genome-scale	metabolic	models	(GEMs),	which	contain	information	on	all	metabolites,	
enzyme-coding	genes,	and	biochemical	reactions	in	a	biological	system.	Drosophila	
melanogaster	GEM	has	not	been	reconstructed	to	date.		
Constraint-free	genome-wide	metabolic	model	of	the	fruit	fly	has	been	reconstructed	in	
our	lab,	identifying	gaps,	where	no	enzyme	was	identified	and	metabolites	were	either	
only	produced	or	consume.	The	main	focus	of	the	work	presented	in	this	thesis	was	to	
develop	a	pipeline	for	efficient	gap	filling	using	metabolomics	approaches	combined	with	
standard	reverse	genetics	methods,	using	5-hydroxyisourate	hydrolase	(5-HIUH)	as	an	
example.	5-HIUH	plays	a	role	in	urate	degradation	pathway.	Inability	to	degrade	urate	can	
lead	to	inborn	errors	of	metabolism	(IEMs)	in	humans,	including	hyperuricemia.		
Based	on	sequence	analysis	Drosophila	CG30016	gene	was	hypothesised	to	encode	5-
HIUH.	CG30016	knockout	flies	were	examined	to	identify	Malpighian	tubules	phenotype,	
and	shortened	lifespan	might	reflect	kidney	disorders	in	hyperuricemia	in	humans.	
Moreover,	LC-MS	analysis	of	mutant	tubules	revealed	that	CG30016	is	involved	in	purine	
metabolism,	and	specifically	urate	degradation	pathway.	However,	the	exact	role	of	the	
gene	has	not	been	identified,	and	the	complete	method	for	gap	filling	has	not	been	
developed.	Nevertheless,	thanks	to	the	work	presented	here,	we	are	a	step	closer	
towards	the	development	of	a	gap-filling	pipeline	in	Drosophila	melanogaster	GEM.	
Importantly,	the	areas	that	require	further	optimisation	were	identified	and	are	the	focus	
of	future	research.	Moreover,	LC-MS	analysis	confirmed	that	tubules	rather	than	the	
whole	fly	were	more	suitable	for	metabolomics	analysis	of	purine	metabolism.		
Previously,	Dow/Davies	lab	has	generated	the	most	complete	tissue-specific	
transcriptomic	atlas	for	Drosophila	–	FlyAtlas.org,	which	provides	data	on	gene	expression	
across	multiple	tissues	of	adult	fly	and	larva.	FlyAtlas	revealed	that	transcripts	of	many	
genes	are	enriched	in	specific	Drosophila	tissues,	and	that	it	is	possible	to	deduce	the	
functions	of	individual	tissues	within	the	fly.	Based	on	FlyAtlas	data,	it	has	become	clear	
that	the	fly	(like	other	metazoan	species)	must	be	considered	as	a	set	of	tissues,	each	
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with	its	own	distinct	transcriptional	and	functional	profile.	Moreover,	it	revealed	that	for	
about	30%	of	the	genome,	reverse	genetic	methods	(i.e.	mutation	in	an	unknown	gene	
followed	by	observation	of	phenotype)	are	only	useful	if	specific	tissues	are	investigated.	
Based	on	the	FlyAtlas	findings,	we	aimed	to	build	a	primary	tissue-specific	metabolome	of	
the	fruit	fly,	in	order	to	establish	whether	different	Drosophila	tissues	have	different	
metabolomes	and	if	they	correspond	to	tissue-specific	transcriptome	of	the	fruit	fly	
(FlyAtlas.org).	Different	fly	tissues	have	been	dissected	and	their	metabolome	elucidated	
using	LC-MS.	The	results	confirmed	that	tissue	metabolomes	differ	significantly	from	each	
other	and	from	the	whole	fly,	and	that	some	of	these	differences	can	be	correlated	to	the	
tissue	function.	The	results	illustrate	the	need	to	study	individual	tissues	as	well	as	the	
whole	organism.	It	is	clear	that	some	metabolites	that	play	an	important	role	in	a	given	
tissue	might	not	be	detected	in	the	whole	fly	sample	because	their	abundance	is	much	
lower	in	comparison	to	other	metabolites	present	in	all	tissues,	which	prevent	the	
detection	of	the	tissue-specific	compound.		
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Credit:	Lisa	Hanawalt	(http://www.nytimes.com/2012/01/15/opinion/sunday/fruit-flies-
and-love.html?_r=0)	
	
																																									Fruit	flies	
																																				by	Nicholas	Friedman	
	
In crooked paths, they waft 
through August, pinging from 
fruit to fruit, gang aft 
 
agley, then rest on plum 
or Brandywine to lay 
their careful schemes: in sum, 
 
thousands of eggs per day. 
They curse each coffee cup 
to drink the cream, and pay 
with life for that one taste. 
But I, being a man, 
have countless tries to waste 
 
in winging rot to rot, 
pursuing finer things. 
The hands of others swat 
 
me, rising up and up— 
a driven little fly 
bound for a coffee cup. 
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1 Introduction	
1.1 Drosophila	as	a	genetic	model	
Drosophila	melanogaster	(fruit	fly)	was	first	introduced	to	the	scientific	research	in	1901	
by	William	Castle	at	Harvard	University	and	subsequently	used	as	an	experimental	
organism	by	T.H.	Morgan	in	1906,	who	described	for	the	first	time	the	white	mutant.	Ever	
since,	researchers	from	different	fields,	including	genetics,	developmental,	cancer	
research	and	many	more,	have	extensively	used	Drosophila	in	their	investigations.		
Drosophila	is	currently	one	of	the	most	popular	genetic	model	organisms	used	in	
biomedical	research.	There	are	many	reasons	for	its	success.	First	of	all,	its	short	life	cycle	
(around	2	weeks)	means	that	it	grows	and	reproduces	very	fast	in	comparison	to	other	
model	organisms,	such	as	mouse.	Importantly,	the	maintenance	of	fly	lines	is	inexpensive	
($20	per	year	per	fly	line)	and	relatively	easy.	Moreover,	Drosophila	research	has	an	
ethical	advantage	(3Rs:	‘replacement,	reduction,	refinement)	[1]	over	mammalian	genetic	
models.		
Another	advantage	is	the	availability	of	Drosophila	genome	sequence	published	in	2000	
[2],	as	well	as	a	number	of	stock	centers	that	can	provide	strains	that	carry	a	mutation	in	
a	given	gene.	As	a	result,	it	only	takes	several	months	from	obtaining	mutant	flies	to	
starting	lab	work.	Finally,	availability	of	fruit	fly	specific	online	resources,	such	as	FlyBase	
(http://flybase.org/)	[3],	FlyAtlas	[4],	Homophila	[5]	and	many	more,	is	a	great	advantage	
for	Drosophila	research.	FlyBase	provides	information	about	fly	gene	sequences,	RNAi	
(RNA	interference)	knockdown	lines,	mutant	alleles,	human	disease	homologues,	etc.	It	is	
also	linked	to	all	Drosophila	websites,	including	stock	centers.	It	has	recently	introduced	a	
new	tool	for	searching	fly	models	of	human	diseases	(Human	Disease	Model	Reports),	
which	is	an	initiative	to	encourage	collaborations	with	scientists	from	different	fields,	who	
do	not	have	the	expertise	in	fly	research	[3].	FlyAtlas.org	provides	a	tissue-specific	
transcriptome	of	Drosophila	melanogaster,	which	revealed	how	important	looking	at	
individual	tissues	is,	as	opposed	to	the	whole	organism	alone.	Based	on	FlyAtlas	data,	
tissue-specific	activities	and	functions	in	the	fly	have	been	identified	[6].		
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1.1.1 Drosophila	genome		
Drosophila	genome,	containing	four	chromosomes,	is	much	smaller	than	human	genome,	
which	makes	genetic	experiments	simpler.	The	size	of	the	genome	is	180	Mb	(mega	base	
pairs),	comprising	around	130	Mb	of	euchromatin	and	around	16,000	genes,	which	is	
comparable	to	the	number	of	genes	in	the	human	genome.	Out	of	these	13,000	encode	
proteins	[2].	Moreover,	around	70%	of	Drosophila	genes	have	human	homologs	[7],	and	
over	65%	of	known	human	disease	genes	have	fly	orthologues	[5,	8].	However,	even	
though	the	fly	genome	is	sequenced	and	well	studied,	nearly	a	quarter	of	all	genes	have	
no	known	function.	Moreover,	only	around	20%	of	genes	were	named	and	researched	in	
depth	[9].	This	results	in	the	so-called	phenotype	gap,	where	there	are	no	causative	
connections	between	the	genome	and	the	phenotype	variations	[10].		
One	of	the	advantages	of	Drosophila	genetics	is	the	presence	of	balancer	chromosomes.	
They	prevent	recombination	and	enable	the	maintenance	of	deleterious	mutations	in	
stable	fly	populations.	This	is	due	to	the	presence	of	chromosomal	inversions	in	the	
balancers,	which	prevent	the	formation	of	crossovers.	As	a	result,	there	is	no	
recombination	between	homologous	chromosomes,	and	the	mutation	is	maintained.	
Moreover,	they	carry	visible	dominant	marker	genes	(such	as	curly	wings	or	stubbly	
bristles),	which	enable	selection	of	progeny,	which	inherited	the	balancer.	Balancer	
chromosomes	also	carry	at	least	one	recessive	lethal	locus	in	order	to	maintain	mutations	
in	the	stocks.		
1.1.2 Drosophila	molecular-genetic	tools	
There	are	multiple	genetic	tools	available	in	the	field	of	Drosophila	research,	including	P-
element	transgenesis,	Gal4-UAS	system	and	RNAi.	These	can	be	used	to	manipulate	the	
expression	of	target	genes	in	the	fly	at	different	life	stages	and	in	different	tissues.		
Obtaining	a	mutant	for	a	given	fly	gene	could	not	be	easier	due	to	the	presence	of	public-
domain	stock	centres.	Around	half	of	all	fly	genes	have	mutants	available	in	stock	centres	
and	were	generated	by	systematic	mutagenesis	programs[11].	Mutant	fly	lines	include	
classical	mutants,	generated	by	X-ray	or	chemical	mutagenesis	or	spontaneously	arising.	
Moreover,	RNAi	lines	are	available	for	nearly	all	genes,	and	P-element	insertional	mutants	
targeting	many	fly	genes	have	been	generated	and	maintained	in	the	stock	centres	[12].	
Driver	lines	are	also	available,	allowing	expression	of	transgenic	constructs	in	specific	
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tissues/cells	at	a	given	time.		
1.1.3 Transposable	elements	
The	most	common	spontaneous	mutations,	that	alter	gene	expression	in	the	fruit	fly,	are	
triggered	by	the	insertion	of	transposable	elements	into	the	genome	[13-16].	Several	
classes	of	transposable	elements	naturally	occur	in	Drosophila.	They	represent	around	
10%	of	the	fly	genome	[17].	P-elements	belong	to	the	most	widely	studied	transposable	
elements	in	the	fly.	They	can	be	used	to	insert	genetic	material	into	the	germ-line	cells	at	
high	frequency	[12].	This	system	provides	an	efficient	mechanism	for	the	insertion	of	DNA	
fragments	into	the	germ-line,	without	rearrangements	and	providing	stable	inheritance	in	
future	fly	generations.	This	is	possible	due	to	certain	features	of	the	P-elements.	They	are	
DNA	fragments,	which	are	2.9	kilobases	(kb)	and	contain	a	short	31	base	pair	(bp)	
terminal	sequence	(terminal	inverted	repeats).	These	repeats	flank	four	open	reading	
frames,	which	encode	transposase	[18].	Expression	of	the	transposase	is	required	for	the	
mobilization	and	insertion	of	the	P-element	into	the	recipient	genome.		Transposase	can	
only	be	expressed	in	the	germ-line	because	it	is	dependent	on	the	presence	of	a	specific	
splicing	event	that	takes	place	in	germ-line	cells	[19].	Moreover,	P-element	transposition	
can	be	regulated	by	the	repressor	protein,	which	is	present	in	some	germ-line	cell	types	
[20].	P-elements	are	particularly	useful	mutagens	as	they	can	carry	other	DNA	fragments	
including	RNAi	constructs	and	visible	markers,	such	as	miniwhite	gene.	Genes	can	be	
inserted	into	a	specific	site	of	the	P-element	in	order	not	to	affect	the	expression	of	
transposase.	However,	most	commonly,	defective	P-elements	are	generated	that	do	not	
express	transposase	and	are	stable.	These	are	co-injected	with	the	complete	P-elements	
(expressing	transposase)	into	Drosophila	embryos,	resulting	in	their	insertion	into	the	fly	
genome.	P-elements	tend	to	insert	on	a	5’end	of	genes	and	so	the	expression	of	genes	
they	carry	occurs	in	a	similar	pattern	to	the	nearest	gene.	This	is	referred	to	as	an	
enhancer	trap	[21].	The	exact	insertion	site	depends	on	the	size	and	orientation	of	the	P-
element	[22].	Because	the	insertion	sites	are	effectively	tagged	with	known	sequences	
and	the	full	sequence	of	Drosophila	is	now	available,	it	is	possible	to	identify	the	insertion	
point	by	plasmid	rescue	or	inverse	PCR	(Polymerase	Chain	Reaction)	[23].	Finally,	because	
of	the	large	size	of	the	P-element,	the	insertion	itself	(regardless	of	the	inserted	
sequence)	can	be	mutagenic.		
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Gene	Distribution	Project	was	started	by	the	Berkereley	Drosophila	Genome	Project	in	
order	to	obtain	P-element	insertions	in	all	fly	genes	[24,	25].	However,	it	is	predicted	that	
around	30%	of	all	P-elements	are	inserted	within	400bp	of	transcription	start-site[24,	25]	
and	cluster	in	hot-spots	(areas	of	the	genome	that	‘attract’	multiple	P-elements).	In	order	
to	obtain	insertions	in	as	many	genes	as	possible,	other	transposable	elements	have	been	
used,	which	show	less	insertional	specificity	[26],	including	piggyBacs	[27-29]	and	Minos	
element	[30,	31].		
1.1.4 GAL4-UAS	system	
P-element	mutagenesis	system	is	commonly	used	in	conjunction	with	GAL4-UAS	binary	
expression	system	[32]	(Figure	1-1).	The	system	employs	GAL4	driver,	which	is	the	yeast	
transcriptional	activator,	and	a	UAS	(Upstream	Activation	Sequence)	line,	which	carries	a	
gene	of	interest	containing	GAL4	binding	sites.	GAL4	can	activate	gene	expression	in	
Drosophila,	where	the	GAL4	binding	sites	are	present	in	the	promoter	region	of	the	gene	
[33].	Moreover,	the	GAL4	binding	site	has	been	modified	in	order	to	allow	binding	of	
GAL4	with	high	affinity	[34].	For	the	UAS-gene	to	be	expressed,	the	line	has	to	be	crossed	
to	GAL4	driver	line.	Otherwise,	the	gene	remains	silent	due	to	the	absence	of	the	
activator.	This	way,	the	phenotypic	manifestations	of	the	gene	expression	can	be	
observed	in	the	progeny.	Importantly,	in	case	where	the	expression	of	the	UAS-cargo	is	
lethal,	it	is	possible	to	maintain	the	transgenic	lines,	and	observe	the	lethal	phenotype	in	
the	progeny.		
Moreover,	a	library	of	transgenic	lines	expressing	GAL4	activator	in	different	fly	tissues	
and	cells	has	been	generated	[32],	and	at	present	there	are	multiple	activator-expressing	
lines	available	from	stock	centers.	This	allows	for	the	time-	and	tissue-specific	regulation	
of	the	gene	expression.	The	system	is	particularly	useful	for	experimental	study	due	to	
the	availability	of	vectors	allowing	generation	of	UAS-RNAi	lines,	GAL4	lines,	or	UAS	lines	
with	GFP	(green	fluorescent	protein)	or	epitope	tags.	This	allows	generation	of	new	
constructs	targeting	any	gene	of	interest	and	expressed	in	any	cell/tissue	type.	The	use	of	
UAS-RNAi	lines	is	particularly	useful	for	reverse	genetics	studies.	Moreover,	UAS	lines	
with	epitope	tags	can	be	used	to	generate	overexpressor	lines.	For	a	review	on	RNAi	
techniques	see	[35].	
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Fig.	1-1	Induction	of	transgenes	using	GAL4-UAS	binary	expression	system,	from	[36].	(1)	
One	part	of	the	system	employs	a	fly	line	carrying	GAL4	(a	yeast	transcriptional	activator)	
in	their	genome.	(2)	Another	fly	line	has	UAS	(Upstream	Activation	Sequence)	in	its	
genome,	which	contains	GAL4	binding	sites.	(3)	UAS	is	fused	to	a	gene	of	interests,	whose	
expression	is	controlled	by	UAS,	and	gets	switched	on	upon	GAL4	binding	to	the	UAS.	(4)	
The	gene	of	interest	can	be	expressed	in	a	time-	and	tissue-	specific	manner	in	the	progeny	
produced	by	crossing	these	two	fly	lines.	
1.2 	Drosophila	as	a	model	organism	
As	previously	mentioned,	Drosophila	is	one	of	the	most	popular	model	organisms.	This	is	
due	to	its	short	life	cycle,	inexpensive	and	easy	maintenance,	complete	genome	
sequence,	availability	of	genome-scale	reagent	collections,	and	numerous	optimized	
transgenic	tools	and	molecular	techniques	for	gene	manipulation	(reviewed	in	[37])	[3,	
38,	39].	Among	publicly-available	available	Drosophila	resources	(reviewed	in	[40])	are	
complementary	DNA	(cDNA)	resource	[41],	insertional	mutagenesis	collections	[24,	42],	
RNA	interference	(RNAi)	collections	for	targeted	gene	knockdown	in	cells	[43,	44]	or	in	
flies	[11]).		
Drosophila	melanogaster	is	a	powerful	model	for	studying	human	physiology,	
development	and	disease.	Despite	obvious	morphological	differences	between	the	fly	
and	the	human,	there	is	a	functional	analogy	between	many	internal	organ	systems	of	
Drosophila	and	vertebrates,	including	humans.	Moreover,	molecular	processes	that	
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control	and	conduct	cellular	and	physiological	functions	are	conserved	between	both	
species	[38].	Finally,	it	has	been	estimated	that	more	than	65%	of	human	disease	genes	
have	functional	homologues	in	the	fruit	fly	[5,	8].	Moreover,	Chintapalli	et	al.	showed	that	
many	of	these	homologues	are	expressed	or	enriched	in	fly	tissues	that	have	the	same	
role	of	the	equivalent	human	tissue	[6].	Since	evolutionarily	conserved	genes	usually	
share	molecular	functions,	Drosophila	has	been	used	as	a	model	for	studying	molecular	
mechanisms	underlying	genetic	disturbance,	development	and	behaviour	[38].	As	a	result	
Drosophila	melanogaster	has	greatly	contributed	to	our	understanding	of	mammalian	
biology	[45].	Moreover,	it	has	been	widely	used	as	a	model	in	geneticists,	developmental	
biology,	and	biomedicine	[39].		
1.2.1 Genetics	and	epigenetics		
Drosophila	has	been	used	as	a	model	for	studying	genetics	for	decades.	It	contributed	to	
the	understanding	of	the	chromosomal	basis	of	inheritance	[46,	47],	and	facilitated	the	
studies	on	X-rays	mutagenesis	[48].	Moreover,	studies	in	the	fly	revealed	that	unequal	
crossovers	led	to	duplications	and	deletions	[49]	and	are	the	cause	of	many	human	
genetic	disorders	[50].	Previous	studies	have	shown	that	epigenetic	gene	regulation	and	
chromatin	modification	are	a	result	of	genes	that	influence	position-effect	variegation	
[51],	which	have	been	discovered	thanks	to	fruit	fly	research	[52].		
1.2.2 Developmental	biology	
Studies	in	Drosophila	have	provided	a	lot	of	insight	into	organismal	development.	These	
include	research	on	Notch	signalling	system	[53],	which	mediates	cell-cell	interactions,	
and	when	defective,	can	lead	to	cancer	and	other	human	diseases	[8,	54].	Another	
example	is	investigation	of	homeotic	genes	in	the	fly	[55].	Homeobox	genes	influence	
body	plan	in	flies,	and	have	many	functions	in	all	higher	eukaryotes	[56].	Their	
aberrations	lead	to	cancer	in	humans	[57].	Other	developmental	signalling	pathways	were	
studied	in	Drosophila,	including	Toll,	Wnt,	Hedgehog,	and	BMP/TGFb	pathways	[58].	
Moreover,	fruit	fly	research	contributed	the	understanding	of	the	human	nervous	system	
development	and	wiring	[59],	as	well	as	heart	development	[60].	These	studies	greatly	
aided	the	understanding	of	vertebrate	development	(including	human	development)	and	
related	diseases	as	well	as	cancer	[61].		
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1.2.3 Biomedicine		
Drosophila	melanogaster	is	the	most	commonly	used	model	organism	for	studying	human	
pathology.	It	is	a	particularly	attractive	model	organism	in	biomedicine	because	it	allows	
time-	and	cost-effective	research,	and	is	not	limited	by	ethical	considerations,	as	is	the	
case	of	other	model	organisms,	such	as	mouse.		
Interestingly,	the	fly	reproduces	phenotypic	manifestations	of	certain	human	diseases,	
such	as	renal	diseases	[62,	63]	or	neurological	disorders	[64].	Manipulations	of	Drosophila	
gene	homologous	of	human	disease	genes	have	been	shown	to	result	in	phenotypic	
manifestations	in	different	tissues,	including	MTs	(Malpighian	tubules)	[65-68],	abdomen	
[69],	antennae	and	bristle	[70].	Moreover,	phenotypes	related	to	physiological	functions	
have	been	reported,	such	as	altered	fluid	secretion	rate	[71-74],	and	altered	longevity	and	
survival	in	different	stress	conditions	[75,	76].	This	makes	it	particularly	suitable	for	
studying	human	conditions	(more	on	Drosophila	phenotypes	in	Chapter	4).		
Due	to	the	features	mentioned	above,	Drosophila	melanogaster	is	the	most	commonly	
used	model	organism	for	studying	human	pathology.	It	contributed	to	the	understanding	
of	many	neurological	disorders	[45],	including	Huntington	disease	[77],	Parkinson	disease	
[64],	neurodegenerative	diseases	[78],	amyloid	lateral	sclerosis	[79],	and	narcolepsy	and	
restless	leg	syndrome	[80].	It	has	also	been	used	for	studying	cardiovascular	disease	[81]	
and	cardiac	function	[82],	obesity	[83],	and	drug	addition	[84].	Moreover,	fruit	fly	
research	aided	our	understanding	of	animal	metabolism	and	metabolic	disorders	[85,	86].	
Finally,	Drosophila	is	a	particularly	powerful	tool	for	studying	vector-borne	diseases.	
These	diseases	present	a	huge	threat	to	human	health,	and	mosquito	is	one	of	the	most	
dangerous	vector	species.	Mosquito	is	a	vector	for	West	Nile	virus,	yellow	fever,	dengue	
fever,	and	malaria	[87].	Majority	of	fruit	fly	research	can	be	translated	to	other	insect	
species,	and	aid	our	understanding	of	insect	genetics	and	molecular	biology.	Hence,	
Drosophila	has	a	great	impact	on	development	of	new	methods	for	controlling	mosquito	
populations.	For	example,	many	insecticides	have	used	as	a	defence	against	disease	
vectors.	Their	mechanism	has	been	studied	in	Drosophila	for	years,	which	aided	their	
specificity	and	effectiveness	in	disease	vectors,	including	mosquitos	[88,	89].	Recently,	
metabolomics	has	been	used	to	elucidate	how	a	common	insecticide,	permethrin,	affects	
insect	metabolome	and	survival.	It	revealed	that	lipid	and	energy	metabolism	were	
altered	upon	application	of	the	drug	[90].	These	kinds	of	studies	have	a	great	potential	to	
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aid	our	understanding	of	insecticide	drug	action,	and	identify	new	drug	targets	in	disease	
vectors.		
One	of	the	main	advantages	of	Drosophila	in	biomedical	research	is	the	speed,	at	which	
drugs	can	be	discovered	and	tested,	which	is	much	greater	than	in	other	model	organisms	
(e.g.	mouse),	as	well	as	low	cost	[91].	Due	to	fast	life	cycle,	as	well	as	visible	and	easily	
assessed	phenotypes,	many	chemicals	can	be	tested	in	the	fly	with	high	efficiency.	
Primary	screens	as	well	as	secondary	validation	of	potential	drugs	for	various	human	
disorders	have	been	conducted	in	Drosophila	[91].	For	example,	Drosophila	model	of	
fragile	X	syndrome	(FXS)	has	been	successfully	developed,	exhibiting	phenotypes	typical	
of	FXS	[92,	93].	The	fruit	fly	was	then	used	to	screen	a	drug	library	of	2000	FDA	approved	
potential	therapeutics	for	FXS,	61	of	which	were	discovered	to	rescue	lethality	in	FXS	flies,	
at	least	to	a	certain	degree	[94].	Subsequently,	15	of	these	compounds	were	chosen	for	
further	validation,	and	nine	of	these	exhibited	a	dose-dependent	effect	for	lethality	
rescue	in	FXS	flies.	These	compounds	require	further	validation	in	a	mammalian	model	
and	subsequent	human	clinical	trials	to	be	approved	as	a	treatment	for	FXS.	However,	
primary	screening	in	Drosophila	can	narrowed	down	collections	of	potential	therapeutic	
in	a	time-	and	cost-effective	manner	and	hence	greatly	reduced	the	time	and	cost	of	the	
drug	development	process.	Other	than	primary	screening,	flies	can	be	used	for	a	
secondary	validation	screen	[91].	For	example,	using	Drosophila	model	of	Huntington’s	
disease	has	assisted	development	of	new	therapeutics	that	can	inhibit	polyglutamine	
protein-mediated	aggregation	[95].	Potential	drugs	were	first	screened	using	yeast	as	a	
primary	platform.	Nine	selected	compounds	were	then	tested	in	mammalian	cell	culture	
models,	identifying	four	compounds	that	were	subsequently	tested	using	mouse	
hippocampal	slice	culture	[96].	One	compound	was	then	identified	as	the	most	effective	
in	its	ability	to	inhibit	aggregation,	and	tested	in	a	whole-animal	model,	Drosophila	
Huntington’s	disease	model.		
In	summary,	Drosophila	models	can	be	widely	used	in	biomedicine,	in	order	to	aid	
understanding	of	genetic	and	molecular	basis	of	pathological	processes,	as	well	as	drug	
development	and	screening.	The	fly	provides	a	relatively	easy,	time-	and	cost-effective	
platform	for	biomedical	research,	and	has	proven	to	be	a	successful	tool	for	new	
discoveries.	Moreover,	it	is	particularly	useful	for	studying	rare	diseases,	for	which	there	
is	limited	funding,	such	as	inborn	errors	of	metabolism	(IEMs)	discussed	in	the	next	
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section.			
1.2.3.1 IEMs	and	Drosophila		
Inborn	errors	of	metabolism	(IEMs)	result	from	mutations	in	metabolic	enzymes	and	
comprise	the	majority	of	human	genetic	diseases.	IEMs	lead	to	accumulation	of	
metabolites	[97],	which	can	be	directly	harmful	(e.g.	accumulation	of	upstream	
metabolites	to	toxic	levels,	or	deficiency	in	downstream	metabolites),	or	impose	a	burden	
on	the	urinary	system	leading	to	kidney	damage	[98].	Lack	of	feasible	therapies	as	well	as	
relatively	little	information	on	the	molecular	basis	of	IEMs	necessitates	the	urgent	
development	of	new	research	approaches.	However,	a	small	number	of	IEM	cases	in	
Caucasian	population	limits	research	funding.	Hence,	development	of	a	simple	and	cheap	
animal	model	is	required	for	the	study	of	IEMs	and	development	of	possible	treatments.	
Importantly,	the	maintenance	of	fly	lines	is	inexpensive	and	relatively	easy.	For	the	study	
of	human	metabolism	and	metabolic	imbalances,	fruit	flies	are	particularly	suitable	for	
tissue-specific	analysis	and	thus	are	an	attractive	in	vivo	‘bridge’	between	the	unicellular	
organisms	in	which	systems	biology	was	developed,	and	the	complexity	of	the	human	
body.	
The	work	in	this	thesis	has	been	based	on	research	on	Drosophila	melanogaster	purine	
metabolism.	Enzyme	defects	within	purine	metabolism	result	in	IEMs	including,	
xanthinuria	type	I	[62,	63,	99]	and	type	II	[100,	101],	and	hyperuricemia	[97,	102].	IEMs	
that	have	been	successfully	modelled	in	Drosophila	include	Xanthinuria	type	I	(deficiency	
in	rosy)	[62,	63,	99]	and	type	II	(deficiency	in	maroon	like)	[100,	101].	Both	mutations	
result	in	bloated	MTs	and	sensitivity	to	dietary	purines	[103].	Both	genes	are	involved	in	
purine	metabolism	and	the	molecular	basis	of	both	IEMs	has	been	elucidated	thanks	to	
studies	in	the	fly	[104-106].	Another	IEM,	which	has	a	potential	as	a	Drosophila	model,	is	
hyperuricemia,	which	is	associated	with	many	different	disorders,	including	
cardiovascular	disorders	(for	example,	coronary	heart	disease,	congestive	heart	failure,	
stroke,	and	peripheral	artery	disease)	[107-109],	renal	failure	[98],	hypertension	[107-
109],	chronic	kidney	disease	[107],	metabolic	syndrome	(including	insulin	resistance)	
[110],	and	gout	[111-117].	Humans	are	susceptible	to	hyperuricemia	due	to	their	inability	
to	degrade	urate	[118,	119]	(for	details	see	Chapter	3).	As	a	result	urate	levels	in	the	
blood	are	increased,	which	leads	to	oxidative	stress	and	related	conditions	mentioned	
above.	Fruit	flies,	on	the	other	hand,	break	down	urate	to	allantoin	due	to	presence	of	
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functional	urate	degradation	enzymes	in	their	genome	(see	Chapter	3).	It	would	be	
interesting	to	establish	Drosophila	model	of	hyperuricemia	in	order	to	elucidate	
molecular	basis	of	the	disease	and	develop/test	new	therapeutics	for	this	disease.	
Currently,	there	are	no	effective	drugs	for	hyperuricemia,	and	the	treatment	is	based	on	
application	of	compounds	to	lower	urate	levels,	such	as	urate	oxidase	agents	and	
xanthine	oxidase	inhibitors	(to	lower	the	production	of	urate).	These	treatments	are	not	
very	effective	and	result	in	numerous	side	effects	[117,	120].	Hence,	an	animal	model	of	
the	disease	would	allow	identification	of	new	potential	therapeutics,	as	well	as	screening	
tool.	Moreover,	relatively	little	information	on	the	molecular	basis	of	IEMs	necessitates	
the	urgent	development	of	new	research	approaches.	
1.2.3.2 The	need	to	study	individual	tissues	
Previously,	Dow/Davies	lab	has	generated	the	most	complete	tissue-specific	
transcriptomic	atlas	for	Drosophila	–	FlyAtlas.org,	which	provides	data	on	gene	expression	
across	multiple	tissues	of	adult	fly	and	larva	[6].	FlyAtlas	revealed	that	transcripts	of	many	
genes	are	enriched	in	specific	Drosophila	tissues,	and	that	it	is	possible	to	deduce	the	
functions	of	individual	tissues	within	the	fly.	Based	on	FlyAtlas	data,	it	has	become	clear	
that	the	fly	(like	other	metazoan	species)	must	be	considered	as	a	set	of	tissues,	each	
with	its	own	distinct	transcriptional	and	functional	profile.	Moreover,	it	revealed	that	for	
about	30%	of	the	genome,	reverse	genetic	methods	(i.e.	mutation	in	an	unknown	gene	
followed	by	observation	of	phenotype)	are	only	useful	if	specific	tissues	are	investigated.	
This	stresses	the	importance	of	a	research	approach	focusing	on	individual	tissues	as	well	
as	the	whole	organism,	rather	than	the	whole	organisms	only.	Moreover,	FlyAtlas	showed	
that	many	fly	homologues	of	human	disease	genes	are	enriched	in	fly	tissues	that	have	
the	same	role	of	the	equivalent	human	tissue	[6].		
Interestingly,	the	importance	of	tissue-specific	metabolomics	approach	in	other	
organisms	have	been	noted,	for	example,	in	the	understanding	of	the	resistance	against	
herbivores	in	Jacobaea	vulgaris	or	metabolism	of	auxin	in	different	tissues	of	Arabidopsis	
thaliana	[121,	122].		
Altogether,	these	findings	show	that	it	is	important	to	consider	an	organism	as	a	whole	as	
well	as	a	set	of	individual	tissues	in	order	to	improve	our	understanding	of	organismal	
function,	and	validate	Drosophila	as	a	model	organism.	
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1.3 Metabolomics		
Metabolomics	is	one	of	the	omics	among	genomics,	transcriptomics	and	proteomics.	The	
aim	of	metabolomics	is	to	identify	and	quantify	all	small	molecules	(<1500	Da)	in	a	
biological	system	[123,	124].	All	small	molecules	present	in	a	sample	are	referred	to	as	
the	metabolome	[123,	124].	Metabolomics	is	unique	in	comparison	to	other	omics	in	that	
it	has	a	direct	correlation	to	the	physiology	of	the	cell/tissue	and	refelcts	its	activities	at	a	
functional	level.	As	a	result,	it	provides	insights	into	complex	phenotypes	of	biological	
systems	[124,	125].	In	contrast,	other	omics	reflect	the	flow	of	gene	expression	but	are	
not	directly	correlated	to	function	and	phenotype	[125,	126].	Moreover,	the	diversity	and	
dynamics	of	metabolites	is	much	greater	than	these	of	genes	or	proteins.	
Metabolomics	is	divided	into	two	main	approaches:	targeted	and	untargeted	approach.	
Targeted	metabolomics	focuses	on	a	specific	group	of	metabolites,	for	example,	involved	
in	the	same	enzymatic	pathway	or	metabolites	that	belong	to	the	same	class	of	
compounds.	Most	commonly	its	aim	is	to	provide	absolute	quantification	of	metabolites	
of	interest,	which	is	necessary	to	elucidate	metabolic	dynamics	of	enzymes	[125].	
Untargeted	(or	non-targeted)	metabolomics,	on	the	other	hand,	is	a	comprehensive	
analysis	of	endogenous	metabolites	and	metabolic	shifts	in	response	to	different	stimuli,	
including	genetic	mutation,	environmental	changes,	disease,	etc.	[127-131].	It	aims	to	
simultaneously	identify	and	relatively	quantify	all	metabolites	in	a	given	system.	It	is	a	
hypothesis-free	approach,	which	generates	new	hypotheses.	Subsequently,	these	can	be	
tested	by	targeted	profiling	to	provide	absolute	quantification	of	selected	metabolites	
[127,	132].			
Targeted	metabolomics	is	typically	performed	using	mass	spectrometry	(MS)	based	
methods,	including	GC–MS	(gas	chromatography-MS),	LC–MS/MS	(liquid	
chromatography-MS/MS)	or	FIA–MS/MS	(flow	injection	analysis	MS/MS)	[124,	133].	
Absolute	quantification	is	possible	due	to	presence	of	authentic	standards	for	each	
metabolite	of	interest,	which	are	at	known	concentrations	and	are	analysed	in	the	same	
experiment.	On	the	other	hand,	untargeted	metabolomics	typically	employs	MS	or	NMR	
(nuclear	magnetic	resonance)	spectroscopy	in	order	to	measure	relative	abundance	of	all	
metabolites	in	the	system	[124].	As	opposed	to	the	targeted	approach,	absolute	
compound	concentrations	are	not	available,	due	to	limited	access	to	internal	standards.	
However,	a	small	set	of	standards	is	used	to	monitor	the	performance	of	analytical	
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instrument,	and	to	provide	semi-quantitative	measurements	for	each	metabolite.	
1.3.1 What	is	metabolomics	used	for?	
Metabolomics	has	gained	popularity	in	recent	years	and	offers	a	huge	potential	to	life	
science	reasearch	[134].	There	are	plenty	of	advantages	of	holistic	metabolomic	profiling,	
which	were	described	by	Gika	et	al.	[135].	In	summary,	by	elucidating	the	metabolome	of	
any	given	system,	its	real-time	metabolic	status	is	obtained,	which	reflects	responses	of	
the	system	to	the	environment	it	is	in,	including	genetic	perturbations,	environmental	
stimuli,	drugs,	disease	factors	etc.	Furthermore,	untargeted	metabolomics	is	a	useful	tool	
in	the	identification	of	novel	markers	(including	markers	of	disease),	which	provide	new	
insights	into	biochemical	functions.	Finally,	metabolomics	complements	genomic,	
transcriptomics	and	proteomic	data,	which	altogether	aid	the	development	of	holistic	
understanding	of	the	organismal	function.		
Metabolomics	has	been	used	in	numerous	research	fields	including	medicine,	animal	
biology,	microbial	research,	food	science	[125,	127,	136],	plant	biology,	including	
genetically	modified	(GM)	crops	[137]	and	research	on	the	model	plant	Arabidopsis	
thaliana	[138],	environmental	studies	[139],	functional	genomics	[140]	and	integrative	
systems	biology	[141-144].		
1.3.1.1 Medicine	
In	biomedical	research,	metabolomics	has	been	used	to	elucidate	the	correlation	
between	metabolic	changes	and	to	understand	physiological	and	pathophysiological	
processes	[127].	Previous	research	has	applied	metabolomics	to	the	study	of	kidney	
diseases	[129]	cardiac	research	[145],	metabolic	syndromes	and	related	diseases,	
including	cardiovascular	disease	[146],	diabetes	[147,	148],	atherosclerosis	[149]	and	
ischemia	[150].		
Metabolomics	is	a	powerful	tool	for	biomarkers	discovery	[151],	especially	in	case	of	
diseases	with	complex	diagnostic	criteria,	for	example,	psychiatric	disease,	including	
Parkinson’s	disease	[152],	Huntington	disease	[153]	and	schizophrenia	[154].	Biomarkers	
have	been	discovered	in	renal	diseases,	including	autosomal	dominant	polycystic	kidney	
disease,	kidney	cancer	and	acute	kidney	injury	[129].	Biomarkers	can	be	also	used	to	
study	toxicity	and	therapeutic	effects.	One	of	the	biggest	targets	of	medical	
metabolomics	is	cancer.	Metabolomics	tools	can	be	used	for	its	early	diagnosis	to	
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improve	prognosis	[125,	155-157].		
Finally,	metabolomics	can	improve	the	understanding	of	the	mechanisms	of	drug	action	
and	the	response	of	organisms	to	drugs	[136,	158].	
1.3.1.2 Microbial	research	
Metabolomics	has	been	applied	in	microbial	research,	including	studies	in	Trypanosomes	
[141,	142,	159],	Escherichia	coli	[160]	and	Saccharomyces	strains	[161].	Various	analytical	
approaches	have	been	used,	including	snapshot	metabolomics	for	phenotyping	of	silent	
mutations	to	aid	the	understanding	of	gene	function	[162],	quantitative	metabolite	
analysis	by	stable	isotope	dilution	[163]	and	the	relationship	between	cellular	
metabolome	and	global	regulation,	such	as	growth	rate	[164].	
1.3.1.3 Food	science		
In	food	science,	metabolomics	has	been	used	to	evaluate	quality	and	safety	[125,	165].	
Major	crops	have	been	studied,	including	potato	[166]	and	fruits	[167]	as	well	as	popular	
beverages:	wine	[168]	and	beer	[169].	Metabolomics	has	also	been	applied	in	herbal	
medicine	[125].		
1.3.1.4 Animal	research	
Most	of	animal	metabolomics	focuses	on	physiology,	development	and	disease	of	model	
organisms,	including	zebra	fish	[170-172],	Drosophila	melanogaster	[173-177]	(discussed	
in	Chapter	5)	and	Caenorhabditis	elegans	[178,	179].	Metabolomics	research	in	these	
organisms	has	provided	new	insights	into	development,	biochemical	profiles	of	different	
tissues,	study	of	silent	mutations,	and	metabolic	changes	triggered	by	different	stimuli,	
including	environmental	stress,	genetic	perturbations	and	breeding.	Altogether,	it	has	
provided	a	better	understanding	of	organismal	physiology,	development	and	disease,	
which	can	be	applied	to	research	in	other	species,	including	humans.	Moreover,	
accumulation	and	integration	of	metabolomics	data	in	model	organisms	will	provide	a	
holistic	understanding	of	organismal	function.		
1.3.2 Metabolomics	technologies	
At	present	there	is	no	single	platform	that	can	measure	all	metabolites	in	a	biological	
system	due	to	huge	diversity	of	small	molecules	in	terms	of	chemical	structure	and	
concentration	as	well	as	the	dynamic	nature	of	the	metabolome	[124,	127,	158].	Different	
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technologies	have	their	advantages	and	limitations	and	are	suitable	for	different	type	of	
analyses.	It	is	important	to	take	this	into	consideration	when	designing	an	experiment	
and	choosing	an	appropriate	instrument.	It	is	a	compromise	between	chemical	selectivity,	
sensitivity,	speed	and	cost.	Moreover,	the	choice	of	technology	often	depends	on	existing	
collaborations	and	available	tools.		
The	most	commonly	used	technologies	for	metabolomics	are	NMR	[128,	180-182]	and	MS	
-	based	methods	[62,	106,	127,	177,	183-187].	For	some	analyses,	which	do	not	require	
high	sensitivity	but	rely	on	higher	throughput,	other	platforms	can	be	employed,	
including	Raman	spectroscopy	and	Fourier	transform	infra-red	(FTI)	spectroscopy	[188].	
Other	less	commonly	used	separation	methods	include	(CE)	and	supercritical	fluid	
chromatography	(SFC)	[189].	A	comparison	between	NMR	and	MS-based	platforms	for	
metabolomics	is	summarized	in	Table	1-1.		
1.3.2.1 NMR	
As	illustrated	in	Table	1-1,	NMR	has	many	advantages	and	disadvantages	in	comparison	
to	MS-based	technology	[136,	145,	190-192].	It	has	been	commonly	used	in	
metabolomics	research,	including	biomedical	and	pharmaceutical	research	[149,	181,	
190]	as	well	as	drug	discovery	and	toxicity	[180,	182].	Developments	in	NMR	techniques,	
including	high-resolution	1H	NMR	spectroscopy	and	13C	NMR	spectroscopy,	made	it	a	
powerful	tool	for	studying	biofluids	and	intact	tissues	[193].	These	technologies	can	be	
used	to	measure	biochemical	changes	without	separation	and	sample	preparation.	
However,	as	is	the	case	with	other	metabolomics	platforms,	obtained	spectra	require	
laborious	analysis	and	data	interpretations	(see	Chapter	1.3.3.3).	
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Table	1-1	Comparison	between	MS-based	and	NMR	metabolomics	including	advantages	
and	disadvantages	of	both	methods.		
Technology	 Advantages	 Disadvantages	
M
S	
• greater	sensitivity	
• greater	selectivity	
• precision	
• robustness	
• high	resolution		
• wide	dynamic	range	
• coverage	of	a	wide	chemical	diversity	
• feasible	elucidation	of	the	molecular	
weight	and	structure	of	unknown	
compounds	
• variable	detection	responses,	
such	as	differential	
volatilization	or	ionization		
• cost	
• samples	not	reusable		
N
M
R	
• high-information	content	of	the	spectra	
• relative	stability	of	NMR-chemical	shifts	
• ease	of	quantification	
• no	need	to	pre-select	the	conditions	for	
the	analysis	
• cost	
• samples	can	be	reused	
• no	requirement	for	sample	
preparation,	such	as		
• derivatization		
• higher	amounts	of	sample	
required	
• less	sensitive,	only	detects	
most	abundant	metabolites	
• lower	resolution	
• lower	coverage	of	chemically	
diverse	species	
	
1.3.2.2 MS-based	platforms	
The	overall	sensitivity	and	resolution	of	MS	is	considered	greater	than	that	of	NMR.	
Moreover,	it	covers	a	wider	range	of	chemical	diversity	and	is	better	suited	for	the	
identification	of	unknown	metabolites	[136,	194].	Many	mass	spectrometry	instruments	
have	been	developed	over	the	years	and	are	described	in	[195].	In	summary,	different	
tools	have	advantages	and	limitations	and	require	different	sample	preparation	and	
analysis.	There	is	a	compromise	between	the	number	and	the	quality	of	detected	ions	by	
different	MS	systems	[132].	One	of	the	most	commonly	used	platforms	is	time	of	flight	
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(TOF)	MS.	Its	main	advantages	are	high	resolution,	sensitivity	and	speed	[196].	High	
resolution	MS,	such	as	Orbitrap	MS	is	considered	the	most	sensitive	MS	system	[136]	due	
to	its	high	resolving	power.	This	is	achieved	by	decreasing	the	background	noise	and	the	
interference	from	co-eluted	compounds	[197].	It	allows	unambiguous	assignment	of	a	
molecular	formula	to	many	observed	masses	due	to	high	mass	accuracy,	resolution	and	
dynamic	range	[159].	Orbitrap	has	become	more	popular	for	the	study	of	metabolomics	
in	recent	years	[106,	186,	198].	In	global	metabolomics	studies,	it	performs	best	when	
coupled	to	LC	to	analyse	samples	in	both	positive	and	negative	ion	modes.	The	Orbitrap	
Exactive	tool	is	suitable	for	this	kind	of	analysis	due	to	its	positive-negative	polarity	switch	
mode.	For	higher	scan	speed	and	higher	quality	metabolomics	data,	the	Q-Exactive	MS	
(QEMS)	Orbitrap	system	is	the	best	choice.	It	can	be	used	simultaneously	for	targeted	and	
untargeted	metabolomics	[199].	
MS	enables	metabolite	identification	based	on	its	mass,	and	compound	quantification	
[127].	The	coupling	of	MS	to	an	additional	separation	technique	allows	higher	
quantitative	accuracy	and	more	confident	metabolite	identification.	MS	can	be	combined	
with	the	following	systems:	liquid	chromatography	(LC),	high	performance	liquid	
chromatography	(HPLC),	ultra	high	performance	liquid	chromatography	(UHPLC),	gas	
chromatography	(GC),	capillary	electrophoresis	(CE),	and	flow	injection	analysis	(FIA)	
[158].	Each	separation	method	has	its	advantages	and	disadvantages	and	hence	is	most	
suited	for	different	purposes.	Additional	separation	reduces	background	noise,	which	
results	in	higher	quality	MS	spectra	[127].		
In	summary,	FIA	is	a	fast	analysis	mostly	applied	in	targeted	metabolomics	for	
simultaneous	identification	and	quantification	of	multiple	metabolites,	where	mass	
spectra	for	different	compounds	are	available	before	analysis	[158].	CE	is	another	fast	
method,	which	results	in	separation	of	polar	metabolites	by	charge,	frictional	forces	and	
hydrodynamic	radius	[200].	It	employs	a	capillary	with	high	voltage,	which	allows	
electrophoretic	migration	of	metabolites	in	an	electro-osmotic	flow	[158].	GC	separation	
has	been	commonly	used	to	separate	fatty	acids	and	sugars	[201].	This	method	can	only	
be	used	to	analyse	volatile	compounds	or	compounds	that	can	be	made	volatile	by	
derivatisation	[202,	203]	and	hence	is	mainly	limited	by	molecule	size	and	volatility.	GC-
MS	utilises	electron	ionisation	(EI)	to	ionise	and	fragment	volatile	molecules.	It	requires	
more	complicated	sample	preparation	than	other	separation	methods,	for	example,	LC.	
Additionally,	it	is	not	suitable	for	detection	of	many	polar	compounds	and	can	only	
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measure	the	most	abundant	positively	charged	ions	because	of	the	EI	technique	used	in	
this	method	[204].	On	the	other	hand,	metabolite	identification	is	much	easier	in	GC-MS	
in	comparison	with	LC-MS.	This	is	because	the	fragments	generated	by	EI	are	more	
reproducible	and	can	be	matched	to	existing	GC-MS	spectral	databases.	Moreover	
retention	times	produced	by	GC-MS	are	more	stable	compared	to	LC-MS	[188].		
1.3.2.3 LC-MS	for	metabolomics	
LC-MS	(as	well	as	FIA–MS)	is	one	of	the	best	methods	for	the	detection	of	soluble	and	
lipophilic	metabolites	[203,	205].	It	has	been	commonly	applied	in	proteomics,	lipidomics	
and	metabolomics	[62,	90,	106,	177,	186,	187,	193].	More	sensitive	techniques	were	
developed	from	LC-MS,	including	HPLC	and	UHPLC.	In	this	thesis	LC-MS	(specifically	
UHPLC)	was	used	for	metabolomics	analysis.	Hence,	this	technique	will	be	discussed	here	
in	more	detail.		
LC	is	one	of	the	most	commonly	used	separation	methods,	coupled	to	MS.	Combining	LC	
with	MS	reduces	samples	complexity	and	separates	metabolites	before	detection.	It	
enables	separation	of	isomers,	which	would	otherwise	appear	as	same	metabolites	in	MS	
analysis,	and	reduces	ion	suppression	of	less	ionisable	compounds	by	more	ionisable	ones	
[206].	Dissolved	compounds	are	separated	in	a	liquid	mobile	phase	along	a	solid	
stationary	phase	(for	example,	silica)	[158].	As	opposed	to	GC,	it	utilises	electrospray	
ionization	(ESI)	for	molecule	ionisation	and	separation	[207].	The	separation	phase	is	
relatively	longer	than	in	case	of	CE	and	FIA.	However,	in	UHPLC	separation	is	increased	
and	faster	thanks	to	smaller	particle	size	of	material	used	for	the	stationary	phase	[208].	
Moreover,	HPLC	can	be	used	for	separation	of	molecules	of	a	wide	range	of	polarity,	
which	makes	it	a	very	versatile	and	powerful	tool.			
Different	systems	have	been	developed	to	perform	LC,	including	reverse-phase	(RP)	
columns,	Sub-2	micron	based	columns	and	HILIC	(hydrophilic	interaction	liquid	
chromatography)	columns	[135,	209-211].	RP	LC	provides	high	resolution,	wide	
metabolite	coverage	and	high	reproducibility	and	is	most	commonly	used	for	detection	of	
non-polar	and	medium	polar	metabolites	[132,	189].	Sub-2	micron	based	columns	in	
combination	with	UHPLC	are	currently	the	most	popular	method	for	metabolic	analysis	of	
clinical	samples	[212,	213].	It	provides	higher	throughput	than	other	LC-MS	techniques,	
with	increased	sensitivity	and	higher	resolution	[209].	One	of	the	most	popular	LC	
systems,	together	with	RP	LC,	is	the	HILIC	column	[186,	214,	215].	It	has	an	advantage	
	42	
over	RP	as	it	allows	separation	of	polar	and	lipophilic	metabolites.	It	enables	retention	of	
polar	metabolites,	while	lipophilic	metabolites	elute	rapidly	from	the	column.	On	the	
other	hand,	lipids	do	not	elute	easily	from	the	RP	column,	which	can	lead	to	their	
accumulation	and	ion	suppression	[106].	As	a	result,	HILIC	column	is	the	preferred	
method	for	separation	of	polar	and	charged	metabolites	[186,	216].	
Within	the	HILIC	system,	there	are	different	types	of	columns	available,	for	example,	with	
a	different	inner	diameter.	Comparison	of	2.1	mm	and	4.6	mm	columns	has	been	
described	in	[135].	On	the	2.1	mm	column	more	compounds	were	putatively	identified	
[217].	However,	the	results	obtained	from	the	wider	column	were	more	reproducible.	
Hence,	both	columns	are	suitable	for	different	applications,	for	example,	4.6	mm	HILIC	is	
more	suitable	for	large	batch	analysis.	There	is	no	single	LC-MS	method	that	can	analyse	
all	types	of	compounds.	In	order	to	obtain	the	most	comprehensive	results,	the	
combination	of	different	types	of	columns	might	be	the	best	solution.	In	order	to	improve	
the	resolution	of	LC,	new	systems	have	been	developed,	including	two-dimensional	(2D)	
LC	systems	[218,	219].	These	systems	can	provide	better	separation	and	coverage	as	well	
as	higher	resolution	than	other	LC	methods.	However,	further	research	is	required	to	
optimise	these	techniques.		
LC-MS	is	considered	a	highly	sensitive	metabolomics	method,	much	more	so	than	NMR	
spectroscopy.	It	requires	minimal	sample	preparation	and	enables	effective	ionisation	
with	minimal	fragmentation	of	a	large	variety	of	compounds.	Hence,	it	offers	a	greater	
metabolite	coverage	than	GC-MS	[132].	Moreover,	it	can	be	coupled	with	tandem	MS	
(MS/MS)	to	obtain	compound	structural	information,	which	is	not	possible	in	case	of	CE-
MS	[183].	
1.3.3 Sample	preparation	for	LC-MS	analysis		
Since	metabolomics	methods	are	high-resolution	techniques,	they	require	highly	
controlled	and	strict	experimental	conditions	[125].	Regardless	of	a	chosen	LC-MS	system,	
several	steps	must	be	followed	in	order	to	obtain	high	quality	metabolomics	data.	These	
consist	of	experimental	design,	sample	collection	and	pre-treatment,	instrument	analysis,	
data	analysis	and	biological	explanation	[132,	220].	Metabolomics	workflow	is	
summarised	in	Figure	1-2.			
Appropriate	experimental	design	is	crucial	to	obtaining	high	quality	metabolomics	data.	
	 43	
One	of	the	considerations	is	selection	of	controls,	which	should	be	of	the	same	genetic	
background	and	grown	in	the	same	strictly	controlled	conditions	[135].	Moreover,	quality	
control	(QC)	samples	should	be	analysed	with	each	experiment	to	ensure	measurement	
repeatability.	QC	samples	are	usually	prepared	from	a	mixture	of	small	aliquots	of	each	
sample	in	the	experiment.	Previous	research	showed	that	many	factors	could	affect	
sample	quality	and	the	result	of	metabolomics	analysis,	including	type	of	collection	tubes	
[221]	as	well	as	sample	storage	and	transportation	[222].	Hence,	it	is	critical	for	the	
experimental	conditions	to	be	strictly	controlled,	and	sampling	protocol	to	be	
standardised	in	order	to	minimise	biological	and	technical	variability	[158].	Another	
consideration	in	terms	of	sample	collection	is	homogenisation	and	quenching	(bringing	
metabolism	rapidly	to	a	halt).	This	can	be	achieved	by	using	liquid	nitrogen	for	quenching,	
or	organic	solvents	(for	example,	methanol,	isopropanol,	chloroform	or	their	mixture)	for	
quenching,	metabolite	extraction	and	protein	precipitation	[132].	Finally,	chemical	
derivatisation	is	commonly	required	in	case	of	LC-MS	and	GC-MS	in	order	to	improve	
compound	ionisation	before	separation.		
Following	experimental	design	and	appropriate	sample	preparation,	LC-MS	measurement	
is	conducted.	In	summary,	LC-MS	provides	exact	mass	measurements	(from	MS)	and	
retention	time	(RT)	values	(from	LC)	that	define	ion	features	(m/z,	RT).	This	is	the	first	
step	towards	compound	identification.	Different	LC-MS	platforms	can	be	used	as	
described	in	the	previous	chapter.	Following	primary	data	acquisition,	data	processing	
must	be	performed	for	metabolite	identification	and	analysis	[123].	
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Fig.	1-2	Scheme	of	metabolomics	workflow.	Adapted	from	[136].		
1.3.4 LC-MS	data	processing	
Data	processing	and	biological	interpretation	of	metabolomics	data	are	the	most	
laborious	and	challenging	steps	of	metabolomics	analysis,	including	LC-MS	metabolomics.	
Acquired	datasets	are	very	complex	and	diverse.	In	order	to	enable	metabolomics	data	
processing,	plenty	of	bioinformatics	tools	(utilising	different	programming	languages,	
tools	and	algorithms)	have	been	developed	in	recent	years,	for	review	see	[130].	In	this	
thesis,	untargeted	LC-MS-based	metabolomics	analysis	was	performed.	Hence,	here	I	will	
focus	on	data	processing	methods	applied	to	global	LC-MS	metabolomics.	However,	many	
of	described	tools	can	also	be	successfully	used	for	targeted	metabolomics	data.		
In	an	untargeted	LC-MS	experiment,	metabolome	data	of	the	whole	sample	are	acquired.	
General	processing	steps	are	then	followed,	including	data	pre-treatment,	peak	detection	
[223],	peak	matching,	and	steps	resulting	in	signal	filtering	and	noise	removal	[224].	
These	steps	allow	putative	identification	of	compounds	based	on	exact	mass	and	
predicted	retention	time,	or	accurate	identification,	where	authentic	standards	are	
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available.	Following	metabolite	identification,	multivariate	and	univariate	data	analyses	
are	performed	in	order	to	elucidate	statistically	significant	results.	The	final	step	of	data	
processing	is	correlation	of	the	results	to	metabolic	databases	and	pathways,	and	
biological	explanation	of	the	results	[130,	132].		
1.3.4.1 Data	pre-treatment	
Data	pre-treatment	and	processing	is	the	initial	step	after	raw	data	acquisition.	It	
commonly	involves	MS	spectra	normalisation,	clustering	and	quality	assessment,	internal	
standard	calibration,	as	well	as	precursor	charge	determination	[225].	Data	pre-treatment	
is	necessary	due	to	two-dimensional	nature	of	LC-MS	data	[136].	As	a	result,	it	provides	
easier	access	to	ion	features,	such	as	retention	time,	m/z	values,	ion	intensity	and	isotope	
distribution	[130].		
1.3.4.2 Peak	annotation	and	matching	
Following	data	pre-processing,	peak/feature	detection	and	matching	(also	referred	to	as	
peak	picking)	is	performed	[158],	and	can	be	achieved	using	several	different	
bioinformatics	tools,	including	XCMS	(several	versions	are	currently	available)	[226-228],	
MzMine	[229,	230],	msInspect	[231],	MetAlign	[232],	CentWave	[233],	and	many	more	
[234].	Coble	et	al.	reported	that	the	best	tools	for	peak	detection	for	LC-MS	data	are	
MetAlign,	XCMS,	and	MZmine	[235].	Moreover,	XCMS	is	an	open-source	algorithm	and	is	
the	most	commonly	used	for	feature	detection	of	LC-MS	data	[123].		
One	of	major	challenges	in	the	processing	of	MS	data	are	missing	values,	which	can	arise	
due	to	technical	and	biological	reasons	[130].	They	are	a	result	of	metabolite	absence	or	
their	abundance	below	detection	limit.	Missing	values	are	particularly	problematic	for	
statistical	analysis,	which	is	not	optimised	to	process	‘zero’	values.	They	can	be	dealt	with	
by	using	numerous	tools	and	data	imputation,	such	as	x-VAST	[236],	metabomxtr	[237]	
and	MzMatch	[238,	239].	Another	source	of	variance	in	LC-MS	data	is	retention	time	drift.	
Retention	time	drifts	are	relatively	common	in	LC-based	systems.	As	a	result	two	different	
features	can	be	annotated	as	the	same	feature	and	then	compared	across	different	
samples,	leading	to	incorrect	data	interpretation.	Once	again,	different	tools	have	been	
developed	to	deal	with	RT	drift	[130].	Moreover,	many	peak	picking	tools,	including	
XCMS,	can	carry	out	RT	correction	and	features	grouping	to	overcome	this	issue.	As	a	
result	of	peak	picking,	a	list	of	all	detected	peaks	is	generated.		
	
	46	
The	data	is	then	processed	in	order	to	match	and	group	peaks	of	four	biological	replicates	
from	each	sample,	to	generate	a	single	dataset	for	each	sample.	This	can	be	achieved	
using	parameters,	such	as	PPM	(mass	error	in	parts	per	million,	PPM),	and	RT	window,	
which	represent	deviation	from	sample	to	sample	in	terms	of	mass	and	RT	respectively.	
Moreover,	noise	reduction	steps	are	performed,	including	RSD	(relative	standard	
deviation),	noise,	intensity	and	detections	filters	[238].	RSD	filter	elucidates	peak	
reproducibility	for	replicates	of	each	sample,	noise	filter	assesses	peak	shape,	whereas	
intensity	filter	removes	features	that	are	below	intensity	threshold	in	all	samples,	and	
detection	filter	determines	a	minimum	number	of	samples,	in	which	a	feature	peak	has	to	
be	present.	Furthermore,	related	peaks/ion	annotation	is	performed	to	distinguish	
features,	which	originated	from	the	same	compound.	This	is	required	because	LC-MS	
measurements	often	produce	multiple	peaks	that	correspond	to	the	same	metabolite.	
These	peaks	represent	isotopes,	dimers,	adducts	and	fragments,	which	have	different	m/z	
values	but	similar	retention	times	[127].	These	can	be	recognised	because	their	extracted	
ion	chromatograms	(EICs)	have	similar	signal	shape	and	intensity	patterns	[158],	and	then	
clustered	together.	Noise	reduction	methods	and	related	peaks	annotation	can	be	
performed	using	software	tools,	such	as	MzMatch	[238,	239],	CAMERA	[240],	PUTMEDID-
LCMS	[241].		
1.3.4.3 Metabolite	identification	
The	next	step	in	LC-MS	data	processing	is	metabolite	identification,	which	is	the	major	
bottleneck	in	LC-MS.	It	is	based	on	neutral	masses	of	each	compound	calculated	from	
mass	differences	of	adducts/isotopes	[127,	238].	These	calculated	masses	are	then	
searched	against	existing	metabolite	databases,	such	as	HMDB	(Human	Metabolome	
Database)	[191,	242],	Metlin	[224]	and	KEGG	(Kyoto	Encyclopaedia	of	Genes	and	
Genomes)	(http://www.genome.jp/kegg/)	[191,	224,	243].	KEGG	is	currently	the	most	
comprehensive	knowledge	base	on	organismal	metabolism.	Metabolites	with	molecular	
masses	within	the	specified	tolerance	range	to	the	query	m/z	value	(within	specified	mass	
error	(PPM))	are	extracted	from	databases	as	putative	identifications	[127].	However,	
confident	metabolite	identification	is	rarely	possible	by	matching	calculated	mass	to	the	
database,	which	commonly	results	in	multiple	identifications,	due	to	presence	of	isomers	
(one	feature	can	have	ion	can	have	over	100	putative	identifications)	and	relative	
inaccuracy	of	MS	[244].	To	increase	the	efficiency	of	feature	identification,	additional	
methods	have	been	developed.	Creek	et	al.	proposed	a	model	called	quantitative	
	 47	
structure	retention	relationship	(QSRR)	for	elucidation	of	predicted	retention	times	for	
compounds	similar	to	authentic	standards	[238].	By	adding	this	step,	metabolite	
identification	was	highly	improved,	and	40%	of	falsely	identified	compound	were	
removed.	Moreover,	for	higher	specificity	features,	preferential	fragmentation	can	be	
performed,	which	provides	additional	fragmentation	data.	This	allows	more	confident	
metabolite	annotation	[123].	However,	in	order	to	obtain	reliable	and	unambiguous	
metabolite	identification,	mass,	retention	time	and	fragmentation	spectrum	must	be	
compared	to	those	of	authentic	standards	analysed	in	the	same	LC-MS	experiment	[158].	
1.3.4.4 Statistical	analysis	of	LC-MS	data	
Once	metabolite	identifications	are	acquired,	the	data	can	be	analysed	using	various	
statistical	tools	[130],	in	order	to	extract	biologically	relevant	information	[245].	This	is	a	
crucial	step	in	obtaining	meaningful	metabolomics	data	before	biological	interpretation.	
Its	aim	is	to	determine	the	cause	of	unwanted	variation	(due	to	various	biological	and	
technical	reasons,	such	as	instrumental	errors)	and	normalise	the	data	by	removing	these	
variations	[246].	The	‘real’	differences	can	then	be	assessed	and	analysed	in	order	to	
obtain	statistically	significant	results.	Statistical	analyses	can	be	divided	into	two	groups:	
univariate	and	multivariate	methods.	Univariate	statistics	includes	methods,	such	as	t-
test,	ANOVA	(analysis	of	variance)	and	multiple	regression,	and	analyses	a	single	variable	
of	interest.	In	metabolomics	analysis,	this	means	that	these	methods	are	used	to	analyse	
each	feature	independently,	for	example,	the	analysis	is	used	to	elucidate	whether	
difference	in	metabolite	abundance	between	samples	are	statistically	significant.	
Multivariate	statistics,	on	the	other	hand	includes	principal	component	analysis	(PCA)	
[247],	partial-least-squares	discriminant	analysis	(PLS-DA)	[248],	hierarchical	cluster	
analysis	(HCA)	[136],	discriminate	analysis,	and	self	organizing	networks	(GEDI)	[32].	
These	are	used	to	analyse	two	to	more	variables	of	interest,	for	example,	in	case	of	PCA,	
all	features	of	all	samples	are	analysed	resulting	in	simplified	representation	of	the	data,	
providing	clustering	tendency	and	outliers.	PCA	is	recommended	as	a	first	step	in	
metabolomics	data	analysis	as	it	provides	an	overview	of	the	patterns	of	each	sample	and	
relationships	between	different	samples.	These	statistical	tools	can	reduce	the	complexity	
of	data	by	allowing	researchers	to	focus	efforts	on	groups	of	features	that	exhibit	similar	
abundance	patterns.	Among	most	commonly	used	statistical	tool	for	metabolomics	data	
analysis	are	PCA,	PLS-DA,	the	t-test	and	ANOVA	[249].	In	recent	years,	many	statistical	
platforms	were	developed	for	metabolomics	in	order	to	make	the	data	analysis	more	
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varied,	efficient	and	user-friendly	(for	review	see	[130,	158]).	A	commonly	used,	freely	
available	statistical	package	that	enables	a	wide	variety	of	data	analyses	is	
MultiExperiment	Viewer	(MeV)	[250].	It	has	been	widely	used	for	microarray	data	
analysis,	but	also	provides	some	very	useful	tools	for	metabolomics	data	analysis.		
1.3.4.5 Biological	interpretation	of	LC-MS	data	
The	final	step	in	metabolomics	data	processing	is	biological	interpretation.	One	of	the	
most	important	steps	towards	it	is	linking	the	obtained	results	to	known	metabolic	
pathways.	This	can	be	achieved	by	pathway	analysis,	network	reconstruction	and	
visualisation	tools	[158].	This	kind	of	analysis	for	global	metabolome	is	only	possible	
thanks	to	bioinformatics	tool.	Manual	analysis	would	be	extremely	time	consuming	and	
expensive.	There	are	plenty	of	bioinformatics	tools	available	and	some	examples	include	
TrackSM,	which	assigns	chemical	compounds,	based	on	their	molecular	structure,	to	
metabolic	pathways	[251];	MarVis-Pathway	enables	annotation	of	pathways	from	
different	omics	data,	and	provides	pathway	enrichment	and	meta-analysis	[252];	
PathWhiz	is	a	server	that	interprets	metabolomics	data	by	assigning	metabolites	to	
known	pathways,	and	generates	colourful	and	aesthetic	results	[253];	InCroMAP	is	used	
for	data	integration,	analysis	and	visualisation	and	provides	enrichment	analysis	and	
pathway	visualisation.	It	also	deals	with	multiomics	data	[254].	
1.3.4.6 Tools	for	metabolomics	data	processing		
Recent	years	witnessed	a	huge	development	of	bioinformatics	tools	for	metabolomics	
data	analysis.	These	include	tools	for	data	pre-treatment,	peak	picking,	noise	removal,	
statistical	analysis	and	pathway	analysis	etc.,	as	well	as	multifunctional	tools	that	can	deal	
with	raw	LC-MS	data	and	perform	all	the	necessary	sample	processing,	annotation	and	
statistical	analysis	[158].	For	a	comprehensive	review	of	newly	developed	bioinformatics	
tools	for	LC-MS	data	processing	and	analysis	see	[158].	Among	available	software	for	the	
processing	of	raw	LC-MS	data,	one	of	the	most	commonly	used	toolkits	is	mzMatch	[255].	
It	includes	noise	filtering,	gap	filling,	peak	matching,	related	peaks	annotation	and	
compound	identification	by	matching	calculated	masses	to	databases	[239].	Moreover,	it	
uses	PeakML	file	format,	which	is	compatible	with	other	software,	including	XCMS,	
mzMine	and	IDEOM	[238].	This	allows	flexible	access	to	additional	data	processing	tools.	
For	example,	IDEOM	is	an	Excel	interface	to	mzMatch,	which	allows	comprehensive	data	
processing	of	LC-MS	data	followed	by	statistical	analysis	and	data	visualisation	tools	
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[238].		
In	terms	of	statistical	analysis,	data	processing	software	include	BioStatFlow	version	2.7.7.	
(http://www.inra.fr/),	which	is	a	web	tool	for	analysis	of	–omics	data,	including	
metabolomics.	Another	tool,	RepExplore,	is	also	a	web	service,	which	provides	fully	
automated	data	processing	as	well	as	statistical	tools,	including	ranking	tables,	whisker	
plots,	heat	maps,	and	PCA	[256].	Another	open-source	tool,	Normalyzer,	can	be	employed	
for	data	normalisation	using	12	different	methods	[257].	Multivariate	statistical	analyses	
can	be	performed	using	platforms,	such	as	DeviumWeb	(Dynamic	MultivariatE	Data	
Analysis	and	VIsUalization	PlatforM)	(https://github.com/dgrapov/DeviumWeb).	It	
provides	statistical	analysis,	such	as	data	normalization,	clustering,	PCA	etc.,	as	well	as	
data	interpretation	(pathway	enrichment	analysis)	and	visualization.	
Among	multifunctional	tools,	the	most	commonly	used	ones	are	MetaboAnalyst	
(www.metaboanalyst.ca)	[258],	XCMS	Online	(http://masspec.scripps.edu/)	[227],	
MASSyPup	[259],	IDEOM	[238],	and	MeKO	[260].	They	are	all	designed	to	analyse	raw	
metabolomics	data,	perform	all	the	necessary	steps	for	data	processing,	annotation,	data	
analysis,	interpretation	and	visualisation.	They	require	minimal	bioinformatics	knowledge,	
minimise	the	time	spent	on	data	processing	and	provide	multiple	statistical	and	
visualisation	tools.	However,	it	is	important	to	adjust	the	settings	of	these	tools	
accordingly	to	the	analysis	performed	to	avoid	user	bias	[158].	For	a	comprehensive	
review	of	analytical	tools	for	metabolomics	from	data	processing	to	pathway	analysis,	see	
[261].	
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1.3.5 Limitations	and	challenges	of	LC-MS	for	metabolomics	
Despite	recent	developments	in	metabolomics	techniques	and	tools,	metabolomics	
analysis	presents	numerous	challenges	due	to	technological	limitations	as	well	as	issues	
with	data	interpretation	[158].	Metabolomics	measurements	commonly	identify	more	
than	40,000	features,	which	have	diverse	physical	and	chemical	properties	[136,	191,	
262].	Moreover,	the	range	of	compound	concentrations	is	very	broad,	with	over	12	
orders	of	magnitude	[132].	As	a	result	of	this	complexity,	and	due	to	the	dynamic	nature	
of	a	metabolome,	there	is	no	single	platform	that	can	detect	and	analyse	all	metabolites	
in	a	given	system	[124,	127,	130,	158].	
1.3.5.1 Metabolite	identification	
The	main	challenge	in	MS	data	analysis,	prior	to	biological	interpretation,	is	metabolite	
identification	[127].	It	has	been	estimated	that	about	70%	of	features	extracted	from	LC-
MS	are	not	used	in	the	final	data	analysis	due	to	lack	of	accurate	identification.	As	
explained	in	previous	chapter,	metabolite	annotation	based	on	detected	mass	of	
compounds	gives	rise	to	putative	identification,	which	can	result	in	in	multiple	
identifications,	due	to	presence	of	isomers	and	relative	inaccuracy	of	MS	[244].	
Combining	mass	data	with	predicted	and	standards-matched	retention	times	enables	
more	accurate	identification.	However,	in	order	to	obtain	confident	metabolite	
identification,	internal	standards	for	every	metabolite	has	to	be	analysed	in	the	same	
experiment.	Due	to	large	size	of	untargeted	metabolomics	datasets,	this	is	not	feasible.	
This	is	because	standards	are	not	available	commercially	for	all	analysed	compounds,	and	
a	lot	of	metabolites	are	not	stable	and	hence	obtaining	standards	is	impossible	[135].	An	
exception,	where	no	standards	are	required,	is	ultra	high	performance	liquid	
chromatography	coupled	with	Fourier	transform	ion	cyclotron	resonance	mass	
spectrometry	(UHPLC–FT-	ICR–MS)	[208],	which	provides	an	accurate	metabolite	mass	
with	a	great	precision	allowing	evaluation	of	its	molecular	composition.	This	enables	
confident	metabolite	identification	without	addition	of	authentic	standards	[263].		
One	of	the	main	limitations	of	LC-MS	is	the	fact	that	it	only	enables	semi-quantitative	
analysis	[47].	Challenges	in	metabolite	identification	and	quantification	arise	due	to	
technical	issues	in	LC-MS	analysis	because	LC-MS	spectra	are	highly	variable	[123].	This	is	
due	to	instrumental	drifts,	for	example	retention	time	drifts	[264]	or	MS	detection	
instability	[135].	Moreover,	instrument	sensitivity	presents	a	limitation	in	case	of	poorly	
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ionised	metabolites	or	compounds	at	a	very	low	abundance	[127].	As	mentioned	earlier,	
metabolites	can	be	chemically	derivatised	in	order	to	improved	ionisation.	However,	
derivatisation	does	not	always	solve	this	problem.	A	novel	approach,	called	isotope	coded	
derivatisation	(ICD)	further	enhances	ionisation,	and	addition	of	isotope	labelled	
derivatisation	reagents	results	in	the	generation	of	isotope	labelled	ions	as	well	as	non-
labelled	ones	[265-267].	These	methods	improve	feature	separation	and	identification,	
and	thanks	to	isotope	labelled	standards,	absolute	quantification	of	selected	metabolites	
is	possible	[28,60]	in	LC-MS	analysis.	Moreover,	technical	improvements	could	improve	
the	reproducibility	and	resolution	of	LC-MS	spectra,	for	example	designing	more	stable	
columns,	mass	spectrometers	with	higher	resolving	power	and	mass	accuracy	etc.	[158].		
One	of	the	strategies	that	can	improve	metabolite	identification	is	preferential	
fragmentation	achieved	by	MS/MS,	which	provides	additional	fragmentation	data	and	
chemical	structure	[268,	269].	The	fragmentation	spectra	can	be	then	compared	to	
spectra	of	tandem	MS	databases,	such	as	MassBank	[http://www.massbank.jp,	[223]],	
METLIN	[http://metlin.scripps.edu/,	[224],	or	NIST	MS/MS	
[http://www.nist.gov/mml/bmd/data/tandemmass-speclib.	cfm].	However,	in	contrast	to	
well-annotated	gene	and	protein	databases,	these	databases	are	not	complete.	However,	
they	can	aid	metabolite	identification	by	elucidating	its	structure	or	determine	its	
function.	Moreover,	fragmentation	data	are	highly	depend	on	the	type	of	LC-MS	
instrument,	and	hence	they	are	not	highly	replicable	[135].	As	a	result,	there	are	no	
comprehensive	spectral	libraries	for	LC-MS,	which	could	be	used	for	confident	metabolite	
identification	[158].	Hence,	when	standards	are	not	available,	spectral	data	cannot	be	
evaluated	using	general	databases	for	mass	fragmentation	spectra.	This	is	the	main	
advantage	of	GC-MS	over	LC-MS.	In	case	of	GC-MS,	fragmentation	spectra	are	stable	and	
can	be	compared	to	existing	spectral	databases	[136].		
In	order	to	improve	the	process	of	searching	tandem	MS	databases,	several	tools	have	
been	developed,	such	as	BioSM	[270],	competitive	fragmentation	modelling	(CFM)	[271],	
HAMMER	[272]	and	many	more.	If	a	metabolite	is	not	found	in	a	database	and	a	standard	
is	not	available,	it	is	impossible	to	provide	100%	identification.		
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1.3.5.2 Data	interpretation	
Another	major	challenge	in	metabolomics	is	data	interpretation	[158].	LC-MS	analysis	
gives	rise	to	large	and	complex	datasets,	which	are	impossible	to	interpret	manually.	As	a	
result,	specific	software	tools	have	been	developed	in	order	to	enable	this	process,	as	
described	in	previous	chapter.	An	overview	of	currently	available	tools	is	presented	here	
[234].	Data	interpretation	is	the	most	time	consuming	and	laborious	step	in	
metabolomics	data	analysis.	It	requires	a	lot	of	biochemical	expertise	as	well	as	
programming	knowledge,	in	order	to	make	the	most	out	of	available	bioinformatics	tools.	
Despite	constant	development	of	new	platforms	for	pathway	analysis,	network	
reconstruction	and	visualisation	tools	[158]	there	is	a	requirement	for	more	user-friendly	
software,	with	increased	capacity	to	process	complex	datasets	and	better	correlation	of	
data	to	biological	phenotype	[130,	135].	Moreover,	as	is	the	case	with	other	steps	in	
metabolomics	data	analysis,	standardised	protocols	for	data	interpretation	are	required	
in	order	to	produce	results	with	real	biological	relevance	and	that	can	be	compared	to	
other	experiments.	Another	solution	is	to	analyse	the	same	datasets	using	different	
bioinformatics	tools	to	provide	the	most	reliable	set	of	results.		
1.3.5.3 Data	visualisation	
Once	LC-MS	data	are	analysed	and	interpreted,	visualisation	of	the	findings	presents	
another	challenge.	Multiple	complex	metabolic	pathways	are	difficult	to	represent	in	a	
simple	and	understandable	format.	Pathway	analysis	tools	have	been	developed	to	aid	
this	process,	which	take	advantage	of	existing	databases,	such	as	KEGG	[273]	or	HMDB	
[191,	242],	including	Biocyc	(http://biocyc.org),	Metabolights	[274],	Reactome	
(http://www.reactome.org),	MGI	Genome	(http://www.informatics.jax.org),	and	
MassTrix	[275].		
1.3.5.4 Integration	of	metabolomics	data	
Finally,	challenges	in	LC-MS	metabolomics	arise	from	inability	to	compare	data	analysed	
in	different	laboratories	and/or	on	different	platforms	[276],	which	is	not	the	case	for	
spectra	obtained	from	NMR	and	GC–MS/MS	experiments	[191,	192].	This	is	particularly	
limiting	in	case	of	large-scale	studies.	Other	than	differences	between	LC-MS	instruments,	
this	is	due	to	the	lack	of	standardised	protocols	for	experimental	design,	sample	
preparation	and	analysis	[135].	Moreover,	different	data	analysis	platforms	use		
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incompatible	programming	languages	and	are	only	available	for	single	operating	systems.	
In	order	to	increase	data	reproducibility	and	the	ability	to	correlate	results	from	different	
experiments,	standard	protocols	of	metabolomics	analysis	need	to	be	developed	and	
followed	by	all	researchers	involved	in	metabolomics	studies	[123,	132].	Moreover,	new	
platforms	allowing	normalisation	methods	to	combine	data	collected	at	different	times,	
using	different	instruments	etc.	are	required.		
Finally,	in	order	to	improve	metabolite	coverage	and	data	quality,	new	metabolomics	
techniques	have	to	be	developed.	At	present,	this	issue	can	be	tackled	by	using	different	
chromatographic	columns	and	improved	compound	ionisation	[132,	277,	278].	Moreover,	
combining	targeted	and	untargeted	metabolomics	approaches	would	yield	more	
understanding	of	the	tested	system,	including	improved	coverage	and	quantification	
[279,	280].	Moreover,	in	order	to	improve	metabolite	identification	and	structure	
prediction	based	on	tandem	MS,	new	LC/MS	and	MS/MS	databases,	as	well	as	search	
algorithms	are	required	[226].		
In	summary,	major	challenges	exist	in	LC-MS	data	analysis,	including	metabolite	coverage,	
compound	identification	and	quantification,	measurement	reproducibility,	data	
interpretation,	visualisation	and	results	correlation	between	different	experiments.	There	
are	numerous	strategies	and	tools	available	to	improve	these	limitations.	However,	it	is	
currently	necessary	to	develop	robust	annotation	methods,	reliable	metabolomics	
databases,	and	more	sensitive	and	accurate	instruments,	improve	data	comparability,	
and	expand	current	analytical	platforms	to	provide	more	user-friendly	multifunctional	
tools	for	data	processing.	
1.4 Systems	biology	
Living	systems	are	complex	and	this	complexity	is	perhaps	particularly	noticeable	when	
looking	at	vast	datasets	produced	by	high-throughput	techniques,	including	
metabolomics,	genomics,	transcriptomics	etc.	Systems	biology	approaches	have	been	
used	to	integrate	this	kind	of	data	and	obtain	a	holistic	picture	of	organismal	function.	
Systems	biology	is	a	field	of	science	that	studies	whole	living	systems	rather	than	its	
individual	components	in	isolation.	As	opposed	to	the	reductionist	approach,	which	
focuses	for	example	on	single	genes	or	proteins,	systems	approach	looks	at	networks	and	
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interactions	between	all	components	of	the	whole	system.	Moreover,	it	attempts	to	
understand	biological	processes	in	quantitative	and	qualitative	way	[281].	This	is	achieved	
by	observing	patterns	of	behaviour	in	a	complex	system	and	elucidating	principles	that	
govern	it.	These	can	then	be	applied	to	generate	predictive	models	of	biological	systems	
[282].	The	models	can	then	provide	information	on	how	manipulating	the	system	can	
affect	it,	for	example	a	model	of	healthy	and	diseased	states	of	the	system	[283],	or	they	
can	be	applied	to	other	living	systems.		
Systems	biology	aims	to	condense	the	knowledge	and	asks	questions	in	the	context	of	a	
whole	system.	For	example,	it	terms	of	single-gene	mutation,	it	does	not	only	look	at	its	
direct	effect	on	protein	expression,	but	also	how	it	affects	activity	of	other	genes,	
proteins	and	metabolites	and	how	they	interact	as	a	result	of	the	genetic	manipulation	
[284,	285].	Developing	a	model	to	test	this	kind	of	genetic	challenges,	allows	a	fast	and	
often	correct	prediction	of	how	the	system	will	behave	in	different	conditions.	This	can	
also	be	used	in,	for	example,	faster	preliminary	drug	screening.			
Systems	biology	is	particularly	useful	for	the	study	of	multicellular	organisms.	This	is	
because,	for	example,	it	is	particularly	important	to	take	into	consideration	cross	talk	
between	different	tissues	or	cell	types	in	these	organisms.	It	is	useful	to	look	at	individual	
pathways	or	cells.	However,	in	order	to	obtain	a	clear	understanding	of	organismal	
function,	we	must	look	at	the	living	system	as	a	whole.	For	example,	single	gene	mutation	
in	ry	has	been	shown	to	not	only	affect	metabolites	directly	upstream	and	downstream	of	
the	lesion,	but	also	metabolites	several	reactions	away	from	it,	as	well	as	apparently	
unrelated	metabolic	pathways	[62].	Moreover,	in	order	to	understand	the	basis	of	
phenotypic	manifestations	caused	by	the	mutation,	it	is	necessary	to	take	the	whole	
system	into	consideration,	rather	than	just	a	single	component.	It	is	clear	from	this	study	
that	single	gene	alterations	have	a	much	broader	effect	than	altered	expression	of	a	
single	protein.	It	suggests	that	the	results	of	genetic	manipulation	depend	on	numerous	
factors,	including,	cell	type,	developmental	stage,	and	cellular	processes,	in	which	it	
functions.	Moreover,	compensatory	mechanisms	exist	that	can	overcome	genetic	
manipulations	and	affect	the	phenotype	[286].	
1.4.1 Functional	genomics	for	systems	biology	
Functional	genomics	technologies	provide	vast	wealth	of	data	produced	by	‘omics’	
	 55	
methods,	including	genomics,	transcriptomics,	proteomics	and	metabolomics.	They	
provide	semi-quantitative	data	on	the	levels	of	genes,	proteins	and	metabolites	in	the	
living	system	[287].	This	enables	to	observe	effects	of	conditional	perturbation	on	an	
organism,	including	the	effects	on	interactions	between	macromolecules,	functional	
correlations	between	phenotypes,	and	the	dynamics	of	the	system	[288].	The	goal	of	
functional	genomics	is	to	experimentally	validate	gene	function	and	to	elucidate	the	link	
between	the	functional	phenotype	and	genes,	between	DNA	sequence	and	function	[162,	
289,	290].		
The	‘omics’	data	are	the	key	to	constructing	biological	models	at	different	stages	and	
different	conditions	of	the	living	system,	for	example	at	different	environmental	
conditions	or	disease	states	[291].	This	is	exactly	the	aim	of	systems	biology,	to	generate	
mathematical	models	and	use	them	to	predict	a	response	of	a	living	system	to	different	
stimuli.	Altogether,	this	provides	a	more	holistic	understanding	of	the	behaviour	of	a	
complex	system.		
Finally,	thanks	to	a	wider	use	of	‘omics’	technologies	in	recent	years,	hypothesis	
generation	and	testing	has	been	accelerated.	For	example,	development	of	FlyAtlas.org,	
tissue-specific	transcriptome	of	Drosophila	melanogaster,	allowed	prediction	of	tissue-
specific	activities	and	functions	in	the	fly	[6].		
1.4.2 Metabolomics	for	functional	genomics		
Metabolomics	is	one	of	the	techniques	employed	in	functional	genomics.	It	forms	the	
basis	for	understanding	the	biochemical	phenotype	of	an	organism,	and	aids	
understanding	of	gene	function	by	analysis	of	the	metabolome	[288].	As	opposed	to	
other	omics,	metabolomics	has	a	direct	correlation	to	the	physiology	of	the	cell/tissue,	
provides	the	most	functional	information,	and	hence	is	directly	linked	to	phenotype	[124,	
125,	142].	In	contrast,	other	omics	reflect	the	flow	of	gene	expression	but	are	not	directly	
correlated	to	function	and	phenotype	[125,	126,	292].	Metabolomics	aids	the	
understanding	of	real	functional	correlations	between	metabolite	changes	and	
physiological/	developmental	phenotypes	[293].	These	can	then	be	linked	to	the	gene(s)	
responsible	for	the	metabolite	change,	and	as	a	result	elucidate	gene	function.		
A	large	proportion	of	genes	present	in	the	genome	encode	protein	of	unknown	function.	
Among	these	genes,	many	are	‘silent’,	which	means	that	they	do	not	produce	any	
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apparent	phenotype	when	they	are	disrupted	[294].	Metabolomics	has	been	employed	to	
elucidate	the	function	of	these	genes	[162].	It	provides	identification	and	relative	
quantification	of	all	compounds	in	the	metabolic	network.	By	comparing	metabolite	
concentrations	to	the	concentration	of	one	selected	metabolite,	the	site	of	action	of	a	
silent	gene	can	be	elucidated.	Moreover,	metabolomics	can	provide	metabolic	profiles	in	
mutants	of	unknown	genes.	By	comparing	these	to	profiles	of	controls	with	known	
genetic	backgrounds,	metabolomics	can	reveal	the	function	of	unknown	genes	[162].		
Altogether,	metabolomics	is	a	powerful	tool	in	functional	genomics,	used	to	predict	and	
define	complex	phenotypes	in	biological	systems	[125].	It	complements	other	omics,	
which	reflect	the	flow	of	gene	expression,	and	is	directly	linked	to	cell	phenotype,	
physiology	and	function	[126].	As	a	result,	metabolomics	has	the	potential	to	elucidate	
gene	function	of	poorly	characterised	genes,	and	map	phenotypes	of	silent	mutations	
[295,	296].		
	
1.4.3 Metabolomics	–	a	systems	biology	tool		
Metabolomics	provides	an	insight	into	the	mechanisms	underlying	biological	and	
biochemical	processes	of	living	systems	[127].	It	simultaneously	identifies	and	quantifies	
all	small	molecules,	and	provides	a	comprehensive	understanding	of	all	biochemical	
reactions	and	metabolite	fluxes	in	a	system	[297].	Hence,	it	is	the	core	of	systems	biology,	
which	aims	to	elucidate	obtain	a	holistic	picture	of	organismal	function	[298].	Moreover,	
combining	metabolomics	with	genomics,	transcriptomics	and	proteomics	data	can	
provide	a	unique	insight	into	the	interactions	between	different	components	of	a	living	
system	[158].	Integration	of	different	omics	data	can	be	used	for	the	construction	of	
molecular	networks,	which	can	aid	the	understanding	of	the	complex	biochemical	
processes	in	a	system	[299].	Moreover,	it	can	reveal	how	these	complex	interaction	lead	
to	a	specific	behaviour	and	result	in	a	phenotype	[300].	This	enables	capturing	the	full	
functional	genomic	picture	of	an	organism.		
As	opposed	to	functional	genomics,	systems	biology	does	not	study	individual	genes,	
proteins,	or	metabolites.	On	the	other	hand,	it	looks	at	interactions	and	relationships	of	
all	elements	in	a	given	system,	while	it	is	functioning	[301].	The	general	approach	is	to	
disturb	the	system	(by	genetic	manipulation,	environmental	change	etc.)	and	then	
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observe	the	effects	of	the	perturbation	at	the	genomic,	proteomic,	and	metabolomic	
level	[126].	Obtained	omics	data	can	then	be	combined	and	used	to	generate	
computational	models	of	organismal	function.	This	method	has	a	great	potential	in	
metabolite	engineering,	drug	discovery,	and	medicine,	for	diagnosis	and	prevention	of	
disease	[302].	
However,	the	integration	of	metabolomics	data	with	other	omics	data	poses	several	
challenges.	Data	obtained	from	different	platforms	have	different	formats,	and	samples	
are	collected	using	different	experimental	conditions,	which	altogether	might	be	difficult	
to	correlate.	Moreover,	the	datasets	are	very	large	and	complex,	and	require	improved	
bioinformatics	tools	to	process	and	interpret	[158].		
Current	platforms	for	omics	data	integration	include	KeyPathwayMiner	4.0	[303],	MarVis-
Pathway,	which	enables	annotation	of	pathways	from	different	omics	data	[252],	
InCroMAP,	which	can	be	used	for	multiomics	data	integration,	analysis	and	visualisation	
and	provides	enrichment	analysis	and	pathway	visualization	[254].		
1.4.4 Genome-scale	metabolic	map	reconstruction	
As	mentioned	earlier,	one	of	the	main	goals	of	systems	biology	is	to	elucidate	principles	
that	govern	a	living	systems,	and	apply	them	to	generate	predictive	mathematical	models	
of	the	system	function	[282].	Genome-scale	metabolic	map	reconstructions	or	genome-
scale	metabolic	models	(GEMs)	are	an	example	of	this	kind	of	models.	They	are	a	huge	
step	up	from	one-dimensional	biochemical	databases,	such	as	KEGG	[158].	GEMs	are	
mathematical	and	computational	models	containing	data	on	all	metabolites,	enzyme-
coding	genes,	and	biochemical	reactions	in	a	given	system	(usually	a	specific	cell	or	whole	
organism)	[304,	305].	Moreover,	they	provide	representation	of	cellular	biochemistry,	
and	information	on	biophysical	constraints	on	the	system,	such	as	oxygen	and	nutrient	
availability	[306].	They	facilitate	the	study	of	metabolic	pathways	in	the	context	of	the	
whole	genome	[307].	Furthermore,	GEMs	can	be	compared	to	experimental	data	to	
increase	their	validity	[307].	
These	computational	models	can	be	studied	using	various	mathematical	algorithms,	in	
order	to	answer	important	biological	questions	[308].	For	example,	they	can	be	used	to	
predict	phenotypes	by	changing	environmental	conditions	or	introducing	genetic	
mutations	[309].	This	have	been	used	to	model	physiological	and	pathological	states	of	
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living	systems,	for	example	disease	[283,	305].	Human	global	metabolic	map	Recon	1	has	
been	applied	to	study	cancer,	diabetes,	host-pathogen	interactions,	and	heritable	
metabolic	disorders	[310-313].	Another	purpose	of	GEMs	is	to	generate	and	test	
hypotheses	[304,	314].	For	example,	by	introducing	genetic	mutations	of	poorly	
characterised	or	unknown	genes,	their	effect	on	the	system	can	be	observed,	and	as	a	
result	their	function	predicted.	These	observations	combined	with	experimental	data	
provide	a	powerful	tool	for	functional	genomics.	Finally,	GEMs	can	be	used	to	identify	
biomarkers	and	novel	drug	targets	[305].	For	example,	a	global	metabolic	models	of	
Mycobacterium	tuberculosis	[315],	Campylobacter	jejuni	[316],	and	Plasmodium	
falciparum	[317],	have	been	utilised	towards	development	of	new	therapeutics.		
In	recent	years,	over	70	genome-scale	metabolic	map	reconstructions	have	been	
generated	of	various	organisms	[306,	318],	including	Plasmodium	falciparum	[314],	E.	coli	
[319],	Mycobacterium	tuberculosis	[315],	Campylobacter	jejuni	[316],	Pseudomonas	
aeruginosa,	Pseudomonas	putida	[320,	321],	human	[310]	and	mouse	[322].These	models	
are	available	a	publically	available	knowledgebase	of	Biochemically,	Genetically	and	
Genomically	(BiGG)	structured	genome-scale	metabolic	network	reconstructions	
(http://bigg.ucsd.	edu)	[304].	The	website	provides	access	to	75	standardised	GEMs,	
which	are	connected	to	annotations	and	external	databases.		
Stoichiometric	metabolic	maps	are	built	by	integrating	the	genome	sequence	and	
annotation	of	an	organism	with	many	different	resources	on	organismal	metabolism,	
including	databases	(e.g.	KEGG	[323],	BRENDA	[324],	BioCyc	[325],	MetaCyc	[325])	and	
primary	literature	[326].	Maps	can	be	generated	using	semi-automated	tools	[158,	305].	
A	review	of	available	tools	is	described	in	[158].	Some	examples	include	PathCase	
Metabolomics	Analysis	Workbench	(PathCaseMAW),	used	for	mammalian	map	
reconstruction	[327],	MetaMapR,	which	is	based	on	KEGG	and	PubChem	[328],	and	
Integrated	Interactome	System	(IIS)	[329].	In	constraint-based	models,	constraints	can	be	
then	applied	(biophysical	constraints	on	reaction	and	transport	rates),	followed	by	
expressing	each	reaction	mathematically.	Finally,	different	model	calculations	and	
predictions	can	be	performed	using	computational	mathematical	tools,	such	as	the	
COBRA	toolbox	for	MATLAB	[330,	331].	Generated	GEMs	contain	missing	information,	
where	there	is	no	connectivity	between	metabolites	in	the	model,	and	as	a	result	it	is	
incomplete	and	does	not	produce	biomass	[311].	This	indicates	missing	reactions	and/or	
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pathways,	and	has	to	be	manually	curated	with	the	aid	of	sequence	alignments	and	
literature	to	allow	connectivity	within	the	model	[319].	
1.4.4.1 Gaps	in	GEMs	
All	GEMs	contain	gaps,	where	the	model	produces	biomass	effectively	but	reactions	are	
blocked	and	do	not	carry	flux	at	steady	state	because	metabolites	are	either	only	
produced	or	consumed	[332-334].	These	gaps	are	a	result	of	limitations	of	the	model	or	
knowledge	gap,	where	our	knowledge	on	organismal	metabolism	is	limited.	Different	
types	of	gaps	are	present	in	metabolic	maps,	where	enzymatic	reaction	is	absent	[335]:	
1. The	homologue	of	enzyme-coding	gene	is	present	in	an	organism	of	interest	but	there	is	
no	experimental	evidence	confirming	the	function	of	the	homologous	gene	
2. Enzyme	exists	in	other	species	but	there	is	no	homologue	in	the	genome	of	the	organism	
of	interest	
3. Global	gap	(orphan	enzyme),	where	no	sequence	of	enzyme-coding	gene	is	available	in	
any	known	species	
The	first	type	of	gap	is	the	easiest	to	fill	in,	and	requires	integration	of	experimental	
evidence	with	the	map.	However,	in	practice,	experimental	evidence	is	not	always	easy	to	
obtain	due	to	complexity	and	dynamic	nature	of	metabolism.	The	second	type	of	gap	can	
result	from	various	scenarios.	For	example,	the	reaction	occurs	spontaneously	in	the	
organism	of	interest	or	is	catalysed	by	an	enzyme	unique	to	this	species	or	a	group	of	
species.	Another	possibility	is	that	there	is	an	alternative	pathway	producing	the	
metabolite,	or	a	symbiotic	organism	(e.g.	gut	microbiota)	that	carries	out	the	reaction.	
Finally,	the	whole	pathway	may	not	be	required	in	the	organism	of	interest,	for	example	
bacteria-specific	pathway	in	the	fruit	fly.	The	third	type	of	gap	is	the	most	challenging	
one.	Orphan	enzymes	have	been	predicted	to	represent	30-40%	of	all	known	enzyme	
activities	[336-338].	It	is	particularly	difficult	to	predict	function	of	these	genes.	However,	
many	of	these	genes	are	thought	to	be	of	ancient	origin,	and	involved	in	essential	
metabolic	reactions	[337,	339].	GEMs	present	a	tool	to	identify	and	study	these	gaps	in	
the	context	of	available	metabolic	knowledge,	and	hence	are	a	powerful	tool	for	gene	
discovery,	and	understanding	essential	metabolic	processes.		
1.4.4.2 Filling	in	the	gaps	
Several	computations	tools	and	algorithms	have	been	developed	to	identify	network	gaps	
and	aid	gap	filling	process	[335].	For	constraint-based	models	several	methods	exist,	
	60	
including	SMILEY	[340],	GapFind/GapFill	[341]	and	GrowMatch	[342].	SMILEY	has	been	
successfully	used	to	predict	gap-filling	reactions	in	the	human	GEM	(Recon	1)	[311].	The	
other	two	methods	have	been	used	in	predictions	of	E.	coli	and	yeast	metabolic	gaps	
[342].	For	non-constraint-based	models,	other	algorithms	can	be	employed,	such	as	
Pathway	Tools	software	(http://bioinformatics.ai.sri.com/ptools/)	that	can	be	used	for	
gap	list	generation	and	gap-filling	for	BioCyc	databases	[343].	Alongside	these	predictive	
algorithms,	integrated	omics	data,	as	well	as	tissue-specific	information	can	aid	the	
process	of	gap	filling	by	suggesting	candidate	metabolic	reactions	[344-346].	Finally,	
automatically	generated	gap-filling	hypotheses	should	be	validated	by	manual	literature	
review	and	experimental	data.		
Despite	the	number	of	available	tools	and	algorithms,	there	is	no	single	method	for	
complete	gap	filling	of	a	given	model.	More	complete	genome	annotations,	metabolic	
databases	as	well	as	more	powerful	tools	are	currently	required	for	elucidation	of	
comprehensive	metabolic	models.	As	a	result,	there	is	currently	no	GEM	that	is	complete	
and	fully	realistic.	
1.4.5 Towards	global	metabolic	model	of	Drosophila	melanogaster	
Generation	of	GEMs	of	model	organisms,	including	Drosophila	melanogaster,	has	been	
recognised	as	a	priority	in	systems	biology	[347].	It	would	improve	our	understanding	of	
holistic	function	of	this	species,	and	as	a	result	of	all	organisms,	including	humans.	
Identification	of	all	metabolites	and	mapping	them	to	metabolic	pathways	would	allow	a	
greater	understanding	of	global	metabolism	of	all	species.	GEM	of	the	fruit	fly	would	have	
numerous	applications.	First	of	all,	it	would	be	the	first	global	metabolic	model	of	an	
insect	species,	and	hence	it	could	be	used	as	a	basis	for	the	development	of	GEMs	of	
other	insect,	including	pests	and	disease	vectors,	such	as	mosquito.	Insect	pests	kill	over	
20%	of	the	world’s	crops	and	kill	millions	of	people	every	year.	There	is	a	high	demand	for	
new	insecticides	and	insect	GEMs	have	a	potential	to	identify	new	drug	targets	and	
provide	a	tool	for	computational	modelling	of	drug	action.	Secondly,	by	elucidation	the	
core	metabolome	of	Drosophila,	various	fly	models	of	human	diseases	could	be	modelled	
and	tested,	in	particular	metabolic	disease,	such	as	IEMs.	Finally,	GEMs	provide	a	
powerful	tool	for	systems	biology	and	functional	genomic.	Metabolomics	has	a	potential	
to	elucidate	functions	of	novel	genes,	including	those	coding	for	orphan	enzymes.		
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There	is	currently	no	authoritative	global	metabolic	map	for	Drosophila	melanogaster	or	
any	other	insect	(http://bigg.ucsd.	edu)	[304].	Only	partial	reconstructions	of	the	fly	
metabolism	have	been	previously	reported,	including	a	constraint-based	model	of	ATP-
producing	pathways,	during	hypoxia	and	aging	[176,	348,	349].	A	basic	computational	
model	of	core	metabolism	of	Drosophila	has	been	generated	by	Dow/Davies	lab	(Dr	D.	
Erben,	personal	communication).	The	stoichiometric	model	was	built	using	D.	
melanogaster	BioCyc	database	version	4.0.1.1	and	curated	using	literature	and	KEGG	
(http://www.genome.jp/kegg/)	database.	The	model	was	under	the	steady-state	
assumption	[305],	which	means	that	there	is	no	metabolite	accumulation	and	the	sum	of	
reaction	fluxes	synthesising	a	compound	must	be	the	same	as	the	sum	of	reaction	fluxes	
breaking	it	down.	The	model	is	constraint-free	(no	biophysical	constraints	on	reaction	
and	transport	rates	were	applied)	[335]	because	there	are	currently	no	data	on	reaction	
rates	in	the	fly.	PathwayTools	was	then	used	to	visualise	and	query	the	map	during	
curation	and	to	generate	the	list	of	metabolic	gaps.	The	ability	to	produce	biomass	
precursors	with	no	priority	(all	components	equally	important)	was	assessed	using	
COBRA	toolbox	for	Matlab.	The	model	identified	2484	metabolites,	2759	reactions	and	
145	metabolic	gaps.	Further	literature	review	revealed	that	not	all	of	these	gaps	are	
relevant	to	the	fruit	fly.	The	remaining	gaps	were	searched	against	the	Drosophila	
genome	using	the	Protein	Basic	Local	Alignment	Search	Tool	(pBLAST),	identifying	26	
candidate	fly	genes	with	at	least	partial	sequence	similarity	to	the	missing	enzymes.	In	
order	to	select	the	gaps	that	were	the	easiest	to	study,	genes	enriched	in	single	tissues	
(FlyAtlas.org)	and,	for	which	knockout	fly	lines	were	available	in	stock	centres,	were	
selected.	These	genes	were	then	correlated	to	human	disease,	with	focus	on	IEMs,	and	a	
single	gap,	CG30016	gene,	has	been	selected	(more	details	on	CG30016	are	presented	in	
Chapter	3).	Drosophila	CG30016	gene	was	chosen	because	it	has	a	high	sequence	
homology	with	5-hydroxyisourate	hydrolase	(5-HIU)	of	other	species,	which	is	involved	to	
urate	degradation	pathway.	Due	to	the	absence	of	this	pathway	in	humans	high	urate	
levels	can	lead	to	an	IEM,	hyperuricemia.	Understanding	the	molecular	basis	of	urate	
degradation	in	the	fly	could	increase	our	knowledge	on	hyperuricemia	and	potentially	
lead	to	the	development	of	Drosophila	model	of	the	disease.	This	could	contribute	to	the	
development	of	much	needed	novel	treatments	for	hyperuricemia.	Moreover,	Drosophila	
CG30016	gene	is	highly	enriched	in	the	tubules,	and	CG30016	knockout	flies	are	available	
in	stock	centers.			
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1.5 Project	aims	
The	aim	of	this	project	was	to	develop	an	efficient	method	to	assess	and	fill	in	gaps	of	the	
primary	global	metabolic	model	of	Drosophila	melanogaster	using	metabolomics	
approaches	combined	with	standard	reverse	genetics	tools.	Selected	gap	was	5-
hydroxyisourate	hydrolase	(5-HIUH),	which	plays	a	role	in	urate	degradation	pathway.	
Inability	to	degrade	urate	can	lead	to	IEMs	in	humans,	including	hyperuricemia.	Filling	in	
gaps	of	the	fly	metabolic	map,	would	aid	better	understanding	of	urate	degradation.	This	
in	turn	could	allow	generation	of	the	fly	model	of	hyperuricemia,	and	development	of	
new	much	needed	therapeutics	for	the	disease.	Moreover,	developing	a	method	for	filling	
in	metabolic	gaps,	would	allow	fast	and	efficient	gap-filling	process.	Our	approach	was	to	
obtain	a	fly	line,	in	which	the	expression	of	5-HIUH	gene	was	disrupted,	followed	by	its	
validation	as	a	knockout.	The	next	step	was	to	assess	the	tissue,	in	which	the	gene	was	
enriched	in	order	to	identify	phenotypes.	Finally,	LC-MS	metabolomics	analysis	was	
performed	in	order	to	determine	whether	the	expected	reaction	was	disrupted,	and	to	
observe	the	results	of	the	knockout	on	the	whole	metabolism.		
Moreover,	we	aimed	to	build	a	primary	tissue-specific	metabolome	of	the	fruit	fly,	in	
order	to	establish	whether	different	Drosophila	tissues	have	different	metabolomes	and	if	
they	correspond	to	tissue-specific	transcriptome	of	the	fruit	fly	(FlyAtlas.org).	This	was	
done	by	dissecting	different	fly	tissues	and	elucidating	their	complete	metabolome	using	
LC-MS	metabolomics	analysis.		
Development	of	an	efficient	gap-filling	protocol,	together	with	tissue-specific	
metabolome	of	the	fly,	would	aid	the	reconstruction	of	a	more	comprehensive	Drosophila	
metabolic	map.	This	in	turn	would	allow	testing	the	validity	of	a	fruit	fly	as	an	in	vivo	
model	for	human	metabolism	and	metabolic	imbalances	including	IEMs.	It	would	also	
identify	any	limitations	of	this	model.	Understanding	of	the	core	of	Drosophila	
metabolism	is	essential	for	this	undertaking.	Development	of	such	powerful	animal	model	
would	enable	identification	and	testing	of	new	drugs	for	IEMs	and	other	metabolic	
imbalances	in	humans	and	other	animals.	Moreover,	it	would	provide	a	holistic	
understanding	of	organismal	function	and	increase	understanding	of	the	interplay	
between	individual	tissues	in	a	whole	organism.
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2 Materials	and	Methods	
All	materials	were	obtained	from	Sigma	(Sigma	Aldrich,	UK)	unless	otherwise	specified.		
2.1 Drosophila	maintenance	and	stocks	
2.1.1 Fly	stocks	
Fly	lines	used	in	the	following	experiments	were	either	obtained	from	publicly	available	
stock	centres,	or	generated	in-house.	All	fly	lines	are	described	in	the	table	below	(Table	
2-1),	including	their	fly	ID,	genotype,	description	and	the	source.		
2.1.2 Fly	maintenance		
Drosophila	melanogaster	flies	were	maintained	in	standard	conditions	unless	otherwise	
specified.	Flies	were	reared	on	standard	yeast	cornmeal,	sucrose	and	agar	medium	
(Appendix	I	for	full	medium	recipe)	in	ventilated	plastic	vials.	The	insectary	conditions	
were	tightly	controlled,	with	temperature	of	23°C,	55%	atmospheric	humidity	and	a	12:12	
h	light:dark	cycle.	Adult	flies	were	transferred	to	fresh	vials	every	two	weeks	unless	flies	
of	specific	age	were	required.	In	order	to	collect	adult	flies	of	specific	age,	a	laying	
population	of	around	20	males	and	20	females	were	transferred	to	fresh	vials	every	day.	
The	progeny	was	then	collected	in	fresh	vials	when	adults	emerged	(1	day	old).	This	
allowed	precise	age	determination	of	adult	flies.	For	most	experiments,	flies	of	5-7	days	
were	used.	Where	larvae	were	used,	they	were	collected	directly	from	the	medium,	on	
which	egg	laying	flies	were	feeding.	Larval	stages	and	corresponding	sizes	are	represented	
in	Table	2-2.	
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Table	2-1	Fly	lines	used	in	this	study.	Each	fly	line	used	is	described	including	its	ID,	
genotype,	brief	description	and	source.	Flies	were	either	made	in	the	lab	or	purchased	
from	stock	centres.	
Fly	ID	 Genotype	 Description	 Source	
Canton	S	 w+;+/+;+/+	 Wild	type	–	Drosophila	melanogaster	
Bloomington	
Drosophila	Stock	
Center	
BDSC	17767	 w
1118;	
PBac[279]hbsc06523	
PiggyBac	insertion	in	w1118	
background	targeting	hbs	
gene.	No	effect	on	hbs	
gene	expression	
Bloomington	
Drosophila	Stock	
Center	
BDSC	18554	
w1118;	
PBac{WH}CG30016
f02466	
PiggyBac	insertion	in	w1118	
background	targeting	
CG30016	gene.	Loss	of	
function	mutation	
Bloomington	
Drosophila	Stock	
Center	
BDSC	18814	 w
1118;	
PBac{WH}Urof04888	
PiggyBac	insertion	in	w1118	
background	targeting	Uro	
(urate	oxidase)	gene.	Loss	
of	function	mutation 
Bloomington	
Drosophila	Stock	
Center	
BDSC	225	 Ry506(CS)	
Deletion	of	~1/3	coding	
region	in	ry	(rosy,	xanthine	
dehydrogenase)	in	a	
Canton	S	background.	Loss	
of	function/amorphic	
allele.	
Bloomington	
Drosophila	Stock	
Center	
c42-GAL4	 w-;	+/+;	c42-	GAL4/c42-GAL4	 
GAL4	enhancer	trap	
specific	to	the	tubule	
principal	cells	
(Sozen	et	al.,	
1997);	
Dow/Davies	Labs	 
capaR-GAL4	 w-;	+/+;	c42-	GAL4/capaR-GAL4	
GAL4	enhancer	trap	
specific	to	the	tubule	cells	
Selim	Terhzaz,	
Dow/Davies	Lab	
12888-3-8M-
Ch2	
w-;	UAS-	
CG30016.His6/Cyo	
CG30016	tagged	with	6xHis	
under	UAS	control	
Dominika	
Korzekwa,	
Dow/Davies	Lab		
12888-3-10M-
Ch3	
w-;	+/+;	UAS-	
CG30016.His6/TM3	
Sb	
CG30016	tagged	with	6xHis	
under	UAS	control	
Dominika	
Korzekwa,	
Dow/Davies	Lab	
UAS-RelHis-
C42Gal4	
w*;{UAS-Rel.His6}2	
/CyO;GAL4c42	/TM3	
Sb	
Relish	tagged	with	6xHis	
under	UAS	control	driven	
by	c42	GAL4 
Dow/Davies	Lab	
UAS-pHIuorin	
w1118;	+/+;	UAS-
pHluorin(Perox)	
/TM3	
pHluorin	fusion	with	
upstream	UAS;	localizes	to	
peroxisomes 
Dow/Davies	Lab	
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Table	2-2	Developmental	Drosophila	larval	stages.	Different	stages	of	fly	larvae	were	used	
in	the	study;	larva	size	and	picture	is	illustrated	for	each	stage.		
	 Larval	stage	 Size	(length	in	mm)	
	 First	instar	(L1)	 ∼1.0	
	 Second	instar	(L2)	 ∼2.0	
	
Early	third	instar	(L3E)	 ∼3.0	
	
	
Third	instar	(L3)	
	
∼3.8	
2.1.3 Fly	mating		
After	constructing	appropriate	transgenic	plasmids	as	described	in	Section	2.8.6,	
UAS/GAL4	system	(Section	1.1.4)	was	employed	to	express	transgenes	in	a	desired	tissue.	
Female	virgin	flies	of	UAS-transgene	line	were	crossed	to	GAL4	males.	In	order	to	collect	
adult	virgin	flies,	a	laying	population	of	around	20	males	and	20	females	were	transferred	
to	fresh	vials	every	day.	The	progeny	was	then	collected	in	fresh	vials	when	adults	
emerged	early	in	the	morning	to	select	female	virgin	flies.	5-10	virgin	flies	of	UAS-
transgene	strain	were	then	mated	to	10-20	GAL4	male	flies.	They	were	transferred	to	a	
new	vial	every	2-3	days	and	tested	for	the	presence	of	the	transgene	by	visual	markers	
and	qPCR	(quantitative	PCR).		
2.2 Drosophila	tissue	dissection	
Seven-day	old	were	anaesthetised	briefly	on	ice	and	immediately	used	for	tissue	
dissection.	Tissues	were	dissected	in	Drosophila	Schneider’s	medium	(Invitrogen,	UK).	
Tissues	were	either	directly	transferred	to	slides	containing	a	drop	of	PBS	(Phosphate-
buffered	saline	pH	7.4:	137	mM	NaCl,	2.7	mM	KCl,	10	mM	Na2HPO4,	1.8	mM	KH2PO4)	for	
Immunocytochemistry/microscopic	visualisation	or	transferred	every	30	min	to	
appropriate	buffers	for	other	experiments.	Male	and	female	tissues	were	collected	
separately.		
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2.3 RNA	extraction		
RNA	extraction	was	performed	in	a	nuclease-free	environment.	Nuclease-free	
environment	was	achieved	by	working	and	storing	all	equipment	used	for	RNA	extraction,	
in	a	specifically	designated	RNase	(ribonuclease)-free	zone	of	the	lab.	All	working	surfaces	
were	washed	using	RNaseZap®	reagent	(Thermo	Fisher	Scientific,	UK)	before	and	after	
each	experiment.	Gloves	were	used	at	all	times	and	replaced	frequently.	Tubes	and	tips	
used	in	the	experiments	were	certified	RNase-free	and	came	from	an	unopened	sterile	
box.	The	tips	were	RNase-free	barrier	pipette	tips	to	ensure	no	cross-contamination	of	
RNA	samples.	Water	and	buffers	were	Diethylpyrocabonate	(DEPC)	–	treated	in	order	to	
inactivate	RNases.		
2.3.1 RNA	extraction	using	whole	flies	and	whole	larvae	
Seven-day	old	adult	flies	(five	males	and	five	females)	were	collected	and	anasthetised	
under	CO2.	They	were	then	homogenised	using	a	micropestle	in	250	μl	Trizol	(Life	
Technologies,	UK),	followed	by	10	second	of	sonication	using	ultrasonic	cell	disruptor	
(Misonix,	Inc.,	USA).	Additional	Trizol	was	added	to	a	total	volume	of	1	ml	following	
incubation	at	room	temperature	(RTm)	for	5	min	and	addition	of	200	μl	of	Chloroform.	
The	homogenates	were	then	vortexed	for	15	sec	and	subsequently	centrifuged	at	12000	g	
and	4°C	for	15	min.	The	aqueous	upper	layer	was	then	transferred	to	a	new	1.5	ml	
microcentrifuge	tube	without	disturbing	the	interphase.	Isopropyl	alcohol	(½	of	total	
sample	volume)	was	then	added	followed	by	precipitation	at	RTm	for	10	min.	The	
samples	were	then	centrifuged	at	12000	g	and	4°C	for	10	min.	After	removing	the	
supernatant,	the	pellets	were	washed	with	70%	ice-cold	ethanol	and	vortexed.	Following	
centrifugation	at	8000	g	and	4°C	for	5	min,	the	supernatant	containing	ethanol	was	
discarded	without	disturbing	the	pellet.	In	order	to	remove	all	ethanol,	the	pellets	were	
air	dried	at	RTm	for	∼5	min.	They	were	then	resuspended	in	30	μl	of	RNAse-free	water	
and	gently	mixed.	Extracted	RNA	was	immediately	used	for	cDNA	synthesis.	Remaining	
RNA	was	stored	at	-80°C.	 	
Where	larvae	were	used,	10	third	instar	feeding	larvae	were	collected.	The	same	RNA	
extraction	protocol	was	followed	as	with	adult	flies.	
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2.3.2 RNA	extraction	using	Malpighian	tubules	
Malpighian	tubules	were	dissected	as	described	in	paragraph	2.2.2.	Seven-day	old	flies	
(30	males	and	30	females)	were	collected	and	used	for	dissection.	Dissected	tubules	were	
homogenised	using	a	micropestle	in	250	μl	RLT	lysis	buffer	(Qiagen,	UK)	containing	10%	β-
mercaptoethanol,	followed	by	10	second	of	sonication	using	ultrasonic	cell	disruptor	
(Misonix,	Inc.,	USA).	The	homogenates	were	then	centrifuged	for	5	min	at	4°C	and	13000	
g	and	the	supernatants	were	collected	and	transferred	to	a	new	1.5	ml	microcentrifuge	
tube.	RNA	was	extracted	using	the	Qiagen	RNeasy	Mini	Extraction	Kit	(Qiagen,	UK)	
following	manufacturer’s	instructions.	DNA	digestion	(Qiagen	RNase-Free	DNase	Set)	was	
performed	in	order	to	reduce	genomic	DNA	contamination.	RNA	was	eluted	from	the	
column	using	30	μl	of	nuclease-free	water	and	immediately	used	for	cDNA	synthesis.	
Remaining	RNA	was	stored	at	-80°C.	 
2.3.3 Complementary	DNA	synthesis	
Complementary	DNA	was	synthesised	using	500-1000	ng	of	RNA	using	Superscript	II	
reverse	transcriptase	(SuperScript®	II,	Invitrogen,	UK).	The	synthesis	of	cDNA	was	
performed	following	the	manufacturer’s	protocol	and	the	total	reaction	volume	was	20	
μl.	Synthesised	cDNA	was	stored	at	-20°C	until	further	use.	The	cDNA	was	used	for	
standard	PCR	and	qPCR	described	in	sections	below.			
In	order	to	control	for	genomic	contamination,	samples	were	prepared	without	
SuperScript	II.	In	these	cases,	cDNA	was	not	synthesised.	Hence,	any	product	detection	in	
PCR	and	qPCR	experiments	was	due	to	genomic	contamination	rather	than	amplification	
of	cDNA.		
2.3.4 Quantification	of	nucleic	acid	
Both	RNA	and	cDNA	were	quantified	using	the	NanoDrop™	1000	spectrophotometer	
(Thermo,	UK)	in	2	μl	sample	volume.	NanoDrop	analyser	uses	1.0	mm	and	0.2	mm	path	
lengths,	which	makes	it	more	robust	than	a	standard	spectrophotometer	with	a	path	
length	of	10.0	mm.	Background	absorbance	was	measured	using	a	reference	sample	
(water	sample	or	the	sample	elution	buffer)	in	order	to	provide	the	‘blank’	reading.	The	
absorbance	was	measured	at	two	wavelengths:	A260	and	A280	nm.		Sample	concentration	
was	calculated	using	the	equation	below:	
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C	=	(A	*	e)/b	
where	C	corresponds	to	the	nucleic	acid	concentration	in	ng/μl,	A	corresponds	to	the	
absorbance	in	AU,	e	is	the	extinction	coefficient	in	ng-cm/μl	(which	is	50,	33	and	40	for	
double-stranded	DNA,	single-stranded	DNA	and	RNA	respectively),	and	b	corresponds	to	
the	path	length	in	cm.		
Sample	purity	was	also	monitored	using	the	A260/A280	ratio.	For	RNA	ratio	values	of	∼2.0	
and	for	DNA	values	of	∼1.8	were	considered	pure.	In	cases	where	ratio	values	were	
considerably	lower	or	higher,	the	samples	were	discarded.		
2.4 Oligonucleotide	synthesis		
Oligonucleotides	were	used	as	PCR	and	qPCR	primers.	The	primers	were	designed	and	
tested	using	the	software	MacVector	11.1.1	(MacVector,	Inc.,	UK).	They	were	then	
synthesised	using	Integrated	DNA	Technologies®	(IDT)	services.	Provided	oligonucleotides	
were	desalted	and	scaled	up	to	1	μmol	by	IDT,	and	the	quality	was	monitored	by	mass	
spectrometry.	Purchased	primers	were	resuspended	in	IDTE	buffer	(10	mM	Tris,	pH	7.5,	
0.1	mM	EDTA)	to	obtain	stock	concentration	of	100	μM.	Primers	were	stored	at	-20°C	at	a	
working	concentration	of	10	μM.	
2.5 Polymerase	chain	reaction	(PCR)	
2.5.1 Standard	PCR	
Standard	PCR	was	performed	using	DreamTaq	Green	PCR	Master	Mix	(Thermo,	UK).	The	
master	mix	contained	DreamTaq	DNA	Polymerase,	optimised	DreamTaq	buffer	(two	
tracking	dyes	and	density	reagent),	4	mM	MgCl2,	and	dNTPs	(0.4	mM	each).	Each	reaction	
contained	the	master	mix,	forward	and	reverse	primers,	template	DNA	and	nuclease-free	
water	and	the	total	reaction	volume	was	25	μl.	The	reactions	were	set	up	according	to	the	
manufacturer’s	recommendations.	Thermal	cycling	conditions	are	described	in	the	table	
below	(Table	2-3).		
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Table	2-3	Standard	PCR	thermal	cycling	conditions.		
Step	 Number	of	cycles	 Temperature	 Time	
Initial	denaturation	 1	 95°C	 5	min	
Denaturation	 	
30	
95°C	 30	sec	
Annealing	 55-65°C	(Tm-5)	 30	sec	
Extension	 72°C	 1	min/kb	
Final	extension	 1	 72°C	 10	min	
	
DreamTaq	DNA	Polymerase	is	an	enhanced	high-efficiency	Taq	DNA	Polymerase	and	has	
5’	to	3’	polymerisation	and	exonuclease	activity	and	lacks	proofreading	activity.	PCR	
products	were	analysed	using	agarose	gel	electrophoresis	(described	below).		
Gradient	PCR	using	DreamTaq	enzyme	was	performed	to	test	PCR	and	qPCR	primers	and	
establish	their	annealing	temperature.	Once	the	annealing	temperature	was	confirmed	
and	a	single	band	was	isolated	on	an	agarose	gel,	Herculase	II	Fusion	DNA	Polymerase	
(Agilent	Technologies,	UK)	was	used	to	amplify	the	product	of	interest.	The	Herculase	II	is	
a	Pfu	DNA	Polymerase	based	enzyme.	It	has	a	significantly	higher	fidelity	than	Taq	
Polymerase,	results	in	higher	yields	and	can	be	used	for	longer	PCR	products.	Hence,	it	
was	the	preferred	enzyme	for	cloning	experiments.	The	reactions	were	set	up	according	
to	the	manufacturer’s	protocol.		
2.5.2 Quantitative	reverse-transcriptase	PCR	(qPCR)	
Quantitative	PCR	is	a	powerful	technique	used	to	determine	gene	expression	of	a	gene	of	
interest.	QPCR	was	performed	using	TaqMan®	Gene	Expression	Master	Mix	and	Applied	
Biosystems	StepOne™	Real-Time	PCR	System.	Reaction	mix	contained	AmpliTaq	Gold®	
DNA	Polymerase,	UP	(Ultra	Pure),	Uracil-DNA	Glycosylase	(UDG),	deoxyribonucleotide	
triphosphates	(dNTPs)	with	deoxyuridine	triphosphate	(dUTP),	ROX™	Passive	Reference,	
and	optimised	buffer.	Components	of	each	reaction	are	represented	in	a	table	below	
(Table	2-4).	
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Table	2-4	QPCR	reaction	components.		
Reaction	component	 Quantity	
TaqMan®	Gene	Expression	Master	Mix	 5	μl	
cDNA	template	 2	μl	
Primers	and	probe	 0.5	μl	
Water	 2.5	μl	
Total	reaction	volume	 10	μl	
	
PCR	products	were	quantitatively	synthesised	from	cDNA	templates	using	AmpliTaq	DNA	
Polymerase.	The	enzyme	is	suitable	for	Hot	Start	PCR	and	is	a	form	of	Amplu	Taq®	DNA	
Polymerase.	This	means	that	it	is	only	active	at	temperatures	where	DNA	templates	are	
fully	denatured.	It	is	also	more	pure	than	Amplu	Taq®	DNA	Polymerase,	which	prevents	
bacterial	contamination	and	inaccurate	quantification	of	PCR	products.		
TaqMan	primers	and	probes	were	designed	and	generated	as	described	in	Section	2.4	and	
their	sequences	are	provided	in	Appendix	II.	They	contained	a	6FAM™	reporter	dye	at	the	
5’	end	and	a	nonfluerescent	quencher	at	the	3’end.	The	increase	in	fluorescence	of	the	
reporter	dye	allows	the	quantification	of	PCR	products.	QPCR	cycling	parameters	used	
here	were	consistent	with	the	manufacturer’s	protocol.		
Several	types	of	controls	were	used.	In	order	to	control	for	genomic	contamination	
negative	controls	prepared	during	cDNA	synthesis	without	the	Superscript	II	were	used	as	
a	template.	Moreover,	reactions	without	any	template	were	prepared	in	order	to	monitor	
and	subtract	background	fluorescence	from	the	experimental	samples.	Endogenous	
controls	were	prepared	for	each	sample	to	normalise	the	data	and	account	for	variability	
in	the	initial	concentration	and	quality	of	cDNA.	Reference	control	samples	contained	α-
Tubulin84B	primers.	α-Tubulin84B	gene	is	constitutively	expressed.	Four	replicates	were	
prepared	for	each	reaction.		
2.5.3 Data	analysis	
QPCR	results	were	analysed	using	the	StepOne™	Software	v2.1.	The	analysis	was	based	
on	the	2-∆∆CT	method	[350]	and	relative	gene	expression	levels	(either	percentage	
expression	or	fold	changes)	were	calculated.	Statistical	analyses,	including	P-values	and	
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standard	error	of	the	mean	(SEM),	were	performed	using	GraphPad	Prism	software	
(GraphPad	Software,	USA).	
2.6 Agarose	gel	electrophoresis	
PCR	products	were	separated	on	a	1%	agarose	gel	in	order	to	determine	their	specificity	
and	quality.	Agarose	gels	were	prepared	in	0.5x	TBE	buffer	containing	90	mM	Tris,	90	mM	
boric	acid	(pH	8.3),	2	mM	EDTA	and	0.1	μg/	ml	EtBr	(ethidium	bromide).	Where	required,	
5x	loading	dye	was	added.	20-30	μl	samples	and	5	μl	1	kb	ladder	(Invitrogen,	UK)	were	
loaded	into	the	wells.		
Gels	were	run	at	100	V	and	they	were	visualised	using	high	performance	ultraviolet	
transilluminator	(UVP,	UK).	PCR	product	band	sizes	were	compared	to	the	ladder.	If	
required,	PCR	product	bands	were	extracted	from	the	gel	as	described	in	the	section	
below.		
2.7 PCR/Gel	purification	
PCR	products	excised	from	gels	were	purified	using	QIAquick	Gel	Extraction	Kit	(Qiagen,	
UK)	following	manufacturer’s	protocol.	PCR	products	were	purified	using	QIAquick	PCR	
Purification	Kit	(Qiagen,	UK)	following	manufacturer’s	protocol.	DNA	was	eluted	in	30	μl	
of	nuclease-free	water	and	quantified	using	NanoDrop	as	described	in	Section	2.3.4.		
2.8 Molecular	cloning		
Molecular	cloning	protocols	were	used	in	order	to	clone	Drosophila	melanogaster	genes.	
They	were	then	expressed	using	several	different	expression	systems	described	below.	
Expressed	proteins	were	quantified	using	Bradford	Assay	and	visualised	using	Western	
blotting	and	immunocytochemistry	(ICC).	Where	required,	proteins	were	purified	and	
used	in	enzymatic	assays.		
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2.8.1 Bacterial	strains	and	plasmids	
Table	2-5	Bacterial	strains	and	vectors	used	in	the	study.		
Bacterial	strain	 Use	
One	Shot®	TOP10	chemically	
competent	E.	coli	(Invitrogen)	
Stable	propagation	and	maintenance	of	recombinant	
plasmids	
BL21	Star™(DE3)	 Regulated	expression	of	recombinant	plasmids		
Plasmid	 Use	
pF25A	ICE	T7	Flexi®	Vector	 Cell-free	expression	system		
pET101/D-TOPO®	 Expression	in	E.	coli	
pMT/V5-His-TOPO®	vector	 Expression	in	S2	cells		
pUAST	 UAS/GAL4	binary	induction	of	transgenes	in	vivo 
2.8.2 Construct	generation	
Recombinant	plasmid	constructs	were	generated	for	Drosophila	gene	expression	using	
several	expression	systems	described	below.	Standard	cloning	procedures	were	
performed.	Drosophila	genes	were	amplified	using	Herculase	II	DNA	Polymerase	as	
described	in	Section	2.5.	PCR	products	were	then	separated	on	an	agarose	gel	and	gel	
purified.	They	were	then	digested	using	specific	restriction	enzymes	(purchased	from	
New	England	Biolabs	or	Promega)	following	manufacturer’s	protocol	and	PCR	purified.	
Plasmids	were	also	digested	with	the	same	restriction	enzymes,	CIP	(Calf	Intestine	
Phosphatase)	treated	(NEB,	UK)	and	gel	purified.	Ligation	reactions	were	performed	using	
Quick	Ligation™	Kit	(NEB,	UK)	and	following	manufacturer’s	protocol.	Several	molar	ratios	
of	PCR	product:vector	were	used	for	optimal	results.	Generated	constructs	were	then	
used	for	transformation	of	competent	cells	described	in	Section	2.8.7.	
2.8.3 Cell-free	protein	expression	system		
TNT®	T7	Insect	Cell	Extract	Protein	Expression	System	(Promega,	UK)	is	a	quick	and	simple	
expression	system	for	cell-free	expression	of	proteins.	It	employs	TNT	technology	and	a	
coupled	transcription/translation	reaction,	which	makes	it	faster	than	other	expression	
systems.	The	system	was	used	for	Drosophila	melanogaster	protein	expression	followed	
by	protein	purification	(described	in	Section	2.10).	Vector	used	in	the	experiment	was	
pF25A	ICE	T7	Flexi®	Vector	illustrated	in	Fig.	2.1	(Promega,	UK)	and	all	steps	were	
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performed	in	ribonuclease-free	environment	following	manufacturer’s	protocol.		
	
Fig	2.1	Map	of	pF25A	ICE	T7	Flexi®	Vector.	The	vector	was	used	for	Drosophila	gene	cloning	
and	expression	using	TNT®	T7	cell-free	expression	system.	It	contains	SgfI	and	PmeI	
restriction	sites	and	ampicillin	resistance	gene.	
https://www.promega.co.uk/resources/protocols/product-information-sheets/g/pf25a-
ice-flexi-vector-protocol/	
	
2.8.3.1 Cloning	primers	and	PCR	amplification	
Oligonucleotide	primers	were	designed	as	described	in	Section	2.4.	Forward	primer	
contained	SgfI	restriction	site,	and	the	reverse	primer	contained	PmeI	restriction	site	as	
well	as	6xHis	tag	for	detection.	Complete	primer	sequences	are	available	in	Appendix	II.	
PCR	amplification	was	performed	using	Herculase	II	DNA	Polymerase	as	described	in	
section	2.5.		
2.8.4 TOPO	pET100	expression	system		
Champion™	pET100	Directional	TOPO®	Expression	Kit	(Invitrogen,	UK)	uses	T7	RNA	
Polymerase	and	was	used	to	express	Drosophila	genes	in	chemically	competent	E.	coli	
cells,	BL21	Star™(DE3)	(Invitrogen,	UK).	The	system	allows	regulation	of	T7	RNA	
polymerase	expression.	BL21	cells	contain	lac	repressor,	which	prevents	expression	of	T7	
RNA	polymerase.	In	order	for	the	gene	to	be	expressed,	isopropyl	β-D-thiogalacto-	side	
(IPTG)	must	be	added.	Vector	used	in	the	experiment	was	pET101/D-TOPO®	(Figure	2-2).	
All	reactions	were	performed	according	to	manufacturer’s	protocol.		
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Fig	2.2	Map	of	pET101/D-TOPO®	plasmid.	The	vector	was	used	for	Drosophila	gene	cloning	
and	expression	in	E.coli	cells.	It	contains	multiple	restriction	sites,	V5	epitope,	6xHis	tag	
and	ampicillin	resistance	gene.	
https://www.thermofisher.com/order/catalog/product/K10101	
	
2.8.4.1 Cloning	primers	and	PCR	amplification	
Oligonucleotide	primers	were	designed	as	described	in	Section	2.4.	Forward	primer	was	
designed	to	contain	CACC	sequence	required	for	directional	cloning	and	EcoRI	restriction	
site.	Reverse	primer	contained	XbaI	restriction	site	and	6xHis	tag	for	detection.	Full	
primer	sequences	are	available	in	Appendix	II.	PCR	amplification	was	performed	using	
Herculase	II	DNA	Polymerase	as	described	in	section	2.5.		
2.8.5 DES	TOPO	cloning		
DES®	TOPO®	TA	Expression	Kit	was	used	to	generate	constructs	for	transient	inducible	
expression	of	Drosophila	protein	in	vitro	in	S2	cells.	This	technology	does	not	require	the	
ligation	step	or	post-PCR	procedures.	Drosophila	genes	were	PCR	amplified	using	Taq	
DNA	Polymerase	resulting	in	PCR	products	with	polyA	(Adenine)	overhangs.	PCR	products	
were	then	directly	cloned	into	the	pMT/V5-His-TOPO®	vector	(see	Figure	2-3).	In	order	to	
induce	protein	expression	in	S2	cells,	CuSO4	was	added	to	the	cells	to	activate	the	
metallothionein	promoter.	These	constructs	were	used	to	determine	protein	subcellular	
localization	as	well	as	protein	purification	followed	by	enzyme	assay.		
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Map and Features of pET101/D-TOPO® 
 
pET101/D-TOPO® 
Map 
The figure below shows the features of the pET101/D-TOPO® (5753 bp) vector. 
The complete sequence of the vector is available for downloading from our 
Web site (www.invitrogen.com) or by contacting Technical Service (see 
page 56).  
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Fig	2.3	Map	of	pMT/V5-His-TOPO®	vector.	The	vector	was	used	for	gene	expression	in	S2	
cells.	Drosophila	genes	were	PCR	amplified	to	contain	polyA	overhangs,	which	allowed	
direct	cloning	into	Topoisomerase	(TOPO)	containing	vector.	TOPO	catalyses	bond	
formation	between	vector	thymidines	and	polyA	overhangs.	The	vector	contains	multiple	
restriction	sites,	V5	epitope,	6xHis	tag	and	ampicillin	resistance	gene.	
https://www.thermofisher.com/order/catalog/product/K412501	
2.8.6 Cloning	into	pUAST	plasmid		
Drosophila	genes	were	cloned	into	the	pUAST	vector	for	germ	line	transformation	of	
Drosophila	embryos.	These	were	subsequently	used	for	UAS/GAL4	system	induction	of	
transgene	expression	in	vivo	in	flies.	Cloning	into	the	pUAST	vector	(Figure	2-4)	was	
carried	out	using	standard	cloning	procedures.	In	order	to	confirm	the	insertion	of	
transgenes	into	the	pUAST	vector,	constructs	were	transient	expressed	in	S2	cells.	
Constructs	were	then	sequenced	and	used	for	microinjection	into	Drosophila	embryos	as	
well	as	tranformant	identification	and	balancing	(Best	Gene,	USA).		
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Fig	2.4	Map	of	pUAST	vector.	The	vector	was	used	for	gene	expression	in	S2	cells	followed	
by	microinjection	into	Drosophila	embryos	and	in	vivo	transgene	expression	in	the	flies.	
The	vector	contains	multiple	restriction	sites	and	ampicillin	resistance	gene.	
http://www.snapgene.com/resources/plasmid_files/basic_cloning_vectors/pUAST/	
	
2.8.6.1 Cloning	primers	and	PCR	amplification	
Oligonucleotide	primers	were	designed	as	described	in	Section	2.4.	Forward	primer	was	
designed	to	contain	EcoRI	restriction	site.	Reverse	primer	contained	XbaI	restriction	site	
and	6xHis	tag	for	detection.	Full	primer	sequences	are	available	in	Appendix	II.	PCR	
amplification	was	performed	using	Herculase	II	DNA	Polymerase	as	described	in	section	
2.5.		
2.8.7 Transformation	of	E.coli	cells	
TOP10	competent	cells	were	transformed	with	generated	constructs	following	
manufacturer’s	protocol.	5	μl	of	ligation	reaction	was	used	to	transform	the	cells.	Cells	
were	transformed	with	uncut	plasmids	and	cut	unligated	plasmids	to	provide	positive	and	
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negative	controls	respectively.	Transformation	reactions	(100	μl	and	200	μl	separately)	
and	controls	(30	μl)	were	spread	on	L-agar	plates	containing	100	μg/ml	ampicillin	or	
another	appropriate	antibiotic	depending	on	the	resistant	marker	of	the	plasmid,	and	
incubated	overnight	at	37°C.	Positive	colonies	were	identified	using	antibiotic	resistance	
markers.		
For	high	yield	protein	expression	of	confirmed	transgenic	plasmids,	BL21	cells	were	
transformed	with	5-10	ng	of	plasmid	and	incubated	on	ice	for	30	min.	Cells	were	then	
heat-shocked	for	30	sec	at	42°C	and	immediately	transferred	to	ice.	Following	the	
addition	of	250	μl	of	S.O.C	medium	at	RTm	to	each	samples,	cells	were	incubated	at	37	°C	
for	30	min	with	shaking	(200	rpm).	The	entire	transformation	reaction	was	then	added	to	
10	ml	of	LB	containing	the	appropriate	antibiotic	and	incubated	overnight	at	37°C	with	
shaking.		
2.8.8 Purification	of	plasmid		
Positive	colonies	were	picked	from	agar	plates	and	resuspended	in	10	μl	of	water.	They	
were	then	added	to	5	ml	of	lysogeny	broth	(LB)	containing	appropriate	antibiotic	and	
incubated	with	shaking	overnight	at	37°C.	Liquid	colonies	were	then	centrifuged	to	form	a	
pellet	and	resuspended	in	DNA	lysis	buffer.	Plasmid	DNA	was	purified	using	QIAprep	Spin	
Miniprep	or	Maxiprep	Kit	(Qiagen,	UK)	following	manufacturer’s	protocol.	Plasmid	DNA	
was	eluted	using	30	μl	(Miniprep)	or	500	μl	(Maxiprep)	of	water	or	TE	buffer.		
2.8.9 	Validation	of	cloning	products	
In	order	to	determine	whether	intact	PCR	products	were	present	in	the	construct	in	the	
right	orientation,	validation	experiments	were	carried	out,	including	PCR,	restriction	
digest	and	sequencing.		
2.8.9.1 PCR	
PCR	was	performed	in	order	to	establish	whether	full-length	transgenes	were	inserted	in	
in	the	correct	orientation.	Oligonucleotide	primers	were	used:	one	primer	starting	in	the	
transgene	and	the	other	one	in	the	cloning	vector.	The	results	were	monitored	using	gel	
electrophoresis.		
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2.8.9.2 Restriction	digest	
Restriction	digests	were	performed	in	order	to	determine	the	orientation	of	inserts.	
Restriction	products	were	monitored	on	an	agarose	gel.	Different	size	bands	were	
observed	depending	on	the	orientation	of	the	transgene.		
2.8.9.3 Sequencing	
In	order	to	determine	whether	the	full-length	transgenes	were	inserted	in	the	vector	and	
no	mutations	occurred	during	PCR,	DNA	sequencing	was	performed.	Sequencing	primers	
were	designed;	both	in	the	vector	in	order	to	obtain	the	full	transgene	sequence.	
Sequencing	was	carried	out	by	GATC	Biotech,	UK.	Obtained	sequences	were	analysed	
using	Mac	Vector	Software.	Glycerol	stocks	(20%	peptone,	40%	glycerol)	of	correct	
constructs	were	stored	at	-80°C.		
2.8.10 	Pilot	expression	of	Drosophila	protein	in	BL21	cells		
After	overnight	incubation	of	transformed	BL21	cells,	500	μl	of	cells	were	added	to	10	ml	
of	LB	containing	the	appropriate	antibiotic	were	grown	at	37°C	with	shaking	till	they	
reached	density	of	0.6-0.8	at	OD600	(typically	1-2	h).		
Once	the	right	cell	density	was	reached,	1	ml	of	each	sample	was	collected	and	
centrifuged	at	8000	rpm	for	5	min.	Pellets	were	then	frozen	at	–	20°C	and	subsequently	
used	in	SDS-PAGE	and	Western	blotting	as	a	negative	control	(uninduced	sample).		
The	remaining	9	ml	of	cells	were	used	for	pilot	expression.	In	order	to	induce	Drosophila	
protein	expression,	1	M	IPTG	was	added	to	a	final	concentration	of	0.4	mM.	The	
expression	was	performed	at	two	different	temperatures	(25°C	and	37°C)	for	3	h	or	
overnight	in	order	to	establish	the	best	expression	conditions.	After	the	expression,	OD600	
was	measured	and	1	ml	of	each	sample	was	centrifuged	at	8000	rpm	for	5	min.	Pellets	
were	then	stored	at	–	20°C	and	subsequently	used	for	SDS-PAGE	and	Western	blotting.		
Once	the	best	expression	conditions	were	determined,	the	transformation	reaction	of	
BL21	cells	was	scaled	up	to	500	ml.	The	protein	expression	was	then	induced	using	IPTG	
as	described	above	and	cells	were	grown	in	optimal	expression	conditions.	Cells	were	
then	harvested	by	centrifugation	at	3000	g	for	10	min	at	4°C	and	stored	at	-80°C.	Pellets	
were	resuspended	in	20	ml	of	TBS	containing	1	mg/ml	protease	inhibitor	cocktail	and	
lysed	using	French	press	at	8000	psi.	Samples	were	then	centrifuged	at	13000	rpm	for	30	
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min	at	4°C.	The	supernatant	was	transferred	to	a	fresh	tube	and	centrifuged	at	5000	rpm	
for	50	min.	Pellets	were	discarded	and	the	supernatant	stored	at	-80°C	till	it	was	used	for	
protein	purification	and	enzyme	assay.		
2.9 Drosophila	S2	Cell	Techniques	
2.9.1 	Maintenance	
Drosophila	Schneider	2	(S2)	cells	(Invitrogen,	UK)	were	maintained	according	to	
manufacturer’s	protocol.	All	procedures	were	carried	out	in	sterile	conditions.	Cells	were	
maintained	in	complete	Schneider’s	medium	(CSM)	containing	10%	fetal	calf	serum	(FCS)	
at	25°C.	Cell	density	was	monitored	daily	until	it	reached	107	cells/ml.	They	were	then	
passaged	by	diluting	6	ml	of	cells	into	9	ml	of	CSM.	Cells	were	maintained	in	15	ml	
volumes	in	T75	flasks.		
2.9.2 Transient	transfection	
S2	sells	used	for	transient	transfection	were	transferred	to	tissue	culture	six-well	plates.		
When	they	reached	the	density	of	6	x	106	cells/	3	ml,	they	were	seeded	into	individual	
wells.	24	hours	later	transient-transfection	was	carried	out	using	calcium	phosphate	
transfection	method	following	manufacturer’s	protocol.	Plasmid	DNA	was	prepared	using	
a	maxi-prep	kit	(Qiagen)	and	eluted	in	TE	buffer.	Transient	transfection	reaction	is	
described	in	Table	2-6	
Table	2-6	Reaction	components	and	the	quantities	used	for	transient	transfection	of	S2	
cells.		
Reaction	component	 Quantity	
Plasmid	DNA	 19	μg	
Plasmid	DNA	(GAL4	transgene,	if	required)	 1	μg/	μl	
CaCl2	 240	mM	
Total	reaction	volume	 300	μl	
	
Reactions	were	set	up	and	well	mixed	followed	by	drop-wise	addition	to	300	μl	of	2x	
HEPES	buffered	saline	(HBS)	(50	mM	HEPES,	1.5	mM	Na2HPO4,	280	mM	NaCl,	pH	7.1)	and	
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mixing	by	bubbling	air	through	with	a	sterile	Pasteur	pipette.	The	DNA/calcium	phosphate	
was	then	incubated	at	RTm	for	30	min	to	precipitate.	It	was	then	added	drop-wise	to	the	
S2	cells	with	continuous	gentle	mixing	by	swirling.	Cells	were	then	incubated	overnight	at	
25°C.	Following	the	overnight	incubation,	transfected	cells	were	mixed	and	resuspended	
followed	by	centrifugation	at	1500	g	at	RTm	for	1	min	to	form	a	pellet.	Pellets	were	then	
resuspended	in	3	ml	fresh	CSM.	The	centrifugation	and	resuspension	steps	were	repeated	
three	times.	Following	final	resuspension	in	3	ml	CSM,	cells	were	transferred	into	the	six-
well	plates.	In	order	to	induce	the	expression	of	Drosophila	transgenes,	CuSO4	(final	
concentration	of	0.5	mM)	was	added	to	the	cells.	They	were	incubated	at	25°C	for	24-48	h	
to	allow	expression.	Finally,	cells	were	centrifuged	at	1500	g	for	1	min	at	RTm	to	harvest,	
washed	in	PBS	and	if	not	used	immediately,	stored	at	-80°C.		
2.10 	Protein	purification	and	analysis	
Following	Drosophila	gene	cloning	and	expression,	proteins	were	purified	and	analysed	as	
described	below.		
2.10.1 	Protein	purification		
Constructs	were	generated	to	contain	6xHis	tags	to	allow	protein	purification	and	
visualisation.	Protein	purification	was	performed	using	HisPur	Ni-NTA	Spin	Columns	
(Pierce,	UK)	following	manufacturer’s	protocol.	His-tagged	proteins	were	eluted	in	100	μl	
of	elution	buffer.	Protein	concentrations	were	then	measured	using	NanoDrop.		
2.10.2 	Changing	protein	buffer	and	concentration	
Where	required,	protein	buffer	was	changed	using	Slide-A-Lyser®	Dialysis	Cassette	
(Thermo	Scientific,	UK)	following	manufacturer’s	protocol.	Proteins	were	concentrated	
using	VivaSpin500,	10	kDa	MWCO	(GE	Healthcare,	UK)	following	manufacturer’s	protocol.		
2.10.3 	Bradford	assay	
Following	protein	purification,	the	protein	concentration	was	quantified	using	the	
Bradford	protein	assay.	The	assay	was	performed	in	96-well	culture	plates.	Bovine	serum	
albumin	(BSA)	protein	standards	were	prepared	of	0-5	μg	BSA	in	water.	These	were	set	up	
in	triplicates	in	a	final	volume	of	50	μl.	Typically,	eight	different	standard	concentrations	
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were	used	to	establish	the	concentration	of	expressed	Drosophila	proteins.	Several	
different	dilutions	of	protein	were	prepared	and	5	μl	of	each	sample	were	set	up	in	
triplicates	in	a	final	volume	of	50	μl.	Subsequently,	200	μl	Bradford	reagent	concentrate	
(BioRad,	UK),	diluted	1	in	5,	was	added	to	all	the	samples	and	standards.	The	absorbance	
at	590	nm	was	monitored	using	Mithras	LB	940	Multimode	Microplate	Reader	(Berthold	
Technologies).	Absorbance	readings	of	samples	were	then	plotted	against	known	
concentrations	of	standards	to	interpolate	sample	absorbance	and	calculate	their	
concentration.		
2.10.4 	SDS-PAGE	separation	
In	order	to	determine	the	size	of	expressed	protein,	sodium	dodecyl	sulfate	
polyacrylamide	gel	electrophoresis	(SDS-PAGE)	was	performed.	Electrophoretic	
separation	was	carried	out	using	Novex	NuPAGE︎  electrophoresis	system	(Life	
Technologies,	UK).	12-well	4-12%	Bis-	Tris-HCl	(Bis(2-hydroxyethyl)	imino-tris	
(hydroxymethyl)	methane-HCl)	buffered	(pH	6.4)	polyacrylamide	gels	were	used.	The	
running	buffer	was	prepared	by	diluting	20x	20x	NuPAGE™	MOPS	SDS	running	buffer	
stock	solution.	Electrophoresis	was	performed	at	a	constant	voltage	of	200	V	for	about	an	
hour.		
Samples	were	prepared	as	described	in	Table	2-7.	Samples	were	then	mixed	and	
incubated	at	70°C	for	10	min	followed	by	loading	into	gel	wells.	In	order	to	determine	the	
size	of	the	protein,	Novex®	Sharp	Pre-Stained	Protein	Standard	(Life	Technologies,	UK)	
was	also	loaded	into	gel	wells.		
Table	2-7	Sample	components	and	quantity	for	SDS-PAGE.		
Sample	component	 Quantity	
Protein		 20	μg	
NuPAGE	LDS	sample	buffer	(4x)	 5	μl	
Total	reaction	volume	 20	μl	
	
2.10.5 	Western	blotting	
SDS-PAGE	separated	proteins	where	transferred	onto	a	Hybond	ECL	membrane	(GE	Life	
Sciences,	UK).	The	membrane	was	activated	by	incubation	in	methanol	for	2	min.	The	
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transfer	buffer	used	was	Nupage	Transfer	Buffer	(Life	Technologies,	UK)	with	5%	
methanol.	The	transfer	was	performed	at	100	V	for	1	hour.	Following	the	transfer,	
Ponceau	S	staining	was	performed	for	rapid	detection	of	protein.	The	membrane	was	
incubated	in	Ponceau	S	solution	for	5	min	following	washes	with	5%	glacial	acetic	acid	
and	water.	Subsequently,	the	membrane	was	washed	three	times	with	TBST	(TBS	(500	
mM	NaCl,	20	mM	Tris-HCl	pH	7.5)	containing	0.1%	Tween	20),	blocked	at	RTm	for	1	hour	
in	TBST	containing	5%	non-fat	milk	powder	(Marvel)	and	incubated	with	primary	anti-
Histidine	antibody	overnight	at	4°C	(for	details	on	used	antibodies	and	their	
concentrations	see	Appendix	III).	Following	the	overnight	incubation,	the	membrane	was	
washed	in	TBST	3-5	times,	blocked,	incubated	with	a	secondary	antibody	(Appendix	III),	
washed	three	times	in	TBST	and	washed	in	TBS	for	10	min.	Chemiluminescence	detection	
was	performed	using	Amersham	ECL	Western	Blotting	Detection	Reagents	following	
manufacturer’s	protocol.		
2.11 	Immunocytochemistry	
Immunocytochemistry	(ICC)	staining	was	performed	in	S2	cells	and	dissected	Drosophila	
tissues	in	order	to	determine	the	localisation	of	expressed	protein	in	vitro	and	in	vivo.		
2.11.1 	ICC	of	S2	cells	
Following	transfection	and	protein	expression	in	S2	cells,	cells	were	mixed	and	
resuspended	and	then	collected	in	15	ml	falcon	tubes.	They	were	subsequently	
centrifuged	at	3000	g	for	5	min	in	a	free	rotating	tabbletop	centrifuge.	Pellets	were	
washed	twice	with	PBS.	80	μl	of	cells	were	then	transferred	to	Poly-L-lysine	coated	plates	
(Merk	Millipore,	UK)	at	a	density	of	6x106	cells/ml	and	incubated	at	RTm	for	30	min	to	
adhere.	Samples	were	fixed	with	4%	(w/v)	paraformaldehyde	in	PBTA	(PBS	containing	
0.5%	Triton	X-100)	for	20	min	and	then	washed	three	times	with	PBTA.	Following	20	min	
blocking	with	PBTA	containing	10%	(w/v)	goat	serum,	the	cells	were	incubated	with	
appropriate	concentration	of	primary	anti-His	antibody	(Appendix	III)	for	1	h	at	RTm.	After	
three	washes	with	PBTA,	samples	were	blocked	for	another	30	min	and	incubated	with	
appropriate	secondary	antibody	for	1	h	at	RTm.	Cells	were	then	washed	three	times	with	
PBTA,	incubated	with	100	μl	of	500	ng/ml	DAPI	in	PBS	for	2	min.	Following	three	washes	
with	PBS,	cover	slips	were	mounted	on	slides	using	VectaShield	medium	(Vector	
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Laboratories,	UK)	and	sealed	with	Glycerol	Gelatin	Finally,	samples	were	visualised	using	
confocal	microscope	(see	Section	2.12	for	details).		
2.11.2 	ICC	of	Drosophila	Malpighian	tubules	
Malpighian	tubules	were	dissected	in	Schneider’s	medium	and	immediately	transferred	to	
Poly-L-lysine	coated	slides	containing	a	drop	of	PBS	(pH	7.4).	Tubules	were	then	fixed	for	
20	min	with	PBS	containing	4%	paraformaldehyde,	washed	three	times	with	PBS	and	
permeabilised	for	30	min	using	0.3%	(v/v)	Triton	X-100	in	PBS	(PBT).	Following	1	h	
blocking	with	PBT	containing	5%	(v/v)	goat	serum	(PBT-GS),	tubules	were	incubated	
overnight	at	4°C	with	primary	anti-His	antibody	at	a	desired	concentration.	Subsequently,	
samples	were	washed	five	times	with	PBT.	Following	1-2	h	blocking	with	PBT-GS,	tubules	
were	incubated	overnight	at	4°C	with	secondary	antibody	diluted	to	a	desired	
concentration.	The	following	day,	samples	were	washed	with	PBT	three	times	for	1	h	per	
wash.	They	were	then	DAPI	(4',6-diamidino-2-phenylindole)-stained	(500	ng/ml	DAPI	in	
PBS)	for	2	min	and	washed	three	times	with	PBS.	Cover	slips	were	then	mounted	on	to	
the	slides	using	VectaShield,	sealed	with	glycerol-gelatine	and	visualised	using	confocal	
microscopy.		
2.12 	Imaging	
2.12.1 	Fluorescent	imaging	
Following	immunocytochemistry,	S2	cells	or	Malpighian	tubules	were	imaged	using	
confocal	microscopy	Zeiss	500	meta	system	(Zeiss,	UK).	In	this	study	40x	objective	was	
used.	In	order	to	image	Alexafluor	568	antibody,	HeNe1	543	nm	laser	was	used,	as	well	as	
561-625	band	pass	filter.	DAPI	staining	was	visualised	using	UV	source	(mercury	lamp)	
and	the	confocal	photomultipliers.	Images	obtained	from	different	channels	were	then	
merged	using	the	LSM	Meta	Software.	 
2.12.2 	Polarised	light	microscopy	
Polarising	microscopy	was	used	to	visualise	urate	crystals.	It	is	possible	due	to	
birefringent	property	of	urate	[351].	In	order	to	visualise	birefringent	specimens,	
poliarised	microscope	is	equipped	with	two	polarisers:	one	in	the	light	path	between	the	
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light	source	and	the	specimen,	and	the	other	one	(analyser)	in	the	optical	pathway	
between	the	objective	and	the	observation	tubes	(Figure	2-5).		The	polariser	can	be	
rotated	through	360	degrees,	which	enables	regulation	of	the	intensity	of	the	polarisation	
light.	When	maximum	brightness	was	achieved,	samples	were	visualised.		All	samples	
were	imaged	using	the	same	settings.		
Using	this	technique,	Malpighian	tubules	were	assessed	for	the	presence	or	absence	of	
urate	crystals.	Tubules	were	dissected	and	slides	were	prepared	as	described	in	Section	
2.2.		
	
Fig.2-5	Polarised	light	microscope	configuration	
(https://www.microscopyu.com/articles/polarized/polarizedintro.html).	Light	passes	
through	the	polariser	and	the	specimen	before	it	hits	the	objective,	the	analyser	and	the	
observation	tubes.		
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2.13 	Stress	and	survival	experiments		
2.13.1 	Oxidative	stress	survival	assay	
Five-	to	seven-day	old	flies	were	anasthetised	using	CO2	and	females	were	separated	from	
males.	Thirty	male	and	thirty	female	flies	were	collected	in	separate	empty	vials	for	5-6	h	
to	ensure	that	once	placed	in	vials	with	survival	food	preparation,	they	eat	immediately.	
Two	different	types	of	food	containing	different	oxidising	agents	(either	hydrogen	
peroxide	or	paraquat)	were	prepared	as	described	in	Table	2-8.		
Table	2-8	Types	of	food	preparations	used	in	oxidative	stress	survival	assay.	For	each	type,	
its	components	are	described	as	well	as			
Oxidising	agent	 Components	 Mode	of	action	
Hydrogen	peroxide		 1%	UltraPure	low	melting	
point	agarose	(Thermo	
Fisher,	UK)	
Hydrogen	peroxide	is	one	of	
the	simplest	peroxides.	
Through	catalysis	it	is	
converted	to	highly	reactive	
hydroxyl	radicals	1%	sucrose	
1%	hydrogen	peroxide	
Paraquat	 1%	UltraPure	low	melting	
point	agarose	(Thermo	
Fisher,	UK)	
Paraquat	is	an	electron	
acceptor	and	produces	
reactive	oxygen	species	(ROS)	
1%	sucrose	
10	mM	paraquat	
	
Flies	were	counted	every	2-6	h	and	the	number	of	dead	flies	was	recorded.	The	numbers	
were	then	analysed	using	Kaplan-Meier	survival	curve	as	means	±	SEM	(GraphPad	
Software).	Median	survival	was	also	calculated	using	the	same	software.	Appropriate	
controls	were	used	and	experiments	were	carried	out	in	triplicates	with	n	>	100.		
2.13.2 	Longevity	assay	
Flies	used	for	the	longevity	assay	were	reared	at	26°C.	One-day	old	flies	were	collected	
from	enclosing	pupae	over	the	period	of	24	h.	They	were	then	mated	for	48	h	and	
separated	into	males	and	females.	Ten	male	and	ten	female	flies	were	collected	in	fresh	
food	vials	and	kept	at	26°C.	They	were	transferred	to	fresh	food	vials	every	2-3	days	till	all	
of	them	were	dead.	Number	of	dead	flies	was	recorded	every	day.	Data	was	analysed	
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using	Kaplan-Meier	survival	curve	as	means	±	SEM	(GraphPad	Software)	and	median	
survival	was	calculated.	Appropriate	controls	were	used	and	the	experiment	was	
repeated	three	times	with	n	>	100.		
2.14 	Fluid	secretion	assay	
2.14.1 	Principles	of	the	assay		
Fluid	secretion	assay	(Figure	2-6)	based	on	a	classical	Ramsay	assay	for	tubule	secretion	
was	performed	in	order	to	establish	secretion	rates	in	different	fly	strains	as	described	in	
Dow	et	al.	[352].	Tubules	were	dissected	with	the	ureter	intact	over	a	period	of	30	min.	
One	end	of	the	tubule	was	wrapped	around	a	metal	pin	and	immersed	in	heavy	mineral	
oil.	The	other	end	was	placed	in	a	small	well	filled	with	10	μl	of	Drosophila	saline	
(Appendix	IV):	Schneider’s	medium	(50:50)	containing	a	small	amount	of	Amaranth	(red	
dye)	to	visualise	secreted	fluid.	The	whole	tubule	including	the	ureter	was	immersed	in	
the	oil.	Pink	bubbles	emerging	from	the	ureter	were	removed	using	a	fine	glass	rod	every	
10	min	over	a	period	of	1	h	and	then	measured	using	microscope	eyepiece	reticle.	Data	
was	analysed	using	Microsoft	Excel	(Microsoft	Office	Package).		
	
Fig.	2-6	Fluid	secretion	assay	performed	in	Drosophila[352].Malpighian	tubules	were	
dissected	with	intact	ureter.	One	end	of	the	tubule	was	then	wrapped	around	a	metal	pin	
and	the	other	end	was	immersed	in	Drosophila	saline:	Schneider’s.	Drops	emerging	from	
the	ureter	were	measured	every	10	min	over	a	period	of	1.5	h.			
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Figure 2-6 Fluid secretion assay schema (Dow et al., 1994b). 
Intact tubules are dissected along with their common ureter from the flies in Schneider’s 
medium using fine forceps (left panel). Tubule ureter is cut just before its joining with gut 
(middle pan l). One tubule is wrapped ar und the nee le and other tubule is in the 
Schneider:saline mix; all are immersed in the mineral oil (right panel; above). Finally tubule 
secreted droplets emanating from the ureter are measured using the microscope graticule 
and converted in to nl/min (right panel; below) 
2.26 [Ca2+]i measurements using recombinant aequorin 
Intracellular Ca2+ concentrations [Ca2+]i  were measured in tubules, using 
recombinant transgenic aequorin probes, according to the published protocols  
(Rosay et al., 1997; Southall et al., 2006). Briefly, 40 pairs of tubules ectopically 
expressing apo-aequorin were dissected, incubated at RT (in dark) with 2.5 µM 
coelenterazine to reconstitute aequorin for 3 h in a volume of 170 µl of 
Schneider’s medium. Then the Ca2+-dependent aequorin luminescence was 
measured using Lumat LB 9507 ultrasensitive luminometre (Berthold 
Technologies UK). At the end of each experiment, total aequorin was released 
using 300 µl of lysis buffer (1% (v/v) Triton X-100, 100 mM CaCl2) from tubules in 
order to calculate the total luminescence; and data were back-integrated using 
a program written in Perl, based on the method described by (Button and 
Eidsath, 1996).  
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2.14.2 	Collection	of	fluid	for	LC-MS	
For	the	metabolomics	analysis	using	LC-MS,	secretion	assay	was	set	up	as	described	
above.	Drops	emerging	from	the	ureter	were	removed	every	10	min	and	then	pulled	
together	and	collected	in	200	μl	LC-MS	solvent	mixture	(methanol:	chloroform:	water	
3:1:1).	Samples	were	stored	at	-80°C	before	LC-MS	analysis	was	performed.		
2.15 	Haemolymph	extraction	
Small	0.5	ml	ependorf	tubes	were	prepared	and	four	holes	were	made	in	the	bottom	of	
each	small	tube	using	0.8	x	40	mm	needle	(BD	Microlance,	UK).	A	drop	of	mineral	oil	was	
added	to	the	bottom	of	1.5	ml	tubes.		Small	tubes	were	placed	inside	1.5	ml	tubes	and	
placed	on	ice.	Thirty	flies	were	anaesthetised	under	CO2.	They	were	then	pierced	with	a	
0.45	x	12	mm	needle	(BD	Microlance,	UK)	between	the	thorax	and	the	abdomen	(below	
the	wing)	and	placed	in	prepared	tubes.	Samples	were	centrifuged	at	4°C	and	5000	rpm	
for	1	min.	This	was	repeated	until	5	μl	of	haemolymph	was	obtained	(around	4	times	and	
120	flies).	The	haemolymph	collected	in	the	mineral	oil	was	then	carefully	pipetted	using	
the	P2	pipette	and	transferred	to	200	μl	LC-MS	solvent	mixture	(methanol:	chloroform:	
water	3:1:1).	Samples	were	stored	at	-80°C	before	LC-MS	analysis	was	performed.		
2.16 	Metabolomics	analysis		
2.16.1 	Metabolite	extraction	
Samples	were	collected	of	male	and	female	fly	tissues	separately.	Five	whole	flies	or	60	
tubules	were	collected	in	1.5	ml	microcentrifuge	tubes	containing	250	μl	solvent	mixture	
of	methanol:	chloroform:	water	in	the	ration	of	3:1:1.	They	were	then	snap-frozen	in	
liquid	nitrogen,	crushed	with	micropestles	and	sonicated	for	20	sec	using	ultrasonic	cell	
disruptor.	Samples	were	centrifuged	for	10	min	at	10000	rpm	at	4°C.	The	supernatant	was	
transferred	to	a	fresh	tube	and	stored	at	-80°C.	Four	biological	replicates	were	prepared.	
Quality	control	samples	were	prepared	by	mixing	small	aliquots	of	each	sample.	Blanks	
were	also	prepared	by	using	solvent	mixture	on	its	own.		
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2.16.2 	Liquid	chromatography-Mass	spectrometry	(LC-MS)		
Samples	were	analysed	at	University	of	Glasgow	Polyomics	Facility	using	hydrophilic	
interaction	liquid	chromatography-mass	spectrometry.	The	instrument	used	was	
Orbitrap™	Exactive™	mass	spectrometer	combined	with	UltiMate™	3000	RSLC	(rapid	
separation	LC)	separation	system,	which	is	a	UHPLC	system.	The	LC	system	was	equipped	
with	a	150	x	4.6mm	ZIC-HILIC	column	running	at	300	μl/min,	and	the	separation	was	run	
in	binary	gradient	mode.	The	mobile	phase	conditions	were:	solvent	A	0.1%	formic	acid	in	
HPLC	grade	water	and	solvent	B	0.1%	formic	acid	in	acetonitrile;	80%	B	at	(0	min)	-	20%	B	
at	(30	min)	–	20%	B	at	(36	min)	–	80%	B	at	(37	min)	–	80%	B	at	(46	min).	10	μl	of	the	
sample	was	injected	onto	the	column.	The	mass	spectrometer	was	set	at	50,000	
resolution,	and	was	run	in	positive	and	negative	ionisation	modes.		
2.16.3 	Data	processing		
Raw	LC-MS	data	was	processed	using	the	IDEOM	application	(http://	
mzmatch.sourceforge.net/ideom.php)	and	default	parameters	[238].	The	application	
consists	of	XCMS	[228],	MzMatch	[239]	and	IDEOM	processing	[238]	(Figure	2-7).	XCMS	
and	MzMatch	were	run	in	R.	For	peak	detection,	XCMS	was	used	using	default	
parameters,	including	PPM	set	at	2,	and	peak	with	range	at	min	set	at	2	s	and	max	set	at	
100	s.	MzMatch	was	used	for	peak	matching	(among	the	replicates),	noise	filtering	and	
removal	(peak	shape,	reproducibility,	intensity,	number	of	detections),	gap	filling,	and	
related	peaks	annotation	(adducts,	isotopes,	fragments	etc.).	Finally,	IDEOM	tools	(in	MS	
Excel)	were	used	for	additional	filtering	(samples	allocation	to	experimental	groups,	
contaminant	filter	applied	to	blanks,	RSD	as	described	in	the	Introduction),	metabolite	
identification,	and	univariate	statistics	and	data	visualisation.	Thanks	to	data	export	tools	
in	IDEOM,	data	could	then	be	exported	for	further	analysis,	including	multivariate	
statistics	(R	algorithms,	Metaboanalyst),	pathway	analysis	(Metexplore,	Pathos),	etc.	
Statistical	and	pathway	analyses	performed	for	each	dataset	are	described	further	in	
Chapter	5.2.		 
Metabolite	identification	was	based	on	exact	mass	and	RTm,	where	authentic	standards	
were	available.	Otherwise,	putative	identification	was	based	on	exact	mass	and	predicted	
RTm.	Automated	RTm	prediction	was	performed	as	previously	described	in	[353].	All	
masses	where	within	3	ppm	of	the	exact	molecular	formula.	This	means	that	the	only	
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competing	metabolites	within	the	database	search	were	isomers.	Metabolite	levels	for	
each	experimental	group	were	expressed	as	mean	peak	intensity	(height)	relative	to	the	
mean	peak	intensity	of	the	control	group.	Metabolite	levels	were	coloured	according	to	
relative	intensity	(blue	=	low,	red	=	high).		
	
Fig.	2-7	IDEOM:	data	processing	pipeline	used	for	LC-MS	data	processing,	adapted	from	
[158].	Raw	LC-MS	data	was	uploaded	to	R	followed	by	peak	detection	using	XCMS,	data	
processing	steps	in	MzMatch	and	IDEOM,	resulting	in	metabolite	identification	and	data	
analysis	using	IDEOM	tools	as	well	as	external	tools.		
	
Data	obtained	at	Strathclyde	University	were	analysed	using	Xcalibur	software	combined	
with	Sieve	Software	1.3	(Thermo	Fisher	Co.).	Data	were	acquired	and	processed	using	
Xcalibur	software,	which	uses	three	user-created	files:	instrument	methods,	processing	
methods	and	sequences.	Instrument	methods	are	used	to	choose	chromatographic	and	
data	acquisition	settings	for	the	LC	and	the	MS	respectively.	Subsequently,	processing	
methods	are	used	to	analyse	the	raw	files.	These	include	peak	detection	parameters,	such	
as	baseline	settings	and	the	void	time	(the	elution	time	of	an	unretained	peak)	to	
	XCMS	
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•  Addi)onal	ﬁltering		
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calculate	the	relative	retention	time	of	peaks.	Finally,	sequences	specify	volumes	of	
injected	samples,	names	of	each	sample	and	sample	types,	including	QC	samples,	
standards	and	blanks.	Extracted	ion	chromatograms	were	analysed	using	Sieve	software,	
an	automated	data	mining	and	identification	tool.	Sieve	performs	statistical	analysis	using	
MS	intensities	from	raw	data	and	generates	P-values	for	each	metabolite.	Obtained	
features	were	identified	based	on	exact	mass	and	relative	retention	time.	They	were	then	
searched	against	a	database	of	accurate	masses	taken	from	KEGG	[323],	HMDB	[191,	242]	
and	Metlin	[224]	using	an	Excel-based	macro	written	‘in	house’	at	Strathclyde	University.	
Retention	times	of	some	metabolites	were	matched	to	retention	times	of	82	standards,	
which	were	run	in	the	same	experiment.	All	masses	where	within	1.5	ppm	of	the	exact	
molecular	formula.	
2.17 	CD-spectroscopy	
All	CD	(Circular	Dichroism)-spectroscopy	experiments	were	performed	at	the	Scottish	
Circular	Dichroism	Facility	(University	of	Glasgow).	The	system	contained	stopped	flow	
instrument	(Applied	Photophysics	SX.17MV,	SK.1E	and	CD.1C	components)	allowing	
recording	in	absorbance,	fluorescence	and	CD	modes,	a	JASCO	J-810	spectropolarimeter	
with	peltier	device	and	automatic	titrator	system	and	biologic	SFM20	stopped	flow	
instrument.	The	aperture	used	was	a	Jasco	J-810	spectropolarimeter	(Jasco	UK	LTD),	
equipped	with	an	additional	photomultiplier,	which	allows	data	collection	over	the	
wavelength	range	from	180	nm	to	1000	nm.		
CD	spectra	were	recorder	in	a	cell	of	0.5	cm	path	length	at	20°C.	The	readings	were	
obtained	over	the	wavelength	range	from	350	nm	to	204	nm,	data	pitch	of	0.2	nm,	band	
with	of	1	nm,	response	of	1	sec,	standard	sensitivity	and	scanning	speed	of	20	nm/min.	
2.18 	Bioinformatics	tools	for	CG30016	and	urate	oxidase	
sequence	analysis	
All	bioinformatics	analyses	were	performed	using	publically	available	tools.	Drosophila	
melanogaster	protein	sequences	were	obtained	from	FlyBase	(http://flybase.org).	
Sequences	of	other	species	were	from	UniProt	(http://www.uniprot.org).	Protein	BLAST	
(http://blast.ncbi.nlm.nih.gov/Blast.cgi)	was	performed	with	expected	threshold	of	100.	
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Sequence	alignments	were	carried	out	using	blastp	suite-2	sequences.	Pfam:	protein	
family	database	(http://pfam.xfam.org/search/sequence)	was	used	to	determine	protein	
family	signatures.	Intracellular	protein	localisation	was	predicted	using	PSORT	II	
Prediction	Tool	(http://psort.hgc.jp/cgi-bin/runpsort.pl).
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3 Urate	degradation	pathway	
3.1 Introduction	
Purine	metabolism	is	one	of	the	key	metabolic	pathways	involved	in	synthesis	and	
degradation	of	nucleic	acids	and	production	of	important	metabolites,	such	as	ATP	
(Adenosine	triphosphate)	[354].	Excessive	purines	are	broken	down	to	urate,	which	can	
be	secreted,	stored	or	converted	to	allantoin	via	the	urate	degradation	pathway.	Urate	
degradation	pathway	involves	three	reactions	that	can	occur	spontaneously	or	catalysed	
by	three	distinct	enzymes.	The	spontaneous	reaction	is	much	slower	(several	hours)	than	
the	enzymatic	one	and	gives	rise	to	racemic	allantoin	(R-allantoin)	[355,	356].	Enzymatic	
degradation	of	urate,	on	the	other	hand,	involves	its	stereo-specific	conversion	to	
dextrorotary	allantoin,	S-(+)-allantoin	on	a	time	scale	of	seconds.	There	are	three	
enzymes	responsible	for	this	conversion:	urate	oxidase	(UO),	5-hydroxyisourate	(5-HIU)	
hydrolase	and	2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline	(OHCU)	decarboxylase	
[102,	355,	357]	(Figure	3-1).		
	
Fig	3-1	Formation	and	breakdown	of	urate.	Degradation	of	purines	results	in	the	
production	of	xanthine,	which	gets	oxidised	by	xanthine	dehydrogenase	to	urate	1).	Urate	
is	subsequently	converted	by	urate	oxidase	to	5-HIU	2).	(a)	5-HIU	is	either	spontaneously	
degraded	to	OHCU	3)	and	R-allantoin,	which	takes	several,	or	(b)	converted	by	5-HIU	
hydrolase	to	OHCU	and	then	by	OHCU	decarboxylase	to	S-allantoin	4).	The	enzymatic	
conversion	of	urate	to	S-allantoin	takes	several	seconds.	Figure	adopted	from	[102].	
Urate	oxidase	catalyses	the	conversion	of	urate	to	metastable	5-hydroxyisourate	[356,	
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358].	5-HIU	hydrolase	is	responsible	for	stereo-specific	conversion	of	5-HIU	to	OHCU	
[359],	which	is	also	metastable.	OHCU	then	gets	broken	down	to	stable	S-allantoin	by	
OHCU	decarboxylase.	S-allantoin	can	be	converted	to	urea	via	two	enzymatic	reactions,	
catalysed	by	allantoinase	and	allantoicase.		
3.1.1 Evolution	of	urate	degradation	pathway	
Purine	metabolism	has	been	proposed	as	a	candidate	for	one	of	the	most	ancient	
pathways	on	the	planet	[360].	The	activity	of	urate	degradation	enzymes	has	been	lost	
and	gained	several	times	during	evolution	(at	least	five	independent	events),	with	parallel	
loss	or	gain	of	activity	of	all	enzymes	[102,	361].	As	a	result,	humans	and	other	hominoids,	
as	well	as	birds,	some	reptiles,	Dalmatian	dogs	and	several	bacterial	species,	are	not	able	
to	degrade	urate	and	are	prone	to	hyperuricemia	[118,	119].		
In	humans	and	other	hominoids	urate	degradation	enzymes	are	present	as	pseudogenes,	
i.e.	they	are	present	in	the	genome	but	do	not	produce	functional	proteins	[362].	
Inactivation	of	the	UO	gene	occurred	in	a	primate	ancestor	around	15	Myr	(million	years)	
ago,	which	resulted	in	their	inability	to	degrade	urate	[361].	Moreover,	human	5-HIU	
hydrolase	(5-HIUH)	gene	has	been	inactivated	by	several	independent	mutations,	
whereas	the	expression	of	OHCU	decarboxylase	gene	is	absent	[102].	In	several	bacterial	
species	urate	degradation	enzymes	are	not	present	in	the	genome,	whereas	in	other	
species	only	one	or	two	of	the	genes	are	present.	However,	wherever	UO	is	present,	at	
least	one	of	the	downstream	enzymes	is	also	present	(Figure	3-2).	This	is	surprising	
considering	that	5-HIU	and	OHCU	can	be	converted	spontaneously	to	R-allantoin.	One	of	
the	reasons	for	the	maintenance	of	5-HIU	hydrolase	and	OHCU	decarboxylase	could	be	
the	reaction	rate.	The	enzymatic	reaction	is	much	faster	than	the	spontaneous	reaction.	
Moreover,	the	spontaneous	reaction	results	in	the	formation	of	R-allantoin,	which	cannot	
be	used	as	substrate	for	allantoinase	[363,	364]	and	produce	urea.	Moreover,	only	S-
allantoin	has	been	observed	in	living	cells	[362].	R-allantoin	can	be	converted	to	S-
allantoin	in	a	separate	reaction	catalysed	by	racemase.	However,	it	takes	around	10	h	for	
this	reaction	to	take	place	[363].	Once	again,	the	enzymatic	reaction	would	be	favoured	in	
terms	of	its	rate.	Finally,	urate	degradation	intermediates	can	be	further	oxidised	to	yield	
reactive	chemical	species	[365].	Hence,	in	order	to	limit	their	lifetime,	the	enzymatic	
reaction	would	be	favoured.			
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Fig.	3-2	Phylogenetic	genome	comparison	of	urate	degradation	enzymes.	Urate	
degradation	enzymes	have	been	lost	and	gained	several	times	during	evolution.	They	are	
present	in	most	vertebrates,	bacteria	and	plants.	However,	they	are	absent	or	present	as	
pseudogenes	in	humans,	birds	and	several	species	of	bacteria.	Figure	adopted	from	[102].	
3.1.2 Drosophila	enzymes	involved	in	urate	degradation	pathway		
Drosophila	melanogaster	expresses	UO	and	5-HIU	hydrolase	and	hence	is	able	to	degrade	
urate	(Figure	3-2)	[102].	There	is	no	homologous	sequence	to	OHCU	decarboxylase	in	
Drosophila	genome.	Whereas	there	are	several	studies	confirming	the	structure	and	
function	of	UO	in	the	fly,	there	is	no	experimental	evidence	for	the	expression	of	
functional	5-HIU	hydrolase	in	the	fly	or	its	function	in	urate	degradation	pathway	[366-
371].	Based	on	sequence	homology,	Drosophila	CG30016	gene	codes	for	5-HIU	hydrolase	
(http://blast.ncbi.nlm.nih.gov).	Moreover,	functional	relationship	between	UO	and	
CG30016	has	been	suggested	by	Ramazzina	et	al.	due	to	correlated	gained	or	loss	of	
activity	of	these	two	genes	during	evolution	[102].	FlyAtlas	revealed	that	both	UO	and	
CG30016	are	enriched	in	MTs,	which	also	suggests	a	functional	relationship	between	the	
two	genes	[4,	6].	
One	possibility	is	that	Drosophila	gene	CG30016	encodes	functional	5-HIU	hydrolase,	
which	converts	5-HIU	to	OHCU,	which	spontaneously	degrades	to	R-allantoin.	Another	
possibility	is	that	CG30016	catalyses	both	reactions,	resulting	in	the	production	of	S-
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allantoin,	or	is	involved	in	another	metabolic	pathway	altogether.		
3.1.2.1 Drosophila	Urate	oxidase	
Drosophila	UO	has	been	extensively	studied	in	terms	of	its	structure,	function	and	
temporal	regulation	[366-371].	UO	gene	is	located	on	chromosome	2	[367]	and	UO	mRNA	
is	expressed	in	the	main	segment	cells	of	MTs	[369].	As	previously	mentioned,	UO	is	
expressed	almost	exclusively	in	the	MTs	[4,	6,	368]	(Figure	3-3),	where	it	localises	to	the	
peroxisome	[369].	Temporal	regulation	of	its	activity	is	tightly	controlled.	It	is	not	
detectable	in	L1	and	L2	larval	stages	or	pupae,	whereas	its	expression	is	the	highest	
during	L3	stage	and	detectable	in	adult	stages	[368,	370].	Sudden	decrease	in	UO	activity	
right	before	pupation	results	in	the	accumulation	of	urate	[367].	Research	suggests	that	
this	temporal	regulation	is	control	by	developmental	clock	in	the	MTs	as	well	as	
haemolymph	factors	[371].	Moreover,	there	is	evidence	suggesting	that	steroid	hormone	
20-hydroxyecdysone	represses	UO	activity	by	either	limiting	its	transcription	or	increasing	
degradation	of	UO	mRNA	[367].	Whereas	UO	expression	is	induced	by	urate	in	some	
microorganisms,	it	is	not	the	case	in	the	fruit	fly	[370].	Moreover,	its	activity	is	inhibited	
by	xanthine	and	hypoxanthine.		
	
Fig.	3-3	Tissues-specific	expression	of	Urate	oxidase	in	Drosophila	melanogaster.	Fly	UO	is	
almost	exclusively	expressed	in	MTs,	with	very	low	expression	in	the	fat	body,	salivary	
glands,	heart,	virgin	spermatheca,	accessory	glands	and	carcass.	Figure	adopted	from	
http://flyatlas.gla.ac.uk.		
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3.1.2.2 5-Hydroxyisourate	hydrolase		
5-Hydroxyisourate	hydrolase	has	been	studied	in	several	species	including	soybean	[102,	
359,	372],	mouse	[102,	118],	Aspergillus	nidulans	[373],	rainbow	trout	[374],	zebra	fish	
[375],	Salmonella	dublin	[376],	Escherichia	coli	[377,	378],	Cryptococus	neoformans	[379],	
Klebsiella	pneumoniae	[380],	South	American	opossum	[381],	the	platypus	[381],	
Caenorhabditis	elegans	[377],	Herbaspirillum	seropedicae	[382],	Branchiostoma	
japonicum	[383]	and	Bacillus	subtilis	[384].	With	exception	of	the	soybean	enzyme,	5-HIU	
hydrolase	is	a	member	of	transthyretin-related	protein	(TRP)	family.	TRPs	have	around	
30-40%	sequence	similarity	with	transthyretin,	vertebrate	transport	protein	of	the	thyroid	
hormone	and	retinol,	but	are	not	functionally	related	[377,	384,	385].	This	is	an	example	
of	divergent	evolution,	which	took	place	around	500-700	Myr	ago	[386-388].	It	has	been	
proposed	that	during	that	time	transthyretin	arose	as	a	result	of	gene	duplication	of	5-
HIU	hydrolase	gene	[102,	375].	As	a	result,	transthyretin	is	only	present	in	vertebrates,	
whereas	TRPs	are	present	in	bacteria,	plants	and	animals	[389,	390].	Both	proteins	have	a	
similar	homotetrameric	structure.	Moreover,	5-HIU	hydrolase	active	site	corresponds	to	
thyroid	hormone	binding	site	of	transthyretin	[376].	As	opposed	to	transthyretin,	TRPs	do	
not	bind	thyroid	hormone	[377].	However,	single	or	multiple	mutations	in	TRP	active	site	
have	been	shown	to	abolish	5-HIU	hydrolase	activity	and	result	in	thyroid	hormone	
binding	[375].	General	characteristics	of	TRP	family	are	summarised	in	Table	3-1.		
Table	3-1	Characteristic	TRP	features.	
TRP	feature		 Description	
Protein	size	 Around	120	amino	acids	
Sequence	similarity	to	transthyretin		 30-40%	
C-terminal	tetrapeptide	sequence		 Y-R/K-G-S/T	-	part	of	the	active	side		
Conserved	residues	 His-14,	Arg-49,	His-105	
Tertiary	structure	 Two	β-sheets	and	one	short	α-helix	
Quaternary	structure	 Homo-tetramer 
	
In	terms	of	cellular	localization,	5-HIU	hydrolases	can	be	divided	into	three	different	
groups.	Peroxisomal	enzymes	contain	N-terminal	peroxisomal	targeting	signal	2	(PTS2)	
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with	a	consensus	of	RLX2LX2HL,	and	are	mostly	found	in	plants	and	most	metazoans	[102,	
391,	392].	Peroxisomal	localisation	is	consistent	with	5-HIU	hydrolase	role	in	urate	
degradation	pathway,	as	UO	also	localises	to	the	peroxisome.	The	second	group	
comprises	cytoplasmic	enzymes,	which	lack	any	signal	signature	[377,	393,	394].	This	is	
usually	the	case	for	bacterial	5-HIU	hydrolases.	The	third	group	represents	periplasmic	
proteins,	which	are	found	in	enterobacteria	[388].		
As	previously	mentioned,	soybean	5-HIU	hydrolase	is	not	related	to	TRPs	and	shares	no	
sequence	similarity	with	5-HIU	hydrolases	of	other	species	[395].	The	soybean	enzyme	is	
a	member	of	family	one	glycosidases,	which	suggests	it	emerged	through	a	different	
evolutionary	event	[359,	372].	In	fact,	purine	metabolism	of	leguminous	plants	is	distinct	
from	other	species	and	is	not	well	defined	[119].		Moreover,	there	is	another	protein	in	
soybean	identified	as	TRP,	which	does	not	have	5-HIU	hydrolase	activity	[395].	
3.2 Results	
3.2.1 Drosophila	melanogaster	CG30016	gene	
Drosophila	CG30016	is	expressed	almost	exclusively	in	the	MTs	[4,	6,	368]	(Figure	3-4),	
which	is	consistent	with	the	expression	of	the	upstream	Drosophila	enzyme,	UO,	and	
suggests	functional	correlation.	Moreover,	it	exhibits	features	consistent	with	TRPs	as	
well	as	5-HIU	hydrolase.	It	is	113	amino	acids	long	and	contains	the	C-terminal	YRGS	
tetrapeptide	and	conserved	residues	characteristic	to	TRPs.	It	shares	sequence	homology	
with	5-HIU	hydrolases	of	other	species	and	has	transthyretin	and	5-HIU	hydrolase	
domains	(http://www.ncbi.nlm.nih.gov).	
	
	98	
	
Fig.	3-4	Tissue-specific	expression	of	CG30016	in	Drosophila	melanogaster.	CG30016	is	
almost	exclusively	expressed	in	MTs,	with	low	expression	in	the	hindgut,	fat	body,	carcass	
and	larval	trachea.	Figure	adopted	from	http://flyatlas.gla.ac.uk.		
	
A	sequence	alignment	of	the	fly	CG30016	gene	with	experimentally	confirmed	5-HIU	
hydrolases	of	other	species	was	performed	using	protein	BLAST	(blastp-2	sequences).	The	
alignment	revealed	30-41%	sequence	similarity	to	5-HIU	hydrolases	and	presence	of	
conserved	amino	acids	in	CG30016	gene,	specifically	C-terminal	YRGS,	His-14,	Arg-49	and	
His-105	(mouse	numbering)	(Figure	3-6).	CG30016	was	also	aligned	with	mouse	and	
human	transthyretin	genes	(Figure	3-5).	This	revealed	sequence	identities	of	24%	(E	value	
=	4e-05)	and	23%	(E	value	=	5e-09)	to	human	and	mouse	gene	respectively.	Finally,	Pfam	
(http://pfam.xfam.org/search/sequence),	the	protein	family	database	that	uses	multiple	
sequence	alignment,	was	used	to	establish	whether	CG30016	belongs	to	a	known	protein	
family.	The	search	revealed	that	the	Drosophila	protein	has	the	transthyretin	family	
signature	(HIUase/transthyretin	family)	and	the	E	value	was	4.8e-33.	Altogether,	these	
results	show	that	Drosophila	CG30016	gene	is	related	to	transthyretin	protein	family	and	
hence	has	a	common	ancestor	with	transthyretin.		
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Fig.	3-5	Sequence	alignment	of	CG30016	with	mouse	(A)	and	human	(B)	transthyretin	
genes.	CG30016	has	(A)	23%	sequence	identities	with	mouse	transthyretin,	E	value	=	5e-09	
and	(B)	24%	sequence	identity	with	human	transthyretin,	E	value	=	4e-05.		
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Fig.	3-6	Similarity	metrics	of	CG30016	gene	with	5-HIU	hydrolases	from	other	species,	
revealing	30-41%	sequence	identity.	E-values	for	each	species	are	also	provided.		
	
Finally,	CG30016	gene	was	aligned	with	soybean	5-HIU	hydrolase	in	order	to	establish	
whether	the	fly	protein	was	related	to	TRPs	or	family	one	glycosidases.	The	alignment,	
showed	no	sequence	similarity	between	the	two	genes	with	E	value	of	5.4	(Figure	3-7),	
suggesting	they	are	not	related.	Moreover,	protein	BLAST	search	revealed	that	the	
soybean	enzyme	had	33%	sequence	similarity	with	other	Drosophila	gene,	which	is	not	
related	to	urate	degradation	pathway.		
	 101	
Fig.	3-7	Sequence	alignment	of	CG30016	with	soybean	5-hydroxyisourate	hydrolase.	Very	
little	sequence	similarity	was	revealed	between	the	two	proteins	with	the	E	value	of	5.4,	
suggesting	that	the	proteins	are	not	related.		
	
Based	on	its	sequence,	it	is	not	clear	where	CG30016	localises	to	in	the	cell.	It	lacks	N-
terminal	peroxisomal	targeting	signal	2	(PTS2),	which	suggests	it	is	not	a	peroxisomal	
enzyme.	Moreover,	intracellular	localization	was	predicted	based	on	the	presence	of	
signal	peptides	using	PSORT	II	Prediction	Tool	(http://psort.hgc.jp/cgi-bin/runpsort.pl).	
This	revealed	that	CG30016	is	most	likely	a	cytoplasmic	protein	(Figure	3-8).	However,	
absence	of	signaling	peptide	does	not	confirm	or	refute	localization	of	a	protein.		
	
Fig.	3-8	Prediction	of	intracellular	localisation	of	CG30016.	Localisation	of	CG30016	is	most	
likely	cytoplasmic.		
	
3.2.2 Drosophila	CG30016	and	Urate	oxidase	mutants	
In	order	to	study	the	function	of	Drosophila	CG30016	and	uro	genes,	mutant	flies	thought	
to	lack	CG30016	or	UO	activity	were	obtained	from	Bloomington	Stock	Centre	(see	Table	
2-1	for	details	of	fly	lines	ordered).	In	order	to	validate	deletion	lines,	qPCR	was	
performed	using	CG30016	and	UO	primers	(see	Appendix	II	for	primer	sequences).	
Control	line	(BDSC	1776)	was	selected	with	the	same	genetic	background	as	the	mutant	
lines.	BDSC	17767	flies	have	the	same	P	element	(PiggyBac)	as	mutant	flies,	inserted	in	
the	intron	region	of	hbs	gene	without	affecting	its	expression.	This	was	confirmed	using	
qPCR	and	by	comparing	hbs	expression	in	Canton	S	wild-type	flies	and	BDSC	17767	flies	
(Figure	3-9).	Absolute	percentage	hbs	expression	in	BDSC	17767	flies	was	87.75	±	5.7,	and	
there	was	no	statistically	significant	difference	in	the	expression	between	BDSC	17767	
and	Canton	S	(CS)	flies.		
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Fig.	3-9	Expression	of	hbs	gene	in	BDSC	17767	line	(control	flies).	A	qPCR	was	run	and	hbs	
expression	in	BDSC	17767	flies	was	compared	to	Canton	S	flies.	There	was	no	significant	
change	in	the	expression	levels	of	hbs	between	these	two	lines,	validating	BDSC	17767	as	a	
good	control	for	subsequent	experiments.		
Having	validated	BDSC	17767	line	as	a	control	with	the	same	genetic	background	and	not	
disrupting	expression	of	any	Drosophila	genes,	qPCR	was	performed	to	confirm	BDSC	
18554	and	BDSC	18814	deletion	lines	using	RNA	extracted	from	adult	Malpighian	tubules.	
The	expression	levels	were	monitored	and	represented	as	values	of	0.0	–	1.0,	with	1.0	
corresponding	to	100%	expression.	Absolute	knockdown	of	CG30016	for	BDSC	18554	was	
0.073	±	0.004	(t-test,	P	<	0.0001),	whereas	knockdown	of	UO	for	BDSC	18814	was	0.11	±	
0.013	(t-test	<	0.005).	The	results	are	illustrated	in	Figure	3-10.		
	
Fig.	3-10	QPCR	validation	of	mutant	flies	BDSC	18554	and	BDSC	18814;	gene	expression	
was	compared	to	BDSC	17767	control	flies	and	expressed	as	0.0	–	1.0,	with	1.0	
corresponding	to	100%	expression.	(A)	Expression	of	CG30016	gene	in	BDSC	18554	line	
Ca
nto
n&S
&&
BD
SC
&17
76
7&&&
0
50
100
150
%
&e
xp
re
ss
io
n
BD
SC
 17
76
7 (
co
ntr
ol)
  
BD
SC
 18
81
4 (
mu
tan
t) 
0.0
0.5
1.0
1.5
ur
at
e&
ox
id
as
e&
ex
pr
es
sio
n
BD
SC
 17
76
7  
(co
ntr
ol)
BD
SC
 18
55
4 (
mu
tan
t)
0.0
0.5
1.0
1.5
CG
30
01
6!
ex
pr
es
sio
n
A" B"
	 103	
showing	over	99%	knockout	of	CG30016	(t-test,	P<0.0001)	(B)	Expression	of	UO	gene	in	
BDSC	18814	line	confirming	over	85%	knockout	of	urate	oxidase	(t-test,	P<0.005).		
3.2.3 CG30016	and	Urate	oxidase	expression	at	different	developmental	
stages	in	Drosophila	larvae	
As	previously	mentioned,	UO	is	not	expressed	in	Drosophila	larvae	before	L3	stage.	In	
order	to	confirm	that	this	is	also	the	case	in	studied	fly	lines,	PCR	was	performed	using	
DNA	templates	from	different	larval	stages	(L1-L3).	Results	are	illustrated	in	Figure	3-11	
and	confirm	that	UO	is	not	expressed	in	larvae	before	L3E	stage	in	control	flies.	Moreover,	
it	is	not	expressed	in	CG30016	mutant	until	L3	stage,	where	its	expression	appears	to	be	
reduced	compared	to	the	control	line.	This	suggests	that	CG30016	knockdown	in	BDSC	
18554	line,	also	affects	the	expression	of	UO.		
To	test	whether	CG30016	has	the	same	expression	pattern	during	larval	development,	
PCR	was	also	performed	using	CG30016	primers.	As	opposed	to	UO	expression,	CG30016	
is	present	at	all	larval	stages.	However,	its	expression	appears	to	be	the	highest	in	L3	
larvae.	Moreover,	there	is	no	difference	in	CG30016	expression	levels	between	the	
control	and	UO	mutant.	This	suggests	that	UO	knockdown	has	no	effect	on	CG30016	
expression.	Tubulin	expression	was	monitored	to	provide	a	loading	control.		
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Fig.	3-11	Expression	of	UO	and	CG30016	genes	throughout	larval	development.	PCR	was	
performed	and	gene	expression	was	monitored	in	control	flies	(BDSC	17767),	CG30016	
deletion	flies	(BDSC	18554)	and	UO	deletion	flies	(BDSC	18814).	Tubulin	expression	was	
monitored	as	a	loading	control.	L1	–L3	represent	different	larval	developmental	stages	(see	
Table	2-2	for	details).		
3.2.4 Expression	of	CG30016	and	Urate	oxidase	in	mutant	L3	larvae		
Following	from	the	PCR	results	and	the	observation	that	both	CG30016	and	UO	are	
expressed	at	high	levels	in	L3	larvae,	qPCR	was	performed	to	validate	these	results	in	
whole	L3	larvae.	Absolute	knockdown	value	of	CG30016	for	BDSC	18554	was	0.034	±	0.05	
(t-test,	P	<	0.0001),	whereas	for	BDSC	18814,	it	was	0.87	±	0.08	(not	statistically	
significant)	(Figure	3-12	A).		
Expression	values	of	UO	were	0.17	±	0.01	and	0.01	±	0.01	for	BDSC	18554	and	BDSC	
18814	respectively	with	P	<	0.0001	(Figure	3-12	B).		
These	results	confirm	that	both	UO	and	CG30016	are	expressed	in	control	L3	larvae.	
Moreover,	the	expression	of	UO	is	affected	by	the	knockout	of	CG30016,	whereas	the	
opposite	is	not	the	case.	Knocking	out	of	CG30016	significantly	reduced	the	expression	of	
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Fig.	3-12	Expression	of	UO	and	CG30016	genes	in	L3	mutant	larvae.	(A)	Expression	of	
CG30016	in	UO	and	CG30016	deletion	larvae	compared	to	BDSC	17767	larvae,	confirming	
over	90%	knockout	of	CG30016	(t-test,	P<0.0001)	in	BDSC	18554	line.	No	significant	change	
in	expression	of	CG30016	was	observed	in	BDSC	18814	larvae	(B)	Expression	of	UO	in	UO	
and	CG30016	deletion	flies,	confirming	over	90%	knockout	of	uro	(t-test,	P<0.0001)	in	BDSC	
18814	line,	as	well	as	over	80%	knockout	of	uro	(t-test,	P<0.0001)	in	BDSC	18554	line.		
3.3 Discussion	
The	results	suggest	that	Drosophila	gene	CG30016	codes	for	5-HIU	hydrolase.	Sequence	
analysis	of	CG30016	revealed	that	it	is	related	to	TRPs	and	homologous	to	5-HIU	
hydrolases	of	other	species.	However,	it	is	not	related	to	soybean	5-HIU	hydrolase,	which	
is	thought	to	be	a	member	of	family	one	glycosidases	[359].	Interestingly,	another	
Drosophila	gene,	CG33964,	has	been	previously	reported	as	a	member	of	TRP	family,	
based	on	its	sequence	[377].	However,	looking	at	our	results,	it	is	clear	that	CG30016	is	a	
more	likely	candidate	for	a	TRP	due	to	higher	sequence	similarity,	presence	of	conserved	
residues	and	its	enrichment	in	MTs.		
TRPs	and	transthyretin	are	an	interesting	case	of	divergent	evolution.	Transthyretin	
domain	evolved	from	5-HIU	hydrolase	[375,	388].	Even	though	the	two	types	of	protein	
have	a	completely	different	function,	and	transthyretin	is	only	present	in	vertebrates,	
they	exhibit	high	sequence	homology	and	have	similar	structure	and	functional	domains.	
5-HU	hydrolase	does	not	bind	thyroid	hormone	[377].	However,	single	or	multiple	
nucleotide	substitutions	in	the	active	site	have	been	shown	to	result	in	thyroid	hormone	
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binding	[375].	Insects	and	other	invertebrates	do	not	produce	thyroid	hormone.	Hence,	it	
is	interesting	to	see	that	they	produce	a	protein	so	closely	related	to	transthyretin,	which	
has	no	functional	significance	in	these	species.		
Based	on	its	sequence,	it	is	not	clear	which	cellular	compartment	CG30016	localises	to.	It	
does	not	have	any	known	signal	peptides	and	hence	has	been	hypothesised	to	localise	to	
the	cytoplasm.	Interestingly,	in	rainbow	trout,	5-HIU	hydrolase	localizes	to	the	cytoplasm,	
even	though	it	contains	PTS2	signal	[374].	This	suggests	that	5-HIU	hydrolase	localization	
might	depend	on	various	different	factors	rather	than	solely	the	presence	of	a	signal	
sequence.	Moreover,	several	peroxisomal	proteins	have	been	identified,	which	did	not	
have	a	known	signal	peptide,	suggesting	a	unique	means	of	targeting[394].	Hence,	it	
requires	further	studies	to	determine	the	intracellular	localization	of	the	protein	encoded	
by	CG30016.		
Further	experimental	evidence	is	required	to	confirm	the	role	of	CG30016	as	5-
hydroxyisourate	hydrolase.	Here,	we	proposed	the	reverse	genetics	approach,	where	the	
function	of	the	gene	is	investigated	by	studying	the	effects	of	its	knockout.	CG30016	and	
UO	knockout	flies	were	obtained	from	stock	centres	and	validated.	Two	controls	were	
also	selected:	wild-type	Canton	S	flies	as	well	as	flies	with	the	same	genetic	background	as	
mutants.		
Finally,	the	results	confirmed	that	UO	is	only	expressed	in	L3	and	adult	stages	of	
Drosophila.	Hence,	all	our	studies	were	conducted	using	either	L3	larvae	or	adult	flies.	We	
also	showed	that	UO	expression	is	affected	by	the	knockout	of	CG30016.	Expression	of	
UO	was	significantly	reduced	in	CG30016	knockout	larvae.	This	could	be	a	result	of	a	
feedback	mechanism,	where	CG30016	or	products	of	a	reaction	it	catalyses	are	required	
for	the	transcription	of	UO,	or	the	substrate	of	a	reaction	it	catalyses	inhibits	UO	
transcription.	For	example,	whenever	CG30016	is	absent,	it	results	in	built	up	of	5-HIU.	In	
turn,	there	is	no	need	for	the	conversion	of	urate	to	5-HIU,	and	UO	transcription	is	
repressed.	To	test	this,	further	experimental	evidence	is	required.	The	correlation	
between	expression	of	UO	and	CG30016	also	confirms	that	the	two	genes	are	functionally	
related	and	strengthens	our	hypothesis	that	CG30016	is	involved	in	urate	degradation	
pathway	as	5-HIU	hydrolase.	
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4 Phenotypic	manifestations	in	Drosophila	
melanogaster	mutants	of	urate	degradation	
pathway		
4.1 Introduction	
Manipulations	of	Drosophila	genes	have	been	shown	to	result	in	various	phenotypic	
manifestations	including	MTs	phenotypes	[65-68],	bloated	abdomen	[69],	antennae	and	
bristle	phenotype	[70],	altered	fluid	secretion	rate	[71-74],	and	altered	longevity	and	
survival	in	different	stress	conditions	[75,	76].	In	this	chapter,	the	effects	of	CG30016	and	
UO	knockout	mutants	on	Drosophila	melanogaster	phenotype	are	evaluated.		
4.1.1 Drosophila	melanogaster	Malpighian	tubules		
Fruit	flies	have	two	pairs	of	Malpighian	tubules	(anterior	and	posterior	tubules),	each	pair	
connected	to	the	hindgut	of	the	alimentary	canal	via	a	ureter	(Figure	4-1).	Two	tubule	
pairs	are	asymmetrical	and	are	morphologically	and	functionally	distinct	[352,	396].	
Anterior	tubules	have	an	enlarged	initial	segment,	which	is	responsible	for	Ca2+	titreing.	
Posterior	tubules,	on	the	other	hand,	have	a	smaller	initial	segment.	In	terms	of	their	
function,	anterior	tubules	are	involved	in	immune	defence	and	handling	of	calcium	ions.	
Posterior	tubules	play	a	role	in	ammonia	generation	[396].	Drosophila	tubules	are	
composed	of	around	150	specialised	excretory	cells	[397].	Moreover,	the	main	segment	
of	the	tubules	consists	of	two	cell-types:	principal	and	stellate	cells	[352,	398].	They	differ	
in	terms	of	morphology	and	function;	principal	cells	are	responsible	for	electrogenic	
cation	transport,	whereas	stellate	cells	play	a	role	in	anion	conductance	[69].	
Main	physiological	function	of	MTs	is	generation	and	reabsorption	of	primary	urine,	
regulation	of	ions	and	acid-bases,	as	well	as	excretion	of	waste	and	toxins.	Moreover,	
tubules	have	been	shown	to	play	a	role	in	immunity,	osmoregulation,	metabolism	and	
xenobiotic	excretion	[397,	399].		
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Fig	4-1	Drosophila	melanogaster	morphology.	(A)	Two	pairs	of	Malpighian	tubules	(blue,	
marked	with	arrows)	are	connected	to	the	hindgut	(orange)	via	a	ureter.	Tubule	pairs	are	
asymmetrical;	the	anterior	tubule	(right)	is	wrapped	around	the	midgut;	the	left	pair	is	
directed	posteriorly.	Adopted	from	[396]	(B)	Morphology	of	the	adult	Drosophila	
melanogaster	Malpighian	tubules.	Anterior	tubule	(top)	has	an	enlarged	initial	segment	
and	the	posterior	tubule	(bottom)	has	a	smaller	initial	segment.	Adopted	from	[36].			
4.1.1.1 Waste	and	fluid	secretion		
Terrestrial	insects,	including	Drosophila	melanogaster,	eliminate	nitrogenous	waste	
products	as	urate	[68].	This	strategy	has	been	developed	to	preserve	water	in	these	
species.	Soluble	urate	is	transported	to	the	MT	lumen,	where	it	gets	acidified	and	forms	
uric	acid	crystals	[400].	The	crystals	can	be	visualised	due	to	their	birefringent	property	
under	polarized	light	[401].	UO	can	further	degrade	urate	as	described	in	Section	3.1.2.1.	
However,	due	to	temporal	regulation	of	its	activity	(UO	is	not	detectable	in	L1	and	L2	
larval	stages	or	pupae	[368,	370]),	urate	crystals	can	be	observed	in	the	tubule	lumen	of	
wild	type	pupae,	L1,	L2	and	L3E	larvae	but	not	L3	larvae	and	adult	flies.		
Drosophila	tubules	have	been	used	as	a	model	of	insect	fluid	secretion	[352].	They	are	a	
remarkable	transporting	epithelium;	with	the	highest	per-cell	transport	rate	known	in	
nature	[69].	Moreover,	it	is	possible	to	study	fluid	secretion	in	dissected	fly	tubules	for	
over	5	h	from	dissection,	which	makes	the	tissue	particularly	suitable	as	a	model	for	fluid	
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secretion	[352].	Previous	studies	showed	that	different	factors,	including	gene	
manipulation,	can	influence	fluid	secretion	rate	or	even	arrest	the	process	altogether	[71-
74].		
4.1.1.2 Tubule	phenotypes	
Manipulation	of	genes	enriched	in	Drosophila	Malpighian	tubules	has	been	shown	to	
result	in	various	MTs	phenotypes.	Bloated	tubule	phenotype	has	been	reported	in	fly	
mutants	for	blot	gene	[65].	This	was	a	result	of	morphological	distortion	of	the	apical	
membrane	of	MT	cells	in	these	flies	and	the	tubules	had	bloated	appearance.	Similar	
bloated	phenotype	was	observed	in	Drosophila	maroon-like	mutants	[103].	Moreover,	
rosy	knockout	in	flies	resulted	in	xanthine	oxidase/dehydrogenase	inactivation	(an	
enzyme	in	purine	metabolism	directly	upstream	from	UO)	and	accumulation	of	xanthine,	
2-	amino-4-hydroxypteridine	and	hypoxanthine	[62,	402].	Hypoxanthine	enrichment	led	
to	calculi	formation	in	the	MTs	resulting	in	their	bloating	and	distortion	[104,	403].		
Another	phenotype	observed	in	Drosophila	MTs,	is	urate	crystals	accumulation	in	L3	
larvae	and	adult	flies.	Moreover,	accumulation	of	urate	crystals	has	been	reported	in	UO	
mutant	flies	[404]	On	the	other	hand,	transparent	tubule	phenotype	has	also	been	
reported	in	Drosophila	melanogaster	[67].	It	has	been	associated	with	mutations	in	V-
ATPase	(vha55)	and	related	proteins	[67,	68,	405].	These	mutants	fail	to	accumulate	urate	
crystals	in	embryos,	when	their	presence	is	expected.	The	phenotype	has	been	described	
as	the	loss	of	birefringence	in	the	tubule	lumen	[406]	and	has	been	associated	with	
urinary	acidification	defect	[67,	68,	405,	407].	Moreover,	further	research	has	shown	that	
a	mutation	in	the	human	B1	subunit	of	the	V-ATPase	results	in	renal	tubular	acidosis	
[408].	This	observation	of	urate	crystals	presence/lack	formation	is	possible	due	to	
tissue’s	transparency.		
Several	other	tubule	phenotypes	were	previously	described	[66].	These	were	mostly	
related	to	tubule	development	and	altered	morphology	caused	by	disruption	of	
transcription	regulation.	For	example,	rib	and	raw	mutants	are	thought	to	alter	MT	shape	
due	to	interruption	of	early	stages	of	tubule	development	[409].	Moreover,	wingless	
mutant	exhibits	wrong	number	of	MTs	[410].			
4.1.1.3 Tubules	in	biomedicine		
As	described	in	Chapter	1.2	Drosophila	melanogaster	has	been	extensively	applied	as	a	
model	for	studying	human	physiology	and	disease.	Even	though	Drosophila	tubules	differ	
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structurally	from	mammalian	kidneys,	they	are	functionally	analogous	[63,	397].	Both	
human	kidney	and	fly	tubules	excrete	waste	products,	produce	urine	and	have	similar	
transporters.	Moreover,	FlyAtlas	revealed	that	a	large	number	of	genes	enriched	in	MTs	
are	homologs	of	human	disease	genes	involved	in	kidney	disease	and	IEMs	(described	in	
more	detail	is	Chapter	1.3.1)	[6,	397,	411],	for	example	vacuolar-type-ATPases	(V-
ATPases),	Na+/K+-ATPase,	aquaporins	and	several	ion	channels	and	transporters	[63].	
Some	of	these	genes	have	been	extensively	studied	and	Drosophila	disease	models	
experimentally	confirmed	[62,	63,	99-101,	397,	412-416]	(Table	4-1).	For	example,	kidney	
stone	formation	has	been	recently	studied	in	fly	tubules.	This	is	possible	due	to	MTs	being	
transparent,	which	allows	real-time	observation	of	stone	formation	and	growth	of	oxalate	
crystals	[417,	418].	Finally,	MTs	can	be	easily	dissected	and	remain	physiologically	active	
for	several	hours	after	dissection.	This	makes	the	tissue	particularly	suitable	for	
biomedical	research.		
Table	4-1	Human	kidney	diseases	modelled	in	Drosophila	and	fly	genes	homologous	to	
human	genes	associated	with	the	disease.		
Human	kidney	disease	 Drosophila	gene	
Xanthinuria	type	I		 rosy	
Xanthinuria	type	II	 maroon-like	
Bartter	syndrome	types	3	and	4	 CG31116	
Bartter	syndrome	type	2	 ir	
Colchicine	resistance	 CG10226		
Renal	tubular	acidosis	 vha55	
4.1.2 Physiological	role	of	urate		
As	described	in	Section	3.1.1,	the	ability	to	degrade	urate	has	been	lost	and	gained	
several	times	during	evolution	[102,	361].	As	a	result,	urate	is	the	final	product	of	purine	
metabolism	in	humans	and	other	hominoids,	as	well	as	birds,	some	reptiles,	Dalmatian	
dogs	and	several	bacterial	species	[118,	119].	Fruit	flies,	on	the	other	hand,	as	well	as	
other	species,	can	degrade	urate	to	allantoin	and	then	to	urea	[102].	Due	to	inability	to	
degrade	urate,	humans	are	susceptible	to	hyperuricemia	[118,	119].	However,	it	has	been	
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proposed	that	increased	concentration	of	serum	urate	has	an	evolutionary	advantage	
[419-421].	On	the	other	hand,	urate	has	also	been	reported	to	induce	oxidative	stress	in	
certain	conditions	and	lead	to	disease	[111,	113-115,	422-427].		
4.1.2.1 Benefits	of	uric	acid	
According	to	the	oxidative	stress	theory	of	aging,	free	radicals	lead	to	cellular	damage,	
which	if	unrepaired,	results	in	aging	and	death	[428,	429].	Moreover,	ROS	have	been	
suggested	to	contribute	to	cancer	and	cardiovascular	disease.	Uric	acid	has	been	shown	
to	act	as	a	powerful	antioxidant	[419,	421]	and	a	scavenger	of	reactive	oxygen	species	
[119,	420,	430,	431].	Its	anti-oxidative	properties	prevent	oxidative	damage	of	
macromolecules	[421,	432].	As	a	result,	uric	acid	has	been	associated	with	greater	
longevity	of	invertebrates	[433]	and	mammals	[434],	including	primates	[420].	Previous	
research	has	also	suggested	that	it	has	a	preventive	role	in	cancer	and	cardiovascular	
disease	[420,	421,	435].	As	a	result,	animals	with	high	urate	concentration	in	the	blood	
stream	(including	humans)	are	more	likely	to	have	increased	life-span	[420].	
Studies	in	Drosophila	melanogaster	showed	that	rosy	mutants,	which	do	not	produce	
urate,	are	hypersensitive	to	oxidative	stress	(induced	by	paraquat),	confirming	urate	role	
as	an	antioxidant	[76,	430,	436-438].	Moreover,	flies	unable	to	synthesise	urate	showed	a	
shortened	life-span	as	compared	to	the	wild	type	flies	[430].	Interestingly,	ROS	levels	
have	been	shown	to	increase	during	aging	[439].	Altogether,	these	studies	suggest	that	
urate	acts	as	an	antioxidant	in	fruit	flies	and	as	a	result	extends	life	span.		
4.1.2.2 Urate	as	an	inducer	of	oxidative	stress	
On	the	other	hand,	uric	acid	has	been	associated	with	increased	oxidative	stress	and	
disease	[111,	113-115,	422-427].	Abnormally	high	serum	urate	in	humans	results	in	
hyperuricemia,	which	is	associated	with	gout	and	insulin	resistance	[111-115].	Moreover,	
uric	acid	is	thought	to	play	a	role	in	cardiovascular	disease,	hypertension	and	metabolic	
syndrome	[422,	423].		
Previous	research	showed	that	uric	acid	increases	the	production	of	ROS	and	induces	
oxidative	damage	[425,	427].	One	of	the	explanations	for	this	is	the	fact	that	production	
of	urate	is	catalyzed	by	xanthine	dehydrogenase.	During	this	reaction	ROS	are	generated	
as	by	product	[117,	440,	441].	Another	study	suggests	that	urate	becomes	pro-oxidative	
when	it	reacts	with	other	oxidants	[423].	There	are	currently	no	studies	on	negative	
effects	of	urate	in	Drosophila	melanogaster.	
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4.2 Results	
By	knocking	out	CG30016	and	UO	genes	in	Drosophila,	we	expected	to	disrupt	its	ability	
to	degrade	urate.	We	expected	to	observe	certain	phenotypic	manifestations	of	these	
mutations	related	to	urate	accumulation,	including	urate	crystals	formation,	MT	
phenotype,	altered	survival	and	longevity.	Since	CG30016	mutant	flies	are	deficient	in	
both	CG30016	and	UO,	UO	mutant	was	used	as	a	control	to	distinguish	between	
phenotypes	associated	with	UO	knockout	and	not	CG30016	knockout	alone.		
4.2.1 Urate	crystals	
Mutant	flies	including	BDSC	18814	and	BDSC	18554	were	compared	to	Canton	S	wild-type	
flies	as	well	as	BDSC	17767	control	flies.	L1-L3	larvae	were	dissected	and	their	Malpighian	
tubules	observed	using	light	and	polarised	light	microscopy.	Polarised	light	microscopy	
allows	visualisation	of	urate	crystals	due	to	their	birefringent	property	[401].			
Urate	crystals	were	present	in	both	anterior	and	posterior	tubules	of	Cantos	S	L1,	L2	and	
L3E	larvae	but	not	in	L3	larvae	(Figure	4-2).	This	is	consistent	with	UO	expression	at	
different	larval	stages.	UO	is	not	expressed	during	L1	and	L2	stages,	and	it	is	only	
expressed	at	low	levels	during	L3E	stage.	However,	it	is	expressed	in	L3	larvae.	Hence,	no	
urate	crystals	in	both	posterior	and	anterior	tubules	are	present	at	this	developmental	
stage.	Interestingly,	more	crystals	were	observed	in	the	posterior	tubule	of	Canton	S	
larvae.		
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Fig.	4-2	Malpighian	tubules	of	Drosophila	Cantos	S	L1-L3	larvae	and	urate	crystals.	(A)	
Malpighian	tubules	of	L1-L3	Canton	S	larvae	visualised	using	light	microscopy	(B)	L1-L3	
tubules	of	Canton	S	flies	visualised	using	polarised	light	microscopy.	Urate	crystals	are	
present	in	L1,	L2	and	L3E	larval	stages	due	to	the	absence	of	UO	activity.	There	are	no	
crystals	observed	in	L3	larvae	as	UO	is	expressed	at	this	stage.		
	
In	BDSC	17767	control	larvae,	urate	crystals	were	present	in	both	posterior	and	anterior	
tubules	of	L1-L3E	larvae	(Figure	4-3).	Moreover,	in	contrast	to	Canton	S	flies,	crystals	were	
also	observed	in	the	anterior	tubule	of	L3	larvae.	This	is	not	consistent	with	the	
expression	patterns	of	UO	at	different	larval	stages	and	is	somewhat	puzzling.	This	could	
be	due	to	accumulation	of	urate	crystals	in	early	larval	stages	and	lower	activity	of	UO	in	
the	anterior	tubule	of	the	control.	Similarly	to	Canton	S	tubules,	more	crystals	were	
visible	in	the	posterior	tubule	of	L1-L3E	larvae.		
	
Fig.	4-3	Urate	crystals	in	Drosophila	BDSC	17767	L1-L3	larval	Malpighian	tubules.	Urate	
crystals	are	present	in	L1,	L2	and	L3E	larval	stages	due	to	the	absence	of	UO	activity.	
Crystals	are	also	observed	in	the	anterior	but	not	the	posterior	tubule	of	L3	larva.		
	
Both	posterior	and	anterior	tubules	of	BDSC	18814	and	BDSC	18554	flies	had	urate	
crystals	in	their	lumen	at	all	larval	stages	(Figure	4-4).	Moreover,	markedly	more	crystals	
were	observed	in	BDSC	18814	than	in	BDSC	18554	larvae.	This	makes	sense	because	UO	
knockout	in	BDSC	18814	larvae	is	greater	than	in	BDSC	18554	larvae.	This	suggests	that	
low	expression	of	UO	in	BDSC	18554	flies	has	an	effect	on	urate	levels	in	these	flies.	
Moreover,	this	suggests	that	the	knockout	of	CG30016	alone	does	not	seem	to	increase	
the	accumulation	of	urate	in	mutant	flies.	Instead,	urate	crystals	accumulation	is	the	
result	of	the	UO	knockdown	in	these	flies.	Once	again,	more	crystals	were	observed	in	the	
posterior	tubule	than	in	the	anterior	tubule.	This	could	be	due	to	differential	expression	
of	UO	in	posterior	and	anterior	tubules.		
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Finally,	this	experiment	validated	temporal	expression	of	UO	in	the	fruit	fly.	Further	
experiments	were	carried	out	in	either	L3	larvae	or	adult	flies,	as	the	expression	of	UO	is	
the	highest	at	these	stages.		
	
Fig	4-4	Urate	crystals	in	Drosophila	Malpighian	tubules.	Urate	crystals	are	present	
throughout	L1-L3	larval	stages	due	to	the	absence	of	UO	activity	in	these	fly	lines.	Crystals	
do	not	disappear	in	L3E	or	L3	stages.	(A)	Tubules	of	BDSC	18814	mutant	flies	(UO	
knockout),	lack	of	UO	expression	and	presence	of	urate	crystals	in	all	larval	stages.	(B)	
Tubules	of	BDSC	18554	mutant	flies	(CG30016	knockout	with	reduced	UO	expression),	lack	
of/reduced	UO	activity	and	presence	of	urate	crystals	in	all	larval	stages.	Less	crystals	are	
observed	in	BDSC	18554	flies	in	comparison	to	BDSC	18814	flies.		
	
4.2.2 Inflated	ureter	phenotype		
Tubule	phenotype	was	predicted	in	BDSC	18554	line	due	to	high	levels	of	expression	of	
UO	and	CG30016	in	MTs.	Tubules	of	BDSC	18554	and	BDSC	18814	mutant	flies	were	
visualised	using	light	microscopy	and	compared	to	BDSC	17767	control	flies.	As	predicted,	
about	half	of	the	tested	BDSC	18554	flies	exhibited	an	inflated	ureter	phenotype	(Figure	
4-5).	T-test	revealed	that	there	was	a	statistical	difference	between	knockout	and	control	
ureter	lengths	(p	=	0.0001,		n	=	100).	As	expression	of	CG30016	is	much	higher	in	male	
than	female	flies,	we	compared	the	length	of	ureter	separately	in	mutant	males	and	
females.	For	both	male	and	female	flies	the	ureter	length	was	statistically	bigger	in	
knockout	flies	(P-value	=	0.0003).	However,	there	was	no	significant	difference	between	
the	size	of	male	and	female	ureters	in	mutant	flies	(P-value	=	0.465).	It	is	thought	that	
there	are	functional	differences	between	anterior	and	posterior	Malpighian	tubule	in	
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Drosophila	because	of	different	expression	patterns	so	we	also	compared	the	anterior	
and	posterior	tubules	of	mutant	flies.	In	both	anterior	and	posterior	tubules	there	was	
statistically	significant	difference	in	the	ureter	length	when	compared	to	controls	(P-value	
=	0.0003).	There	were	no	significant	differences	between	the	size	of	inflation	in	anterior	
and	posterior	tubules	in	mutant	flies	(P-value	=	0.2344).	These	results	suggest	that	
disruption	of	CG30016	gene	in	Drosophila	leads	to	inflated	ureter	irrespective	of	the	
tubule	orientation	or	the	sex	of	the	fly.		
As	opposed	to	BDSC	18554	flies,	no	inflated	ureter	was	observed	in	BDSC	18814	flies.	This	
suggests	that	the	inflation	is	not	a	result	of	the	knockout	of	UO	and	the	accumulation	of	
urate	in	mutant	flies.	Instead,	it	seems	to	be	an	effect	of	the	knockout	of	CG30016	gene	
alone.	This	could	be	due	to	accumulation	of	another	metabolite,	fluid	retention	in	mutant	
ureter,	inflammation	or	structural	change	of	mutant	tubules.		
	
Fig.	4-5	Inflated	ureter	phenotype	in	BDSC	18554	mutant	flies.	Inflated	ureter	phenotype	
was	observed	in	the	mutant	flies	(red	arrow)	but	not	the	control	flies.	The	size	of	the	
inflation	was	measured	(ureter	length)	and	compared	to	the	size	of	control	ureter.	There	
was	a	significance	difference	between	ureter	lengths	in	mutant	flies	compared	to	the	
controls	(p=0.0001).		
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Filling in the ‘gaps’ of the Drosophila melanogaster 
metabolic map using metabolomics approaches  
 
Dominika Korzekwa, Dan Erben, Anthony J. Dornan, Elizabeth M. Cannell, Karl V. Burges, Shireen A. Davies, Julian A. T. Dow 
 
Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow 
 
 
Introduction 
 
A computer-annotated metabolic map of Drosophila 
has been predicted by Kyoto Encyclopedia of 
Genes and Genomes (KEGG) 1. ‘Gaps’ still remain 
with no identified Drosophila orthologues for 
metabolic enzymes.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The CG30016 gene in Drosophila is hypothesised 
to be a homologue of 5-hydroxyisourate hydrolase 
(5-HIUH) involved in urate degradation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In humans, urate is commonly known as an 
antioxidant 3. Moreover, enzyme defects within 
urate degradation in humans result in 
hyperuricemia. Increased blood urate is a 
biomarker of heart failure 4. In order to identify and 
screen new treatments, a simple model of the 
disease is required.  
 
 
 
 
 
 
 
 
 
 
 
 
Here, we propose a method for identifying 
metabolic ‘gaps’ in Drosophila melanogaster using 
metabolomics approaches. CG30016 knockout flies 
also exhibit phenotypic manifestations, which might 
reflect abnormalities in hyperuricemia.  
Methods 
 
Fly strains used were: 
-  CG30016 knockout strain  
-  Control with the same P-element but not disrupting 
expression of any genes 
RT-PCR was carried out to establish whether a clear 
CG30016 knockout is observed and no other genes are 
disrupted. 
 
Untargeted metabolomics analysis was performed 
using LC-MS.  
-  Samples were homogenised in ice-cold methanol/
chloroform/water (3:1:1 V/V/V) 
-  LC-MS was performed with a 150 x 4.6mm ZIC-
HILIC column running at 300ul/min and Orbitrap 
Exactive  
-  Raw MS data was processed using a pipeline 
consisting of XCMS, MzMAtch and IDEOM 
 
7-day old flies were dissected. Tissues of interest were 
observed using light and confocal microscopy. 
 
 
Results 
 
1. CG30016 knockout fly line 
 
 
 
 
 
2.  Metabolomics analysis - Changes in purine 
metabolism in CG30016 knockout tubules 
 
 
 
 
 
 
 
3. Inflated ureter phenotype in the knockout 
  Control                          Knockout 
 
 
 
 
 
 
4. Absence of urate crystals formation in 
CG30016 knockout 
 
 
     +ve control  
     Tubule                      Ureter 
 
 
 
 
 
 
      
     knockout 
     Tubule                      Ureter 
 
 
 
 
 
 
 
 
 
 
 
5. Inflated crop phenotype in CG30016 knockout 
Absence of urate crystals in the crop   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusions 
 
1.  Our results are paradoxical; metabolomics data 
suggests urate built up but urate crystals are not 
observed 
2.  The biggest metabolite increase is OHCU  
downstream of 5-HIUH 
3.   CG30016 might be a bifunctional enzyme acting 
as both 5-HIUH and OHCU decarboxylase 
4.  Enlarged and white crop phenotype, which 
disappears in starved flies suggests that crop 
fails to empty in the knockout fly 
5.  Curr nt work:  in vitro studies directly measuring 
enzyme activity 
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Fig. 4 RT-PCR result illustrating a clear  
CG30016 knockout 
Fig. 1 KEGG map of Drosophila purine metabolism 
Fig. 2 (left) Like the upstream enzyme, urate oxidase, the 
online resource FlyAtlas.org shows that CG30016 is almost 
exclusively expressed in Malpighian (renal) tubules of the 
adult fly 2 (right in blue). This increases our confidence that 
CG30016 encodes a bona fide 5-HIUH. 
Fig. 6 Comparison of ureter sizes in control (left)  
and knockout (right) flies; red arrow indicates inflated ureter 
Fig. 3 Hyperuricemia results in gout (left) and heart 
failure (right) 
Fig. 5 Changes in purine metabolism in Malpighian 
tubules of CG30016 knockout flies; red arrows show 
metabolites, which are enriched in the knockout vs. control, 
umbers represent fold increa e in the knockout  
Fig. 8 Comparison of crop sizes in control (top), knockout 
(middle) and knockout starved overnight (bottom) 
Fig. 7 Birefringence results showing lack of urate  
crystals in the tubules and the ureter of CG30016  
knockout   
Control Knockout 
Starved  
knockout 
Healthy heart Congestive heart 
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4.2.3 Inflated	abdomen	phenotype	
Several	tissues,	including	gut	and	salivary	glands,	as	well	as	whole	BDSC	18554	and	BDSC	
18814	flies,	were	examined	using	light	microscopy,	in	order	to	determine	whether	other	
phenotypes	were	present	in	these	flies.	There	were	no	differences	in	the	appearance	of	
gut	and	salivary	gland	tissues	of	mutants	when	compared	to	the	control.	However,	
CG30016	knockout	flies	appeared	to	have	enlarged/bloated	abdomen	(Figure	4-6A)	as	
well	as	distorted	abdominal	patterns	(Figure	4-6B)	in	comparison	to	BDSC	17767	control	
flies.	This	was	not	the	case	for	BDSC	18814	mutants.	Once	again,	this	suggests	that	this	is	
a	result	of	CG30016	knockout	rather	than	UO	knockout.	It	could	be	a	result	of	fluid	
retention,	accumulation	of	metabolite(s),	defective	osmoregulation	or	inflammation.	
However,	it	requires	further	examination	and	statistical	analysis.			
	
Fig.	4-6	Inflated	abdomen	phenotype	(A)	and	distorted	abdominal	pattern	(B)	in	BDSC	
18554	mutant	flies.	CG30016	knockout	appear	to	have	bloated	abdomen	as	well	as	
distortion	of	abdominal	patterns.	
	
4.2.4 Tubule	secretion	rate	
In	order	to	establish	whether	CG30016	knockout	affected	tubule	physiology	and	the	
inflated	ureter	phenotype	in	BDSC	18554	flies	arose	due	to	fluid	retention	and/or	reduced	
secretion	rate,	secretion	assay	was	performed	using	MTs	of	mutant	flies.	Secretion	rates	
were	compared	to	the	ones	of	BDSC	17767	control	flies.	No	significant	differences	were	
observed	between	the	rates	of	these	two	fly	lines	(Figure	4-7),	showing	that	CG30016	
knockout	had	no	effect	on	basal	fluid	secretion	levels.	This	suggests	that	the	inflated	
ureter	was	not	a	result	of	altered	secretion	rate	or	fluid	retention	related	to	the	secretion	
rate	of	the	tubule.		
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Fig.	4-7	Basal	secretion	rate	(nl/min)	comparison	between	BDSC	18554	and	BDAC	17767	
flies.	Tubule	secretion	rates	were	comparable	in	the	mutant	flies	and	the	control.	No	
statistically	significant	differences	were	observed	between	the	two	fly	lines.		
	
4.2.5 Oxidative	stress	survival	
As	previously	mentioned,	urate	is	a	known	antioxidant.	Hence,	urate	accumulation	in	
mutant	flies	was	expected	to	prolong	fly	survival	in	oxidative	stress	conditions.	In	order	to	
establish	whether	UO	and	CG30016	knockouts	have	an	effect	on	fly	survival	in	oxidative	
stress	conditions,	survival	assays	were	performed.	Two	types	of	oxidative	stress	were	
induced	using	10	mM	paraquat	or	1%	H2O2.	Both	mutant	lines	(BDSC	18814	and	BDSC	
18554)	as	well	as	BDSC	17767	control	and	Canton	S	flies	were	tested.		
4.2.5.1 Oxidative	stress	induced	by	1%	H2O2	
All	female	flies	cope	much	better	with	oxidative	stress	than	male	flies.	Moreover,	BDSC	
18554	flies	survived	significantly	longer	in	oxidative	stress	conditions	than	BDSC	17767	
control	and	Canton	S	wild-type	flies	and	had	a	higher	median	survival	than	the	two	
controls	(Figure	4-8	1A).	Male	mutant	flies	cope	better	with	oxidative	stress	than	both	
BDSC	17767	controls	and	Canton	S	flies	(Figure	4-8	1C).	On	the	other	hand,	in	female	flies,	
CG30016	knockout	resulted	in	better	survival	and	higher	median	survival	value	compared	
to	BDSC	17767	flies	but	not	Canton	S	flies	(Figure	4-8	1B).		
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BDSC	18814	survival	in	response	to	oxidative	stress	is	similar	to	both	controls	(Figure	4-8	
2A).	However,	its	median	survival	is	slightly	higher	compared	to	BDSC	17767	and	Canton	S	
flies.	Female	Canton	S	flies	live	longer	than	UO	mutants	as	well	as	BDSC	17767	controls	
and	their	median	survival	is	higher	(Figure	4-8	2B).	UO	knockout	in	male	flies	extends	
survival	in	oxidative	stress	conditions	and	their	median	survival	is	higher	than	the	controls	
(Figure	4-8	2C).			
In	both	mutants,	male	flies	cope	better	than	female	flies	with	oxidative	stress.	The	reason	
for	this	is	not	likely	due	to	CG30016	or	UO	knockout	affecting	males	and	females	
differently.	Instead,	it	seems	to	be	a	result	of	female	Canton	S	flies	coping	particularly	
well	with	oxidative	stress	compared	to	other	flies	(Figure	4-8	1B	and	2B).	Moreover,	
extension	of	survival	is	greater	in	CG30016	mutants	than	in	UO	mutant	flies.	Since	BDSC	
18554	flies	have	decreased	UO	expression	and	no	expression	of	CG30016,	it	suggests	that	
both	genes	affect	oxidative	stress	survival,	and	in	BDSC	18554	flies	their	effect	is	
synergistic.
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Fig.	4-8	Oxidative	stress	survival	assay	induced	by	1%	H2O2.	(1A-1C)	Comparison	of	survival	in	oxidative	stress	conditions	of	BDSC	18554	mutant,	BDSC	17767	
control	and	Canton	S	flies;	(1A)	Male	and	female	flies,	BDSC	18554	flies	survived	significantly	longer	than	the	two	controls	and	their	median	survival	is	
higher.	(1B)	Female	flies,	survival	of	BDSC	18554	and	Canton	S	flies	is	comparable	and	higher	than	this	of	BDSC	17767	flies.	(1C)	Male	flies,	knockout	of	
CG30016	in	BDSC	18554	flies	results	in	increased	survival	and	higher	median	survival	in	comparison	to	controls.	(2A-2C)	Comparison	of	survival	in	oxidative	
stress	conditions	of	BDSC	18814	mutant,	BDSC	17767	control	and	Canton	S	flies;	(2A)	Male	and	female	flies,	all	flies	respond	to	oxidative	stress	in	a	similar	
manner,	median	survival	of	UO	mutant	is	slightly	higher	than	that	of	the	controls.	(2B)	Female	flies,	mutant	and	BDSSC	17767	flies	have	comparable	median	
survival	values	and	both	survive	shorter	than	Canton	S	flies.	(2C)	BDSC	18814	flies	cope	better	with	oxidative	stress	than	the	controls	and	have	higher	
median	survival.	
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4.2.5.2 Oxidative	stress	induced	by	10	mM	paraquat	
Paraquat	(1,1'dimethy-4,4'-bipyridinium	dichloride)	is	a	redox	cycling	compound	and	
induces	oxidative	stress	using	a	different	mechanism	than	H2O2.	In	its	reduced	state	it	
forms	a	stable	radical	species	(Pq+).	It	then	reacts	with	O2	and	generates	the	superoxide	
anion	[442].	In	order	to	establish	whether	different	types	of	oxidative	stress	have	a	
different	effect	on	UO	and	CG30016	mutants,	paraquat-induced	oxidative	stress	survival	
assay	was	performed.		
As	was	the	case	for	H2O2-induced	oxidative	stress,	BDSC	18554	flies	survive	significantly	
longer	and	have	higher	median	survival	than	the	controls	(Figure	4-9	1A).	As	opposed	to	
H2O2-induced	assay,	both	male	and	female	flies	cope	better	with	paraquat-induced	
oxidative	stress	than	BDSC	17767	and	Canton	S	flies	and	have	higher	median	survival	
rates	(Figure	4-9	1B	and	1C).	This	suggests	that	the	knockout	of	CG30016	has	a	protective	
property	in	oxidative	stress	conditions;	both	induced	by	paraquat	and	H2O2.	However,	the	
effect	is	greater	in	paraquat-induced	oxidative	stress.		
As	opposed	to	H2O2-induced	oxidative	stress,	UO	knockout	does	not	affect	fly	survival	in	
paraquat-induced	oxidative	stress	(Figure	4-9	2A).	In	both	male	and	female	flies,	survival	
of	BDSC	18814	mutant	flies	is	comparable	to	BDSC	17767	control	and	Canton	S	flies	
(Figure	4-9	1B	and	1C).	However,	median	survival	of	Canton	S	flies	(both	males	and	
females)	is	slightly	higher	than	that	of	BDSC	17767	control	and	the	mutant.		
In	agreement	with	H2O2-induced	survival,	the	effect	of	CG30016	knockout	on	survival	is	
greater	in	males.	Once	again,	it	seems	to	be	due	to	better	survival	of	female	Canton	S	flies	
than	male	Canton	S	flies.	
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Fig.	4-9	Survival	assay	in	oxidative	stress	conditions	induced	by	10	mM	paraquat.	(1A-1C)	Survival	assay	using	BDSC	18554	mutants,	BDSC	17767	control	and	
Cantos	S	wild	type	flies.	(1A)	Male	and	female	flies,	BDSC	18554	flies	survived	significantly	longer	than	the	two	controls	and	their	median	survival	is	higher.	
(1B)	Female	flies,	survival	of	BDSC	18554	is	significantly	higher	than	Canton	S	and	BDSC	17767	flies.	(1C)	Male	flies,	knockout	of	CG30016	in	BDSC	18554	flies	
results	in	increased	survival	and	higher	median	survival	in	comparison	to	controls.	(2A-2C)	Comparison	of	survival	in	oxidative	stress	conditions	of	BDSC	
18814	mutant,	BDSC	17767	control	and	Canton	S	flies;	(2A)	Male	and	female	flies,	all	flies	respond	to	oxidative	stress	in	a	similar	manner	and	their	median	
survival	is	comparable.	(2B)	Female	flies,	all	flies	have	similar	survival	patters,	median	survival	of	Canton	S	flies	is	higher	than	BDSC	17767	control	and	the	
mutant.	(2C)	Survival	of	all	fly	lines	is	comparable,	median	survival	value	of	Canton	S	flies	is	slightly	higher	than	the	other	two	lines.	
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4.2.6 Longevity	assay	
In	order	to	investigate	the	effects	of	UO	and	CG30016	knockouts	on	the	fly	life	span,	
longevity	assay	was	performed.	Life	span	of	BDSC	18554	flies	is	significantly	shorter	then	
that	of	BDSC	17767	control	and	Canton	S	flies	(Figure	4-10	1A-1C).	This	is	the	case	for	
both	male	and	female	flies.	However,	the	difference	is	much	greater	in	females.	Median	
survival	values	correspond	to	the	life	span,	and	so	there	is	an	apparent	difference	
between	median	survival	of	mutant	flies	in	comparison	to	both	controls,	and	the	
difference	is	greater	in	female	flies.	Interestingly,	female	Canton	S	flies	live	significantly	
longer	than	BDSC	17767	flies.		
In	contrast,	there	is	no	difference	between	life	spans	of	male	BDSC	18814,	BDSC	17767	
control	and	Canton	S	flies	(Figure	4-10	2B).	However,	female	control	and	Canton	S	flies	
live	longer	than	mutant	flies	(Figure	4-10	2A).	Once	again,	female	Canton	S	flies	also	live	
significantly	longer	than	female	BDSC	flies.	In	fact,	it	seems	that	the	life	span	of	female	
Canton	S	flies	is	much	greater	than	the	life	span	of	all	other	flies	tested	in	the	experiment.	
This	suggests	that	it	might	be	related	to	adaptive	advantage	of	these	flies	and	does	not	
reflect	effects	of	CG30016	and	UO	expression/knockout.	Altogether,	BDSC	18814	flies	live	
shorter	than	Canton	S	flies	but	not	BDSC	17767	control	flies	(Figure	4-10	2C).	All	life	span	
differences	correspond	to	median	survival	values.	This	result	is	conflicting	with	previous	
observations	that	urate	prolongs	life	span	[430]	and	requires	further	investigation.		
Differences	in	life	span	between	male	and	females	flies	were	observed	in	both	mutants.	
This	could	be	due	to	differential	expression	of	CG30016	and	UO	genes	in	male	and	female	
flies.	For	example,	if	the	expression	of	these	two	genes	is	normally	higher	in	females,	the	
knockout	could	result	in	greater	changes	than	in	males	and	affect	the	life	span	more.	
Another	possibility	is	higher	sensitivity	of	female	flies	to	changes	in	expression	of	these	
two	genes,	having	greater	impact	on	their	life	span.	
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Fig.	4-10	Longevity	assay,	comparison	between	mutant	flies	and	controls.	(1A-1C)	Longevity	assay	in	BDSC	18554	flies	compared	to	Canton	S	wild-type	flies	
and	BDSC	17767	controls.	Both	control	and	wild-type	flies	live	significantly	longer	than	mutant	flies	and	their	mean	survival	is	greater	(1C).	(1A)	Life	span	of	
female	mutant	flies	is	significantly	shorter	in	comparison	to	the	control	and	wild-type.	This	is	also	true	in	case	of	male	mutant	flies	(1B).	However,	the	
difference	is	smaller	than	in	female	flies.	(2A-2C)	Longevity	assay	in	BDSC	18814	flies	compared	to	Canton	S	wild-type	flies	and	BDSC	17767	controls.	(2C)	Life	
span	of	BDSC	18814	flies	is	comparable	to	the	life	span	of	BDSC	17767	controls,	but	shorter	than	that	of	Canton	S	flies.	(2A)	Female	Canton	S	flies	as	well	as	
control	flies	live	longer	than	the	mutant	flies.	(2B)	In	case	of	male	flies,	there	is	no	difference	in	longevity	between	the	three	fly	lines.	
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4.3 Discussion	
Our	results	show	that	both	UO	and	CG30016	knockouts	produce	phenotypes	in	
Drosophila	melanogaster,	including	MT	and	abdomen	phenotypes,	as	well	as	alteration	in	
longevity	and	survival	in	oxidative	stress	conditions.	The	results	indicate	that	CG30016	is	
involved	in	urate	degradation	pathway.	However,	they	do	not	confirm	its	function	as	5-
HIU	hydrolase.		
4.3.1 Urate	Crystals	
Previous	research	suggested	that	UO	starts	being	expressed	in	the	fruit	fly	during	the	L3	
larval	stage	[368,	370].	As	a	result,	urate	crystals	should	be	present	in	the	tubules	of	
earlier	larvae	but	not	L3	and	adult	flies.	As	shown	in	Chapter	3,	we	confirmed	that	UO	is	
highly	expressed	in	the	L3	stage	but	not	earlier	stages.	Here,	we	confirmed	this	by	looking	
at	the	presence	of	urate	crystals	throughout	larval	development.	Urate	crystals	are	visible	
in	L1,	L2	and	L3E	stages	in	all	tested	fly	lines,	which	is	consistent	with	the	expression	
pattern	of	UO.	Moreover,	in	mutant	flies,	which	do	not	express	UO,	crystals	are	also	
present	in	L3	larvae,	confirming	the	role	of	UO	in	the	breakdown	of	urate.	Interestingly,	
transparent	tubule	phenotype	was	previously	described	in	rosy	mutants,	which	are	
unable	to	synthesised	urate	[403].	This	is	an	opposite	scenario,	where	accumulation	of	
urate	results	in	the	formation	of	crystals	beyond	L3E	larval	stage.	
CG30016	knockout	alone	does	not	seem	to	affect	the	formation	of	urate	crystals.	In	fact,	
more	crystals	were	observed	in	UO	mutant.	This	is	likely	due	to	greater	knockout	of	UO	in	
this	line	as	compared	to	CG30016	mutant.	More	crystals	are	observed	in	posterior	tubules	
in	all	fly	lines.	This	could	be	due	to	differential	expression	of	UO	in	the	MTs	due	to	
functional	and	morphological	differences	between	anterior	and	posterior	tubules	[352,	
396].	It	has	been	previously	suggested	that	differential	orientation	of	the	MTs	in	the	body	
cavity,	corresponds	to	their	function	in	transport	processes	from	the	organs	near	them	
(i.e.	posterior	tubule	is	involved	in	transporting	metabolites	produced	by	the	hindgut).	As	
a	result,	the	posterior	tubule	is	enriched	in	genes	associated	with	ammonia	detoxification	
of	the	hindgut	[396].	Even	though	uric	acid	is	not	toxic,	its	accumulation	most	likely	has	
an	impact	on	the	whole	insect.	Because	of	this,	it	would	make	sense	for	it	to	be	
compartmentalized	to	the	back	end	of	the	fly	body,	away	from	sensitive	tissues.	However,	
	 125	
this	does	not	explain	why	there	are	also	uric	acid	crystals	present	in	the	anterior	tubule.	
In	order	to	understand	this,	further	research	is	required.	It	would	be	interesting	to	
measure	the	expression	of	genes	related	to	urate	formation	and	degradation	pathways	in	
both	anterior	and	posterior	tubules	and	see	whether	they	have	a	differential	expression	
depending	on	tubule	orientation.		
4.3.2 Inflated	tubule	and	abdomen	phenotype	and	fluid	secretion	rate	
As	expected	based	on	the	expression	of	UO	and	CG30016	almost	exclusively	in	the	MTs,	
BDSC	18554	mutant	flies	produced	a	tubule	phenotype,	characterised	by	inflated	ureter.	
It	was	only	present	in	half	of	tested	flies	and	was	not	gender	–	or	tubule	orientation	–	
specific.	The	phenotype	was	not	observed	in	controls	or	UO	mutant.	This	suggests	that	
the	inflation	is	a	result	of	CG30016	knockout	only,	and	not	accumulation	of	urate	due	to	
UO	deficiency.	The	phenotype	could	be	a	result	of	accumulation	of	a	metabolite	
associated	with	CG30016	activity,	fluid	retention,	inflammation,	defective	osmoregulation	
or	structural	abnormality.	Mutant	flies	also	appeared	to	have	a	bloated	abdomen	
resulting	in	distorted	abdominal	patterns.	This	could	also	be	a	result	of	CG30016	knockout	
and	requires	further	examination.		
Previous	research	showed	how	different	genetic	manipulations	in	Drosophila	can	affect	
fluid	secretion	rate	[71-74].	However,	there	is	no	correlation	reported	between	fluid	
secretion	and	enzymes/metabolites	involved	in	urate	metabolism.	Our	results	showed	
that	CG30016	knockout	did	not	lead	to	fluid	retention	and	did	not	affect	basal	secretion	
rate	in	the	fruit	fly.	This	suggests	that	the	inflated	ureter	and	abdomen	are	a	result	of	
either	accumulation	of	a	metabolite	other	than	urate,	or	morphological	change	in	the	
mutant	tissues.	Tubule	phenotypes	including	bloated	tubule	have	been	previously	
described	[65,	103,	104,	403].	Interestingly,	inflated	ureter	is	a	novel	phenotype	that	has	
not	been	described	before.	Bloated	abdomen	has	been	previously	reported	as	a	result	of	
defective	osmoregulation	in	ClC-a	knockdown	flies	[69].	In	order	to	test	whether	the	
abdominal	inflation	in	BDSC	18554	flies	was	a	result	of	increased	haemolymph	water	
content,	further	experiments	could	be	performed	in	the	future,	including	wet-dry	weight	
measurement	(as	described	in	[69]).	In	case	of	both	phenotypes,	it	would	interesting	to	
characterise	them	further	in	order	to	understand	their	molecular	bases.		
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4.3.3 Is	urate	an	antioxidant	or	a	pro-oxidative	factor	in	the	fruit	fly?		
In	agreement	with	previous	studies	in	Drosophila	melanogaster,	the	results	suggest	that	
urate	acts	as	antioxidant.	This	is	true	for	oxidative	stress	condition	induced	by	H2O2	but	
not	paraquat	for	experiments	performed	using	UO	mutant.	Interestingly,	in	flies	with	
both	UO	and	CG30016	knockouts,	flies	survive	better	in	oxidative	stress	conditions	
induced	by	both	H2O2	and	paraquat.	Moreover,	in	H2O2	–	induced	oxidative	stress	
conditions,	survival	of	CG30016	mutant	is	greater	than	that	of	UO	mutant.	This	suggests	
that	the	substrate	for	CG30016	also	acts	as	an	antioxidant	in	the	fly,	and	in	the	mutant	
deficient	for	both	enzymes,	urate	and	another	metabolite	act	synergistically	as	
antioxidants	and	hence	make	the	flies	less	sensitive	to	oxidative	stress	than	urate	alone.	
These	results	are	consistent	with	a	previous	study	in	the	fruit	fly,	which	showed	that	rosy	
mutant,	which	do	not	synthesise	urate,	is	hypersensitive	to	oxidative	stress	[76].	
Altogether,	this	confirms	that	urate	acts	as	an	antioxidant	in	oxidative	stress	conditions.		
Our	results	showed	that	both	mutants	had	a	shorter	lifespan	than	the	controls	in	normal	
conditions,	with	exception	of	UO	male	flies.	This	could	be	due	to	pro-oxidative	properties	
of	urate	suggested	in	previous	studies.	It	has	been	proposed	that	the	main	factor	involved	
in	lifespan	extension	and	cancer	prevention,	have	been	protective	mechanisms	against	
ROS	[443].	Hence,	it	would	make	sense	to	assume	that	increased	levels	of	urate,	which	
might	induce	oxidative	stress,	has	an	opposite	effect	and	leads	to	shorter	life	span.	
However,	based	on	our	result	it	is	not	possible	to	tell	whether	shortened	lifespan	is	due	
to	increased	oxidative	damage	or	other	deleterious	effects	of	increased	urate.	On	the	
other	hand,	previous	research	showed	that	mutant	flies,	which	are	unable	to	produce	
urate,	have	reduced	life	span	[76].	It	is	hence	surprising	to	see	the	same	effect	in	mutants	
unable	to	degrade	urate.	This	suggests	that	reduced	life	span	in	CG30016	and	UO	
knockout	flies	might	be	a	result	of	factors	other	than	urate	enrichment.	For	example,	it	
has	been	shown	that	fly’s	diet	can	influence	life	span	[444].	Perhaps	feeding	of	these	two	
mutants	is	altered	as	a	result	of	the	knockout,	which	in	turn	affects	their	longevity.	
However,	in	order	to	test	this	further	research	is	required.		
As	was	the	case	with	oxidative	stress	survival,	the	difference	between	mutant	flies	and	
controls	is	greater	in	case	of	CG30016	knockout	than	UO	knockout.	Once	again,	it	
suggests	that	CG30016	substrate	has	similar	properties	to	urate,	and	when	both	
metabolites	are	enriched,	they	act	synergistically.	It	would	be	interesting	to	investigate	
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this	correlation	further,	in	order	to	understand	its	underlying	mechanism.			
In	conclusion,	we	confirmed	here	that	urate	acts	as	an	antioxidant	in	oxidative	stress	
conditions.	We	also	showed	that	it	reduces	life	span	in	normal	conditions.	However,	it	is	
not	clear	whether	it	is	due	to	pro-oxidative	properties	of	urate	or	its	other	property.	
Moreover,	it	is	possible	that	the	longevity	of	mutant	flies	is	not	affected	by	urate	
accumulation	at	all.	Instead	the	life	span	reduction	could	be	caused	by	another	
characteristic	of	the	mutant	flies.	Previous	research	suggested	that	antioxidant	enzymes	
improve	organism	survival	in	stressful	conditions	but	are	not	associated	with	the	normal	
aging	process	[438].	This	contradicts	free	radical	theory	of	aging	but	could	explain	our	
results.	Altogether,	based	on	our	research,	it	is	not	clear	whether	urate	can	act	as	a	pro-
oxidative	factor	and	in	order	to	answer	this	question,	further	research	is	required.	
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5 Metabolomics	analysis	in	Drosophila	
melanogaster		
5.1 Introduction	
Metabolomics	has	been	previously	used	to	study	organismal	function	in	Drosophila	
melanogaster.	The	method	has	been	applied	to	fly	research	in	functional	genomics	[62,	
106,	177,	187],	development	[445-447],	effects	of	different	diets	and	dietary	restrictions	
on	the	metabolome	[175,	448-450],	Drosophila	Parkinson’s	disease	model	[451,	452],	
metabolic	responses	to	different	environmental	conditions	and	stresses	(such	as	light	and	
temperature)	[173,	175,	453-455],	as	well	as	pesticides	[90].	Metabolomics	provided	
metabolic	profiles	of	flies	responding	to	different	stimuli,	including	environmental	
changes	and	genetic	perturbation.	This	aided	the	understanding	of	molecular	basis	of	
different	adaptive	mechanisms,	drug/pesticide	action,	gene	function	and	many	more.	For	
example,	metabolomics	analysis	has	been	applied	to	study	how	insecticide	permethrin	
affects	metabolic	pathways.	This	revealed	that	lipid	and	energy	metabolism	were	altered	
upon	application	of	the	drug	[90].	Another	study	showed	that	Drosophila	models	of	
Parkinson’s	disease	(PD)	undergo	similar	metabolic	alterations	to	PD	patients.	As	a	result,	
it	validated	the	fly	as	a	model	for	studying	neurodegenerative	properties	of	
environmental	chemicals	and	molecular	basis	of	PD	[451].		
Most	of	these	studies	focused	on	the	whole	fly	rather	than	individual	fly	tissues.	
However,	it	is	clear	by	looking	at	FlyAltas	data,	that	single	tissue	metabolomes	need	to	be	
investigated.	FlyAtlas	is	a	tissue-specific	transcriptomic	atlas	for	Drosophila	melanogaster,	
which	provides	information	on	gene	enrichment	in	different	adult	and	larval	tissues	[6].	
FlyAtlas	revealed	that	different	tissues	differ	from	each	other	and	the	whole	fly	in	terms	
of	gene	expression.	Moreover,	it	is	estimated	that	each	tissue	contributes	around	5%	of	
the	whole-organism	transcriptome,	so	even	large	changes	in	gene	expression	in	one	
tissue	would	be	underrepresented	in	the	whole	fly	transcriptome	[6].	Hence,	we	are	
expecting	to	see	a	similar	pattern	when	looking	at	metabolomes	of	different	fly	tissues;	
namely	that	the	whole	organism	metabolome	would	be	a	poor	predictor	of	what	was	
taking	place	in	individual	tissues.	Interestingly,	previous	research	in	other	species	has	
showed	that	metabolite	profiles	are	highly	tissue-specific.	For	example,	a	study	in	
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Arabidopsis,	has	revealed	that	various	phytochemicals	were	produced	by	the	plant	in	a	
tissue-specific	way	[125].	The	data	were	also	correlated	to	Arabidopsis	transcriptome,	
which	showed	that	accumulation	of	metabolites	in	a	given	tissue	corresponded	to	
enrichment	of	a	gene	responsible	for	its	biosynthesis	in	the	same	tissue	[138].		
Several	studies	in	Drosophila	have	looked	at	the	correlation	of	the	metabolomics	with	
other	omics	approaches,	including	genomics	and	transcriptomics	[447,	450,	456].	For	
example,	Hoffman	et	al.	showed	that	there	is	an	association	between	metabolomics	and	
age,	sex	and	genotype	in	predicting	life	expectancy.	The	study	identified	metabolic	
pathways	that	helped	to	bridge	the	gap	between	the	genome	and	life	expectancy	[456].	
Another	study	looked	at	the	correlation	between	transcriptome,	metabolome	and	
phenotypic	manifestations	linked	to	human	metabolic	syndrome	(body	weight,	total	
sugar,	and	total	triglycerides)	of	flies	raised	on	different	diets.	It	revealed	that	there	is	
little	association	between	transcriptome/metabolome	and	the	gross	phenotype	of	the	
flies,	which	depends	more	on	the	type	of	diet	consumed.	However,	few	genes	and	
metabolites	were	correlated	to	metabolic	syndrome-like	phenotypes	in	all	flies	on	
different	diets.	For	example,	metabolites	linked	to	body	weight	and	total	triglycerides	and	
sugars	were	L-DOPA	(L-3,4-dihydroxyphenylalanine),	fatty	acids,	and	BCAAs	(branch	chain	
amino	acids),	and	correlated	genes	were	related	to	ATP	synthesis,	TCA	cycle	and	
pupariation	[450].		
Finally,	several	studies	have	looked	at	metabolite	levels	of	individual	Drosophila	tissues,	
including	lipid	composition	of	fat	body,	wing	disc,	salivary	gland,	gut	and	brain	of	fruit	fly	
larvae	[457].	This	study	revealed	that	there	were	significant	differences	in	the	lipid	
content	between	different	tissues.	Another	study	investigated	differences	in	metabolism	
between	head,	thorax	and	abdomen	[396].	Moreover,	Laye	et	al.	studied	dietary	
restriction	(DR)	and	its	effect	on	age-related	diseases	correlated	with	the	metabolome	of	
the	whole	fly,	head,	thorax,	and	abdomen.	The	study	revealed	that	DR	had	a	great	effect	
on	the	metabolomes	of	different	tissues,	and	particularly	on	the	metabolic	pathways	
related	to	aging.	Moreover,	it	showed	that	some	metabolites	enriched	in	DR	were	
common	to	all	tissues.	However,	each	tissue	also	had	a	unique	metabolic	profile	as	a	
result	of	DR	[449].		
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5.1.1 How	do	single-gene	mutations	affect	the	fly	metabolome?	
Previous	studies	on	several	mutations	in	the	fruit	fly	genome	(including	ry,	cho,	y	and	mal)	
investigated	their	effect	on	the	metabolome	[62,	106,	177,	187].	This	research	revealed	
that	by	using	LC-MS-based	metabolomics,	it	is	possible	to	observe	effects	of	single-gene	
mutations	on	the	pathway	the	gene	is	involved	in,	and	also	on	other	apparently	unrelated	
pathways,	and	the	global	metabolome.	The	general	principle	is	that	if	an	enzyme	is	
knocked	down	we	expect	to	observe	increase	in	concentration	of	upstream	metabolites	
and	decrease	in	downstream	metabolites	(Figure	5-1).		
	
Fig.	5-1	The	principle	of	single-gene	knockout	metabolomics.	When	an	enzyme-encoding	
gene	is	knocked	out,	metabolite	levels	upstream	from	the	lesion	increase,	and	the	ones	
downstream	decrease.		
5.1.2 Metabolomics	approaches	to	studying	urate	degradation	mutants		
As	shown	in	previous	chapter,	phenotypic	analysis	of	mutant	flies	did	not	establish	the	
function	of	CG30016	gene	in	Drosophila.	However,	the	results	suggest	that	urate	
degradation	pathway	is	disrupted	in	the	knockout	flies	due	to	accumulation	of	urate	in	
the	tubules.	If	the	hypothesis	that	CG30016	is	5-HIU	hydrolase	is	correct,	we	should	
observe	increased	levels	of	both	urate	and	5-HIU	in	the	mutants	as	well	as	decreased	
levels	of	OHCU	and	allantoin.	Additionally,	by	observing	how	the	mutation	affects	global	
metabolome	of	the	fly,	we	could	gain	an	understanding	of	how	the	disruption	of	urate	
degradation	pathway	leads	to	observed	phenotypes.		
In	this	chapter	we	summaries	the	results	obtained	from	studying	metabolomes	of	urate	
degradation	mutants	using	LC-MS.	We	looked	at	how	single-gene	knockouts	affect	whole	
fly	and	tubule	metabolomes.	Moreover,	metabolomes	of	the	whole	fly	as	well	as	three	
different	tissues	were	generated.	Finally,	we	validated	the	use	of	this	metabolomics	
platform	for	the	study	of	fly	secretion	fluid.		
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5.2 Results	
5.2.1 Tissue-specific	metabolomes	of	Drosophila	melanogaster	
Data	presented	in	this	section	were	obtained	and	analysed	in	collaboration	with	V.	
Chintapali	and	D.	Watson	and	published	[186].	Two	different	analyses	were	performed.	
The	experiments	performed	at	Strathclyde	University	(SU)	compared	whole	fly,	head,	
crop,	mid	gut,	anterior	tubules,	posterior	tubules,	hind	gut,	ovaries,	testes,	accessory	
glands	and	cuticle.	The	analysis	carried	out	at	Polyomics	Facility	(PF),	compared	whole	fly,	
central	nervous	system,	Malpighian	tubules	and	the	gut.	For	the	purpose	of	this	thesis,	
we	focused	on	selected	tissues	and	presented	a	summary	below.	In	case	of	PF	data,	all	
data	collection,	processing	and	analysis	were	performed	by	myself,	and	they	are	
presented	in	this	thesis.	The	data	obtained	from	SU	were	collected	and	processed	by	our	
collaborators.	Data	analysis	and	presentation	was	discussed	and	performed	by	the	
collaborators	and	myself.	SU	data	are	presented	her	for	the	purpose	of	comparison	of	the	
two	sets	of	results,	and	a	validation	of	LC-MS	metabolomics	as	a	tool	for	obtaining	tissue-
specific	metabolomes.		
SU	identified	242	metabolites	that	were	run	alongside	82	standards.	Metabolites	were	
identified	and	quantified	using	Xcalibur	software	combined	with	Sieve	Software	1.3	
(Thermo	Fisher	Co.).	Except	metabolites	that	matched	masses	and	retention	times	of	
standards,	all	metabolites	were	putatively	identified.	All	masses	where	within	1.5	ppm	of	
the	exact	molecular	formula.	This	means	that	the	only	competing	metabolites	within	the	
database	search	were	isomers.	SU	results	are	represented	as	heat	maps	of	peak	areas	
normalised	to	the	protein	content	of	each	tissue.	Repeatability	of	this	method	was	also	
expressed	as	RSD	values	for	the	peak	areas	across	four	replicates.	In	some	instances	these	
values	were	very	low,	which	reflected	variability	between	individual	samples.	Confidence	
levels	of	each	identified	metabolite	were	also	assigned:	1	–	exact	mass	and	RT	matched	a	
standard,	2	–	accurate	mass	matched,	isomers	possible.		
Measurements	obtained	from	PF	identified	202	metabolites	and	run	134	standards	
(Appendix	V	and	VI).	The	instrument	settings	as	well	as	data	analysis	are	described	in	
Materials	and	Methods	(Chapter	2.16).	For	each	metabolite,	mean	signal	intensity	was	
calculated	in	each	sample	(based	on	four	biological	replicates).	IDEOM	algorithm	was	
used	to	express	relative	abundance	of	each	metabolite.	Relative	abundance	of	each	
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metabolite	in	the	control	(whole	fly	(WF))	was	expressed	as	‘0’	(metabolite	absent	in	the	
sample)	or	‘1’	(metabolite	present	in	the	sample).	In	all	other	samples	relative	abundance	
was	expressed	as	a	fold	change	relative	to	the	control	group	calculated	from	mean	signal	
intensity	of	each	metabolite	versus	mean	signal	intensity	of	this	metabolite	in	the	control.	
Metabolite	levels	were	coloured	according	to	relative	abundance	(blue	=	low,	red	=	high).	
Moreover,	t-test	was	performed	for	each	metabolite	as	part	of	IDEOM	pipeline,	and	
where	the	P-value	(each	sample	t-tested	against	control	group)	was	less	than	0.05,	the	
data	was	analysed	further.		
In	case	of	tissue-specific	metabolomes,	the	most	enriched	metabolites	in	individual	
tissues	were	calculated	using	an	additional	formula:	
Tissue	enrichment	=	Relative	abundance	in	a	tissue	of	interest/(the	sum	of	abundance	in	
all	other	tissues+1)	
Both	analyses	are	semi-quantitative	and	hence	represent	the	discovery	stage	and	
generate	hypotheses.	Since	FlyAtlas	revealed	differences	in	gene	expression	between	
different	tissues	and	the	whole	fly	we	investigate	here	whether	the	same	is	true	for	tissue	
metabolomes.	We	expect	that	any	differences	between	tissue	metabolomes	are	likely	to	
have	functional	significance.	As	was	the	case	with	the	fly	transcriptome	[6],	there	are	
clear	differences	between	tissue	metabolomes	as	well	as	some	similarities.	
5.2.1.1 Tissue	metabolomes	differ	from	each	other	and	from	the	whole	fly	
Following	data	processing	by	IDEOM,	additional	multivariate	and	univariate	statistical	
analyses	were	performed	using	MetaboAnalyst	(http://www.metaboanalyst.ca),	an	open-
source	platform	for	metabolomics	data	analysis	[258,	458].	In	order	to	group	samples	
according	to	similar	abundance	profiles,	hierarchical	clustering	analysis,	dendrogram,	was	
performed	(dissimilarity	measure	used	was	Spearman’s	rank	correlation,	and	clustering	
method	was	Ward’s	linkage).	Moreover,	PCA	was	carried	out	in	order	to	determine	how	
varied	the	replicates	were	within	each	sample,	whether	they	clustered	together,	and	
whether	there	were	differences	between	metabolomes	of	analysed	tissues.	Finally,	one-
way	ANOVA	was	performed,	in	order	to	establish	whether	there	were	significant	
differences	between	samples,	i.e.	whether	the	metabolomes	of	different	tissues	varied	
significantly.		
Our	results	clearly	showed	that	tissue	metabolomes	differ	significantly	from	each	other	
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and	from	the	whole	fly	metabolome	(Figures	5-2	and	5-3).	Hierarchical	clustering	analysis	
revealed	that	generally	samples	from	the	same	tissues	clustered	together	and	were	
hence	related	to	each	other	but	not	other	tissues	(Figure	5-2A).	The	whole	fly	as	well	as	
the	gut	samples	clustered	together	and	separately	from	other	tissues,	and	so	did	two	out	
of	three	replicates	of	CNS	and	MTs	samples.	On	the	other	hand,	cns1	and	mt1	samples	
were	more	related	to	each	other	than	to	the	other	two	replicates	of	the	same	tissue.	This	
confirms	that	tissue	metabolomes	differ	from	each	other	but	also	shows	that	there	is	
variability	between	replicates	of	the	same	sample.		
Similar	results	were	illustrated	by	PCA	(Figure	5-2B),	where	whole	fly	replicates	clustered	
together	and	separately	from	other	samples,	and	there	was	variability	between	replicates	
of	different	tissue	samples.	However,	PCA	showed	that	the	biggest	variance	was	present	
in	cns1	sample,	which	did	not	cluster	with	other	CNS	replicates.		
Finally,	one-way	ANOVA	results	are	illustrated	in	Figure	5-3.	Each	dot	represents	a	single	
metabolite;	red	dots	represent	metabolites,	for	which	the	abundance	was	significantly	
different	between	the	samples,	green	dots	represent	metabolites,	for	which	the	
abundance	was	not	significantly	different	between	the	tissues	and	the	whole	fly.	These	
results	confirmed	that	whereas	some	metabolite	abundances	different	between	tissues,	
other	metabolites	had	consistent	abundance	across	samples.		
Altogether,	these	results	showed	that	tissue	metabolomes	differed	from	each	other	and	
from	the	whole	fly	metabolome.	However,	some	metabolites	are	enriched	across	all	the	
tissues,	which	shows	that	some	metabolites	and	metabolic	pathways	are	conserved	in	the	
whole	fly	and	in	all	tested	tissues.	This	might	reflect	that	whereas	some	organismal	
functions	are	tissue-specific,	others	are	performed	by	multiple	tissues.	Finally,	presented	
analyses	revealed	that	tissue	metabolomes	vary	between	replicates.	This	showed	the	
importance	of	standardisation	of	data	collection	protocol,	as	well	as	using	as	many	
replicates	as	is	feasible	in	order	to	obtain	the	most	real	picture	of	tissue	metabolome.	
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Fig.	5-2	Hierarchical	clustering	analysis	(A)	and	PCA	(B)	of	tissue	metabolomes.	(A)	Dendrogram	illustrates	clustering	of	all	samples,	showing	that	all	
replicates	of	the	whole	fly	and	gut	samples	cluster	together,	whereas	in	case	of	MTs	and	CNS	samples,	two	out	of	three	replicates	cluster	together.	On	the	
other	hand,	one	CNS	(cns1)	and	one	MTs	(mt1)	sample	cluster	with	each	other	rather	than	replicates	of	the	same	tissue.	(B)	PCA	analysis	illustrates	that	
whole	fly	(blue),	MTs	(navy	blue)	and	gut	samples	(green)	cluster	together,	whereas	one	CNS	replicate	(cns1)	differs	from	the	other	two	CNS	samples	(red).	
Generated	using	MetaboAnalyst	(http://www.metaboanalyst.ca).	
	 	A	 B	
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Fig.	5-3	Results	of	one-way	ANOVA.	Each	dot	represents	a	single	metabolite;	red	dots	represent	metabolites,	for	which	the	abundance	was	significantly	
different	between	the	samples,	green	dots	represent	metabolites,	for	which	the	abundance	was	not	significantly	different	between	the	samples.	Peaks	
(mz/rt)	refer	to	detected	metabolites	with	a	unique	mass-to-charge	ratio	and	a	unique	retention	time.	Generated	using	MetaboAnalyst	
(http://www.metaboanalyst.ca).
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5.2.1.2 Most	abundant	metabolites	–	amino	acids		
Amino	acids	were	among	the	most	abundant	metabolites	across	all	samples.	Figure	5-4	
shows	the	top	25	most	abundant	metabolites	in	the	whole	fly	and	averaged	over	all	
tissues.	The	single	most	abundant	metabolite	in	the	whole	fly	is	proline,	which	is	also	
highly	abundant	across	all	the	tissues.	Other	metabolites	including	histidine,	alanine,	
glutamine,	arginine	etc.	are	also	highly	abundant.	However,	it	is	interesting	to	see	that	
except	proline,	other	amino	acids	have	a	tissue-specific	pattern	of	enrichment.	Moreover,	
the	levels	of	amino	acids	are	lower	in	Malpighian	tubules	in	comparison	to	other	tissues.	
This	could	reflect	the	role	of	MTs	of	generating	the	primary	urine.	This	involves	selective	
reabsorption	of	desirable	metabolites,	such	as	amino	acids.	Hence,	low	abundance	of	
amino	acids	in	MTs	could	reflect	their	role	in	amino	acid	recycling	back	to	the	
haemolymph.		
Fig.	5-4	The	top	25	most	abundant	metabolites	by	area	response	in	the	whole	fly	and	ten	
fly	tissues.	Red	=	area	>	108	Yellow	=	area	>	107	Blue	=	area	>	105;	WF	-	whole	fly,	HD	–	
head,	MG	–	midgut,	AT	–	anterior	tubule,	PT-	posterior	tubule,	HG	–	hindgut,	OV	–	ovaries,	
TEST	–	testes,	ACCG	–	accessory	glands,	CUT	–	cuticle,	from	[186].	
	
In	agreement	with	SU	data,	the	most	enriched	metabolites	in	the	dataset	analysed	by	PF	
are	part	of	amino	acid	metabolism	(Table	5-1).	Moreover,	other	highly	enriched	
metabolites	belong	to	carbohydrate	metabolism,	and	metabolism	of	vitamins	and	
cofactors.	Moreover,	some	metabolites	have	not	been	assigned	to	any	known	metabolic	
pathway.	This	illustrates	the	limitations	of	the	software	used	and/or	current	knowledge	
gaps.	Once	again,	it	is	clear	by	looking	at	these	results	that	tissue	metabolomes	differ	
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from	each	other	and	from	the	whole	fly.	However,	some	metabolites	are	enriched	across	
all	the	tissues.	
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Table	5-1	The	most	enriched	metabolites	across	all	tissues.	Results	are	represented	as	a	ratio	of	relative	abundance	in	a	given	tissue	in	comparison	to	other	
samples,	with	the	whole	fly	(WF)	as	a	control.	Metabolite	levels	are	coloured	according	to	relative	intensity	(blue	=	low,	red	=	high,	
blue<yellow<orange<red).		
Mass	 RT	 Formula	 Putative	metabolite	 Map	 CNS	 Gut	 MTs	 WF	
195.09	 5.79	 C10H13NO3	 Damascenine	 No	known	pathway	 148.92	 106.28	 70.73	 0.00	
118.03	 6.84	 C4H6O4	 Succinate	 Carbohydrate	
Metabolism	
4.79	 63.15	 34.16	 1.00	
191.06	 6.20	 C7H13NO3S	 N-Acetylmethionine	 No	known	pathway	 7.49	 33.03	 8.56	 0.00	
123.03	 8.13	 C6H5NO2	 Nicotinate	 Metabolism	of	
Cofactors	and	
Vitamins	
10.49	 30.04	 7.65	 1.00	
129.04	 7.64	 C5H7NO3	 L-1-Pyrroline-3-hydroxy-5-carboxylate	 Amino	Acid	
Metabolism	
2.27	 7.34	 33.99	 1.00	
175.06	 6.02	 C10H9NO2	 Indole-3-acetate	 Amino	Acid	
Metabolism	
35.87	 7.25	 15.23	 0.00	
241.11	 7.24	 C25H30N4O6	 Phe-Gly-Pro-Tyr	 Peptide(tetra-)	 3.12	 15.15	 14.45	 1.00	
148.05	 5.79	 C9H8O2	 trans-Cinnamate	 Amino	Acid	
Metabolism	
21.67	 16.07	 12.99	 0.00	
187.08	 5.80	 C8H13NO4	 6-Acetamido-2-oxohexanoate	 Amino	Acid	
Metabolism	
9.20	 12.69	 9.64	 1.00	
758.51	 4.78	 C48H70O7	 (3R,2'S)-Myxol	2'-(2,4-di-O-methyl-alpha-L-fucoside)	 Biosynthesis	of	
Secondary	
Metabolites	
4.65	 2.05	 6.54	 0.00	
163.10	 5.88	 C10H13NO	 N-Acetylphenylethylamine	 No	known	pathway	 20.05	 13.74	 6.53	 1.00	
	 139	
175.03	 5.86	 C9H19O12P	 nonulose	9-phosphate	 No	known	pathway	 10.67	 8.88	 6.06	 1.00	
190.08	 5.81	 C8H14O5	 (R)-3-((R)-3-Hydroxybutanoyloxy)butanoate	 Carbohydrate	
Metabolism	
8.71	 5.32	 5.45	 1.00	
173.07	 6.06	 C7H11NO4	 N-Acetyl-L-glutamate	5-semialdehyde	 Amino	Acid	
Metabolism	
4.64	 9.41	 4.93	 1.00	
145.07	 6.89	 C6H11NO3	 4-Acetamidobutanoate	 Amino	Acid	
Metabolism	
1.65	 10.36	 4.37	 1.00	
141.04	 6.20	 C6H7NO3	 6-oxo-1,4,5,6-tetrahydronicotinate	 Metabolism	of	
Cofactors	and	
Vitamins	
7.10	 9.04	 4.17	 1.00	
138.04	 12.81	 C6H6N2O2	 Urocanate	 Amino	Acid	
Metabolism	
1.98	 6.88	 3.92	 1.00	
159.09	 6.08	 C7H13NO3	 5-Acetamidopentanoate	 Amino	Acid	
Metabolism	
2.22	 4.06	 3.91	 1.00	
113.05	 6.08	 C5H7NO2	 1-Pyrroline-2-carboxylate	 Amino	Acid	
Metabolism	
3.68	 7.14	 3.65	 1.00	
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5.2.1.3 Metabolomes	of	Malpighian	tubules	
SU	results	revealed	that	in	both	posterior	and	anterior	tubules,	the	most	abundant	
metabolites	are	part	of	tryptophan	metabolism,	including	kynurenine,	tryptophan,	
hydroxykyurenate	etc.	(Figure	5-5).	This	is	particularly	interesting	considering	that	MT	
metabolome	is	depleted	for	most	amino	acids	(Figure	5-5).	Tryptophan	is	a	precursor	of	a	
visual	pigment,	and	it	is	known	that	MTs	store	visual	pigment	precursors	[459].	Moreover,	
previous	research	revealed	that	tryptophan	is	actively	transported	into	the	tubule	[460].	
Hence,	it	makes	sense	the	tubule	is	enriched	in	tryptophan	and	related	metabolites.		
Fig.	5-5	The	most	abundant	metabolites	by	area	response	in	Malpighian	tubules.	Red	=	
area	>	108	Yellow	=	area	>	107	Blue	=	area	>	105;	WF	-	whole	fly,	HD	–	head,	MG	–	midgut,	
AT	–	anterior	tubule,	PT-	posterior	tubule,	HG	–	hindgut,	OV	–	ovaries,	TEST	–	testes,	ACCG	
–	accessory	glands,	CUT	–	cuticle,	from	[186].	
	
The	analysis	performed	at	PF	showed	similar	results.	Among	the	most	abundant	
metabolites	in	the	tubule	were	L-kynurenine	and	L-Formylkynurenine,	which	are	part	of	
tryptophan	metabolism	(Table	5-2).	This	validates	the	results	obtained	at	SU.	Moreover,	
metabolites	involved	in	purine	metabolism	were	detected	in	the	tubule,	including	
xanthine,	hypoxanthine,	inosine,	deoxyinosine,	deoxyadenosine,	adenosine	and	adenine	
(Appendix	VI).	This	confirmed	that	the	analysis	of	urate	degradation	mutants	could	be	
performed	using	MTs	rather	than	the	whole	fly.	
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Table	5-2	Metabolites	enriched	in	Malpighian	tubules	(the	highest	tissue	enrichment	value	for	MTs).	Results	are	represented	as	a	ratio	of	relative	abundance	
in	a	given	tissue	in	comparison	to	other	samples.	Metabolite	levels	are	coloured	according	to	relative	intensity	(blue	=	low,	red	=	high,	
blue<yellow<orange<red).		
Mass	 RT	 Formula	 Putative	metabolite	 Pathway	 CNS	 Gut	 MTs	 WF	
129.04	 7.64	 C5H7NO3	 L-1-Pyrroline-3-hydroxy-5-carboxylate	 Arginine	and	proline	metabolism	 2.27	 7.34	 33.99	 1.00	
165.05	 17.63	 C5H11NO3S	 L-Methionine	S-oxide	 Methionine	metabolism	 0.00	 0.27	 16.81	 1.00	
236.08	 13.17	 C11H12N2O4	 L-Formylkynurenine	 Tryptophan	metabolism	 0.00	 0.30	 5.48	 1.00	
109.05	 15.31	 C6H7NO	 2-Aminophenol	 Tryptophan	metabolism	 0.62	 0.18	 5.28	 1.00	
208.08	 13.46	 C10H12N2O3	 L-Kynurenine	 Tryptophan	metabolism	 0.00	 0.03	 5.27	 1.00	
191.04	 8.87	 C7H5N5O2	 6-formyl-H2-pterin	 No	known	pathway	 0.04	 0.13	 4.59	 1.00	
173.14	 14.98	 C9H19NO2	 Muscarine	 No	known	pathway	 0.00	 1.41	 3.76	 1.00	
376.14	 8.00	 C17H20N4O6	 Riboflavin	 Riboflavin	metabolism	 0.00	 0.13	 2.91	 1.00	
154.03	 6.06	 C7H6O4	 2,5-Dihydroxybenzoate	 Tyrosine	metabolism	 0.00	 0.00	 1.85	 0.00	
464.46	 5.25	 C31H60O2	 Hentriacontane-14,16-dione	 No	known	pathway	 0.00	 0.00	 1.47	 0.00	
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5.2.1.4 Metabolomes	of	the	gut	
The	midgut	is	mostly	responsible	for	digestion	and	nutrient	absorption.	Among	the	most	
abundant	metabolites	in	the	midgut	are	acylcarnitines	(Figure	5-6).	Acylcarnitines	are	
responsible	for	buffering	the	levels	of	CoA	within	the	mitochondria	as	well	as	transport	of	
fatty	acids.		FlyAtlas	revealed	that	most	dietary	lipases	are	highly	expressed	in	the	midgut	
[4].	This	is	consistent	with	the	fact	that	the	midgut	is	the	major	site	of	the	fatty	acid	
uptake	and	processing.		
Fig.	5-6	The	most	abundant	metabolites	in	fly	midgut.	Red	=	area	>	108	Yellow	=	area	>	107	
Blue	=	are	>	105;	WF	-	whole	fly,	HD	–	head,	MG	–	midgut,	AT	–	anterior	tubule,	PT-	
posterior	tubule,	HG	–	hindgut,	OV	–	ovaries,	TEST	–	testes,	ACCG	–	accessory	glands,	CUT	–	
cuticle,	from	[186]..	
	
The	results	obtained	from	PF	differ	from	the	ones	above.	This	might	be	because	the	
analysis	was	performed	on	the	whole	gut	tissue	rather	than	the	midgut	alone.	The	results	
showed	that	the	most	abundant	metabolites	in	the	whole	gut	are	part	of	amino	acid	
metabolism,	including	phenylalanine	metabolism	(Table	5-3).	Moreover,	the	tissue	is	rich	
in	peptides.	This	corresponds	to	the	role	of	the	gut	in	digestion,	and	might	reflect	the	
results	of	protein	degradation	as	well	as	abundance	of	digestive	enzymes	and	peptides	in	
the	tissue.		
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Table	5-3	Metabolites	enriched	in	the	gut	(the	highest	tissue	enrichment	value	in	the	gut).	Results	are	represented	as	a	ratio	of	relative	abundance	in	a	given	
tissue	in	comparison	to	other	samples	Metabolite	levels	are	coloured	according	to	relative	intensity	(blue	=	low,	red	=	high,	blue<yellow<orange<red).		
Mass	 RT	 Formula	 Putative	metabolite	 Pathway	 CNS	 Gut	 MTs	 WF	
207.09	 5.94	 C11H13NO3	 N-Acetyl-L-phenylalanine	 Phenylalanine	metabolism		 0.00	 27.14	 0.00	 0.00	
219.11	 6.76	 C9H17NO5	 Pantothenate	 beta-Alanine	metabolism	 2.17	 17.72	 0.98	 1.00	
191.06	 6.20	 C7H13NO3S	 N-Acetylmethionine	 No	known	pathway	 7.49	 33.03	 8.56	 0.00	
118.03	 6.84	 C4H6O4	 Succinate	 Phenylalanine	metabolism	 4.79	 63.15	 34.16	 1.00	
169.07	 16.69	 C8H11NO3	 Pyridoxine	 Vitamin	B6	metabolism		 0.00	 16.40	 8.65	 1.00	
123.03	 8.13	 C6H5NO2	 Nicotinate	 Nicotinate	and	nicotinamide	metabolism	 10.49	 30.04	 7.65	 1.00	
146.06	 6.30	 C6H10O4	 (S)-2-Aceto-2-hydroxybutanoate	 Valine,	leucine	and	isoleucine	biosynthesis		 2.32	 8.71	 1.88	 1.00	
145.07	 6.89	 C6H11NO3	 4-Acetamidobutanoate	 Arginine	and	proline	metabolism	 1.65	 10.36	 4.37	 1.00	
582.44	 5.77	 C41H58O2	 Spheroidenone	 Carotenoid	biosynthesis	 0.00	 2.58	 0.06	 1.00	
114.03	 6.35	 C5H6O3	 2-Hydroxy-2,4-pentadienoate	 Phenylalanine	metabolism	 0.00	 20.85	 18.99	 0.00	
400.23	 11.89	 C18H32N4O6	 Ala-Leu-Thr-Pro	 Hydrophobic	peptide	 0.00	 1.98	 0.00	 1.00	
138.04	 12.81	 C6H6N2O2	 Urocanate	 Histidine	metabolism	 1.98	 6.88	 3.92	 1.00	
473.21	 11.89	 C19H31N5O9	 Glu-Thr-Gln-Pro	 Acidic	peptide	 0.00	 1.70	 0.00	 1.00	
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173.07	 6.06	 C7H11NO4	 N-Acetyl-L-glutamate	5-
semialdehyde	
Arginine	and	proline	metabolism		 4.64	 9.41	 4.93	 1.00	
426.25	 11.76	 C20H34N4O6	 Ile-Thr-Pro-Pro	 Hydrophobic	peptide	 0.00	 1.62	 0.00	 1.00	
241.11	 7.24	 C25H30N4O6	 Phe-Gly-Pro-Tyr	 Hydrophobic	peptide	 3.12	 15.15	 14.45	 1.00	
113.05	 6.08	 C5H7NO2	 1-Pyrroline-2-carboxylate	 Arginine	and	proline	metabolism	 3.68	 7.14	 3.65	 1.00	
244.07	 9.25	 C9H12N2O6	 Uridine	 Pyrimidine	metabolism	 0.11	 1.86	 0.51	 1.00	
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5.2.1.5 Metabolome	of	Drosophila	melanogaster	head	and	central	nervous	system	
Drosophila	head	contains	primarily	the	head	capsule,	some	fat	body,	brain	and	compound	
eyes.	As	a	result,	the	most	abundant	metabolites	in	the	head	are	xanthommatin	and	red	
pterin	metabolites	(Figure	5-7).	This	is	consistent	with	the	fact	that	the	head	is	enriched	in	
pigment-processing	genes,	including	sepia,	Plum,	Henna,	vermillion	and	brown	
(FlyAtlas.org).		
Fig.	5-7	The	most	abundant	metabolites	in	Drosophila	melanogaster	head.	Red	=	area	>	108	
Yellow	=	area	>	107	Blue	=	area	>	105;	WF	-	whole	fly,	HD	–	head,	MG	–	midgut,	AT	–	
anterior	tubule,	PT-	posterior	tubule,	HG	–	hindgut,	OV	–	ovaries,	TEST	–	testes,	ACCG	–	
accessory	glands,	CUT	–	cuticle,	from	[186].	
	
Central	nervous	system	(CNS)	consists	of	the	brain	and	the	ventral	nerve	cord.	
Metabolites	enriched	in	the	CNS	are	part	of	amino	acid	metabolism,	thiamine	metabolism	
and	insect	hormone	biosynthesis	(Table	5-4).	The	nervous	system	is	the	major	site	for	the	
synthesis	and	signalling	molecules	including	hormones	and	neuropeptides.	Hence,	it	
makes	sense	that	the	tissue	is	enriched	in	amino	acids	and	insect	hormones.	
Unfortunately,	it	is	not	possible	to	compare	the	two	datasets.	Even	though,	the	brain	is	
present	in	both	samples,	comparison	of	the	whole	CNS	with	the	head	would	not	be	a	
viable	one.	As	is	clear	from	the	data	obtained	from	SU,	majority	of	enriched	metabolites	
in	the	head	represent	visual	pigments,	which	might	‘mask’	compounds	related	to	the	
brain	and	the	nervous	system.	This	points	out	how	important	it	is	to	study	individual	
tissues,	and	group	samples	according	to	their	function,	i.e.	CNS	tissues	together,	rather	
than	the	whole	head.		
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Table	5-4	Metabolites	enriched	in	central	nervous	system	(the	highest	tissue	enrichment	value	in	CNS).	Results	are	represented	as	a	ratio	of	relative	
abundance	in	a	given	tissue	in	comparison	to	other	samples.	Metabolite	levels	are	coloured	according	to	relative	intensity	(blue	=	low,	red	=	high,	
blue<yellow<orange<red).	
Mass	 RT	 Formula	 Putative	metabolite	 Pathway	 CNS	 Gut	 MTs	 WF	
143.04	 8.33	 C6H9NOS	 5-(2-Hydroxyethyl)-4-methylthiazole	 Thiamine	metabolism	 93.05	 0.00	 0.00	 0.00	
210.08	 5.82	 C13H10N2O	 2-Aminoacridone	 No	known	pathway	 61.63	 0.00	 0.00	 0.00	
167.06	 5.72	 C8H9NO3	 3-Methoxyanthranilate	 Tryptophan	metabolism	 36.98	 0.00	 0.00	 0.00	
175.06	 6.02	 C10H9NO2	 Indole-3-acetate	 Tryptophan	metabolism	 35.87	 7.25	 15.23	 0.00	
251.10	 12.96	 C10H13N5O3	 Deoxyadenosine	 Purine	metabolism	 5.21	 1.18	 0.94	 1.00	
297.09	 11.04	 C11H15N5O3S	 5'-Methylthioadenosine	 Arginine	and	proline	metabolism	 7.10	 1.60	 2.19	 1.00	
158.06	 5.71	 C7H10O4	 2-Isopropylmaleate	 Valine,	leucine	and	isoleucine	
biosynthesis	
2.77	 0.38	 0.97	 1.00	
148.05	 5.79	 C9H8O2	 trans-Cinnamate	 Phenylalanine	metabolism	 21.67	 16.07	 12.99	 0.00	
190.08	 5.81	 C8H14O5	 (R)-3-((R)-3-
Hydroxybutanoyloxy)butanoate	
Butanoate	metabolism	 8.71	 5.32	 5.45	 1.00	
446.34	 5.26	 C28H46O4	 3-Dehydroteasterone	 Brassinosteroid	biosynthesis	 3.95	 3.07	 1.65	 1.00	
270.18	 5.64	 C15H26O4	 (10S)-Juvenile	hormone	III	acid	diol	 Insect	hormone	biosynthesis	 2.61	 1.73	 1.54	 1.00	
282.18	 5.64	 C16H26O4	 12-trans-Hydroxy	juvenile	hormone	
III	
Insect	hormone	biosynthesis	 2.70	 1.86	 1.83	 1.00	
141.04	 6.20	 C6H7NO3	 6-oxo-1,4,5,6-tetrahydronicotinate	 Nicotinate	and	nicotinamide	
metabolism	
7.10	 9.04	 4.17	 1.00	
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Altogether	these	results	confirmed	that	tissue	metabolomes	differ	from	the	whole	fly	and	
from	each	other.	These	differences	seem	to	reflect	functional	differences	between	
individual	tissues	and	provide	new	hypotheses	about	tissue-tissue	interactions.	However,	
some	metabolites	and	metabolic	pathways	are	conserved	among	tissues.	Moreover,	the	
results	validated	the	method	for	the	study	of	individual	Drosophila	tissues.	Based	on	
these	findings,	we	studied	purine	metabolism	mutants	using	whole	flies	as	well	as	
individual	tissues.			
5.2.2 Metabolomics	analysis	of	mutants	of	purine	metabolism	
Two	different	sets	of	experiments	were	performed:	one	using	adult	flies	and	another	one	
using	L3	larva.	Experiments	in	the	adult	consisted	of	whole	flies	and	Malpighian	tubules.	
The	fly	lines	used	were	BDSC	18554,	and	BDSC	17767	flies.	After	performing	these	
experiments,	we	realised	that	it	would	be	more	informative	to	use	larval	tissues	and	
include	BDSC	18814	(UO	mutant)	flies.	Hence,	larval	experiments	were	performed	using	
L3	Malpighian	tubules	and	whole	larvae,	and	the	fly	lines	used	were	BDSC	18554,	BDSC	
18814	and	BDSC	17767	flies.	Complete	data	sets	can	be	viewed	in	Appendix	VII	and	VIII.		
5.2.2.1 Adult	fly	metabolomes	
210	metabolites	were	identified	in	whole	fly	samples,	and	146	metabolites	in	adult	
Malpighian	tubules.	The	instrument	settings	as	well	as	data	analysis	are	described	in	
Materials	and	Methods	(Chapter	2.16).	The	relative	abundance	of	the	experimental	group	
(BDSC18554)	was	expressed	as	explained	in	chapter	5.2.1	relative	to	the	mean	signal	
intensity	of	the	control	group	(BDSC17767).	Metabolite	levels	were	coloured	according	to	
relative	abundance	(blue	=	low,	red	=	high)	(Appendix	VII	and	VIII).	Moreover,	t-test	was	
performed	and	where	the	P-value	(from	t-test	against	control	group)	was	less	than	0.05,	
the	data	was	analysed	further.	Based	on	our	hypothesis	that	CG30016	is	a	5-
hydroxyisourate	hydrolase,	we	expected	to	see	differences	in	purine	metabolism	
between	the	mutant	and	the	control.	If	CG30016	were	a	5-HIU	hydrolase,	metabolites	
upstream	from	the	knockout	would	be	enriched	and	the	ones	downstream	would	be	
decreased.		
In	both	whole	fly	and	MTs,	purine	metabolites	were	detected	and	were	among	the	most	
abundant	metabolites	in	the	mutant	(Tables	5-5	and	5-6).	Metabolites	involved	in	
numerous	other	pathways	were	also	detected	and	enriched	in	both	whole	fly	and	MTs.	It	
	148
is	interesting	to	see	that	a	single	gene	knock	out	in	the	fly	affects	several	unrelated	
pathways	(Figure	5-8).	Among	detected	metabolites,	the	majority	were	part	of	lipid	and	
amino	acid	metabolism.	However,	this	does	not	reflect	the	differences	between	the	
mutant	and	the	control.	This	could	be	because	the	detection	method	is	more	sensitive	to	
these	metabolites	or	simply	because	there	are	more	amino	acids	and	lipids	in	the	samples	
than	other	type	of	compounds.	
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Table	5-5	The	most	abundant	metabolites	in	whole	CG30016	mutant	flies.	Metabolite	
names	in	bold	are	identifications,	for	which	standards	were	available	and	run	alongside	
experimental	samples.		
Metabolite	name	 Map	 KEGG	Pathway	 P-value	 BDSC	18554	
(mutant)	
Xanthurenic	acid	 Amino	acid	
metabolism	
Tryptophan	
metabolism	
0.001	 28.31	
2-
Methoxyhexadecanoic	
acid	
Lipid	
metabolism		
Fatty	acids	and	
conjugates	
0.031	 6.82	
D-Sorbitol	 Carbohydrate	
metabolism	
Fructose	and	
mannose	
metabolism	
0.023	 6.38	
Imidazole-4-acetate	 Amino	acid	
metabolism	
Histidine	
metabolism	
0.040	 4.08	
Guanosine	 Nucleotide	
metabolism	
Purine	
metabolism	
0.008	 3.31	
L-Citrulline	 Amino	acid	
metabolism	
Arginine	and	
proline	
metabolism	
0.001	 2.96	
Inosine	 Nucleotide	
metabolism	
Purine	
metabolism	
0.009	 2.58	
Imidazole-4-
acetaldehyde	
Amino	acid	
metabolism	
Histidine	
metabolism	
0.002	 2.52	
4-
Trimethylammoniobut
anoate	
Amino	acid	
metabolism	
Lysine	
degradation	
0.013	 2.28	
Xanthine	 Nucleotide	
metabolism		
Purine	
metabolism	
0.049	 2.01	
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Table	5-6	The	most	abundant	metabolites	in	Malpighian	tubules	of	adult	CG30016	mutant	
flies.	Metabolite	names	in	bold	are	identifications,	for	which	standards	were	available	and	
run	alongside	experimental	samples.		
Metabolite	name	 Map	 KEGG	Pathway	 P-value	 BDSC	18554	
(mutant)	
5-Hydroxy-2-oxo-4-
ureido-2,5-dihydro-
1H-imidazole-5-
carboxylate	(OHCU)	
Nucleotide	
metabolism	
Purine	
metabolism	
0.036	 5.751	
O-Propanoylcarnitine	
Lipid	
metabolism		
Oxidation	of	
branched	fatty	
acids	
0.044	 4.51	
D-Glucose	6-
phosphate	
Carbohydrate	
metabolism	
Starch	and	
sucrose	
metabolism	
0.011	 3.38	
L-Carnitine	
Amino	acid	
metabolism	
Lysine	
degradation	
0.010	 2.98	
Glutathione	disulfide	
Amino	acid	
metabolism	
Glutathione	
metabolism	
0.018	 2.31	
Urate	
Nucleotide	
metabolism	
Purine	
metabolism	
0.049	 2.25	
Allantoin	
Nucleotide	
metabolism	
Purine	
metabolism	
0.042	 1.83	
5-Hydroxyisourate	
Nucleotide	
metabolism		
Purine	
metabolism	
0.046	 1.52	
Guanosine	
Nucleotide	
metabolism	
Purine	
metabolism	
0.034	 1.48	
L-Kynurenine	
Amino	acid	
metabolism	
Tryptophan	
metabolism	
0.012	 1.44	
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The	top	10	metabolites	enriched	in	whole	knockout	flies	are	illustrated	in	Table	5-5.	
Among	the	most	abundant	metabolites,	three	are	part	of	purine	metabolism:	guanosine,	
inosine	and	xanthine.	Interestingly,	the	single	most	abundant	metabolite	is	xanthurenic	
acid,	which	is	a	part	of	tryptophan	metabolism.	On	the	other	hand,	in	the	tubules,	the	
single	most	abundant	metabolite	is	OHCU	(Table	5-6).	Moreover,	other	metabolites	
involved	in	urate	degradation	are	enriched	in	the	mutant	tubule,	including	urate,	5-HIU	
and	allantoin.		
There	are	clear	differences	between	the	whole	fly	and	the	MTs	analyses.	Some	purine	
metabolism	metabolites,	including	5-HIU	and	OHCU,	were	not	detected	in	the	whole	fly	
at	all.	Moreover,	the	results	for	certain	metabolites	are	very	different	in	the	whole	fly	and	
MTs.	This	could	be	due	to	metabolites	present	in	other	tissues	‘masking’	the	results	
specific	to	MTs	and	purine	metabolism.	Since	the	urate	degradation	pathway	takes	place	
in	the	MTs	and	CG30016	is	expressed	almost	exclusively	in	the	tubule,	it	makes	more	
sense	to	use	individual	tissue	for	this	kind	of	analysis	rather	than	the	whole	fly.	This	way	
the	method	is	more	sensitive	and	provides	more	details	on	the	pathway	of	interest.		
Fig.	5-8	Metabolic	pathways	affected	by	the	knockout	of	CG30016	in	whole	flies.		
	
PCA	analysis	was	performed	using	MetaboAnalyst	(http://www.metaboanalyst.ca),	an	
open-source	platform	for	metabolomics	data	analysis	[258,	458].	The	analysis	was	carried	
out	in	order	to	determine	how	varied	the	replicates	were	within	each	sample,	whether	
they	clustered	together,	and	whether	there	were	differences	between	the	control	and	
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the	mutant	samples.	The	results	are	illustrated	in	Figure	5-9.	In	both	the	whole	fly	(Figure	
5-9A)	and	the	MTs	(Figure	5-9B),	control	samples	(red)	clustered	away	from	mutant	
samples	(green).	Moreover,	there	was	variability	between	replicates	within	both	samples.		
	
Fig.	5-9	Results	of	the	PCA	analysis:	red	dots	represent	control	sample	replicates	(BDSC	
17767),	and	green	dots	represent	mutant	sample	replicates	(BDSC	18554).	(A)	PCA	of	the	
whole	fly	samples,	(B)	and	Malpighian	tubule	samples.	In	Both	the	whole	fly	and	MTs,	
replicates	of	each	sample	are	more	related	to	each	other	than	the	other	sample.	
Generated	using	MetaboAnalyst	(http://www.metaboanalyst.ca).	
	
5.2.2.2 Adult	fly	metabolomes	–	purine	metabolism		
Within	purine	metabolism	9	(Malpighian	tubules)	and	8	(whole	fly)	metabolites	with	
different	abundance	in	the	control	and	the	mutant	were	detected	(Figures	5-10A	and	5-
11A).	Whereas	in	the	whole	fly	most	abundant	purine	metabolites	were	not	directly	
involved	in	5-HIU	hydrolase	reaction,	in	MTs	the	four	most	abundant	metabolites	were	
urate,	5-HIU,	OHCU	and	allantoin.	Moreover,	the	single	most	abundant	metabolite	in	the	
tubule	was	OHCU	(Table	5-6),	which	is	a	product	of	the	reaction	catalysed	by	5-HIUH.	
OHCU	concentration	in	CG30016	mutant	tubules	was	increased	5.75-fold	when	compared	
to	the	control.	This	is	opposite	to	what	we	expected.	It	is	also	surprising	to	see	that	the	
abundance	of	allantoin	is	higher	in	the	mutant	than	the	control	MTs.	On	the	other	hand,	
as	predicted,	5-HIU	and	other	metabolites	upstream	from	5-HIU	hydrolase	were	enriched	
in	the	mutant	(Figure	5-10B	and	5-11B).	The	only	exception	is	adenine,	which	is	enriched	
in	the	control.	
	 	A	 B	
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Fig.	5-10	Changes	in	purine	metabolism	in	the	whole	fly	caused	by	the	knockout	of	CG30016.	(A)	KEGG	map	of	Drosophila	melanogaster	purine	
metabolism;	red	circles	represent	metabolites	that	were	identified	by	the	LC-MS	analysis.	(B)	Abundance	of	metabolites	involved	in	purine	metabolism	
compared	between	the	knockout	and	the	control	flies.	Asterisk	indicates	statistically	significant	differences.	The	abundance	is	represented	as	the	signal	
intensity.		
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The	results	in	the	whole	fly	differ	from	the	ones	in	the	MTs.	For	example,	the	abundance	
of	allantoin	is	higher	in	the	mutant	tubule	than	the	control	(Figure	5-11B).	In	the	whole	fly	
on	the	other	hand,	allantoin	is	enriched	in	the	control	when	compared	to	the	mutant	
(Figure	5-10B).	This	might	reflect	the	differential	distribution	of	metabolites	across	the	
tissues.	Perhaps	the	concentration	of	allantoin	increased	in	mutant	tubules	but	not	other	
tissues	resulting	in	lower	levels	of	allantoin	in	the	whole	fly.	Once	again,	this	confirms	that	
it	is	more	informative	to	perform	metabolomics	analysis	in	the	tissue	of	interest	rather	
than	the	whole	organism.		
Interestingly,	allantoin	has	two	isoforms	and	it	is	impossible	to	distinguish	between	them	
using	LC-MS.	In	fact	one	of	the	isoforms	(R)-allantoin	is	a	product	of	non-enzymatic	
degradation	of	OHCU,	and	(S)-allantoin	is	a	product	of	OHCU	conversion	catalysed	by	
OHCU	decarboxylase	[355,	461].	Here,	it	is	impossible	to	tell,	which	isoform	is	enriched	in	
the	tubules	and	the	whole	fly.	
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Fig.	5-11	Changes	in	purine	metabolism	in	adult	Malpighian	tubules	caused	by	the	knockout	of	CG30016.	(A)	KEGG	map	of	Drosophila	melanogaster	
purine	metabolism;	red	circles	represent	metabolites	that	were	identified	in	adult	Malpighian	tubules	by	the	LC-MS	analysis.	
	
A	
B	
Gu
an
os
ine
Ino
sin
e
Ad
en
os
ine
*
Ad
en
ine
*
Xa
nt
hin
e*
0
50000
100000
150000
200000
Adult	Malpighian	tubules:	urate	synthesis
In
te
ns
ity
BDSC	18554	(mutant)	
BDSC	17767	(control)	
0
1000000
2000000
3000000
4000000
In
te
ns
ity
Adult	Malpighian	 ubules:	ur te
BDSC	18554	(mutant)	
BDSC	17767	(control)	
Urate* 5-
HIU
*
OH
CU
*
All
an
toi
n*
0
50000
100000
150000
200000
250000
In
te
ns
ity
Adult	Malpighian	tubules:	urate	degrada=on
BDSC	18554	(mutant)	
BDSC	17767	(control)	
	156
	
Fig.	5-11	Changes	in	purine	metabolism	in	adult	Malpighian	tubules	caused	by	the	knockout	of	CG30016.	(B)	Abundance	of	metabolites	involved	in	purine	
metabolism	compared	between	the	knockout	and	the	control	flies;	(left)	metabolites	involved	in	urate	synthesis	(upstream	from	5-HIU	hydrolase	and	
predicted	function	of	CG30016),	(middle)	abundance	of	urate	in	both	fly	lines,	(right)	abundance	of	metabolites	downstream	from	urate,	involved	in	
urate	degradation.	Asterisk	indicates	statistically	significant	differences.	The	abundance	is	represented	as	the	signal	intensity.
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Our	results	clearly	indicate	that	CG30016	is	involved	in	purine	metabolism	and	specifically	
urate	degradation	pathway.	However,	it	is	impossible	to	conclude	whether	CG30016	is	a	
5-HIU	hydrolase.	In	fact	there	are	several	possible	conclusions	based	on	the	results.	One	
of	the	possibilities	is	that	the	enrichment	of	OHCU	in	the	mutant	tubule	reflects	
decreased	activity	of	OHCU	decarboxylase.	This	would	indicate	that	the	CG30016	mutant	
is	the	OHCU	decarboxylase	rather	than	a	5-HIU	hydrolase	knockout,	and	that	CG30016	
codes	for	OHCU	decarboxylase.	This	is	unlikely	because	CG30016	has	no	sequence	
similarity	to	other	OHCU	decarboxylases	and	has	no	decarboxylase	domain.		
An	alternative	explanation	is	that	CG30016	is	a	5-HIU	hydrolase	and	its	knockout	can	be	
observed	as	5-HIU	enrichment	in	the	mutant	tubules.	However,	since	5-HIU	can	degrade	
spontaneously	to	OHCU	and	allantoin,	both	metabolites	are	also	enriched	in	the	tubule.	
However,	because	LC-MS	cannot	differentiate	between	different	isoforms	of	allantoin,	it	
is	impossible	to	fully	support	this	hypothesis.		
5.2.2.3 Mutant	larva	metabolomes	
Metabolomics	analysis	was	performed	using	whole	L3	larvae	as	well	as	larval	MTs,	and	
was	carried	out	by	myself	at	SU	facility.	Metabolites	were	identified	and	quantified	using	
Xcalibur	software	combined	with	Sieve	Software	1.3	(Thermo	Fisher	Co.).	The	abundance	
of	metabolites	was	calculated	and	expressed	as	intensity,	and	compared	between	the	
CG30016	and	UO	mutant	and	the	control.	Except	metabolites	that	matched	masses	and	
retention	times	of	standards,	all	metabolites	were	putatively	identified.	All	masses	where	
within	1.5	ppm	of	the	exact	molecular	formula.	This	means	that	the	only	competing	
metabolites	within	the	database	search	were	isomers.	A	t-test	was	performed	to	establish	
statistical	significance,	and	where	the	P-value	was	below	0.05,	the	data	were	analysed	
further.	In	both	cases	there	were	differences	in	metabolite	abundance	within	purine	
metabolism	between	mutants	and	the	control	(Figure	5-12)	(for	original	data	see	
Appendices	X,	XI	and	XII).	Unfortunately,	the	metabolites	directly	upstream	and	
downstream	from	5-HIU	hydrolase	(5-HIU	and	OHCU)	were	not	detected.	This	could	be	
because	they	are	both	unstable	as	opposed	to	urate	and	allantoin	that	were	detected.		
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Fig.	5-13	Changes	in	purine	metabolism	in	whole	larvae	caused	by	the	knockout	of	UO	and	
CG30016.	Abundance	of	metabolites	involved	in	purine	metabolism	compared	between	the	
knockouts	and	the	control	flies	is	represented	as	the	signal	intensity.	Asterisk	indicates	
statistically	significant	differences.	(A-E)	Metabolites	are	represented	in	several	graphs	
depending	on	the	signal	intensity.	Metabolites	upstream	from	UO	and	predicted	CG30016	
are	illustrated	in	figures	A-D,	and	the	ones	downstream	from	the	lesion	are	lustrated	in	
figure	E.		
	
The	analysis	was	also	performed	for	larval	tubules.	It	was	carried	out	separately	for	
anterior	and	posterior	tubules	because	of	an	observation	in	Chapter	3.2.1	that	there	are	
more	urate	crystals	in	the	posterior	tubule	of	L3	larvae.		
In	the	UO	mutant,	levels	of	most	metabolites	upstream	from	UO	were	higher	in	the	
mutant	posterior	tubule	than	in	the	control	(Figure	5-14A-C).	The	only	exception	was	
hypoxanthine,	which	is	higher	in	the	control.	The	greatest	difference	is	urate,	which	is	
highly	enriched	in	the	mutant	(Figure	5-14C).	Similar	results	were	observed	in	the	anterior	
tubule.	However,	the	differences	between	the	mutant	and	the	control	were	smaller	than	
in	the	posterior	tubule.	This	is	consistent	with	the	results	in	Chapter	3.2.1,	where	less	
urate	crystals	were	observed	in	the	anterior	tubule.	Moreover,	there	were	no	significant	
differences	in	the	abundance	of	adenosine,	guanosine,	inosine	and	hypoxanthine	
between	the	mutant	and	the	control.	Altogether,	these	results	confirm	the	role	of	UO	in	
Drosophila	tubules.		
In	both	anterior	and	posterior	tubules	there	were	no	significant	differences	in	the	
abundance	of	allantoin	and	allantoate	between	the	mutant	and	the	control.	This	is	
surprising	as	we	expected	to	observe	a	pattern	similar	to	the	whole	larvae,	with	
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decreased	allantoin	in	the	mutant.		
Fig.	5-14	Changes	in	purine	metabolism	in	larval	posterior	Malpighian	tubules	caused	by	
the	knockout	of	UO	and	CG30016.	Abundance	of	metabolites	involved	in	purine	
metabolism	compared	between	the	knockouts	and	the	control	flies	is	represented	as	the	
signal	intensity.	Asterisk	indicates	statistically	significant	differences.	(A-D)	Metabolites	
are	represented	in	several	graphs	depending	on	the	signal	intensity.	Metabolites	upstream	
from	UO	and	predicted	CG30016	are	illustrated	in	figures	A-C,	and	the	ones	downstream	
from	lesions	are	lustrated	in	figure	D.		
	
In	terms	of	the	CG30016	mutant,	the	results	are	also	different	between	the	posterior	and	
anterior	tubule.	In	the	posterior	tubule,	urate	is	more	abundant	in	the	mutant	than	in	the	
control,	and	so	is	guanosine.	However,	the	levels	of	adenine,	inosine	and	hypoxanthine	
are	lower	in	the	knockout	than	in	the	control	(Figure	5-15A-C).	This	is	surprising	and	might	
not	be	a	direct	result	of	CG30016	knockout	but	rather	a	difference	between	individual	
flies.	In	the	anterior	tubule,	both	urate	and	adenine	are	less	abundant	in	the	mutant	than	
the	control	and	there	are	no	statistically	significant	differences	for	other	metabolites.	In	
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both	posterior	and	anterior	tubules	there	are	no	difference	in	the	level	of	allantoin	and	
allantoate	between	the	mutant	and	the	control.	These	results	suggest	that	CG30016	is	
involved	in	purine	metabolism	and	urate	degradation	pathway.	However,	it	might	play	a	
different	role	or	be	expressed	at	different	levels	in	anterior	and	posterior	tubules.	One	of	
the	reasons	for	this	could	be	a	functional	difference	between	the	anterior	and	posterior	
tubule.	For	example,	the	anterior	tubule	might	not	contribute	to	urate	degradation	
pathway	as	much	as	the	posterior	tubule.	Hence,	more	urate	crystals	were	observed	in	
the	posterior	tubule	(Chapter	3.2.1),	as	well	as	greater	effects	of	UO	and	CG30016	
knockout	on	the	levels	of	urate	degradation	metabolites	in	the	posterior	tubule.		
Fig.	5-15	Changes	in	purine	metabolism	in	larval	anterior	Malpighian	tubules	caused	by	the	
knockout	of	UO	and	CG30016.	Abundance	of	metabolites	involved	in	purine	metabolism	
compared	between	the	knockouts	and	the	control	flies	is	represented	as	the	signal	
intensity.	Asterisk	indicates	statistically	significant	differences.	(A-C)	Metabolites	are	
represented	in	several	graphs	depending	on	the	signal	intensity.	Metabolites	upstream	
from	UO	and	predicted	CG30016	are	illustrated	in	figures	A-B,	and	the	ones	downstream	
from	lesions	are	lustrated	in	figure	C.		
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Fig.	5-12	KEGG	map	of	Drosophila	melanogaster	purine	metabolism	showing	changes	in	
purine	metabolism	in	L3	larvae	caused	by	the	knockout	of	CG30016;	red	circles	represent	
metabolites	that	were	identified	in	by	the	LC-MS	analysis.	
	
In	whole	larva,	metabolites	upstream	from	UO,	were	increased	in	BDSC	18814	mutant	
(Figure	5-13A-D).	The	biggest	difference	between	the	mutant	and	the	control	was	urate,	
which	was	highly	enriched	in	BDSC	18814	flies.	This	confirms	that	the	mutant	is	a	UO	
knockout.	Moreover,	the	abundance	of	allantoin	was	lower	in	the	mutant	than	in	the	
control,	which	is	consistent	with	previous	results.	There	was	no	significant	difference	
between	the	levels	of	allantoate	in	the	mutant	and	the	control	(Figure	5-13E).		
In	CG30016	mutant	on	the	other	hand,	the	levels	of	urate	were	lower	than	in	the	control	
as	well	as	BDSC	18814	flies.	This	was	also	true	for	other	metabolites	upstream	from	UO	
except	hypoxanthine.	There	was	no	significant	difference	in	hypoxanthine	levels	between	
different	fly	lines	(Figure	5-13A-D).	As	was	in	the	UO	mutant,	allantoin	was	more	
abundant	in	the	control	than	the	mutant.	This	suggests	that	CG30016	knockout	results	in	
the	blockage	of	urate	degradation	pathway.	However,	it	does	not	establish	its	exact	role	
in	the	pathway.		
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Altogether,	these	results	confirm	the	role	of	Drosophila	UO	gene	and	suggest	that	
CG30016	is	involved	in	urate	degradation	pathway.	However,	the	role	of	CG30016	as	5-
HIU	hydrolase	has	not	been	confirmed.	Unfortunately,	5-HIU	and	OHCU	were	not	
detected	in	the	analysis.	Once	again,	this	could	be	because	both	metabolites	are	unstable	
and	might	not	always	be	detected	in	LC-MS.		
5.2.3 Metabolomes	of	secreted	fluid		
In	this	experiment	364	metabolites	were	identified	using	methods	described	in	Chapter	
2.16.	Metabolite	levels	for	each	experimental	group	were	expressed	as	mean	peak	
intensity	(height)	relative	to	the	mean	peak	intensity	of	the	control	group	(Schneider’s	
medium).	Metabolite	levels	are	coloured	according	to	relative	intensity	(blue	=	low,	red	=	
high)	(Appendix	IX).	Moreover,	t-test	was	performed	and	where	the	P-value	(from	t-test	
against	control	group)	is	less	than	0.05,	the	intensity	is	highlighted	in	bold	in	the	original	
spreadsheet.		
Metabolites	identified	in	the	secreted	fluid	are	part	of	several	pathways	including	purine	
and	tryptophan	metabolism	(Table	5-7).	This	is	consistent	with	our	previous	results	
showing	that	the	tubule	is	enriched	in	tryptophan-related	metabolites	as	well	as	
members	of	the	purine	metabolism.	
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Table	5-7	The	most	abundant	metabolites	in	secreted	fluid.	Metabolite	levels	are	
expressed	as	mean	peak	intensity	relative	to	the	mean	peak	intensity	of	the	control	group	
(Schneider’s	medium).	Metabolite	names	highlighted	in	bold	are	chemicals	matched	to	
standards	by	exact	mass	and	retention	time.		
Metabolite	name	 Map	 KEGG	Pathway	 Schneider’s	
medium	
(control)	
Canton	S	
(sample)	
L-Kynurenine	 Amino	acid	
metabolism	
Tryptophan	
metabolism	
0.00	 697.73	
3-Hydroxy-L-
kynurenine	
Amino	acid	
metabolism	
Tryptophan	
metabolism	
0.00	 196.37	
Urate	 Nucleotide	
metabolism	
Purine	metabolism	 1.00	 156.89	
Xanthurenic	acid	 Amino	acid	
metabolism	
Tryptophan	
metabolism	
0.00	 125.81	
Guanosine	 Nucleotide	
metabolism	
Purine	metabolism	 0.00	 74.66	
D-Glucose	6-
phosphate	
Carbohydrate	
metabolism	
Starch	and	sucrose	
metabolism	
0.00	 71.29	
5-
Hydroxyindoleacetate	
Amino	acid	
metabolism	
Tryptophan	
metabolism	
0.00	 63.71	
S-Adenosyl-L-
methionine	
Amino	acid	
metabolism	
Arginine	and	proline	
metabolism	
0.00	 56.43	
Inosine	 Nucleotide	
metabolism	
Purine	metabolism	 1.00	 49.25	
3'-AMP	 Nucleotide	
metabolism	
Purine	metabolism	 1.00	 31.57	
4-
Acetamidobutanoate	
Amino	acid	
metabolism	
Arginine	and	proline	
metabolism	
1.00	 26.63	
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Cys-Thr-Ser-Ser	 Peptides	 Polar	peptide	 0.00	 23.01	
2-Methyl-1-
hydroxypropyl-ThPP	
Amino	acid	
metabolism	
Valine,	leucine	and	
isoleucine	
degradation	
0.00	 21.72	
2-Aminophenol	 Amino	acid	
metabolism	
Tryptophan	
metabolism	
0.00	 20.77	
Phe-Ala-Gly	 Peptides	 Hydrophobic	
peptide	
0.00	 18.20	
(S)(+)-Allantoin	 Nucleotide	
metabolism	
Purine	metabolism	 0.00	 17.45	
L-Formylkynurenine	 Amino	acid	
metabolism	
Tryptophan	
metabolism	
1.00	 14.79	
Choline	phosphate	 Lipid	
metabolism	
Glycerophospholipid	
metabolism	
1.00	 13.97	
L-2-Aminoadipate	 Amino	acid	
metabolism	
Lysine	biosynthesis	 0.00	 10.85	
Methylglyoxal	 Amino	acid	
metabolism	
Glycine,	serine	and	
threonine	
metabolism	
0.00	 10.24	
	
The	experiment	was	performed	using	secreted	fluid	of	wild-type	Canton	S	flies.	The	main	
focus	was	on	the	purine	metabolism	in	order	to	test	the	method	as	a	suitable	one	to	
study	purine	metabolism	mutants.	Hence,	we	looked	at	purine	metabolism	metabolites	
to	test	whether	they	are	detected	in	the	secreted	fluid.	Figure	5-16	shows	that	numerous	
metabolites	involved	in	purine	metabolism	were	identified.	Among	these,	most	were	
significantly	enriched	in	the	secreted	fluid	in	comparison	to	the	control.	The	exceptions	
were	adenine	and	xanthine,	which	were	enriched	in	the	Schneider’s	medium	(Figure	5-
16A).	β-Alanine	is	one	of	the	ingredients	found	in	Schneider’s	medium	and	so	it	is	likely	
that	the	results	reflect	this.	However,	it	is	not	clear	why	xanthine	is	enriched	in	the	
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medium	but	not	the	secreted	fluid.		
Altogether	these	results	showed	that	LC-MS	is	a	suitable	technique	not	only	for	tissues	
and	whole	organism	studies	but	also	secreted	fluid.	It	also	validated	the	method	for	the	
study	of	Drosophila	melanogaster	mutants	described	in	previous	Chapter.		
Fig.	5-16	Metabolites	involved	in	purine	metabolism	enriched	in	secreted	fluid	in	
comparison	to	Schneider’s	medium.	Abundance	of	metabolites	is	represented	as	the	signal	
intensity.	Asterisk	indicates	statistically	significant	differences.	(A)	All	metabolites	
involved	in	purine	metabolism	are	illustrated.	(B)	Metabolites	involved	in	urate	
degradation	pathway	and	downstream	from	urate	are	illustrated.		
5.3 Discussion	
Our	results	show	that	tissue	metabolomes	differ	significantly	from	each	other	and	from	
the	whole	fly.	These	differences	seem	to	be	correlated	to	tissue	function	and	require	
further	analysis.	In	the	future	it	would	be	interesting	to	perform	tissue	metabolomics	
using	more	than	four	replicates,	since	we	observed	a	lot	of	variability	between	replicates.	
These	results	are	consistent	with	FlyAtlas	findings	that	tissue	transcriptomes	differ	and	
the	differences	are	functionally	significant	[4].	However,	it	is	important	to	note	that	some	
metabolites	and	metabolic	pathways	are	conserved	among	tissues,	which	might	reflect	
the	fact	that	some	organismal	functions	are	not	tissue-specific.	Moreover,	we	validated	
LC-MS	based	metabolomics	as	a	suitable	method	to	study	individual	tissues	and	changes	
between	flies	with	different	genotypes.	It	is	also	clear	that	comparing	two	different	data	
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sets	performed	at	different	times	and	different	facilities	requires	a	standard	protocol.	
Most	importantly,	it	has	been	noted	here	that	the	comparison	is	possible	only	when	the	
samples	contain	the	same	tissues	(i.e.	the	head	sample	cannot	be	compared	to	CNS,	mid	
gut	cannot	be	compared	to	the	whole	gut	etc.).		
Our	results	confirmed	that	knocking	out	UO	in	the	fruit	fly	results	in	build	up	of	urate	and	
upstream	metabolites	and	decrease	of	downstream	metabolites.	Moreover,	more	urate	
was	detected	in	the	posterior	than	anterior	tubule.	This	is	consistent	with	our	previous	
observation	that	more	urate	crystals	are	visible	in	the	posterior	tubule	of	the	mutant.	This	
validates	the	method	and	confirms	it	is	suitable	for	the	detection	of	changes	in	
metabolite	abundance	as	a	result	of	a	single-gene	mutation.	Moreover,	it	revealed	that	
single	tissue	metabolomics	is	more	informative	in	this	case	than	whole	fly	analysis.		
Following	on	from	this	finding,	metabolomics	analysis	of	urate	degradation	mutants	was	
performed.	These	results	confirm	that	CG30016	is	involved	in	urate	degradation	pathway.	
It	is	clear	that,	in	MTs	of	CG30016	mutant	urate	degradation	is	blocked	because	of	build	
up	of	metabolites	upstream	from	expected	knockout	and	decrease	of	downstream	
metabolites.	However,	it	is	impossible	to	establish	its	exact	role	in	the	pathway	based	on	
the	results.	Moreover,	our	results	of	mutant	tubules	revealed	that	single-gene	mutations	
not	only	influence	levels	of	metabolites	next	to	a	knockout,	but	also	affect	numerous	
unrelated	metabolic	pathways.	This	highlights	how	small	changes	affect	hundreds	of	
reactions	in	an	organism.	In	order	to	determine	the	role	of	CG30016	in	the	fruit	fly,	
further	research	is	required.	Following	hypotheses	would	be	tested:	
1. CG30016	is	a	5-HIU	hydrolase	and	the	increased	5-HIU	in	knockout	tubules	result	in	the	
increase	of	OHCU	and	allantoin,	which	is	the	outcome	of	the	non-enzymatic	reaction.	In	
order	to	test	this	hypothesis,	the	differentiation	between	different	isoforms	would	be	
required,	which	is	currently	not	possible	with	available	equipment.		
2. CG30016	mutant	is	OHCU	decarboxylase.	This	is	unlikely	because	CG30016	has	no	
sequence	similarity	to	other	OHCU	decarboxylases	and	has	no	decarboxylase	domain.	
However,	the	gene	could	code	for	a	novel	decarboxylase,	which	is	not	similar	to	other	
OHCU	decarboxylases	but	catalyses	the	same	reaction.	Once	again,	differentiation	
between	allantoin	isoforms	would	help	answer	this	question.		
3. Drosophila	CG30016	is	a	bifunctional	enzyme	playing	a	role	of	both	5-HIUH	and	OHCU	
decarboxylase.	This	phenomenon	was	observed	in	some	organisms	(A.	thaliana	and	
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Bacillus	subtilis),	in	which	two	enzymes	are	fused	into	a	single	polypeptide	[102,	462-464].	
However,	the	fact	that	CG30016	is	missing	a	decarboxylase	domain	makes	this	hypothesis	
unlikely.		
4. There	are	two	5-HIU	hydrolases	and	only	one	of	them	is	encoded	by	CG30016.	It	forms	a	
complex	with	OHCU	decarboxylase	and	is	essential	for	its	function	so	when	it	is	missing,	
OHCU	is	not	converted	to	allantoin	and	builds	up.	The	other	enzyme	provides	enough	
activity	to	convert	5-HIU	to	OHCU	and	is	not	encoded	by	CG30016,	which	results	in	OHCU	
built	up.	
5. There	is	an	alternative	pathway	for	the	breakdown	of	urate	to	allantoin.		
Moreover,	the	technique	has	several	limitations,	which	we	observed	during	these	
experiments.	Solving	them	would	increase	the	chance	to	identify	the	role	of	CG30016.	For	
example,	it	would	be	useful	to	obtain	all	the	standards	for	urate	degradation	
intermediates.	This	is	particularly	challenging	because	5-HIU	and	OHCU	are	unstable.	
Another	problem	we	encountered	was	no	detection	of	5-HIU	and	OHCU	in	larval	samples.	
Once	again,	this	is	probably	due	to	their	instability.	It	is	necessary	in	this	case	to	come	up	
with	a	solution	or	a	technique	that	would	overcome	this	problem.	Perhaps,	using	another	
column	or	combination	of	different	columns	for	the	LC	would	improve	the	detection	of	
these	metabolites.	Finally,	developing	a	technique	to	distinguish	between	allantoin	
isoforms	would	allow	distinguishing	between	the	spontaneous	and	enzymatic	pathways	
of	urate	degradation.	For	example	CD-spectroscopy	can	be	used	to	obtain	spectra	of	
allantoin	and	determine	its	configuration.		
The	analysis	of	secreted	fluid	showed	that	LC-MS	is	not	only	suitable	for	the	analysis	of	
individual	fly	tissues	but	also	secreted	fluid.	Moreover,	metabolites	involved	in	purine	
metabolism	were	detected,	including	5-HIU	and	OHCU.	It	would	be	interesting	to	perform	
this	experiment	using	secreted	fluid	from	urate	degradation	mutant	tubules.	It	might	be	
easier	to	detect	the	unstable	metabolites	than	in	the	whole	tissue.		
Finally,	general	limitations	of	metabolomics	presented	in	Chapter	1.3.5	are	the	main	
challenge	in	our	work,	including	metabolite	identification	and	quantification,	data	
interpretation,	data	visualisation	and	integration	of	metabolomics	data,	and	data	
obtained	from	other	omics.	Our	results	showed	that	metabolomics	is	very	complex	and	
requires	time-consuming	analysis.	It	is	a	fantastic	method	to	generate	new	hypotheses	
and	provide	a	big	picture	of	metabolic	state	of	a	given	sample.	However,	it	is	quite	
	168
challenging	when	looking	at	individual	pathways	and	metabolites	and	in	order	to	provide	
answers	to	hypotheses.	Statistical	analysis	of	metabolomics	data	presented	a	great	
challenge,	especially	in	case	of	tissue-specific	metabolomes,	where	multiple	study	groups	
were	compared.	It	stresses	the	importance	of	biostatistics	and	bioinformatics	expertise	in	
case	of	metabolomics	studies.	Selecting	the	correct	statistical	method	and	visualisation	
tools	is	crucial	for	data	interpretation	of	LC-MS	results.	Collaboration	with	a	biostatistician	
would	be	beneficial	here	in	order	to	perform	more	statistical	analyses	and	provide	better	
data	presentation.	A	great	example	of	untargeted	metabolomics	data	analysis	is	
presented	in	the	following	study.	Wikoff	et	al.	used	unequal-variance	t-tests	and	fold-
change	to	identify	statistically	significant	differences	between	cerebrospinal	fluid	of	SIV-
infected	and	uninfected	macaques	[465].	As	a	result	out	of	3000	measured	features,	12	
were	selected	and	further	identified	and	analysed.	This	study	shows	a	different	analysis	
approach,	where	statistical	analysis	precedes	the	identification	step.	This	reduces	the	
need	for	painstaking	data	interpretation	of	huge	datasets.	However,	in	case	of	our	results,	
we	aimed	to	compare	as	many	features	as	possible	(in	case	of	tissue-specific	study),	or	
looked	at	specific	pathways	(in	urate	degradation	knockout	study)	so	a	different	type	of	
analysis	is	required.		
Moreover,	constant	developments	in	metabolomics	technologies,	as	well	as	data	
processing	tools	and	algorithms,	require	regular	updating	of	the	current	tissue-specific	
metabolome	of	the	fruit	fly.	Finally,	correlation	of	metabolomics	data	with	
transcriptomics	(FlyAtlas.org)	is	very	challenging	due	to	different	data	formats	and	
samples	obtained	at	different	times	and	from	different	fly	tissues.	A	standardised	method	
for	sample	collection	and	preparation	is	required	to	integrate	tissue-specific	data	
obtained	from	different	omics	approaches.		
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6 In	vitro	expression	of	Drosophila	melanogaster	
CG30016	and	urate	oxidase	
6.1 Introduction	
Following	experiments	in	the	whole	fly	and	individual	fly	tissues,	in	vitro	studies	on	
Drosophila	CG30016	protein	were	performed.	Metabolomics	results	described	in	the	
previous	chapter	confirmed	that	CG30016	is	involved	in	purine	metabolism	and	urate	
degradation	pathway.	However,	because	the	work	has	been	done	in	whole	fly	tissues	and	
due	to	complexity	of	metabolomics	data,	it	was	impossible	to	observe	direct	effects	of	
CG30016	knockout.	In	order	to	do	so,	a	simple	system	has	been	employed,	where	the	
gene	of	interest	was	cloned	and	expressed	using	several	different	in	vitro	expression	
systems.	Purified	fly	protein	was	then	used	in	an	enzyme	assay,	following	assay	conditions	
used	in	similar	studies.	The	same	approach	has	been	previously	described	using	5-HIU	
hydrolase	candidate	proteins	of	other	species,	including	mouse	[102,	118],	zebra	fish	
[375]	and	Escherichia	coli	[377,	378].	The	substrate	for	5-HIU	hydrolase,	5-HIU,	is	
unstable.	Its	half-life	at	neutral	pH	is	around	30	minutes	[355].	Because	of	the	substrate	
instability,	the	enzyme	assay	performed	here	employs	two	enzymatic	reactions:	urate	
conversion	to	5-HIU	catalysed	by	UO	and	the	downstream	reaction	catalysed	by	5-HIU	
hydrolase	(Figure	6-1).	Hence,	Drosophila	melanogaster	UO	and	CG30016	genes	were	
cloned	and	expressed,	and	a	stable	substrate,	urate,	was	used	in	the	assay.		
	
Fig.	6-1	Urate	degradation	pathway,	enzyme	assay.	Fruit	fly	UO	and	CG30016	proteins	were	
added	to	urate	substrate.	Appearance	of	downstream	metabolites	was	monitored	using	
LC-MS	or	CD-spectroscopy.			
6.1.1 Choosing	the	expression	system	
In	order	to	choose	the	most	suitable	expression	system	for	the	expression	of	fruit	fly	
proteins,	several	factors	were	taken	into	consideration,	including	price,	time,	protein	
yield	and	compatibility	of	the	protein	with	the	system	(does	the	system	contain	all	
Urate	 5-Hydroxyisourate	 Allantoin	OHCU	
Urate	oxidase	 CG30016?	 CG30016?	
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components	essential	for	the	expression	of	the	fly	gene).	Three	systems	were	compared	
(Table	6-1).		
Table	6-1	Comparison	of	three	expression	systems	used	in	the	study	including	their	
advantages	and	disadvantages	
Expression	system	 Advantages	 Disadvantages	
TNT®	T7	Insect	Cell	Extract	
Protein	Expression	System		
• Expression	takes	only	4	hours	
• Cost-effective	
• Easy,	quick,	single-tube	
protocol	
• Low	protein	yield	(up	to	
75μg/ml	of	protein)		
Champion™	pET100	
Directional	TOPO®	
Expression	Kit	
• High	protein	yield	
• Regulated	protein	expression		
• Possibly	missing	
Drosophila	gene	
expression	components		
Transient	expression	in	
Drosophila	S2	cells	
• Compatible	with	fruit	fly	
proteins	
• All	Drosophila	protein	
expression	components	
present		
• Time	consuming	
• Low	transfection	
efficiency		
6.1.1.1 Cell-free	expression	system	
TNT®	T7	Insect	Cell	Extract	Protein	Expression	System	was	developed	from	the	commonly	
used	Spodoptera	frugiperda	Sf21	cell	line	[466].	It	is	a	quick	and	easy	protocol,	which	
employs	T7	promoter	for	gene	expression.	All	components	necessary	for	the	
transcription/translation	are	present	in	the	TnT®	T7	ICE	Master	Mix.	To	initiate	protein	
synthesis,	the	only	component	that	must	be	added	is	the	DNA	template.	The	biggest	
disadvantage	of	the	system	is	a	relatively	low	protein	yield	(up	to	75μg/ml),	which	might	
be	too	low	for	the	enzyme	assay.	Moreover,	it	is	impossible	to	predict	whether	expressed	
proteins	will	be	functional	and	what	the	effect	of	the	transcription/translation	
components	is	going	to	be	on	the	proteins.		
6.1.1.2 Expression	using	E.	coli		
E.	coli	is	one	of	the	most	common	systems	used	for	protein	expression.	It	has	been	
previously	used	for	the	expression	of	proteins	involved	in	urate	degradation	pathway	
[102,	118,	375,	377,	378].	The	Champion™	pET100	Directional	TOPO®	Expression	Kit	also	
employs	T7	RNA	Polymerase	and	T7	promoter	[467,	468].	It	allows	direction	cloning	of	a	
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blunt-end	PCR	product,	which	is	fast	and	does	not	require	restriction	digest	and	ligation	
reactions.	Moreover,	it	has	lac	repressor	gene,	lacI	and	T7lac	promoter,	which	is	IPTG-
inducible	[469].	As	a	result	the	basal	transcription	from	T7lac	promoter	is	reduced	and	
can	be	controlled	by	the	addition	of	IPTG.	This	system	is	one	of	the	best-studied	
expression	systems	and	provides	a	high	protein	yield.	However,	there	is	a	risk	that	the	
system	might	not	have	all	the	necessary	components	for	the	expression	of	a	functional	
fruit	fly	protein.		
6.1.1.3 Drosophila	S2	cells	
S2	cells	were	derived	from	primary	culture	Drosophila	melanogaster	embryos	and	have	
been	commonly	used	to	study	Drosophila	proteins	[396,	470,	471].	The	biggest	advantage	
of	this	system	is	that	it	contains	the	complete	fruit	fly	transcription/translation	
machinery.	Hence,	it	has	the	best	chance	of	expressing	a	functional	Drosophila	protein.	
The	biggest	disadvantage	on	the	other	hand	is	low	transfection	efficiency	of	S2	cells.	
Moreover,	out	of	the	three	expression	methods,	this	one	is	the	most	challenging	and	time	
consuming.		
6.1.2 Detection	of	urate	degradation	intermediates	
In	previous	studies	on	5-HIU	hydrolase	candidate	proteins,	various	detection	methods	of	
urate	degradation	intermediates	were	used	including	LC-MS	[102,	118,	375,	377,	378]	and	
CD-spectroscopy	[102].		
6.1.2.1 Detection	using	LC-MS	
As	previously	described	in	several	studies	[102,	118,	375,	377,	378],	intermediates	of	
urate	degradation	can	be	detected	using	LC-MS.	This	includes	urate,	5-HIU,	OHCU	and	
allantoin.	This	is	possible	because	all	intermediates	have	different	mass	peaks	and	
retention	times	(Figure	6-2).	Moreover,	it	is	possible	to	use	standards	to	obtain	100%	
identification	of	metabolites.	However,	standards	of	unstable	metabolites	(5-HIU	and	
OHCU)	are	not	commercially	available.	As	a	result,	it	is	only	possible	to	run	standards	for	
urate	and	allantoin.	This	limits	the	reliability	of	this	technique.	Another	drawback	is	the	
fact	that	LC-MS	produces	a	snap	shot	of	a	metabolic	state	in	the	system,	rather	than	real-
time	changes	triggered	by	enzyme	activity.	In	case	of	urate	degradation	pathway	this	is	
particularly	challenging	because	the	reaction	occurs	both	spontaneously	(slow	reaction)	
and	enzymatically	(fast	reaction).	As	a	result,	it	is	difficult	to	determine	whether	detected	
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metabolites	are	products	of	spontaneous	or	enzymatic	reaction.	However,	we	expect	to	
detect	more	products	in	a	given	time	when	enzymes	(UO	and	CG30016)	are	added	to	the	
system.		
Fig.	6-2	LC-MS	mass	peaks	of	the	urate	degradation	intermediates:	urate,	5-HIU,	OHCU	and	
allantoin,	from	[384].		
6.1.2.2 Detection	using	CD-spectroscopy	
CD-spectroscopy	has	been	previously	used	to	detect	5-HIU	and	OHCU	[102,	382].	It	is	
possible	because	both	5-HIU	and	OHCU	are	optically	active.	Optically	inactive	urate	is	
converted	by	UO	to	levorotatory	5-HIU,	which	turns	into	levorotatory	OHCU	(either	
spontaneously	or	enzymatically).	Decarboxylation	of	OHCU	(spontaneous	or	enzymatic)	
results	in	the	production	of	optically	inactive	allantoin	(Figure	6-3A).	CD	spectra	of	these	
compounds	showed	that	it	is	possible	to	selectively	monitor	formation	and	decay	of	5-
HIU	and	OHCU	because	5-HIU	has	an	appreciable	ellipticity	at	312	nm	but	not	257	nm,	
whereas	OHCU	has	an	appreciable	ellipticity	at	257	nm	but	not	312	nm	(Figure	6-3B).	As	a	
result,	when	UO	is	added	to	the	enzyme	assay,	fast	formation	of	5-HIU	can	be	observed	
followed	by	slow	spontaneous	decay	accompanied	by	slow	formation	and	decay	of	OHCU.	
When	5-HIU	hydrolase	and	OHCU	decarboxylase	are	present,	the	decay	of	5-HIU	as	well	
as	the	formation	and	decay	of	OHCU	are	much	faster.	This	method	is	particularly	relevant	
for	this	assay	because	it	monitors	the	speed	of	urate	degradation	and	allows	
distinguishing	the	spontaneous	reaction	from	the	enzymatic	one.		
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Fig.	6-3	Urate	degradation	pathway	monitored	using	CD-spectroscopy.	(A)	Urate	
degradation	pathway	including	its	intermediates	and	enzymatic/spontaneous	reactions.	
(B)	Approximate	CD	spectra	of	5-HIU	and	OHCU	(top),	5-HIU	(blue)	has	an	appreciable	
ellipticity	at	312	nm,	OHCU	(red)	has	an	appreciable	ellipticity	at	257	nm;	(bottom)	time	
courses	of	urate	degradation	monitored	at	312	nm	(blue)	and	257	nm	(red),	(left)	when	UO	
was	added,	(middle)	when	UO	and	5-HIU	hydrolase	was	added,	(right)	when	UO	and	OHCU	
decarboxylase	was	added;	from	[102].		
6.2 Results	
6.2.1 Cell-free	expression	system	
6.2.1.1 Construct	generation	
Cloning	primers	for	Drosophila	UO	and	CG30016	genes	were	designed	flanking	whole	
gene	sequences,	with	6xHis	tag	at	the	C-terminal	and	SgfI	and	PmeI	restriction	sites.	
Optimal	annealing	temperatures	were	determined	for	both	genes	as	described	in	Section	
2.5.4	(see	Appendix	II	for	primer	sequences):	59.2oC	for	CG30016	and	63.4oC	for	UO.	
cDNA	template	for	PCR	was	generated	from	RNA	extracted	from	Canton	S	wild	type	flies.	
Transgenic	constructs	were	generated	as	described	in	Section	2.8.	Purified	constructs	
were	validated	for	the	presence	of	genes	of	interest	by	PCR	using	gene-specific	primers	
(Figure	6-4).	Restriction	digest	was	performed	to	confirm	the	orientation	of	inserts.	
Constructs	were	then	sequenced	in	order	to	confirm	that	there	were	no	mutations	in	
cloned	sequences.			
Urate	 5-Hydroxyisourate	 Allantoin	OHCU	
Urate	oxidase	 5-HIU	hydrolase	 OHCU	decarboxylase	
Spontaneous	 Spontaneous	
A	
B	
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Fig.	6-4	Transgenic	construct	validation	by	PCR.	(A)	PCR	was	performed	using	optimal	
annealing	temperature	and	CG30016	cloning	primers.	1	–	positive	control	388	bp;	ladder	is	
in	bp;	2-6	constructs	thought	to	contain	CG30016	gene	purified	from	different	bacterial	
colonies.	All	constructs	were	validated	for	the	presence	of	CG30016	gene.	(B)	PCR	was	
performed	using	optimal	annealing	temperature	and	UO	cloning	primers.	2-	positive	
control	1108	bp;	ladder	in	bp;	1-	construct	though	to	contain	UO	gene	purified	from	a	
single	bacterial	colony.	The	construct	contains	the	UO	gene.		
	
6.2.1.2 Expression	and	protein	detection	
Both	proteins	were	expressed	using	TNT®	T7	Insect	Cell	Extract	Protein	Expression	System	
as	described	in	Section	2.8.3.	They	were	then	purified	using	HisPur	Ni-NTA	Spin	Columns	
as	described	in	Section	2.10.1.	Ponceau	staining	and	Western	blotting	were	performed	for	
protein	detection,	using	anti-His	primary	antibody.	Ponceau	staining	detected	protein	of	
different	sizes	in	all	samples	including	the	negative	control	(Figure	6-5A).	This	suggests	
that	these	proteins	were	part	of	the	expression	system	itself.	Western	blotting	resulted	in	
bands	corresponding	to	expected	size	of	CG30016	(13.53	kDa)	and	UO	(40.1	kDa)	(Figure	
6-5B).	This	confirmed	that	the	proteins	were	successfully	expressed	using	the	cell-free	
expression	system	and	purified	thanks	to	the	presence	of	6xHis	tags.		
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Fig.	6-5	Detection	of	protein	expressed	using	the	cell-free	expression	system.	(A)	Ponceau	
staining	and	Western	blotting	results;	1	-	negative	control	(empty	pF25A	ICE	T7	Flexi®	
Vector),	2	–	vector	containing	CG30016	gene,	3	–	vector	containing	UO	gene.	Proteins	of	
different	sizes	were	detected	in	all	samples.	(B)	Western	blotting	result;	2	–	CG30016,	
expected	size	13.53	kDa,	3	–	UO,	40.1	kDa.	Proteins	of	correct	sizes	were	detected	for	both	
CG30016	-	and	UO	–	containing	constructs.		
	
6.2.1.3 Enzyme	assay	and	Liquid	chromatography	–	mass	spectrometry	(LC-MS)	
Purified	proteins	were	then	used	for	urate	degradation	enzyme	assay	(Figure	6-1)	
followed	by	LC-MS.	The	enzyme	assay	was	performed	using	previously	tested	conditions	
[102,	118,	375,	377,	378].	Substrate	solution	used	was	0.1	mM	urate	in	potassium	
phosphate	buffer,	pH	7.6	
For	LC-MS,	commercial	urate	and	allantoin	were	used	as	standards;	100	µM	of	urate	and	
100	µM	of	allantoin.	Extracted	ion	chromatogram	for	urate	was	at	167.02101	m/z	(Figure	
6-6	1A),	with	fragmentation	spectrum	[M-H]-,	167.02	m/z	at	8.68	min,	confirming	
fragments	of	124.01522,	96.02025	and	69.00905	m/z	(Figure	6-6	1B).	A	very	intense	
isomer	eluted	at	9.3	min,	resulting	in	a	shoulder	peak	for	urate	at	8:7	min.	This	might	be	a	
!!Merged!Ponceau!staini g!and!western!blotting!image .!As!pr viously,!Ponceau!staining!is!similar!in!all!samples,!including!negative!control.!Both!CG30016!and!urate!oxidase!are!expressed.!!!CG3 16!band!seems!to!be!fainter!than!in!previous!western!blotting!(possibly!the!protein!gets!degraded!when!it!is!kept!frozen!for!a!while).!!!1H!negative!control!containing!cellHfree!expression!system!components!without!DNA!2H!expression!of!CG30016!(13.53!kDa)!3H!expression!of!urate!oxidase!(40.1!kDa)!!!!!!!
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fragment	of	5-hydroxyisourate.	Allantoin	eluted	10.73	min	with	a	mass	of	159.05127	m/z	
(Figure	6-6	2A).	Fragmentation	spectra	of	allantoin	were	observed	in	both	positive	and	
negative	ion	mode,	with	slightly	greater	signal	measured	in	negative	ion	mode:	in	
negative	ion	mode	[M-H]-	157.04	m/z	and	positive	[M-H]+	159.05	m/z	at	10.79	min.	
Fragments	were	confirmed	in	positive	mode	of	99.01887,	73.03986,	61.04004	m/z,	and	
negative	mode	of	114.03082,	97.00426,	71.02470	m/z	(Figure	6-6	2B).	
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Figure	6-6	Ion	chromatograms	and	fragmentation	spectra	of	urate	and	allantoin	standards.	1A	Ion	chromatogram	for	urate	at	167.02101	m/z,	1B	
fragmentation	spectrum	of	urate	at	8.68	min	confirming	fragments	of	124.01522,	96.02025	and	69.00905	m/z.	2A	Ion	chromatogram	for	allantoin	at	
159.05127	m/z,	2B	fragmentation	spectrum	of	allantoin	in	negative	ion	mode	(above)	at	10.73	min	confirmed	fragments	of	114.03082,	97.00426,	
71.02470	m/z,	and	positive	ion	mode	(below)	at	10.79	min	confirmed	fragments	of	99.01887,	73.03986,	61.04004	m/z.	
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Urate,	5-hydroxyisourate,	OHCU	and	allantoin	were	mass-matched.	Additionally,	urate	
and	allantoin	were	retention	time	–	matched	and	fragmentation	spectrum	–	matched	due	
to	availability	of	standards	(Table	6-2).	Urate	was	detected	in	a	negative	ion	mode,	
whereas	5-HIU,	OHCU	and	allantoin	were	detected	in	both	positive	and	negative	modes.		
Table	6-2	Compounds	detected	in	LC-MS:	name	of	each	compound,	formula,	mass	as	well	
as	type	of	detection	are	provided.		
Compound	Name	 Formula	 Monoisotopic	
Mass	
Mass	
Matched	
RT	
Matched*	
Fragments	
Matched	
Urate	(Neg)	 C5H4N4O3	 167.02106	 Yes	 Yes	 Yes	
5-hydroxyisourate	
(Pos)	
C5H4N4O4	 185.03053	 No	 N/A	 N/A	
5-hydroxyisourate	
(Neg)	
C5H4N4O4	 183.01598	 No	 N/A	 N/A	
OCHU	(Pos)	 C5H5N4O5	 202.03327	 No	 N/A	 N/A	
OCHU	(Neg)	 C5H5N4O5	 200.01872	 No	 N/A	 N/A	
Allantoin	(Pos)	 C4H6N4O3	 159.05127	 Yes	 Yes	 Yes	
Allantoin	(Neg)	 C4H6N4O3	 157.03671	 Yes	 Yes	 Yes	
	
Enzyme	assays	were	performed	for	a	system	containing	urate	and	expressing	UO	and	
CG30016	as	well	as	several	controls	(Table	6-3).	The	controls	used	were:		
1. A	system	expressing	UO	and	CG30016	without	urate	
2. A	system	expressing	UO	containing	urate	
3. A	system	expressing	UO	without	urate	
4. A	system	containing	urate	with	an	empty	vector	(not	expressing	UO	or	CG30016)	
5. A	system	without	urate	with	an	empty	vector	(not	expressing	UO	or	CG30016)	
6. A	system	expressing	CG30016	containing	urate	
7. A	system	expressing	CG30016	without	urate	
LC-MS	spectra	obtained	for	all	controls	containing	urate	(2,	4	and	6)	showed	the	same	
results,	i.e.	urate	and	allantoin	were	detected,	mass-,	RT-	and	fragments-matched;	both	
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5-HIU	and	OHCU	were	mass-matched.	There	were	no	differences	in	abundance	of	these	
compounds	in	different	systems.	The	same	results	were	obtained	for	the	experimental	
sample	containing	urate	and	expressing	UO	and	CG30016.	This	suggests	that	the	presence	
of	detected	metabolites	is	a	result	of	spontaneous	degradation	of	urate,	rather	than	the	
activity	of	expressed	enzymes.	Hence,	it	was	impossible	to	confirm	the	role	of	UO	and	
CG30016	as	urate	degradation	enzymes	based	on	these	results.	Surprisingly,	in	controls	
without	urate	(1,3,5	and	7),	urate	was	also	detected	and	mass-,	RT-	and	fragments-
matched,	so	was	allantoin.	However,	allantoin	was	only	detected	at	low	abundance.	This	
could	be	due	to	equipment	contamination	with	urate	and	small	amounts	of	allantoin,	
perhaps	from	previous	samples	containing	urate.	This	has	to	be	addressed	in	future	
experiments.	The	reason	why	the	enzyme	assay	did	not	produce	expected	metabolites	
might	be	due	to	poor	protein	yield	obtained	from	the	cell-free	expression	system.	
According	to	manufacturer’s	protocol,	the	system	can	produce	15-75	μg/ml	of	protein	
depending	on	type	of	protein	being	expressed.	This	should	be	sufficient	for	the	assay.	
However,	when	Bradford	assay	was	run,	there	was	no	difference	in	protein	concentration	
between	the	experimental	sample	and	the	control,	which	only	contained	expression	
system	components.	This	suggests	that	the	system	did	not	produce	a	lot	of	UO	and	
CG30016	proteins.	Perhaps,	this	was	not	sufficient	to	catalyse	urate	degradation	
reactions.	Another	possibility	is	that	the	cell-free	system	did	not	contain	all	elements	
required	to	produce	functional	UO	and	CG30016	proteins,	and	as	a	result	they	failed	to	
catalyse	urate	degradation.		
Table	6-3	LC-MS	results	of	enzyme	assay.	Several	systems	were	used,	including	one	
expressing	UO	and	CG30016	as	well	as	several	controls.	Detected	compounds,	their	mass	
and	type	of	detection	are	included.		
Experimental:	UO	+CG30016	+	urate	
Compound	Name	 Mass	match	 RT	match		 Evidence	
Urate	 Yes	 Yes	
RT	at	8.8	min,	isotope	pattern,	
fragments	match	
5-hydroxyisourate		 Yes	 No	
Mass	matches	at	9.3	and	11.5	
min	
OCHU		 Yes	 No	 Mass	matches	at	4.9	and	6.4	min	
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Allantoin		 Yes	 Yes	
RT	at	10.8,	isotope	pattern,	
fragments	match	
1.	UO	+	CG30016	–	urate	
Urate		 Yes	 Yes	
RT	at	8.8	min,	isotope	pattern,	
fragments	match	
5-hydroxyisourate		 No	 No	 Not	present	
OCHU		 No	 No	 Not	Present	
Allantoin		 Yes	 No	 RT	at	10.8	min	(low	abundance)	
2.	UO	+	urate	
Urate	 Yes	 Yes	
RT	at	8.75,	isotope	pattern,	
fragments	match	
5-hydroxyisourate		 Yes	 No	 Mass	matches	at	9.2	and	11.5	min	
OCHU	 Yes	 No	 Mass	matches	at	4.9	and	6.6	min	
Allantoin		 Yes	 Yes	
RT	at	10.8,	isotope	pattern,	
fragments	match	
3.	UO	–	urate	
Urate		 Yes	 Yes	
RT	at	8.8	min,	isotope	pattern,	
fragments	match	
5-hydroxyisourate		 No	 No	 Not	present	
OCHU		 No	 No	 Not	Present	
Allantoin		 Yes	 No	 RT	at	10.7	min	(low	abundance)	
4.	Empty	vector	+	urate	
Urate	 Yes	 Yes	
RT	at	8.8	min,	isotope	pattern,	
fragments	match	
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5-hydroxyisourate		 Yes	 No	 Mass	matches	at	9.2	and	11.3	min	
OCHU		 Yes	 No	 Mass	matches	at	4.9	and	6.5	min	
Allantoin		 Yes	 Yes	
RT	at	10.8,	isotope	pattern,	
fragments	match	
5.	Empty	vector	-	urate	
Urate		 Yes	 Yes	
RT	at	8.7	min,	isotope	pattern,	
fragments	match	
5-hydroxyisourate		 No	 No	 Not	present	
OCHU		 No	 No	 Not	Present	
Allantoin	 Yes	 No	 RT	at	10.8	min	(low	abundance)	
6.	CG30016	+	urate	
Urate	 Yes	 Yes	
RT	at	8.8	min,	isotope	pattern,	
fragments	match	
5-hydroxyisourate		 Yes	 No	 Mass	matches	at	9.1	and	11.3	min	
OCHU		 Yes	 No	 Mass	matches	at	4.9	and	6.4	min	
Allantoin		 Yes	 Yes	
RT	at	10.7,	isotope	pattern,	
fragments	match	
7.	CG30016	-	urate	
Urate		 Yes	 Yes	
RT	at	8.8	min,	isotope	pattern,	
fragments	match	
5-hydroxyisourate		 No	 No	 Not	present	
OCHU		 No	 No	 Not	Present	
Allantoin		 Yes	 No	 RT	at	10.8	min	(low	abundance)	
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6.2.2 Expression	of	UO	and	CG30016	in	S2	cells		
6.2.2.1 Construct	generation	
Cloning	primers	for	UO	and	CG30016	genes	were	designed	flanking	whole	gene	
sequences,	with	6xHis	tag	at	the	C-terminal.	Optimal	annealing	temperatures	were	
determined	for	both	genes	as	described	in	Section	2.4	(see	Appendix	II	for	primer	
sequences).	cDNA	template	for	PCR	was	generated	from	RNA	extracted	from	Canton	S	
wild	type	flies.	Transgenic	constructs	were	generated	as	described	in	Section	2.8.	Purified	
constructs	were	validated	for	the	presence	of	genes	of	interest	by	PCR	using	gene-specific	
primers	as	well	as	restriction	digest,	in	order	to	determine	the	orientation	of	inserts	
(Figure	6-7).	Both	genes	were	present	in	transgenic	constructs	in	the	correct	orientation.	
Finally,	the	constructs	were	sequenced	in	order	to	confirm	that	there	were	no	mutations	
in	cloned	sequences.			
	
Fig.	6-7	Validation	of	transgenic	constructs	by	restriction	digest.	(A)	Constructs	thought	to	
contain	CG30016	gene	were	restriction	digested	EcoRI	and	XbaI	enzymes,	expected	band	
size	435	bp	was	observed,	confirming	the	presence	of	CG30016	gene	and	its	correct	
orientation.	(B)	Constructs	containing	UO	gene	were	digested	using	EcoRI	and	XbaI,	
expected	band	sizes	of	1120	bp	was	confirmed.	UO	gene	is	present	in	the	right	orientation	
in	the	transgenic	construct.		
6.2.2.2 Transient	transfection	and	its	efficiency	
Transient	transfection	was	performed	as	described	in	Section	2.9.2.	Cells	were	
transfected	or	co-transfected	with:	
1. Empty	pMT/V5-His-TOPO	vector	
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2. pMT/V5-His-TOPO-UO	
3. pMT/V5-His-TOPO-UO	and	pMT/V5-His-TOPO-CG30016	
4. pMT/V5-His-TOPO-UO,	pMT/V5-His-TOPO-CG30016	and	pMT/V5-His-TOPO-GFP.	
Transfection	with	pMT/V5-His-TOPO-GFP	was	performed	in	order	to	measure	
transfection	efficiency.	When	cells	are	co-transfected	with	several	constructs,	it	can	be	
assumed	that	the	cells	successfully	took	up	either	all	or	none	of	the	plasmids.	Hence,	in	
order	to	calculate	transfection	efficiency,	cells	were	tested	for	the	presence	of	GFP	under	
fluorescent	microscope.	Sections	of	cell	plate	were	examined	for	the	presence	of	GFP	and	
average	transfection	efficiency	was	calculated	by	measuring	the	ratio	of	GFP-positive	cells	
versus	all	cells	(Figure	6-8).	Transfection	efficiency	of	18.6%	was	calculated.	It	was	not	
clear	at	this	stage	whether	this	was	high	enough	efficiency	to	produce	high	yield	of	UO	
and	CG30016	proteins,	required	for	the	enzyme	assay.		
	
A	 B	
C	
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Fig.	6-8	Transient	transfection	of	S2	cells.	(A)	Bright-field	image	of	transfected	S2	cells	
showing	intact	‘healthy’	cells.	(B)	Fluorescent	microscopy	image	showing	GFP-positive	
cells,	which	were	also	assumed	to	contain	pMT/V5-His-TOPO-UO	and	pMT/V5-His-TOPO-
CG30016	constructs.	(C)	Several	sections	of	a	plate	with	transfected	S2	cells;	bright-field	
and	fluorescent	images	were	merged	and	transfection	efficiency	was	calculated	as	a	ratio	
of	GFP-positive	cells	to	all	cells.		
6.2.2.3 Detection	of	expressed	protein	
Following	48	h	protein	expression	in	S2	cells,	Immunocytochemistry	(ICC)	assay	was	
performed	in	order	to	confirm	the	expression	of	proteins	tagged	with	6xHis	tag.	DPAI	
staining	was	performed	as	well	as	incubation	with	anti-His	antibody	(Figure	6-9).	ICC	
results	showed	that	His-tagged	proteins	were	expressed	in	S2	cells	(Figure	6-9	1A,B	and	
2A,B).	This	suggests	that	both	CG30016	and	UO	were	expressed	in	these	cells.		
	
Fig.	6-9	Immunocytochemistry	assay	of	S2	cells	transfected	with	constructs	containing	UO	
and	CG30016	genes.	(1A-C)	Cells	transfected	with	pMT/V5-His-TOPO-CG30016;	(2A-C)	Cells	
transfected	with	pMT/V5-His-TOPO-UO;	(1A,	2A)	Image	of	anti-His	staining	(green)	merged	
with	DAPI	staining	(blue)	showed	cells	expressing	a	protein	tagged	with	6xHis	tag.	This	
confirmed	that	CG30016	(1A)	and	UO	(2A)	were	expressed	in	these	cells.	(1B,	2B)	Staining	
with	anti-His	antibody	(green).	(1C,	2C)	DAPI	staining	nuclei	of	S2	cells	(blue).		
6.2.2.4 LC-MS	of	S2	cells	
S2	cells	produce	urate	and	hence	it	was	not	necessary	to	add	extra	urate	to	the	samples	
in	order	to	observe	products	of	urate	degradation	pathway.	Three	samples	were	analysed	
for	the	presence	of	urate,	5-HIU,	OHCU	and	allantoin	using	LC-MS:	
1B	1A	 1C	
2B	2A	 2C	
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1. Empty	pMT/V5-His-TOPO	vector	(-ve	control)	
2. pMT/V5-His-TOPO-UO	(Urate	oxidase)	
3. pMT/V5-His-TOPO-UO	and	pMT/V5-His-TOPO-CG30016	(Urate	oxidase	+	CG30016)	
The	results	are	illustrated	in	Table	6-4.	Urate	was	detected	in	all	samples,	which	is	
consistent	with	the	fact	that	S2	cells	produce	urate.	Moreover,	relative	abundance	of	
urate	was	slightly	lower	in	samples	2	and	3	compared	to	the	–ve	control.	This	suggests	
that	expressed	UO	might	be	catalysing	the	conversion	of	urate	to	5-HIU	in	these	samples.	
This	is	consistent	with	the	detection	of	5-HIU	in	the	samples,	and	its	higher	abundance	in	
samples	2	and	3.	5-HIU	is	also	detected	in	the	–ve	control.	This	might	be	due	to	
expression	of	UO	in	S2	cells.	According	to	FlyAtlas,	S2	cells	express	low	levels	of	UO[4],	
which	in	this	case	might	result	in	low	abundance	of	5-HIU	in	the	control.	OHCU	was	not	
detected	in	any	of	the	samples.	This	is	puzzling	as	it	should	be	present	in	all	samples	as	a	
result	of	spontaneous	degradation	of	5-HIU.	We	were	also	expecting	to	see	more	OHCU	in	
sample	3	due	to	expression	of	CG30016.	Since	it	was	not	detected	at	all,	it	was	impossible	
to	confirm	whether	CG30016	was	expressed	as	an	active	protein	and	to	confirm	its	role	as	
5-HIU	hydrolase.	Finally,	comparable	abundance	of	allantoin	was	detected	in	all	samples.	
This	suggests	that	it	is	a	product	of	spontaneous	degradation	of	5-HIU	rather	than	an	
enzymatic	reaction.	Once	again,	this	result	did	not	confirm	the	role	of	CG30016.		
Table	6-4	LC-MS	results	of	S2	cells	transfected	with	three	construct:	empty	TOPO	vector				
(-ve	control),	TOPO-UO	and	TOPO-CG30016.	Presence	and	relative	abundance	of	each	
metabolite	of	urate	degradation	pathway	is	included.		
Compound	name	 -ve	control	 urate	oxidase	 urate	oxidase	+	CG30016	
Urate	 Detected	(36.6)	 Detected	(28.4)	 Detected	(34.3)	
5-HIU	 Detected	(2.9)	 Detected	(4.1)	 Detected	(4.4)	
OHCU	 Not	detected	 Not	detected	 Not	detected	
Allantoin	 Detected	(0.7)	 Detected	(0.72)	 Detected	(0.61)	
	
6.2.3 Expression	of	UO	and	CG30016	in	E.	coli	
6.2.3.1 Construct	generation:	PCR,	primers,	gel	purification,	ligation	
Cloning	primers	for	UO	and	CG30016	genes	were	designed	flanking	whole	gene	
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sequences,	with	6xHis	tag	at	the	C-terminal	and	EcoRI	and	XbaI	restriction	sites.	Optimal	
annealing	temperatures	were	determined	for	both	genes	as	described	in	Section	2.4	(see	
Appendix	II	for	primer	sequences):	59.2oC	for	CG30016	and	63.4oC	for	UO.	cDNA	template	
for	PCR	was	generated	from	RNA	extracted	from	Canton	S	wild	type	flies.	Transgenic	
constructs	were	generated	as	described	in	Section	2.8.	Purified	constructs	were	validated	
for	the	presence	of	genes	of	interest	by	PCR	using	gene-specific	primers	as	well	as	
restriction	digest,	in	order	to	determine	the	orientation	of	inserts.	Correct	orientation	
was	confirmed	for	both	genes	(Figure	6-10).	Finally,	constructs	validated	for	the	presence	
of	genes	in	correct	orientation	were	sequenced	and	sequences	without	mutations	were	
confirmed.		
	
Fig.	6-10	Validation	of	transgenic	constructs	by	restriction	digest.	CG30016-pET	constructs	
were	restriction	digested	using	XbaI	and	SacI	with	expected	band	sizes	of	442	bp.	Correct	
band	sizes	were	observed	in	lane	6.	UO-pET	constructs	were	restriction	digested	using	XbaI	
and	SacI	with	expected	band	size	of	1159	bp.	Correct	band	sizes	were	present	in	lane	9.	
These	results	confirmed	the	presence	of	both	genes	in	the	right	orientation.			
	
6.2.3.2 Expression	and	protein	detection		
Pilot	expression	of	confirmed	constructs	was	performed	as	described	in	Section	2.8.10.	In	
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order	to	establish	optimal	expression	time	and	temperature,	Western	blotting	was	
performed	using	anti-His	antibody.	The	results	showed	that	the	optimal	time	and	
temperature	for	both	constructs	was	16	h	induction	and	37°C	(Figure	6-11).	Hence,	scaled	
up	reactions	were	performed	at	these	conditions.		
	
Fig.	6-11	Determination	of	optimal	expression	time	and	temperature	using	Western	
blotting.	Expected	band	sizes	are	40.1	kDa	for	UO	and	13.53	kDa	for	CG30016.	Lanes	2-5	
are	BL21	cells	transfected	with	UO-pET	constructs:	lane	2	–	uninduced	BL21	cells	(-ve	
control),	lane	3	–	3	h	induction	at	37	°C,	lane	4	–	16	h	induction	at	37	°C,	lane	5	–	4	h	
induction	at	28	°C.	Lanes	6-9	BL21	cells	transfected	with	CG30016-pET	constructs:	lane	6	–	
uninduced	BL21	cells	(-ve	control),	lane	7	-	3	h	induction	at	37	°C,	lane	8	-	16	h	induction	at	
°C,	lane	9	-	4	h	induction	at	28	°C.	Optimal	temperature	and	time	for	both	constructs	was	
16	h	induction	at	37	°C.		
	
Following	the	expression	of	UO	and	CG30016	at	optimal	conditions,	both	proteins	were	
purified	thanks	to	the	presence	of	6xHis	tags.	Subsequently,	the	protein	buffer	was	
changed	to	one	suitable	for	further	experiments,	using	Slide-A-Lyzer	Dialysis	Cassettes	
(Thermo	Fisher	Scientific,	UK).	However,	protein	precipitation	was	observed	during	the	
procedure,	suggesting	some	protein	was	lost.	Bradford	assay	was	performed	in	order	to	
determine	the	amount	of	expressed	protein.	Calculated	protein	yield	was	CG30016:	2.6	
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μg/μl	and	UO:	0.4	μg/μl.		
6.2.3.3 Enzyme	assay	and	CD	-	spectroscopy	
Purified	proteins	were	used	for	urate	degradation	enzyme	assay	(Figure	6-1)	followed	by	
CD-spectroscopy.	In	order	to	optimise	the	enzyme	assay	for	CD-spectroscopy,	the	
conditions	were	first	tested	using	urate	substrate	(0.1	mM	uric	acid	sodium	salt	in	
potassium	phosphate	buffer,	pH	7.6)	and	commercially	obtained	UO	(Sigma	Aldrich,	UK).	
Different	concentrations	of	the	substrate	and	enzyme	were	used	to	determine	the	
conditions,	producing	the	desired	reaction	speed	for	CD-spectroscopy.	Initially,	0.4	U	of	
UO	and	0.1	mM	of	urate	were	used	(Figure	6-12).	In	these	conditions	UO	activity	was	fast,	
as	the	conversion	had	commenced	within	the	‘dead	time’	of	the	experiment.	A	20-fold	
dilution	of	the	enzyme	was	prepared	to	capture	the	early	events	in	the	reaction.	0.02	U	of	
UO	and	0.1	mM	of	urate	were	used.	Circular	dichroism	time	course	measurement	of	
conversion	of	0.1	mM	urate	was	obtained	at	0,	15	and	40	min	(Figure	6-13A).	Moreover,	
spectral	changes	over	1	h	were	measured	(Figure	6-13B).	These	spectra	showed	an	
expected	shift	correscponding	to	the	breakdown	of	urate	and	production	and	breakdown	
of	5-HIU	and	OHCU.		
	
Fig.	5-12	Circular	dichroism	time	course	measurement	of	0.4	U	of	UO	conversion	of	0.1	mM	
Urate	(arrows	denote	the	ellipticity	trend	with	time).	Data	represent	spectra	obtained	at	
~3	min	intervals.	UO	activity	was	fast	and	the	conversion	had	commenced	within	the	‘dead	
time’	of	the	experiment	
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Fig.	6-13	Circular	dichroism	of	0.02	U	of	UO	conversion	of	0.1	mM	urate.	(A)	CD	time	course	
measurement,	data	represent	spectra	obtained	at	~0	min	(brown),	15mins	(blue)	and	
40mins	(green).	(B)	Spectral	changes	over	1hr.	
	
Additionally,	CD	Ellipticity	values	were	obtained	at	different	wavelengths	in	order	to	
confirm	the	production	and	breakdown	of	5-HIU	and	OHCU.	Values	were	obtained	at	308	
nm,	277	nm,	240	nm,	220	nm,	230	nm	and	260	nm	(Figure	6-14).	At	308	nm,	277	nm,	240	
nm	and	220	nm	spectra	characteristic	to	the	formation	and	degradation	of	5-HIU	were	
observed	(Figure	6-14A-D).	This	corresponds	to	the	activity	of	UO	and	the	conversion	of	
urate	to	5-HIU,	followed	by	its	spontaneous	degradation	to	OHCU.	At	230	nm	and	260	nm	
spectra	characteristic	to	the	formation	of	OHCU	were	obtained	(Figure	6-14E-F).	This	
corresponds	to	the	spontaneous	degradation	of	5-HIU	to	OHCU.		
A	 B	
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Fig.	6-14	CD	Ellipticity	values	at	different	wavelengths	following	addition	of	0.02	U	of	UO	
to	0.1	mM	urate.	(A-D)	At	308	nm,	277	nm,	240	nm	and	220	nm	peaks	corresponding	to	the	
fomration	and	degradation	of	5-HIU	were	observed.	(E-F)	At	230	nm	and	260	nm	peaks	
characteristic	to	the	formation	of	OHCU	were	seen.		
	
We	expected	to	observe	similar	spectra	upon	the	addition	of	expressed	Drosophila	UO	
and	a	faster	conversion	of	5-HIU	to	OHCU	upon	the	addition	of	expressed	CG30016.	
However,	no	conversion	of	urate	to	5-HIU	and	OHCU	was	observed	in	these	samples.	This	
suggests	that	both	Drosophila	proteins	were	not	expressed	as	active	enzymes.	
Alternatively,	this	could	be	due	to	the	yield	of	expressed	proteins	being	too	low	or	the	
enzyme	assay	conditions	not	suitable	for	this	experiment.	Because	of	this,	it	was	
impossible	to	determine	the	function	of	CG30016	based	on	this	assay.		
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6.3 Discussion		
The	results	illustrated	in	this	chapter	were	inconclusive	and	hence	did	not	confirm	or	
refute	the	role	of	CG30016	as	5-HIU	hydrolase.	Unfortunately,	in	case	of	all	expression	
systems,	the	CG30016	protein	was	expressed	at	either	low	levels	or	inactive.	Because	of	
this,	the	enzyme	assay	did	not	produce	expected	results.		
6.3.1 Problems	with	protein	expression	
In	case	of	the	cell-free	expression	system,	the	enzyme	assay	results	suggest	that	detected	
urate	degradation	intermediates	were	produced	in	non-enzymatic	reactions.	A	likely	
explanation	for	this	is	that	Drosophila	enzymes	were	expressed	at	low	levels	and	hence,	
even	if	they	were	active,	there	was	no	noticeable	difference	between	the	experimental	
and	controls.	A	possible	solution	would	be	to	scale-up	the	expression	reaction	and	repeat	
the	purification	step	and	enzyme	assay	followed	by	one	of	the	detection	methods.		
The	main	disadvantage	of	S2	cells	in	this	study	was	the	low	transfection	efficiency	of	
18.6%.	Moreover,	S2	cells	produce	urate	and	express	UO	at	low	levels.	This	means	that	
the	cells	transfected	with	an	empty	vector	can	still	produce	5-HIU,	which	can	then	
spontaneously	degrade	to	OHCU	and	allantoin.	As	a	result	detected	metabolites	might	be	
a	result	of	these	spontaneous	reactions	or	the	expression	of	UO	and	CG30016,	and	it	
would	be	impossible	to	distinguish	between	the	two.	However,	the	results	indicate	that	
the	expressed	UO	was	active,	as	in	the	cells	transfected	with	transgenic	UO,	less	urate	
and	more	5-HIU	was	detected	compared	to	the	control.	On	the	other	hand,	there	was	no	
evidence	for	the	expression	of	active	CG30016	in	this	experiment	and	hence	its	role	as	5-
HIU	hydrolase	was	not	verified.		
Expression	in	E.coli	produced	a	high	yield	of	both	proteins.	However,	during	the	
purification	process,	protein	precipitation	was	observed.	Our	results	suggest	that	the	
protein	yield	after	purification	was	too	low	for	the	enzyme	assay	or	that	the	expressed	
proteins	were	inactive.	Once	again,	it	was	impossible	to	determine	the	function	of	
CG30016	in	this	experiment.		
Both	UO	and	5-HIU	hydrolase	have	been	successfully	expressed	in	previous	studies	using	
E.	coli	expression	system	[102,	118,	375,	377,	378].	It	suggests	that	the	system	or	the	
purification	process	require	further	optimisation	for	the	expression	of	active	Drosophila	
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UO	and	CG30016	genes,	and	this	should	be	the	focus	of	the	future	work.		
6.3.2 Metabolite	detection:	LC-MS	versus	CD-spectroscopy	
In	previous	studies	both	LC-MS	and	CD-spectroscopy	have	been	used	to	detect	
metabolites	of	urate	degradation,	and	to	validate	5-HIU	hydrolase	candidate	proteins	in	
other	species	[102,	118,	375,	377,	378].		
6.3.2.1 LC-MS	detection	
LC-MS	has	been	previously	used	to	identify	mouse	5-HIU	hydrolase	[118].	It	has	been	
done	by	detecting	urate,	5-HIU,	OHCU	and	allantoin	in	real-time	with	and	without	5-HIU	
hydrolase	candidate	protein.	Moreover,	in	this	study	standards	of	all	urate	degradation	
intermediates	were	provided,	which	allowed	confident	identification	of	metabolites.	In	
our	study	however,	LC-MS	was	performed	after	the	enzyme	assay	was	carried	out	and	
samples	were	stored	for	several	days.	Even	though	the	samples	were	stored	at	-80oC,	it	is	
possible	that	5-HIU	and	OHCU	degraded	spontaneously	and	this	interfered	with	‘true’	
results.	Moreover,	in	case	of	S2	cells	experiments,	OHCU	was	not	detected	at	all.	This	
suggests	that	either	it	degraded	spontaneously	faster	than	expected,	or	that	LC-MS	did	
not	detect	it,	suggesting	it	is	not	the	most	reliable	method	for	the	detection	of	urate	
degradation	intermediates.	This	has	been	previously	observed	and	is	described	in	Chapter	
5.		
It	would	be	interesting	to	perform	the	assay	again	with	real-time	LC-MS	analysis.	
Moreover,	it	would	be	crucial	to	obtain	5-HIU	and	OHCU	standards	for	confident	
identification	of	the	reaction	products.		
6.3.2.2 CD-spectroscopy	detection	
CD-spectroscopy	has	been	used	to	detect	5-HIU	and	OHCU	in	previous	studies	[102,	382].	
5-HIU	and	OHCU	formation	and	decay	were	observed	upon	the	addition	of	mouse	5-HIU	
hydrolase	and	OHCU	decarboxylase	candidates.	Both	proteins	were	identified	using	this	
technique.	The	advantage	of	CD-spectroscopy	over	LC-MS	for	the	detection	of	urate	
degradation	intermediates	is	the	fact	that	CD-spectroscopy	can	be	easily	performed	in	
real-time,	without	the	need	for	standards.	It	is	also	more	cost-effective.		
Our	results	confirmed	that	5-HIU	and	OHCU	could	be	distinguished	using	CD-
spectroscopy.	However,	due	to	problems	with	the	expression	of	active	Drosophila	
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proteins,	it	was	impossible	to	use	this	method	to	determine	the	role	of	CG30016.		
6.3.3 Future	work		
In	conclusion,	all	expression	systems	did	not	yield	enough	active	protein	for	the	enzyme	
assay	and	hence	it	was	impossible	to	determine	the	role	of	CG30016	in	these	
experiments.		
In	order	to	answer	this	question,	the	expression	and	purification	of	CG30016	have	to	be	
optimised.	This	could	be	achieved	by	changing	the	pH,	temperature	and/or	composition	
of	the	purification	medium.	Moreover,	it	might	be	useful	to	investigate	whether	changing	
the	6xHis	tag	to	another	tag	or	to	the	N-terminal	of	the	protein	influences	its	solubility	
and	activity.	The	enzyme	assay	would	then	be	performed	and	reaction	products	identified	
using	CD-spectroscopy.	It	could	be	beneficial	to	use	another	identification	method,	such	
as	
13
C	NMR	spectroscopy,	as	described	in	[102],	in	order	to	identify	the	final	product	of	
urate	degradation	pathway,	allantoin.		
Finally,	it	could	be	more	feasible	to	perform	the	enzyme	assay	in	dissected	Drosophila	
tubules,	and	compare	CG30016	and	UO	mutant	flies	to	a	control.	However,	since	this	
would	use	the	whole	tissue,	the	identification	of	metabolites	using	LC-MS	and	CD-
spectroscopy	might	be	more	difficult	due	to	many	other	metabolites	present	in	the	
sample.	
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7 Conclusions	and	Future	work		
The	primary	goal	of	systems	biology	is	to	integrate	complex	omics	data,	and	data	
obtained	from	traditional	experimental	studies	in	order	to	provide	a	holistic	
understanding	of	organismal	function.	One	way	of	achieving	this	aim	is	to	generate	GEMs,	
which	contain	information	on	all	metabolites,	enzyme-coding	genes,	and	biochemical	
reactions	in	a	biological	[304,	305].	Systems	approaches	[472]	hold	great	promise	in	
genetically	tractable	simple	model	organisms,	like	Drosophila.	The	fly,	with	its	metazoan	
body	plan	and	powerful	genetics,	provides	an	ideal	compromise	in	which	to	work	up	the	
concept	of	interacting	tissues	in	systems	biology.	Generation	of	GEMs	of	model	
organisms,	including	Drosophila	melanogaster,	has	been	recognised	as	a	priority	in	
systems	biology	[347].	It	would	improve	our	understanding	of	the	holistic	function	of	this	
species,	and	validate	the	fly	as	a	model	for	studying	the	metabolism	of	other	species,	
including	humans,	as	well	as	modelling	metabolic	diseases,	and	developing	and	testing	
insecticides.	
Drosophila	GEM	has	been	generated	in	our	lab.	However,	gaps	have	been	identified,	
where	enzymes	producing	or	degrading	metabolites	were	not	identified.	Filling	in	these	
gaps	is	essential	for	completion	of	the	core	metabolome	of	the	fly	and	its	validation	as	a	
model	organism.	The	main	focus	of	my	work	was	to	develop	a	pipeline	for	efficient	gap	
filling	using	metabolomics	approaches	combined	with	standard	reverse	genetics	
methods.	
7.1 Development	of	a	method	for	gap	filling	of	Drosophila	
metabolic	global	metabolic	model		
I	have	not	managed	to	develop	a	complete	pipeline	for	metabolic	gap	filling.	However,	
several	approaches	were	examined	and	discussed,	which	pointed	out	necessary	
improvements	and	future	work	required	towards	effective	gap	filling	method.	Steps	
involved	in	this	process	were	identified,	including	sequence	analysis	of	the	candidate	
gene,	standard	reverse	genetics	methods	(gene	knockout	followed	by	phenotype	
investigation),	and	metabolomics	analysis	of	the	knockout.	Moreover,	in	vitro	
experiments	combined	with	metabolomics	approaches	were	performed	in	the	attempt	to	
close	the	gap.	All	steps	are	described	in	more	detail	in	the	next	section.		
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The	main	challenge	in	the	development	of	gap	filling	method	was	the	fact	that	the	
untargeted	metabolomics	approach	used	here	is	hypothesis-free	in	nature.	As	a	result,	it	
is	not	the	best	method	to	apply	to	obtain	final	answers	to	a	research	question.	Moreover,	
metabolomics	is	a	relatively	young	discipline	in	comparison	to	other	omics,	which	is	
constantly	developing	in	terms	of	techniques	and	data	processing	tools.	Hence,	
metabolomics	experiments	require	further	optimisation	and	standardisation	in	order	to	
be	suitable	for	a	given	study.		
Altogether,	thanks	to	the	work	presented	here,	we	are	a	step	closer	towards	the	
development	of	a	gap-filling	pipeline	in	Drosophila	melanogaster	GEM.	The	areas	that	
require	further	optimisation	were	identified	and	are	the	focus	of	future	research.	
7.2 CG30016	is	involved	in	urate	degradation	pathway		
Even	though	the	development	of	a	gap-filling	pipeline	has	not	been	completed	in	the	
work	presented	here,	several	important	questions	about	the	selected	fruit	fly	candidate	
gene	for	the	metabolic	gap,	5-HIUH,	were	answered.		
Based	on	illustrated	results	it	is	clear	that	Drosophila	gene	CG30016	encodes	a	gene	
involved	in	purine	metabolism,	and	specifically	urate	degradation	pathway.	These	results	
include	qPCR	analysis,	sequence	analysis	and	literature	review,	phenotypic	
manifestations:	
7.2.1 QPCR	analysis	
1. A	knockout	of	CG30016	and	UO	genes	was	confirmed	in	mutant	fly	lines	obtained	from	
stock	centers.		
2. The	most	suitable	larval	stage,	L3,	was	identified	for	further	studies.		
3. UO	expression	is	affected	and	significantly	reduced	by	the	disruption	of	CG30016	gene.	
This	correlation	between	expression	of	UO	and	CG30016	genes	confirms	that	the	two	
genes	are	functionally	related	and	strengthens	our	hypothesis	that	CG30016	is	involved	in	
urate	degradation	pathway.	
7.2.2 Sequence	analysis	and	literature	review	
1. Sequence	analysis	of	CG30016	showed	that	the	gene	has	high	sequence	homology	to	5-
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HIUH	of	other	species,	and	features	consistent	with	TRPs	as	well	as	5-HIU	hydrolase.	
2. A	primary	literature	review	revealed	that	CG30016	is	functionally-related	to	UO,	another	
gene	involved	in	urate	degradation,	due	to	correlated	gained	or	loss	of	activity	of	these	
two	genes	during	evolution	[102].	
3. FlyAtlas	search	showed	that	both	UO	and	CG30016	are	enriched	in	Malpighian	tubules	
(MTs),	which	also	suggests	a	functional	relationship	[4,	6].		
7.2.3 Phenotypic	manifestations	
1. Malpighian	tubules	of	CG30016	mutant	flies	exhibit	an	inflated	ureter	phenotype.	
2. There	is	no	relationship	between	CG30016	knockout	and	urate	crystals	accumulation,	
which	revealed	that	the	MT	phenotype	is	not	caused	by	urate	accumulation	in	the	ureter.		
3. Fluid	secretion	rate	by	MTs	is	not	altered	in	the	CG30016	knockout	when	compared	to	
the	control,	which	indicates	that	the	observed	MT	phenotype	is	not	related	to	aberrant	
fluid	secretion	by	the	tubules.		
4. The	phenotype	could	be	a	result	of	the	accumulation	of	a	metabolite	associated	with	the	
CG30016	activity,	inflammation,	defective	osmoregulation	or	structural	abnormality.		
5. Oxidative	stress	survival	is	improved	in	flies	without	CG30016	expression,	suggesting	that	
blocking	urate	degradation	pathway	has	an	antioxidative	effect.	This	is	most	likely	related	
to	the	accumulation	of	urate	in	CG30016	mutants.	Urate	has	been	shown	before	to	act	as	
an	antioxidant.	However,	our	results	suggested	that	the	substrate	of	a	reaction	catalysed	
by	CG30016	was	also	likely	to	act	as	an	antioxidant.		
6. Longevity	assay	revealed	that	flies	deficient	for	CG30016	had	a	shorter	lifespan	than	the	
controls	when	reared	in	normal	conditions.	This	could	be	associated	with	pro-oxidative	
properties	of	urate	accumulated	in	these	mutants.		
7.2.4 Metabolomics	analysis	
1. The	results	confirmed	that	urate	degradation	is	blocked	in	MTs	of	CG30016	mutant	
because	of	build	up	of	metabolites	upstream	from	expected	knockout	and	decrease	of	
downstream	metabolites.		
2. However,	it	was	not	clear	whether	CG30016	was	the	5-HIUH.	Several	other	hypotheses	
were	proposed	that	require	further	investigation.			
3. 	Metabolomics	results	also	confirmed	that	tubules	rather	than	the	whole	fly	were	more	
suitable	for	metabolomics	analysis	of	purine	metabolism.		
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4. Single-gene	mutations	not	only	affect	levels	of	metabolites	next	to	a	knockout	but	also	
affect	numerous	unrelated	metabolic	pathways.	This	highlights	how	small	changes	affect	
multiple	metabolic	pathways	in	a	given	system.	
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7.2.5 In	vitro	experiments	
Several	expression	systems	were	employed	in	order	to	express	Drosophila	UO	and	
CG30016	genes,	including	cell-free	expression	system,	E.	coli-based	system,	and	
Drosophila	S2	cells.	None	of	the	systems	resulted	in	high	levels	of	expression	of	active	
CG30016	protein.	The	role	of	CG30016	gene	has	not	been	established	in	these	
experiments.	However,	properties	of	CG30016	protein	were	observed:	
1. UO	and	CG30016	were	expressed	using	cell-free	expression	system	at	low	levels	and	
hence	it	was	not	possible	to	detect	the	products	of	enzymatic	reactions	of	urate	
degradation	in	LC-MS	measurements.		
2. UO	and	CG30016	were	expressed	in	Drosophila	S2	cells.	However,	the	transfection	
efficiency	was	too	low	to	observe	the	products	of	enzymatic	reactions	of	urate	
degradation	using	LC-MS.	
3. UO	and	CG30016	were	expressed	in	E.	coli	at	high	levels.	However,	problems	with	protein	
precipitation	resulted	in	the	low	final	yield	of	both	proteins,	and/or	proteins	being	
inactive.	Hence,	it	was	impossible	to	determine	the	role	of	CG30016	in	this	experiment.		
4. LC-MS	is	not	the	most	suitable	method	for	the	detection	of	urate	degradation	
intermediates	following	the	enzyme	assay	because	of	poor	reproducibility	of	LC-MS	
measurements	and	the	instability	of	5-HIU	and	OHCU.		
5. CD-spectroscopy	was	validated	as	a	method	for	detection	of	intermediates	of	urate	
degradation,	and	distinguishing	between	5-HIU	and	OHCU.		
7.2.6 Future	work	
1. Mutant	phenotypes:		
- In	order	to	understand	the	molecular	basis	of	the	inflated	ureter	phenotype	further	
studies	should	be	conducted,	for	example	in-depth	morphological	studies	of	the	tubules.		
- Inflated	abdomen	in	the	mutant	flies	could	be	a	result	of	increased	haemolymph	water	
content.	In	order	to	test	this	hypothesis,	further	experiments	are	required,	for	example	
wet-dry	weight	measurement	(as	described	in	[69]).		
2. Metabolomics	analysis:	
- Metabolomics	results	revealed	the	need	to	obtain	authentic	standards	for	the	accurate	
metabolite	identification.	This	is	particularly	challenging	in	the	case	of	5-HIU	and	OHCU,	
which	are	unstable	and	not	available	from	commercial	sources.	A	possible	solution	would	
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be	to	synthesise	these	compounds	using	commercial	enzymes	involved	in	urate	
degradation	pathway,	followed	by	optimising	a	storage	method	for	both	compounds	in	
order	to	increase	their	stability.		
- It	is	of	crucial	importance	to	distinguish	between	the	spontaneous	and	enzymatic	urate	
degradation	pathway.	One	of	the	methods	would	be	to	differentiate	between	S-	and	R-
allantoin,	for	example	
13
C	NMR	spectroscopy,	as	described	in	[102].		
- Performing	the	fluid	secretion	assay	in	CG30016	mutant	and	the	control	followed	by	LC-
MS	analysis	should	be	performed	as	the	detection	of	metabolites	of	interest	was	more	
robust	in	these	samples	in	comparison	to	whole	fly	or	individual	tissues.		
3. In	vitro	expression:	
- Optimisation	of	in	vitro	expression	of	UO	and	CG30016	is	required	in	order	to	obtain	a	
high	yield	of	active	protein.	Optimisation	should	focus	on	protein	purification	method,	
including	pH,	temperature	and/or	composition	of	the	purification	medium	adjustment.		
- Moreover,	a	possible	method	for	protein	expression	at	higher	yield	would	be	to	generate	
a	stable	S2	cell	line	expressing	both	genes	(as	described	in	[473]).		
- Another	detection	method	should	be	used	alongside	CD-spectroscopy.	For	example	in	
order	to	reduce	spontaneous	degradation	of	purine	metabolism	intermediates,	real-time	
LC-MS	could	be	performed	following	the	enzyme	assay.		
- Finally,	enzyme	assay	could	be	performed	in	dissected	MTs	(CG30016	and	UO	mutant	
MTs	compared	to	the	control),	followed	by	metabolite	identification	using	LC-MS	or	CD-
spectroscopy.	
7.3 Different	Drosophila	tissues	have	different	metabolic	profiles	
Base	on	the	work	on	tissue-specific	metabolomes	presented	in	this	thesis,	and	the	
comparison	of	my	results	with	the	results	obtained	by	collaborators,	several	conclusions	
can	be	drawn:	
1. Tissue	metabolomes	differ	significantly	from	each	other	and	from	the	whole	fly.	
2. Some	of	these	differences	can	be	correlated	to	the	tissue	function.	
3. Some	metabolites	and	metabolic	pathways	are	conserved	among	tissues.	
4. These	results	are	consistent	with	FlyAtlas	findings	that	tissue	transcriptomes	differ	and	
the	differences	are	functionally	significant	[4].	
5. The	results	illustrate	the	need	to	study	individual	tissues	as	well	as	the	whole	organism.	It	
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is	clear	that	some	metabolites	that	play	an	important	role	in	a	given	tissue	might	not	be	
detected	in	the	whole	fly	sample	because	their	abundance	is	much	lower	in	comparison	
to	other	metabolites	present	in	all	tissues,	which	prevent	the	detection	of	the	tissue-
specific	compound.		
6. Isolated	Malpighian	tubules	are	suitable	for	the	study	of	purine	metabolism.		
7. LC-MS	is	a	suitable	method	for	metabolomics	analysis	of	Drosophila	whole	fly	as	well	as	
individual	tissues.		
8. Statistical	analysis,	data	interpretation	and	visualisation	represent	the	major	challenge	in	
metabolomics	studies	of	individual	tissues	and	require	further	optimisation.		
7.3.1 LC-MS	measurement	of	secreted	fluid		
Methodology	for	the	study	of	secreted	fluid	has	been	presented	in	this	thesis	for	the	first	
time.	It	included	sample	preparation,	LC-MS	metabolomics	and	data	processing.	The	
results	showed	that	LC-MS	is	a	suitable	method	for	metabolomics	analysis	of	secreted	
fluid.	Moreover,	data	analysis	revealed	that	compounds	involved	in	purine	metabolism	
are	detected	in	the	secreted	fluid	in	high	abundance.	Hence,	this	method	could	be	utilised	
to	study	purine	metabolism	mutants.		
7.3.2 Future	work	
1. In	order	to	generate	a	comprehensive	atlas	of	tissue-specific	metabolomes,	different	fly	
tissues	have	to	be	carefully	selected	in	terms	of	their	function.	For	example,	CNS	sample	
will	provide	more	informative	results	than	the	head,	which	houses	functionally	diverse	
tissues.		
2. 	Tissues	should	be	selected	that	correspond	to	transcriptomics	data.	Metabolomics	
analysis	should	be	run	in	parallel	to	transcriptomics	analysis.		
3. Due	to	high	variability	between	replicates,	more	replicates	of	each	sample	should	be	
analysed,	as	many	as	is	feasible	(>5).		
4. Several	metabolomics	platforms	can	be	combined	in	order	to	increase	metabolite	
coverage	
5. 	Constant	efforts	should	be	made	to	provide	the	most	suitable	statistical	analysis	of	these	
complex	datasets.	Moreover,	data	interpretation	and	visualisation	could	be	improved.	
This	requires	expertise	in	available	bioinformatics,	which	is	continuously	expanding.		
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Altogether	LC-MS	validated	as	a	method	suitable	for	the	study	of	Drosophila	whole	fly,	
individual	tissues,	as	well	as	secreted	fluid.	Moreover,	preliminary	studies	carried	out	by	
myself	(not	presented	in	this	thesis)	showed	that	the	method	is	also	suitable	for	the	study	
of	Drosophila	haemolymph.	LC-MS	is	a	leading	method	in	untargeted	metabolomics	and	
the	results	presented	here	validate	it	as	a	suitable	tool	for	studying	fruit	fly	specimen.		
	
7.4 Final	conclusion		
Drosophila	melanogaster	GEM	generated	in	our	lab	has	many	metabolic	gaps.	The	
majority	of	the	work	presented	in	this	thesis	was	focused	on	the	development	of	a	
pipeline	for	efficient	gap	filling	using	metabolomics	methods.	The	process	of	the	pipeline	
generation	is	described	and	discussed,	identifying	limitations	and	future	work.		
The	work	presented	in	this	thesis	provided	a	characterisation	of	the	Drosophila	CG30016	
gene.	It	revealed	that	the	gene	is	involved	in	purine	metabolism,	and	specifically	urate	
degradation	pathway.	Moreover,	characteristic	phenotypes	were	identified	as	a	result	of	
CG30016	knockout	that	might	reflect	kidney	disorders	in	hyperuricemia	in	humans.	If	this	
hypothesis	is	confirmed,	a	fly	model	of	hyperuricemia	could	be	developed	in	order	to	test	
new	therapies	for	the	disease.		
Moreover,	methods	for	the	development	of	tissue-specific	metabolic	maps	have	been	
evaluated	and	future	work	identified.	It	is	clear	from	this	study	that	it	is	important	to	
study	individual	tissues	in	the	context	of	the	whole	organism	in	order	to	understand	
holistic	organismal	functions	as	well	as	study	individual	genes,	proteins	and	pathways.		
Future	efforts	should	be	focused	on	the	standardisation	of	metabolomics	methods	for	
Drosophila	melanogaster	research	as	well	as	metabolomics	data	processing,	
interpretation	and	visualisation.	Moreover,	further	curating	of	Drosophila	GEM	is	
required.	The	priority	is	to	establish	biophysical	constraints	on	reaction	and	transport	
rates	once	these	are	available	from	experimental	data	[335].	Once	a	constraint-based	
model	is	available,	it	can	be	used	to	run	simulations	and	test	hypotheses,	for	example,	the	
effects	of	a	single-gene	knockout	on	the	metabolism,	and	as	a	result	validate	Drosophila	
melanogaster	as	a	model	organism	for	studying	human	metabolism	and	metabolic	
disorders,	vector	insects	and	novel	pesticides,	and	poorly	characterised	genes,	including	
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global	orphan	enzymes.	
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Appendices	
Appendix	I:	Fly	food	recipe	
Per	1	litre	of	water	
10	g	agar	
15	g	sucrose	
30	g	glucose	
35	g	dried	yeast	
15	g	maize	meal	
10	g	wheat	germ	
30	g	treacle	
10	g	soya	flour	
Bring	to	boil,	simmer	for	10	min,	cool	to	70°C,	leave	for	20	min,	and	add	the	
following:		
10	ml	Nipagin	(25	g	Nipagin	M	(Tegosept	M,	p-hydroxybenzoic	acid	methyl	ester)	in	
250	ml	Ethanol]	
5	ml	Propionic	acid		
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Appendix	II:	Oligonucleotide	sequences	and	their	use	
Primer	name	 Sequence	(5’	to	3’)	 Use	
Hbs-Taq-1	 CCTCTGAGCTCTCACTTTTGG	 Taq-qPCR	to	test	the	
expression	of	hbs	
Hbs-Taq-2	 GCACGACACTGATCTTAACCG	
CG30016-Taq-1	 TTGGATACTTCGGTGGGAAAG	 Taq-qPCR	to	test	the	
expression	of	CG30016	
CG30016-Taq-2	 GGGATCTCCATTCCTGAATCTC	
Uro-Taq-1	 GACTTCAGCTCCATTGACAAC	 Taq-qPCR	to	test	the	
expression	of	UO	
Uro-Taq-2	 GAGACCCTTGATGCCCG	
Uro-F-SgfI	 TCAG	GCGATCGCC	ACC	
ATGTTTGCCACGCCCCTC	
Cloning	for	the	
expression	in	the	cell-
free	expression	system		
Uro-R-PmeI-6His	 ATGG	GTTTAAAC	
CTAATGGTGATGGTGATGATG	
CAGGTGACTATTGATGTT	
CG30016-F-SgfI	 GACC	GCGATCGCC	ACC	
ATGGATGCACGAAAGTTTTCT	
CG30016-R-PmeI-
6His	
GATG	GTTTAAAC	
CTAATGGTGATGGTGATGATG	
TGTTCCACGATATGTGGA	
Uro-F-EcoRI	 CGGGTACCACCATGTTTGCCACGCCCC
TCAG	
Cloning	for	the	
expression	in	E.	coli	
cells	
Uro-R-XbaI-6His	 CGTCTAGACAGGTGACTATTGATGTTC
C	
CG30016-F-	EcoRI	 CACCATGGATGCACGAAAGTTTTCTAC
CCACATATTGGATACTTCGGTGGGAA
AGG	
CG30016-R-XbaI- CTAATGGTGATGGTGATGATGCTCGTT
	228
6His	 CAGGTAGAACTGGCCTGTTCCACGAT
ATGTGG	
Uro-F	 CACCATGCATCATCACCATCACCATTTT
GCCACGCCCCTCAGACAG	
Cloning	for	the	
expression	in	S2	cells	
Uro-R-6His	 CTACAGGTGACTATTGATGTTCTTCCG
GGCCAATTGGGCATAGATGGTGCCA	
CG30016-F	 CACCATGGATGCACGAAAGTTTTCTAC
CCACATATTGGATACTTCG	
CG30016-R-6His	 CTAATGGTGATGGTGATGATGTGTTCC
ACGATATGTGGAATAC	
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Appendix	III:	Primary	and	secondary	antibodies	and	their	use		
Antibody	name	 Type	of	antibody	 Dilution	 Use	
Anti-6X	His	tag®	
antibody	(abcam,	UK)	
Mouse	
monoclonal	
	
1:1000	
	
Western	blotting	–	primary	
antibody	
ECL™	Anti-Mouse	IgG,	
Horseradish	Peroxidase-	
Linked	(Amersham)	
Sheep	polyclonal	 1:2500	 Western	blotting	-	
secondary	antibody	
Anti-6X	His	tag®	
antibody	(abcam,	UK)	
Mouse	
monoclonal	
	
1:500	 ICC	using	MTs	–	primary	
antibody	
Alexa	Fluor®568-labelled	
anti-mouse	IgG	H	&	L	
(Molecular	Probes)	
Goat	polyclonal	 1:1000	 ICC	using	MTs	-	secondary	
antibody	
Anti-6X	His	tag®	
antibody	(abcam,	UK)	
Mouse	
monoclonal	
	
1:250	 ICC	using	S2	cells	–	primary	
antibody	
Alexa	Fluor®568-labelled	
anti-mouse	IgG	H	&	L	
(Molecular	Probes)	
Goat	polyclonal	 1:500	 ICC	using	S2	cells	-	
secondary	antibody	
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Appendix	IV:	Drosophila	saline	recipe	
Compound	 mM	 g/l	
Dissolve	in	around	800	ml	of	water	while	stirring:	
NaCl	 117.5	 6.86	
KCl	 20	 1.49	
CaCl2*2H2O	 2	 0.29	
MgCl2*6H2O	 2	 0.41	
Glucose	 20	 3.96	
HEPES	 8.6	 2.05	
Dissolve	separately	in	100	ml	water	each,	then	add	to	the	rest	of	the	mixture	
NaHCO3	 10.24	 0.86	
NaH2PO4	 4.5	 0.70	
Adjust	pH	to	6.8	and	volume	to	1	l,	filter	sterilise	and	store	in	a	fridge	
	
Appendix	V:	Standards	used	for	metabolite	identification	at	PF	
Compound	name	 Retention	
time	
Imidazole-4-acetate	 17.77	
N-Acetyl-D-glucosamine	 11.42	
1-Naphthylacetic	acid	 5.51	
Melatonin	 5.92	
Phenylhydrazine	 6.12	
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4-Aminobenzoate	 6.24	
Nicotinate	 8.17	
riboflavin	 8.06	
Glycerol	 9.84	
Inosine	 10.28	
L-Phenylalanine	 13.12	
L-Leucine	 13.93	
L-Tryptophan	 14.05	
2-Phenylglycine	 13.93	
Selenomethionine	 14.22	
L-Methionine	 14.51	
Guanine	 15.09	
Pyridoxine	 16.66	
L-Valine	 15.51	
Adenine	 16.41	
L-Proline	 15.78	
Serotonin	 18.06	
Taurine	 15.45	
trans-4-Hydroxy-L-proline	 16.41	
Creatinine	 19	
N2-Acetyl-L-lysine	 18.89	
L-Threonine	 17.56	
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L-Aspartate	 17.43	
L-Glutamine	 18.12	
beta-Alanine	 19.91	
L-Asparagine	 18.5	
dGMP	 14.82	
L-Serine	 18.62	
L-Citrulline	 19.12	
Cytidine	 20.53	
Ethanolamine	phosphate	 18.44	
Glycine	 18.81	
sn-glycero-3-Phosphocholine	 18.89	
L-Cystine	 22.1	
D-Glucosamine	 24.04	
meso-2,6-
Diaminoheptanedioate	
24.12	
L-Histidine	 26.72	
L-2,4-Diaminobutanoate	 27.53	
L-Lysine	 28.39	
L-Arginine	 28.2	
Thiamin	 33.58	
4-Coumarate	 5.91	
(R)-3-Hydroxybutanoate	 6.77	
Phthalate	 6.1	
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Fumarate	 6.45	
Methylmalonate	 6.58	
3,4-Dihydroxyphenylacetate	 7.13	
Thymidine	 7.4	
Phenolsulfonphthalein	 4.8	
Pyruvate	 6.62	
Malonate	 7.34	
(R)-2-Hydroxyglutarate	 7.82	
Deoxyuridine	 8.09	
pyrazinoate	 8.28	
Xanthine	 9.02	
Gallate	 9.04	
Uridine	 9.29	
cis-Aconitate	 7.15	
L-Rhamnose	 10.21	
Orotate	 8.45	
MOPS	 13.3	
D-Gluconic	acid	 13.44	
Pyridoxal	phosphate	 13.4	
D-Galacturonate	 14.48	
D-Galactarate	 14.54	
3',5'-Cyclic	AMP	 14	
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UMP	 14.98	
IMP	 13.4	
L-Cysteate	 14.65	
D-ribose	5-phosphate	 15.65	
CMP	 18.51	
D-glucose	6-phosphate	 17.38	
Phosphoenolpyruvate	 18.59	
6-Phospho-D-gluconate	 22.28	
L-Glutamate	 17.28	
D-glucose	 13.94	
Picolinic	acid	 9.25	
Nicotinamide	 10.72	
5-Oxoproline	 7.46	
L-isoleucine	 16.57	
Pyridoxal	 14.65	
L-Tyrosine	 14.92	
4-
Trimethylammoniobutanoate	
17	
Betaine	 14.71	
1-Aminocyclopropane-1-
carboxylate	
20.46	
L-Alanine	 19.34	
L-homoserine	 17.98	
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Choline	 19.91	
AMP	 16.53	
1-Aminopropan-2-ol	 20.1	
L-Ornithine	 28.43	
Phenylpyruvate	 5.36	
Mesaconate	 6.47	
succinate	semialdehyde	 6.28	
Succinate	 7.11	
2-Oxoglutarate	 7.3	
N-Acetylglutamine	 8.75	
(S)-Malate	 8.75	
D-Ribose	 12.89	
N-Acetylneuraminate	 12.76	
L-Gulono-1,4-lactone	 13.49	
sucrose	 17.11	
D-Glucuronolactone	 14.97	
DL-Glyceraldehyde	3-
phosphate	
14.58	
3-Phospho-D-glycerate	 17.8	
Isonicotinic	acid	 8.19	
2-Aminobutan-4-olide	 14.43	
Benzoate	 7.01	
Acetoacetate	 8.22	
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Itaconate	 10.82	
N-acetyl-L-glutamate	 7.52	
Maleic	acid	 8.2	
D-Glucono-1,4-lactone	 9.3	
D-Fructose	 15.89	
Orthophosphate	 14.86	
lipoamide	 5.9	
Mercaptoethanol	 8.56	
Biopterin	 14.22	
L-Homocysteine	 15.57	
O-Acetyl-L-serine	 14.43	
L-cysteine	 16.12	
gamma-L-Glutamyl-L-cysteine	 15.31	
glutathione	 15.92	
acetylcysteine	 6.5	
ascorbate	 8.2	
Dihydrolipoamide	 5.79	
Homocystine	 21.9	
L-Cystine	 22.07	
L-Dehydroascorbate	 8.2	
	
	 237	
Appendix	VI:	All	metabolites	identified	in	Drosophila	tissues	and	their	relative	abundance		
Mass	 RT	 Formula	 Putative	metabolite	 CNS	 Gut	 MTs	 WF	
195.09	 5.79	 C10H13NO3	 Damascenine	 148.92	 106.28	 70.73	 0.00	
244.10	 5.99	 C12H12N4O2	 Flavin	 0.00	 0.00	 63.84	 0.00	
193.06	 8.08	 C7H15NOS2	 6-methylthiohexylhydroximate	 161.15	 0.00	 55.44	 0.00	
118.03	 6.84	 C4H6O4	 Succinate	 4.79	 63.15	 34.16	 1.00	
129.04	 7.64	 C5H7NO3	 L-1-Pyrroline-3-hydroxy-5-carboxylate	 2.27	 7.34	 33.99	 1.00	
398.14	 5.67	 C22H22O7	 Deoxypodophyllotoxin	 0.00	 0.00	 23.30	 0.00	
114.03	 6.35	 C5H6O3	 2-Hydroxy-2,4-pentadienoate	 0.00	 20.85	 18.99	 0.00	
165.05	 17.63	 C5H11NO3S	 L-Methionine	S-oxide	 0.00	 0.27	 16.81	 1.00	
175.06	 6.02	 C10H9NO2	 Indole-3-acetate	 35.87	 7.25	 15.23	 0.00	
241.11	 7.24	 C25H30N4O6	 Phe-Gly-Pro-Tyr	 3.12	 15.15	 14.45	 1.00	
148.05	 5.79	 C9H8O2	 trans-Cinnamate	 21.67	 16.07	 12.99	 0.00	
187.08	 5.80	 C8H13NO4	 6-Acetamido-2-oxohexanoate	 9.20	 12.69	 9.64	 1.00	
169.07	 16.69	 C8H11NO3	 Pyridoxine	 0.00	 16.40	 8.65	 1.00	
191.06	 6.20	 C7H13NO3S	 N-Acetylmethionine	 7.49	 33.03	 8.56	 0.00	
123.03	 8.13	 C6H5NO2	 Nicotinate	 10.49	 30.04	 7.65	 1.00	
758.51	 4.78	 C48H70O7	 (3R,2'S)-Myxol	2'-(2,4-di-O-methyl-alpha-L-fucoside)	 4.65	 2.05	 6.54	 0.00	
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163.10	 5.88	 C10H13NO	 N-Acetylphenylethylamine	 20.05	 13.74	 6.53	 1.00	
175.03	 5.86	 C9H19O12P	 nonulose	9-phosphate	 10.67	 8.88	 6.06	 1.00	
236.08	 13.17	 C11H12N2O4	 L-Formylkynurenine	 0.00	 0.30	 5.48	 1.00	
190.08	 5.81	 C8H14O5	 (R)-3-((R)-3-Hydroxybutanoyloxy)butanoate	 8.71	 5.32	 5.45	 1.00	
109.05	 15.31	 C6H7NO	 2-Aminophenol	 0.62	 0.18	 5.28	 1.00	
208.08	 13.46	 C10H12N2O3	 L-Kynurenine	 0.00	 0.03	 5.27	 1.00	
173.07	 6.06	 C7H11NO4	 N-Acetyl-L-glutamate	5-semialdehyde	 4.64	 9.41	 4.93	 1.00	
191.04	 8.87	 C7H5N5O2	 6-formyl-H2-pterin	 0.04	 0.13	 4.59	 1.00	
145.07	 6.89	 C6H11NO3	 4-Acetamidobutanoate	 1.65	 10.36	 4.37	 1.00	
141.04	 6.20	 C6H7NO3	 6-oxo-1,4,5,6-tetrahydronicotinate	 7.10	 9.04	 4.17	 1.00	
138.04	 12.81	 C6H6N2O2	 Urocanate	 1.98	 6.88	 3.92	 1.00	
159.09	 6.08	 C7H13NO3	 5-Acetamidopentanoate	 2.22	 4.06	 3.91	 1.00	
173.14	 14.98	 C9H19NO2	 Muscarine	 0.00	 1.41	 3.76	 1.00	
113.05	 6.08	 C5H7NO2	 1-Pyrroline-2-carboxylate	 3.68	 7.14	 3.65	 1.00	
266.16	 4.46	 C12H26O4S	 sodium	dodecyl	sulfate	 3.86	 3.18	 3.00	 1.00	
376.14	 8.00	 C17H20N4O6	 Riboflavin	 0.00	 0.13	 2.91	 1.00	
115.03	 6.23	 C4H5NO3	 Maleamate	 1.39	 2.76	 2.48	 1.00	
297.09	 11.04	 C11H15N5O3S	 5'-Methylthioadenosine	 7.10	 1.60	 2.19	 1.00	
187.12	 6.00	 C9H17NO3	 N-Heptanoylglycine	 0.96	 3.95	 2.19	 1.00	
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138.03	 5.80	 C7H6O3	 4-Hydroxybenzoate	 0.97	 2.16	 2.11	 1.00	
258.09	 7.39	 C10H14N2O6	 Ribothymidine	 0.00	 0.59	 2.10	 1.00	
242.08	 5.98	 C12H10N4O2	 Lumichrome	 0.63	 0.27	 2.00	 1.00	
122.05	 9.63	 C6H6N2O	 Picolinamide	 4.48	 1.50	 1.99	 1.00	
325.37	 10.93	 C22H47N		 di-n-Undecylamine	 1.73	 1.86	 1.94	 1.00	
146.06	 6.30	 C6H10O4	 (S)-2-Aceto-2-hydroxybutanoate	 2.32	 8.71	 1.88	 1.00	
154.03	 6.06	 C7H6O4	 2,5-Dihydroxybenzoate	 0.00	 0.00	 1.85	 0.00	
282.18	 5.64	 C16H26O4	 12-trans-Hydroxy	juvenile	hormone	III	 2.70	 1.86	 1.83	 1.00	
179.04	 10.64	 C6H5N5O2	 2-Amino-4,7-dihydroxypteridine	 0.00	 0.03	 1.65	 1.00	
446.34	 5.26	 C28H46O4	 3-Dehydroteasterone	 3.95	 3.07	 1.65	 1.00	
216.10	 7.23	 C27H28O5	 Aspulvinone	H	 1.39	 2.18	 1.62	 1.00	
168.07	 13.58	 C11H8N2	 beta-Carboline	 6.15	 1.13	 1.59	 1.00	
131.06	 6.86	 C5H9NO3	 N-Acetyl-beta-alanine	 1.23	 3.54	 1.58	 1.00	
270.18	 5.64	 C15H26O4	 (10S)-Juvenile	hormone	III	acid	diol	 2.61	 1.73	 1.54	 1.00	
124.06	 7.13	 C6H8N2O	 Methylimidazole	acetaldehyde	 1.60	 1.35	 1.49	 1.00	
464.46	 5.25	 C31H60O2	 Hentriacontane-14,16-dione	 0.00	 0.00	 1.47	 0.00	
222.16	 5.45	 C14H22O2	 Rishitin	 2.43	 1.53	 1.41	 1.00	
194.06	 5.78	 C10H10O4	 Ferulate	 1.13	 2.33	 1.39	 1.00	
272.24	 5.59	 C16H32O3	 16-hydroxypalmitate	 4.05	 2.07	 1.33	 1.00	
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112.03	 7.99	 C4H4N2O2	 Uracil	 2.03	 2.09	 1.23	 1.00	
166.06	 5.91	 C9H10O3	 3-(3-Hydroxy-phenyl)-propanoic	acid	 1.87	 3.31	 1.23	 1.00	
99.03	 6.26	 C4H5NO2	 Hymexazol	 1.28	 2.25	 1.23	 1.00	
100.02	 5.60	 C4H4O3	 2-oxobut-3-enanoate	 1.39	 1.03	 1.21	 1.00	
201.14	 5.77	 C10H19NO3	 Capryloylglycine	 1.16	 1.28	 1.17	 1.00	
130.06	 5.69	 C6H10O3	 (S)-3-Methyl-2-oxopentanoic	acid	 0.82	 1.26	 1.13	 1.00	
204.08	 5.37	 C12H12O3	 3-Butylidene-7-hydroxyphthalide	 1.74	 1.56	 1.12	 1.00	
422.23	 4.34	 C20H38O7S	 1,4-Bis(2-ethylhexyl)	sulfosuccinate	 2.02	 1.26	 1.10	 1.00	
205.13	 7.25	 C9H19NO4	 Pantothenol	 0.49	 1.74	 1.05	 1.00	
178.06	 5.77	 C10H10O3	 Coniferyl	aldehyde	 1.17	 2.13	 1.04	 1.00	
215.15	 5.88	 C11H21NO3	 N-Nonanoylglycine	 0.85	 0.87	 1.02	 1.00	
147.04	 10.85	 C5H9NO2S	 Thiomorpholine	3-carboxylate	 2.61	 4.34	 1.02	 1.00	
300.12	 5.71	 C14H20O7	 Salidroside	 0.69	 0.31	 0.99	 1.00	
139.03	 5.72	 C6H5NO3	 6-Hydroxynicotinate	 0.90	 1.05	 0.99	 1.00	
219.11	 6.76	 C9H17NO5	 Pantothenate	 2.17	 17.72	 0.98	 1.00	
328.12	 6.04	 C15H20O8	 Paeonoside	 0.87	 1.12	 0.97	 1.00	
158.06	 5.71	 C7H10O4	 2-Isopropylmaleate	 2.77	 0.38	 0.97	 1.00	
250.16	 5.47	 C15H22O3	 Xanthoxin	 0.93	 1.40	 0.95	 1.00	
408.38	 5.31	 C30H48	 4,4'-Diapophytoene	 2.48	 2.96	 0.94	 1.00	
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229.89	 5.42	 C6H2OCl4	 2,3,5,6-Tetrachlorophenol	 4.77	 1.18	 0.94	 1.00	
131.09	 5.78	 C6H13NO2	 1-nitrohexane	 1.06	 0.97	 0.94	 1.00	
369.29	 5.59	 C21H39NO4	 cis-5-Tetradecenoylcarnitine	 1.06	 1.05	 0.94	 1.00	
164.05	 5.82	 C9H8O3	 4-Coumarate	 0.76	 1.73	 0.94	 1.00	
251.10	 12.96	 C10H13N5O3	 Deoxyadenosine	 5.21	 1.18	 0.94	 1.00	
70.08	 5.60	 C5H10	 butylene	 1.31	 1.40	 0.92	 1.00	
278.15	 5.28	 C16H22O4	 2-Ethylhexyl	phthalate	 1.72	 1.45	 0.92	 1.00	
252.14	 5.50	 C14H20O4	 ubiquinol-1	 1.01	 1.31	 0.90	 1.00	
170.11	 5.73	 C13H14	 Aethusin	 1.41	 0.91	 0.88	 1.00	
184.07	 5.83	 C9H12O4	 3-Methoxy-4-hydroxyphenylethyleneglycol	 0.83	 1.32	 0.82	 1.00	
170.06	 5.98	 C8H10O4	 3,4-Dihydroxyphenylethyleneglycol	 1.21	 1.89	 0.81	 1.00	
220.11	 5.42	 C13H16O3	 Precocene	2	 1.00	 0.82	 0.80	 1.00	
110.04	 6.22	 C6H6O2	 p-Benzenediol	 0.77	 0.82	 0.80	 1.00	
99.07	 7.31	 C5H9NO	 N-Methyl-2-pyrrolidinone	 1.11	 0.89	 0.78	 1.00	
227.22	 5.58	 C14H29NO	 myristic	amide	 1.24	 0.76	 0.75	 1.00	
243.18	 5.75	 C13H25NO3	 N-Undecanoylglycine	 0.91	 0.96	 0.75	 1.00	
161.05	 8.92	 C9H7NO2	 4,6-Dihydroxyquinoline	 0.07	 0.02	 0.75	 1.00	
316.17	 5.39	 C19H24O4	 Gibberellin	A9	 1.00	 1.24	 0.74	 1.00	
264.17	 5.53	 C16H24O3	 Dehydrojuvabione	 1.28	 0.70	 0.73	 1.00	
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120.06	 5.65	 C8H8O	 Phenylacetaldehyde	 0.81	 0.83	 0.71	 1.00	
326.28	 5.43	 C20H38O3	 2-Oxophytanate	 0.90	 0.92	 0.71	 1.00	
126.10	 5.96	 C8H14O	 Sulcatone	 0.95	 0.80	 0.71	 1.00	
229.17	 5.82	 C12H23NO3	 N-Decanoylglycine	 0.92	 0.55	 0.70	 1.00	
284.20	 5.61	 C16H28O4	 (10S)-Juvenile	hormone	III	diol	 1.26	 1.27	 0.69	 1.00	
418.16	 5.80	 C22H26O8	 Euparotin	acetate	 0.94	 0.82	 0.68	 1.00	
88.06	 7.71	 C3H8N2O	 N,N'-Dimethylurea	 1.31	 0.84	 0.68	 1.00	
268.08	 10.27	 C10H12N4O5	 Inosine	 0.00	 1.05	 0.67	 1.00	
386.17	 5.65	 C22H26O6	 Burseran	 0.89	 0.95	 0.67	 1.00	
129.12	 5.90	 C7H15NO	 N-Methylhexanamide	 0.98	 0.96	 0.67	 1.00	
240.07	 5.26	 C10H12N2O5	 Dinoseb	 0.70	 0.71	 0.66	 1.00	
204.12	 5.62	 C13H16O2	 4'-Hydroxy-3'-prenylacetophenone	 0.78	 0.83	 0.65	 1.00	
125.01	 15.50	 C2H7NO3S	 Taurine	 0.11	 0.10	 0.64	 1.00	
352.26	 5.58	 C21H36O4	 Montanol	 0.81	 0.85	 0.63	 1.00	
135.05	 16.39	 C5H5N5	 Adenine	 1.25	 0.79	 0.62	 1.00	
339.35	 5.54	 C22H45NO	 Docosanamide	 1.98	 0.88	 0.61	 1.00	
356.21	 21.06	 C16H28N4O5	 Leu-Gln-Pro	 0.91	 0.73	 0.58	 1.00	
268.17	 5.56	 C15H24O4	 dihydroartemisinic	acid	hydroperoxide	 0.63	 0.55	 0.57	 1.00	
136.05	 5.69	 C8H8O2	 Phenylacetic	acid	 0.90	 0.81	 0.53	 1.00	
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107.07	 16.32	 C7H9N	 Benzylamine	 0.82	 0.71	 0.53	 1.00	
236.18	 5.56	 C15H24O2	 Capsidiol	 0.80	 0.70	 0.52	 1.00	
152.03	 9.06	 C5H4N4O2	 Xanthine	 0.54	 1.20	 0.52	 1.00	
223.12	 5.72	 C12H17NO3	 Cerulenin	 1.16	 0.22	 0.51	 1.00	
194.13	 5.63	 C12H18O2	 4-Hexyloxyphenol	 0.72	 0.71	 0.51	 1.00	
244.07	 9.25	 C9H12N2O6	 Uridine	 0.11	 1.86	 0.51	 1.00	
255.26	 5.59	 C16H33NO	 Palmiticamide	 0.93	 0.69	 0.50	 1.00	
128.08	 5.77	 C7H12O2	 3-Isopropylbut-3-enoic	acid	 0.86	 0.88	 0.50	 1.00	
271.21	 5.66	 C15H29NO3	 Tridecanoylglycine	 0.63	 2.14	 0.49	 1.00	
138.07	 5.62	 C8H10O2	 4-Hydroxyphenylethanol	 0.66	 0.69	 0.45	 1.00	
181.06	 10.75	 C6H7N5O2	 8-Hydroxy-7-methylguanine	 0.00	 0.00	 0.44	 1.00	
166.10	 5.77	 C10H14O2	 Perillic	acid	 0.67	 0.70	 0.44	 1.00	
264.10	 33.43	 C12H16N4OS	 Thiamin	 0.00	 0.39	 0.43	 1.00	
165.07	 15.25	 C6H7N5O	 3-Methylguanine	 0.18	 0.22	 0.42	 1.00	
145.11	 13.96	 C7H15NO2	 Acetylcholine	 0.26	 0.75	 0.39	 1.00	
272.25	 5.26	 C20H32	 Taxa-4(5),11(12)-diene	 2.42	 2.21	 0.39	 1.00	
121.09	 15.26	 C8H11N	 Phenethylamine	 0.52	 0.56	 0.37	 1.00	
182.04	 10.74	 C6H6N4O3	 1-Methyluric	acid	 0.00	 0.02	 0.37	 1.00	
252.09	 9.29	 C10H12N4O4	 Deoxyinosine	 0.00	 0.07	 0.33	 1.00	
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180.11	 5.69	 C11H16O2	 3-tert-Butyl-5-methylcatechol	 0.46	 0.42	 0.33	 1.00	
297.11	 9.73	 C11H15N5O5	 1-methylguanosine	 0.00	 0.00	 0.30	 1.00	
105.08	 20.59	 C4H11NO2	 Diethanolamine	 0.48	 0.35	 0.29	 1.00	
122.07	 5.68	 C8H10O	 Phenylethyl	alcohol	 0.37	 0.36	 0.28	 1.00	
192.03	 5.65	 C6H8O7	 Carboxymethyloxysuccinate	 1.00	 0.59	 0.28	 1.00	
151.05	 9.73	 C5H5N5O	 2-Hydroxyadenine	 0.00	 0.00	 0.28	 1.00	
322.21	 5.54	 C19H30O4	 Decylubiquinone	 0.22	 0.24	 0.27	 1.00	
296.20	 5.62	 C17H28O4	 10-Deoxymethynolide	 0.72	 0.44	 0.26	 1.00	
219.08	 6.92	 C21H26O10	 Glaucolide	B	 0.02	 0.00	 0.25	 1.00	
136.04	 9.65	 C5H4N4O	 Hypoxanthine	 0.24	 0.68	 0.23	 1.00	
385.28	 5.63	 C21H39NO5	 3-Hydroxy-cis-5-tetradecenoylcarnitine	 0.35	 20.58	 0.21	 1.00	
78.01	 8.55	 C2H6OS	 Mercaptoethanol	 0.30	 0.35	 0.21	 1.00	
103.10	 19.85	 C5H13NO	 Choline	 0.01	 0.41	 0.19	 1.00	
85.05	 7.50	 C4H7NO	 Acetone	cyanohydrin	 0.49	 0.17	 0.18	 1.00	
254.19	 5.62	 C15H26O3	 3-hydroxy-15-dihydrolubimin	 0.55	 0.23	 0.18	 1.00	
168.08	 5.78	 C9H12O3	 1,3,5-trimethoxybenzene	 0.28	 0.32	 0.18	 1.00	
150.05	 10.32	 C5H10O5	 D-Xylulose	 0.00	 0.56	 0.17	 1.00	
357.25	 5.63	 C19H35NO5	 2,3-dioctanoylglyceramide	 0.12	 23.41	 0.15	 1.00	
257.20	 5.63	 C14H27NO3	 N-Lauroylglycine	 0.36	 0.98	 0.15	 1.00	
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267.10	 13.42	 C10H13N5O4	 Adenosine	 0.20	 0.51	 0.14	 1.00	
270.05	 5.68	 C15H10O5	 Apigenin	 0.25	 0.30	 0.13	 1.00	
383.27	 5.63	 C21H37NO5	 3-Hydroxy-5,	8-tetradecadiencarnitine	 0.14	 19.11	 0.12	 1.00	
245.16	 5.77	 C12H23NO4	 N-(octanoyl)-L-homoserine	 0.00	 0.23	 0.10	 1.00	
240.15	 16.76	 C12H20N2O3	 Slaframine	 0.00	 0.30	 0.10	 1.00	
582.44	 5.77	 C41H58O2	 Spheroidenone	 0.00	 2.58	 0.06	 1.00	
329.22	 5.67	 C17H31NO5	 6-Keto-decanoylcarnitine	 0.05	 28.88	 0.05	 1.00	
152.05	 5.73	 C8H8O3	 3,4-Dihydroxyphenylacetaldehyde	 0.05	 0.21	 0.05	 1.00	
163.05	 11.02	 C6H5N5O	 Pterin	 0.04	 0.01	 0.03	 1.00	
168.04	 5.93	 C8H8O4	 Homogentisate	 0.04	 0.28	 0.02	 1.00	
169.09	 15.84	 C7H11N3O2	 Nalpha-Methylhistidine	 0.00	 0.14	 0.02	 1.00	
235.07	 8.58	 C9H9N5O3	 6-Succinoaminopurine		 0.00	 0.00	 0.02	 1.00	
427.37	 11.33	 C25H49NO4	 Stearoylcarnitine	 0.20	 0.21	 0.01	 1.00	
207.09	 5.94	 C11H13NO3	 N-Acetyl-L-phenylalanine	 0.00	 27.14	 0.00	 0.00	
244.02	 7.33	 C6H13O6PS	 5-methylthiodeoxyribose-1-phosphate	 0.00	 8.04	 0.00	 1.00	
390.13	 5.91	 C20H22O8	 Piceid	 0.00	 2.09	 0.00	 0.00	
400.23	 11.89	 C18H32N4O6	 Ala-Leu-Thr-Pro	 0.00	 1.98	 0.00	 1.00	
473.21	 11.89	 C19H31N5O9	 Glu-Thr-Gln-Pro	 0.00	 1.70	 0.00	 1.00	
426.25	 11.76	 C20H34N4O6	 Ile-Thr-Pro-Pro	 0.00	 1.62	 0.00	 1.00	
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393.23	 5.80	 C20H31N3O5	 Leu-Val-Tyr	 0.00	 1.27	 0.00	 1.00	
489.20	 11.75	 C21H27N7O7	 Asn-Trp-Asn-Gly	 0.00	 1.23	 0.00	 1.00	
537.22	 11.76	 C22H31N7O9	 Asn-Asn-Gln-Tyr	 0.00	 1.21	 0.00	 1.00	
360.11	 6.52	 C15H20O10	 3-Methoxy-4-hydroxyphenylglycolglucuronide	 0.00	 1.00	 0.00	 1.00	
372.16	 5.60	 C21H24O6	 (-)-Arctigenin	 0.65	 0.83	 0.00	 1.00	
394.42	 5.27	 C27H54O	 2-heptacosanone	 0.00	 0.53	 0.00	 1.00	
178.05	 7.47	 C6H10O6	 2-Dehydro-3-deoxy-D-gluconate	 0.00	 0.46	 0.00	 1.00	
126.04	 7.18	 C5H6N2O2	 Thymine	 0.00	 0.45	 0.00	 1.00	
794.62	 5.29	 C54H82O4	 Ubiquinone-9	 0.10	 0.40	 0.00	 1.00	
414.35	 5.26	 C28H46O2	 22alpha-Hydroxy-campest-4-en-3-one	 0.26	 0.34	 0.00	 1.00	
423.33	 11.39	 C25H45NO4	 Linoelaidylcarnitine	 0.03	 0.33	 0.00	 1.00	
425.35	 11.36	 C25H47NO4	 Elaidiccarnitine	 0.08	 0.25	 0.00	 1.00	
455.40	 11.25	 C27H53NO4	 Arachidylcarnitine	 0.07	 0.19	 0.00	 1.00	
726.56	 5.22	 C49H74O4	 [PR]	Coenzyme	Q8	 0.00	 0.18	 0.00	 1.00	
776.69	 5.34	 C15H11I4NO4	 Thyroxine	 0.08	 0.14	 0.00	 1.00	
143.04	 8.33	 C6H9NOS	 5-(2-Hydroxyethyl)-4-methylthiazole	 93.05	 0.00	 0.00	 0.00	
210.08	 5.82	 C13H10N2O	 2-Aminoacridone	 61.63	 0.00	 0.00	 0.00	
167.06	 5.72	 C8H9NO3	 3-Methoxyanthranilate	 36.98	 0.00	 0.00	 0.00	
163.09	 14.07	 C7H9N5	 1-ethyladenine	 28.24	 0.00	 0.00	 0.00	
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164.03	 7.71	 C6H4N4O2	 2,4-Dihydroxypteridine	 0.30	 0.00	 0.00	 1.00	
142.06	 5.90	 C7H10O3	 4-Oxocyclohexanecarboxylate	 0.00	 0.00	 0.00	 1.00	
109.03	 5.76	 C6H5O2	 Benzosemiquinone	 0.00	 0.00	 0.00	 1.00	
95.04	 16.08	 C5H5NO	 3-hydroxypyridine	 0.00	 0.00	 0.00	 1.00	
284.18	 17.00	 C13H24N4O3	 Melanostatin	 0.00	 0.00	 0.00	 1.00	
209.11	 6.13	 C11H15NO3	 p-Lactophenetide	 0.00	 0.00	 0.00	 1.00	
282.10	 8.30	 C11H14N4O5	 1-Methylinosine	 0.00	 0.00	 0.00	 1.00	
198.05	 5.85	 C9H10O5	 3-(3,4-Dihydroxyphenyl)lactate	 0.00	 0.00	 0.00	 1.00	
139.07	 18.81	 C6H9N3O	 L-Histidinal	 0.00	 0.00	 0.00	 1.00	
191.06	 6.03	 C10H9NO3	 5-Hydroxyindoleacetate	 0.00	 0.00	 0.00	 1.00	
448.36	 5.25	 C28H48O4	 Teasterone	 0.00	 0.00	 0.00	 1.00	
210.09	 5.69	 C11H14O4	 Sinapyl	alcohol	 0.00	 0.00	 0.00	 1.00	
224.07	 5.59	 C11H12O5	 Sinapate	 0.00	 0.00	 0.00	 1.00	
195.08	 10.72	 C7H9N5O2	 2-Amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine	 0.00	 0.00	 0.00	 1.00	
243.12	 18.29	 C10H17N3O4	 Ala-Gly-Pro	 0.00	 0.00	 0.00	 1.00	
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Appendix	VII:	All	metabolites	identified	in	Drosophila	whole	fly	CG30016	mutant	and	the	control	
Mass	 RT	 Formula	 Putative	metabolite	 WFLY17767	 WFLY18554	
205.04	 7.79	 C10H7NO4	 Xanthurenic	acid	 1.00	 28.31	
383.14	 15.89	 C14H25NO11	 N-Acetyllactosamine	 1.00	 21.07	
182.08	 13.85	 C6H14O6	 D-Sorbitol	 1.00	 6.38	
218.05	 13.88	 C13H21N6O9P	 (L-Seryl)adenylate	 1.00	 5.13	
126.04	 15.31	 C5H6N2O2	 Imidazole-4-acetate	 1.00	 4.08	
182.04	 10.84	 C6H6N4O3	 1-Methyluric	acid	 1.00	 3.52	
284.08	 11.78	 C12H16N2O4S	 Cys-Tyr	 1.00	 3.44	
212.01	 18.95	 C5H9O7P	 P-DPD	 1.00	 3.42	
283.09	 12.39	 C10H13N5O5	 Guanosine	 1.00	 3.31	
163.05	 10.68	 C6H5N5O	 Pterin	 1.00	 3.10	
233.13	 15.00	 C10H19NO5	 Hydroxypropionylcarnitine	 1.00	 3.10	
111.99	 16.08	 CH5O4P	 Hydroxymethylphosphonate	 1.00	 3.07	
208.05	 22.30	 C6H12N2O4S	 Cys-Ser	 1.00	 2.99	
175.10	 18.80	 C6H13N3O3	 L-Citrulline	 1.00	 2.96	
141.02	 19.70	 C2H8NO4P	 Ethanolamine	phosphate	 1.00	 2.95	
268.08	 10.29	 C10H12N4O5	 Inosine	 1.00	 2.58	
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110.05	 14.95	 C5H6N2O	 Imidazole-4-acetaldehyde	 1.00	 2.52	
297.05	 24.33	 C8H15N3O5S2	 L-Cysteinylglycinedisulfide	 1.00	 2.30	
145.11	 14.49	 C7H15NO2	 4-Trimethylammoniobutanoate	 1.00	 2.28	
136.04	 9.26	 C5H4N4O	 allopurinol	 1.00	 2.19	
152.03	 8.66	 C5H4N4O2	 Xanthine	 1.00	 2.01	
148.04	 7.54	 C5H8O5	 (R)-2-Hydroxyglutarate	 1.00	 1.97	
278.09	 13.14	 C10H18N2O5S	 Glu-Met	 1.00	 1.96	
132.09	 26.33	 C5H12N2O2	 L-Ornithine	 1.00	 1.93	
134.06	 9.41	 C5H10O4	 Deoxyribose	 1.00	 1.92	
344.33	 5.05	 C21H44O3	 1-O-Octadecyl-sn-glycerol	 1.00	 1.84	
342.12	 15.81	 C12H22O11	 Sucrose	 1.00	 1.82	
198.07	 12.66	 C17H24N4O5S	 Phe-Cys-Gln	 1.00	 1.81	
123.03	 7.27	 C6H5NO2	 Nicotinate	 1.00	 1.78	
188.15	 26.88	 C9H20N2O2	 N6,N6,N6-Trimethyl-L-lysine	 1.00	 1.77	
244.07	 8.98	 C9H12N2O6	 Uridine	 1.00	 1.77	
161.07	 13.83	 C6H11NO4	 L-2-Aminoadipate	 1.00	 1.70	
240.02	 22.27	 C6H12N2O4S2	 L-Cystine	 1.00	 1.68	
243.09	 18.84	 C9H13N3O5	 Cytidine	 1.00	 1.64	
477.31	 9.37	 C21H43N5O7	 Gentamicin	 1.00	 1.61	
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255.10	 11.53	 C9H13N5O4	 2-Amino-4-hydroxy-6-(D-erythro-1,2,3-trihydroxypropyl)-7,8-	
dihydropteridine	
1.00	 1.61	
151.58	 23.91	 C11H21N5O5	 Glu-Arg	 1.00	 1.56	
129.09	 15.14	 C5H11N3O	 4-Guanidinobutanal	 1.00	 1.53	
120.09	 4.97	 C9H12	 1,2,4-Trimethylbenzene	 1.00	 1.47	
212.12	 14.89	 C10H16N2O3	 Pro-Pro	 1.00	 1.47	
446.06	 21.40	 C11H20N4O11P2	 CDP-ethanolamine	 1.00	 1.46	
264.10	 28.46	 C12H16N4OS	 Thiamin	 1.00	 1.45	
165.05	 17.81	 C5H11NO3S	 L-Methionine	S-oxide	 1.00	 1.42	
206.09	 19.65	 C7H14N2O5	 Thr-Ser	 1.00	 1.39	
183.07	 23.33	 C5H14NO4P	 Choline	phosphate	 1.00	 1.37	
168.03	 11.77	 C5H4N4O3	 Urate	 1.00	 1.35	
108.57	 28.99	 C9H19N3O3	 gamma-L-Glutamylputrescine	 1.00	 1.32	
188.03	 6.41	 C7H8O6	 (Z)-But-2-ene-1,2,3-tricarboxylate	 1.00	 1.32	
232.11	 15.94	 C9H16N2O5	 N2-Succinyl-L-ornithine	 1.00	 1.32	
224.08	 5.02	 C15H12O2	 Flavanone	 1.00	 1.30	
357.14	 8.68	 C16H23NO8	 Bakankoside	 1.00	 1.29	
186.10	 15.05	 C8H14N2O3	 Ala-Pro	 1.00	 1.28	
217.11	 19.40	 C8H15N3O4	 Ala-Ala-Gly	 1.00	 1.27	
190.06	 19.46	 C6H10N2O5	 Asp-Gly	 1.00	 1.26	
	 251	
259.05	 17.90	 C6H14NO8P	 alpha-D-Glucosamine	1-phosphate	 1.00	 1.26	
222.07	 22.44	 C7H14N2O4S	 L-Cystathionine	 1.00	 1.24	
173.07	 14.67	 C7H11NO4	 N-Acetyl-L-glutamate	5-semialdehyde	 1.00	 1.24	
126.00	 11.41	 C2H6O4S	 2-Hydroxyethanesulfonate	 1.00	 1.21	
204.07	 18.78	 C7H12N2O5	 Glu-Gly	 1.00	 1.20	
142.07	 14.93	 C6H10N2O2	 Ectoine	 1.00	 1.18	
130.03	 9.66	 C5H6O4	 2,5-Dioxopentanoate	 1.00	 1.18	
203.09	 18.65	 C7H13N3O4	 Ala-Asn	 1.00	 1.17	
123.58	 29.23	 C10H21N3O4	 Lys-Thr	 1.00	 1.16	
234.08	 19.51	 C8H14N2O6	 Glu-Ser	 1.00	 1.16	
509.17	 24.74	 C17H31N7O7S2	 Glu-Cys-Cys-Arg	 1.00	 1.16	
116.57	 29.65	 C9H19N3O4	 Lys-Ser	 1.00	 1.15	
175.55	 21.73	 C12H21N3O7S	 Met-Asp-Ser	 1.00	 1.15	
101.12	 14.20	 C6H15N	 Hexylamine	 1.00	 1.13	
101.56	 29.08	 C8H17N3O3	 Lys-Gly	 1.00	 1.12	
195.09	 8.71	 C10H13NO3	 L-Tyrosine	methyl	ester	 1.00	 1.10	
89.05	 17.74	 C3H7NO2	 L-Alanine	 1.00	 1.10	
145.16	 43.25	 C7H19N3	 Spermidine	 1.00	 1.09	
178.05	 9.66	 C6H10O6	 D-Glucono-1,5-lactone	 1.00	 1.08	
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75.03	 18.26	 C2H5NO2	 Glycine	 1.00	 1.08	
230.16	 12.23	 C11H22N2O3	 Leu-Val	 1.00	 1.08	
593.22	 17.56	 C26H35N5O9S	 Glu-Glu-Met-Trp	 1.00	 1.07	
88.02	 6.93	 C3H4O3	 Pyruvate	 1.00	 1.07	
155.13	 13.06	 C9H17NO	 N-Methylpelletierine	 1.00	 1.06	
129.59	 25.92	 C12H25N3O3	 Leu-Lys	 1.00	 1.06	
386.17	 5.18	 C22H26O6	 Burseran	 1.00	 1.05	
136.59	 27.36	 C11H23N5O3	 Val-Arg	 1.00	 1.05	
135.05	 14.60	 C5H5N5	 Adenine	 1.00	 1.05	
187.05	 6.71	 C7H9NO5	 2-(Acetamidomethylene)succinate	 1.00	 1.02	
260.03	 19.45	 C6H13O9P	 D-Glucose	6-phosphate	 1.00	 1.02	
275.11	 17.75	 C10H17N3O6	 Gamma-Glutamylglutamine	 1.00	 1.02	
132.05	 18.35	 C4H8N2O3	 L-Asparagine	 1.00	 1.01	
175.05	 7.24	 C6H9NO5	 N-Acetyl-L-aspartate	 1.00	 1.01	
155.07	 24.75	 C6H9N3O2	 L-Histidine	 1.00	 0.99	
363.06	 18.59	 C10H14N5O8P	 GMP	 1.00	 0.99	
192.10	 15.03	 C17H28N4O6	 Ala-Thr-Pro-Pro	 1.00	 0.99	
122.05	 8.37	 C6H6N2O	 Nicotinamide	 1.00	 0.98	
115.06	 15.38	 C5H9NO2	 L-Proline	 1.00	 0.98	
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202.13	 13.40	 C9H18N2O3	 Leu-Ala	 1.00	 0.97	
181.18	 10.50	 C12H23N	 Dicyclohexylamine	 1.00	 0.97	
195.08	 10.48	 C7H9N5O2	 2-Amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine	 1.00	 0.97	
138.07	 21.46	 C11H20N2O6	 N6-(L-1,3-Dicarboxypropyl)-L-lysine	 1.00	 0.96	
103.10	 17.24	 C5H13NO	 Choline	 1.00	 0.96	
105.04	 18.38	 C3H7NO3	 L-Serine	 1.00	 0.95	
129.04	 6.93	 C5H7NO3	 L-1-Pyrroline-3-hydroxy-5-carboxylate	 1.00	 0.95	
218.13	 14.69	 C9H18N2O4	 Leu-Ser	 1.00	 0.95	
154.00	 14.92	 C3H7O5P	 Propanoyl	phosphate	 1.00	 0.95	
179.09	 11.81	 C10H13NO2	 (-)-Salsolinol	 1.00	 0.94	
81.98	 15.10	 H3O3P	 Phosphonate	 1.00	 0.94	
702.54	 5.81	 C50H70O2	 demethylmenaquinone-8	 1.00	 0.94	
146.11	 26.04	 C6H14N2O2	 L-Lysine	 1.00	 0.94	
289.13	 15.16	 C11H19N3O6	 Val-Asp-Gly	 1.00	 0.94	
252.11	 14.24	 C12H16N2O4	 Ala-Tyr	 1.00	 0.94	
165.08	 12.19	 C9H11NO2	 L-Phenylalanine	 1.00	 0.94	
131.09	 12.87	 C6H13NO2	 L-Leucine	 1.00	 0.93	
138.03	 5.70	 C7H6O3	 4-Hydroxybenzoate	 1.00	 0.92	
446.19	 25.72	 C20H26N6O6	 Gln-Tyr-His	 1.00	 0.92	
	254
103.06	 16.66	 C4H9NO2	 N,N-Dimethylglycine	 1.00	 0.92	
111.08	 31.22	 C5H9N3	 1H-Imidazole-4-ethanamine	 1.00	 0.92	
229.11	 14.49	 C9H15N3O4	 Asn-Pro	 1.00	 0.91	
423.33	 9.78	 C25H45NO4	 Linoelaidylcarnitine	 1.00	 0.91	
220.11	 18.83	 C8H16N2O5	 Thr-Thr	 1.00	 0.91	
118.03	 6.55	 C4H6O4	 Succinate	 1.00	 0.91	
146.06	 6.17	 C6H10O4	 (S)-2-Aceto-2-hydroxybutanoate	 1.00	 0.91	
345.19	 13.33	 C15H27N3O6	 Leu-Val-Asp	 1.00	 0.90	
345.05	 15.05	 C10H12N5O7P	 3',5'-Cyclic	GMP	 1.00	 0.90	
219.11	 6.85	 C9H17NO5	 Pantothenate	 1.00	 0.90	
279.12	 14.20	 C13H17N3O4	 Phe-Asn	 1.00	 0.90	
305.04	 18.78	 C9H12N3O7P	 2',3'-Cyclic	CMP	 1.00	 0.90	
147.05	 16.65	 C5H9NO4	 L-Glutamate	 1.00	 0.90	
204.09	 12.96	 C11H12N2O2	 L-Tryptophan	 1.00	 0.88	
201.17	 14.92	 C11H23NO2	 Caproylcholine	 1.00	 0.88	
133.04	 17.38	 C4H7NO4	 L-Aspartate	 1.00	 0.88	
294.06	 25.75	 C9H15N2O7P	 Pyrimidine	5'-nucleotide	 1.00	 0.88	
225.11	 14.62	 C20H30N6O6	 His-Thr-Pro-Pro	 1.00	 0.88	
369.04	 12.21	 C9H15N5O7S2	 Amidosulfuron	 1.00	 0.87	
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216.12	 16.19	 C8H16N4O3	 N-acetyl-(L)-arginine	 1.00	 0.87	
327.22	 12.26	 C16H29N3O4	 Leu-Val-Pro	 1.00	 0.87	
149.05	 13.73	 C5H11NO2S	 L-Methionine	 1.00	 0.87	
133.07	 15.74	 C5H11NO3	 DL-&beta;-hydroxynorvaline	 1.00	 0.87	
244.18	 11.61	 C12H24N2O3	 Leucyl-leucine	 1.00	 0.87	
239.10	 12.84	 C9H13N5O3	 Dihydrobiopterin	 1.00	 0.87	
246.12	 14.73	 C10H18N2O5	 Glu-Val	 1.00	 0.86	
197.07	 17.02	 C9H11NO4	 3,4-Dihydroxy-L-phenylalanine	 1.00	 0.86	
235.07	 8.25	 C9H9N5O3	 6-Succinoaminopurine		 1.00	 0.86	
329.05	 14.91	 C10H12N5O6P	 3',5'-Cyclic	AMP	 1.00	 0.85	
467.13	 16.34	 C19H25N5O5S2	 Cys-Trp-Cys-Gly	 1.00	 0.85	
171.03	 19.55	 C3H10NO5P	 serinol	phosphate	 1.00	 0.85	
146.07	 17.89	 C5H10N2O3	 L-Glutamine	 1.00	 0.85	
187.17	 30.27	 C9H21N3O	 N1-Acetylspermidine	 1.00	 0.85	
245.15	 29.91	 C9H19N5O3	 beta-Alanyl-L-arginine	 1.00	 0.84	
264.15	 11.97	 C14H20N2O3	 Phe-Val	 1.00	 0.84	
285.17	 13.80	 C13H23N3O4	 Leu-Gly-Pro	 1.00	 0.83	
262.13	 12.28	 C14H18N2O3	 Phe-Pro	 1.00	 0.83	
347.06	 17.88	 C10H14N5O7P	 dGMP	 1.00	 0.83	
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341.23	 11.72	 C17H31N3O4	 Leu-Leu-Pro	 1.00	 0.83	
228.04	 18.32	 C14H24N4O7S3	 Glu-Cys-Cys-Cys	 1.00	 0.83	
100.06	 14.95	 C4H8N2O	 Gyromitrin	 1.00	 0.82	
224.08	 14.11	 C10H12N2O4	 3-Hydroxy-L-kynurenine	 1.00	 0.82	
208.08	 12.44	 C10H12N2O3	 L-Kynurenine	 1.00	 0.81	
267.10	 12.27	 C10H13N5O4	 Adenosine	 1.00	 0.81	
169.07	 14.86	 C8H11NO3	 Pyridoxine	 1.00	 0.80	
158.04	 12.90	 C4H6N4O3	 Allantoin	 1.00	 0.80	
169.08	 24.82	 C7H11N3O2	 N(pi)-Methyl-L-histidine	 1.00	 0.79	
181.07	 14.56	 C9H11NO3	 3-Amino-3-(4-hydroxyphenyl)propanoate	 1.00	 0.78	
189.04	 6.54	 C10H7NO3	 Kynurenate	 1.00	 0.78	
216.15	 13.06	 C10H20N2O3	 Val-Val	 1.00	 0.78	
172.08	 14.78	 C7H12N2O3	 Glycylproline	 1.00	 0.77	
151.03	 17.07	 C4H9NO3S	 methiin	 1.00	 0.75	
278.16	 11.38	 C15H22N2O3	 Leu-Phe	 1.00	 0.75	
189.06	 6.75	 C7H11NO5	 Glutarylglycine	 1.00	 0.75	
290.12	 23.57	 C10H18N4O6	 N-(L-Arginino)succinate	 1.00	 0.75	
237.09	 11.74	 C9H19NO2S2	 8-[(aminomethyl)sulfanyl]-6-sulfanyloctanoic	acid	 1.00	 0.74	
281.11	 19.05	 C25H34N6O7S	 Glu-Met-Phe-His	 1.00	 0.74	
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240.15	 14.79	 C12H20N2O3	 Slaframine	 1.00	 0.73	
311.18	 14.22	 C15H25N3O4	 Val-Pro-Pro	 1.00	 0.72	
116.07	 27.73	 C10H20N2O4	 Spermic	acid	2	 1.00	 0.71	
297.09	 9.60	 C11H15N5O3S	 5'-Methylthioadenosine	 1.00	 0.71	
116.01	 6.11	 C4H4O4	 Fumarate	 1.00	 0.70	
247.14	 14.35	 C11H21NO5	 Hydroxybutyrylcarnitine	 1.00	 0.69	
152.06	 14.82	 C7H8N2O2	 N1-Methyl-2-pyridone-5-carboxamide	 1.00	 0.69	
190.11	 26.55	 C6H14N4O3	 N-(omega)-Hydroxyarginine	 1.00	 0.69	
181.06	 10.77	 C6H7N5O2	 8-Hydroxy-7-methylguanine	 1.00	 0.66	
145.09	 14.98	 C5H11N3O2	 4-Guanidinobutanoate	 1.00	 0.66	
431.16	 16.59	 C16H25N5O9	 Asn-Asp-Pro-Ser	 1.00	 0.66	
137.08	 14.26	 C8H11NO	 Tyramine	 1.00	 0.66	
175.08	 14.96	 C7H13NO4	 alpha-aminopimelate	 1.00	 0.65	
214.13	 14.41	 C10H18N2O3	 Val-Pro	 1.00	 0.65	
220.08	 12.29	 C11H12N2O3	 5-Hydroxy-L-tryptophan	 1.00	 0.64	
244.15	 14.62	 C20H40N8O6	 Arg-Lys-Val-Ser	 1.00	 0.64	
489.17	 16.58	 C14H30N6O11P	 O-1,4-alpha-L-Dihydrostreptosyl-streptidine	6-phosphate	 1.00	 0.63	
137.05	 15.30	 C7H7NO2	 N-Methylnicotinate	 1.00	 0.63	
157.11	 11.07	 C8H15NO2	 Homostachydrine	 1.00	 0.62	
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310.12	 14.22	 C14H18N2O6	 Glu-Tyr	 1.00	 0.62	
238.00	 9.21	 C12H8OCl2	 2,6-Dichloro-4'-biphenylol	 1.00	 0.61	
306.08	 21.15	 C20H32N6O12S2	 Glutathione	disulfide	 1.00	 0.59	
250.06	 14.87	 C8H14N2O5S	 gamma-L-Glutamyl-L-cysteine	 1.00	 0.57	
152.05	 5.32	 C8H8O3	 3,4-Dihydroxyphenylacetaldehyde	 1.00	 0.56	
176.04	 10.44	 C5H8N2O5	 N-Carbamoyl-L-aspartate	 1.00	 0.54	
167.11	 14.80	 C8H13N3O	 2-Dimethylamino-5,6-dimethylpyrimidin-4-ol	 1.00	 0.53	
213.04	 21.61	 C13H22N4O8S2	 Asp-Cys-Cys-Ser	 1.00	 0.52	
461.17	 17.09	 C17H27N5O10	 Asn-Val-Asp-Asp	 1.00	 0.52	
265.12	 19.28	 C25H34N6O5S	 His-Met-Phe-Pro	 1.00	 0.51	
461.17	 17.08	 C21H27N5O5S	 Cys-Trp-Gly-Pro	 1.00	 0.50	
270.13	 14.71	 C22H36N8O8	 Glu-Lys-Gln-His	 1.00	 0.48	
308.16	 26.76	 C12H24N2O7	 Fructoselysine	 1.00	 0.40	
504.17	 16.45	 C18H32O16	 Maltotriose	 1.00	 0.39	
227.09	 14.30	 C9H13N3O4	 Deoxycytidine	 1.00	 0.38	
324.04	 15.70	 C9H13N2O9P	 Pseudouridine	5'-phosphate	 1.00	 0.38	
189.08	 7.93	 C8H15NO2S	 Prenyl-L-cysteine	 1.00	 0.31	
156.02	 9.95	 C5H4N2O4	 Orotate	 1.00	 0.29	
160.12	 25.55	 C7H16N2O2	 N6-Methyl-L-lysine	 1.00	 0.27	
	 259	
161.05	 10.38	 C6H11NO2S	 allylcysteine	 1.00	 0.25	
121.02	 15.72	 C3H7NO2S	 D-Cysteine	 1.00	 0.10	
407.27	 4.98	 C23H37NO5	 Norerythrostachaldine	 1.00	 0.09	
307.08	 15.50	 C10H17N3O6S	 Ala-Asp-Cys	 1.00	 0.09	
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Appendix	VIII:	All	metabolites	identified	in	Drosophila	adult	MTs	CG30016	mutant	and	the	control	
Mass	 RT	 Formula	 Putative	metabolite	 MT17767	 MT18554	
161.11	 16.64	 C7H15NO3	 L-Carnitine	 1.00	 2.98	
125.01	 16.28	 C2H7NO3S	 Taurine	 1.00	 1.62	
268.08	 10.27	 C10H12N4O5	 Inosine	 1.00	 1.32	
141.02	 19.98	 C2H8NO4P	 Ethanolamine	phosphate	 1.00	 1.31	
267.10	 12.30	 C10H13N5O4	 Adenosine	 1.00	 1.29	
244.07	 8.96	 C9H12N2O6	 Uridine	 1.00	 1.26	
103.10	 17.61	 C5H13NO	 Choline	 1.00	 1.19	
149.05	 13.68	 C5H11NO2S	 L-Methionine	 1.00	 1.12	
257.10	 20.08	 C8H20NO6P	 sn-glycero-3-Phosphocholine	 1.00	 1.08	
132.05	 18.40	 C4H8N2O3	 L-Asparagine	 1.00	 1.06	
155.07	 25.03	 C6H9N3O2	 L-Histidine	 1.00	 1.04	
165.08	 12.19	 C9H11NO2	 L-Phenylalanine	 1.00	 0.99	
146.07	 17.94	 C5H10N2O3	 L-Glutamine	 1.00	 0.98	
204.09	 12.92	 C11H12N2O2	 L-Tryptophan	 1.00	 0.98	
119.06	 17.26	 C4H9NO3	 L-Threonine	 1.00	 0.97	
130.03	 6.22	 C5H6O4	 Itaconate	 1.00	 0.97	
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131.09	 12.87	 C6H13NO2	 L-Leucine	 1.00	 0.97	
118.03	 6.77	 C4H6O4	 Succinate	 1.00	 0.97	
133.04	 17.40	 C4H7NO4	 L-Aspartate	 1.00	 0.95	
147.05	 16.82	 C5H9NO4	 L-Glutamate	 1.00	 0.94	
135.05	 14.68	 C5H5N5	 Adenine	 1.00	 0.88	
75.03	 18.30	 C2H5NO2	 Glycine	 1.00	 0.87	
89.05	 16.95	 C3H7NO2	 L-Alanine	 1.00	 0.86	
105.04	 18.44	 C3H7NO3	 L-Serine	 1.00	 0.81	
190.10	 23.49	 C7H14N2O4	 meso-2,6-Diaminoheptanedioate	 1.00	 0.76	
88.10	 31.94	 C4H12N2	 Putrescine	 1.00	 0.66	
152.03	 8.65	 C5H4N4O2	 Xanthine	 1.00	 0.62	
202.03	 10.49	 C5H6N4O5	 5-Hydroxy-2-oxo-4-ureido-2,5-dihydro-1H-imidazole-5-carboxylate	 1.00	 5.75	
217.13	 12.83	 C10H19NO4	 O-Propanoylcarnitine	 1.00	 4.51	
260.03	 19.44	 C6H13O9P	 D-Glucose-6-phosphate	 1.00	 3.38	
425.35	 9.78	 C25H47NO4	 Elaidiccarnitine	 1.00	 3.26	
427.37	 9.73	 C25H49NO4	 Stearoylcarnitine	 1.00	 3.10	
187.12	 5.73	 C9H17NO3	 N-Heptanoylglycine	 1.00	 2.98	
242.08	 5.58	 C12H10N4O2	 Lumichrome	 1.00	 2.82	
306.08	 21.20	 C20H32N6O12S2	 Glutathione	disulfide	 1.00	 2.31	
	262
168.03	 11.78	 C5H4N4O3	 Urate	 1.00	 2.25	
731.55	 7.64	 C40H78NO8P	 [PC	(14:0/18:1)]	1-tetradecanoyl-2-(11Z-octadecenoyl)-sn-glycero-
3-phosphocholine	
1.00	 2.01	
729.53	 7.63	 C40H76NO8P	 [PC	(14:0/18:2)]	1-tetradecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-
glycero-3-phosphocholine	
1.00	 1.97	
689.50	 5.67	 C37H72NO8P	 PC(14:1(9Z)/15:0)	 1.00	 1.94	
687.48	 5.67	 C37H70NO8P	 [PE	(16:1/16:1)]	1,2-di-(9Z-hexadecenoyl)-sn-glycero-3-
phosphoethanolamine	
1.00	 1.91	
158.04	 12.90	 C4H6N4O3	 Allantoin	 1.00	 1.83	
649.47	 7.83	 C34H68NO8P	 [PE	(14:0/15:0)]	1-tetradecanoyl-2-pentadecanoyl-sn-glycero-3-
phosphoethanolamine	
1.00	 1.74	
685.47	 5.67	 C37H68NO8P	 PE(14:0/18:3(6Z,9Z,12Z))	 1.00	 1.73	
455.40	 9.64	 C27H53NO4	 Arachidylcarnitine	 1.00	 1.59	
228.15	 14.84	 C11H20N2O3	 Leu-Pro	 1.00	 1.55	
184.02	 11.88	 C5H4N4O4	 5-Hydroxyisourate	 1.00	 1.52	
250.06	 15.01	 C8H14N2O5S	 gamma-L-Glutamyl-L-cysteine	 1.00	 1.50	
283.09	 12.43	 C10H13N5O5	 Guanosine	 1.00	 1.48	
537.51	 5.03	 C34H67NO3	 [SP	(16:0)]	N-(hexadecanoyl)-sphing-4-enine	 1.00	 1.45	
208.08	 12.43	 C10H12N2O3	 L-Kynurenine	 1.00	 1.44	
565.54	 5.02	 C36H71NO3	 [SP	(18:0)]	N-(octadecanoyl)-sphing-4-enine	 1.00	 1.41	
467.13	 16.39	 C19H25N5O5S2	 Cys-Trp-Cys-Gly	 1.00	 1.38	
771.58	 7.51	 C43H82NO8P	 [PE	(18:0/20:2)]	1-octadecanoyl-2-(11Z,14Z-eicosadienoyl)-sn- 1.00	 1.37	
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glycero-3-phosphoethanolamine	
213.04	 21.65	 C13H22N4O8S2	 Asp-Cys-Cys-Ser	 1.00	 1.37	
307.08	 15.69	 C10H17N3O6S	 Ala-Asp-Cys	 1.00	 1.37	
137.08	 14.27	 C8H11NO	 Tyramine	 1.00	 1.36	
111.08	 31.29	 C5H9N3	 1H-Imidazole-4-ethanamine	 1.00	 1.36	
165.05	 17.87	 C5H11NO3S	 L-Methionine	S-oxide	 1.00	 1.35	
394.32	 5.08	 C28H42O	 Ergosta-5,7,22,24(28)-tetraen-3beta-ol	 1.00	 1.35	
769.56	 7.54	 C43H80NO8P	 PC(15:0/20:3(5Z,8Z,11Z))	 1.00	 1.35	
259.05	 17.86	 C6H14NO8P	 alpha-D-Glucosamine	1-phosphate	 1.00	 1.34	
876.55	 4.60	 C44H80N2O15	 Megalomicin	A	 1.00	 1.31	
331.19	 5.06	 C20H27O4	 7'-carboxy-gama-tocotrienol	 1.00	 1.31	
351.31	 5.07	 C22H41NO2	 [FA	(20:2)]	N-(11Z,14Z-eicosadienoyl)-ethanolamine	 1.00	 1.30	
528.45	 4.95	 C35H60O3	 [PR]	32,35-anhydrobacteriohopaneterol	 1.00	 1.30	
224.08	 5.03	 C15H12O2	 Flavanone	 1.00	 1.30	
757.56	 7.54	 C42H80NO8P	 [PC	(16:0/18:2)]	1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-
glycero-3-phosphocholine	
1.00	 1.29	
105.08	 16.04	 C4H11NO2	 Diethanolamine	 1.00	 1.27	
744.49	 4.41	 C40H73O10P	 1-18:2-2-trans-16:1-phosphatidylglycerol	 1.00	 1.27	
163.08	 15.82	 C6H13NO4	 D-perosamine	 1.00	 1.22	
215.06	 17.98	 C5H14NO6P	 sn-glycero-3-Phosphoethanolamine	 1.00	 1.22	
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713.50	 5.64	 C39H72NO8P	 [PE	(16:0/18:3)]	1-hexadecanoyl-2-(9Z,12Z,15Z-octadecatrienoyl)-
sn-glycero-3-phosphoethanolamine	
1.00	 1.20	
216.12	 16.75	 C8H16N4O3	 N-acetyl-(L)-arginine	 1.00	 1.20	
148.04	 7.76	 C5H8O5	 (R)-2-Hydroxylglutarate	 1.00	 1.19	
464.17	 5.41	 C23H28O10	 Enhydrin	 1.00	 1.16	
755.55	 7.58	 C42H78NO8P	 [PC	(16:0/18:3)]	1-hexadecanoyl-2-(9Z,12Z,15Z-octadecatrienoyl)-
sn-glycero-3-phosphocholine	
1.00	 1.15	
426.31	 5.10	 C28H42O3	 [ST	(5:0/3:0)]	(5Z,7E,22E,24E)-(1S,3R)-24a-homo-9,10-seco-
5,7,10(19),22,24-cholestapentaene-1,3,25-triol	
1.00	 1.15	
208.09	 5.05	 C15H12O	 Chalcone	 1.00	 1.14	
244.15	 14.63	 C20H40N8O6	 Arg-Lys-Val-Ser	 1.00	 1.14	
155.13	 13.02	 C9H17NO	 N-Methylpelletierine	 1.00	 1.12	
223.01	 17.37	 C6H10NO4PS	 4-Methyl-5-(2-phosphoethyl)-thiazole	 1.00	 1.11	
216.04	 14.68	 C5H13O7P	 2-C-Methyl-D-erythritol	4-phosphate	 1.00	 1.10	
186.14	 11.71	 C9H18N2O2	 N-(3-acetamidopropyl)-4-aminobutanal	 1.00	 1.08	
353.33	 5.02	 C22H43NO2	 [FA	(20:0)]	N-(11Z-eicosaenoyl)-ethanolamine	 1.00	 1.07	
345.05	 14.78	 C10H12N5O7P	 3',5'-Cyclic	GMP	 1.00	 1.05	
104.01	 7.98	 C3H4O4	 Hydroxypyruvate	 1.00	 1.04	
181.04	 15.82	 C5H11NO4S	 DL-Methionine	sulfone	 1.00	 1.04	
324.11	 16.47	 C12H20O10	 Bis-D-fructose	2',1:2,1'-dianhydride	 1.00	 1.04	
248.05	 12.91	 C9H12O8	 pentane-1,3,4,5-tetracarboxylate	 1.00	 1.04	
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136.02	 7.48	 C4H8O3S	 S-Methyl-1-thio-D-glycerate	 1.00	 1.03	
146.02	 9.35	 C5H6O5	 Methyloxaloacetate	 1.00	 1.03	
201.17	 15.19	 C11H23NO2	 Caproylcholine	 1.00	 1.03	
308.16	 26.79	 C12H24N2O7	 Fructoselysine	 1.00	 1.03	
181.07	 14.62	 C9H11NO3	 3-Amino-3-(4-hydroxyphenyl)propanoate	 1.00	 1.02	
121.09	 13.09	 C8H11N	 Phenethylamine	 1.00	 1.02	
428.33	 5.04	 C28H44O3	 Ercalcitriol	 1.00	 1.02	
139.14	 11.96	 C9H17N	 Pinidine	 1.00	 0.99	
422.06	 16.26	 C15H20NO9S2	 Gluconasturtiin	 1.00	 0.98	
737.50	 5.65	 C41H72NO8P	 PE(14:0/22:5(4Z,7Z,10Z,13Z,16Z))	 1.00	 0.98	
139.98	 13.69	 C2H4O5S	 Sulfoacetate	 1.00	 0.98	
81.98	 14.55	 H3O3P	 Phosphonate	 1.00	 0.98	
107.07	 14.05	 C7H9N	 N-Methylaniline	 1.00	 0.97	
243.22	 10.83	 C14H29NO2	 [SP	(14:0)]	tetradecasphing-4E-enine	 1.00	 0.97	
216.10	 7.23	 C27H28O5	 Aspulvinone	H	 1.00	 0.97	
181.18	 10.52	 C12H23N	 Dicyclohexylamine	 1.00	 0.96	
442.34	 5.05	 C29H46O3	 4alpha-Methylzymosterol-4-carboxylate	 1.00	 0.96	
231.06	 16.46	 C22H22O11	 Isoscoparine	 1.00	 0.95	
739.51	 5.59	 C41H74NO8P	 [PE	(16:0/20:4)]	1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-
eicosatetraenoyl)-sn-glycero-3-phosphoethanolamine	
1.00	 0.94	
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101.12	 14.19	 C6H15N	 Hexylamine	 1.00	 0.93	
446.06	 26.01	 C11H20N4O11P2	 CDP-ethanolamine	 1.00	 0.92	
444.32	 5.05	 C28H44O4	 [ST	(4:0/4:0)]	(5Z,7E,22E)-(1S,3R,24R)-9,10-seco-5,7,10(19),22-
ergostatetraene-1,3,24,25-tetrol	
1.00	 0.90	
238.10	 5.05	 C16H14O2	 [Fv	Methox]	4'-Methoxychalcone	 1.00	 0.90	
183.07	 24.23	 C5H14NO4P	 Choline	phosphate	 1.00	 0.89	
129.12	 14.40	 C7H15NO	 4-Trimethylammoniobutanal	 1.00	 0.88	
243.18	 5.35	 C13H25NO3	 N-Undecanoylglycine	 1.00	 0.88	
145.07	 26.81	 C6H11NO3	 5-hydroxy-pipecolate	 1.00	 0.87	
71.07	 14.61	 C4H9N	 3-Buten-1-amine	 1.00	 0.86	
688.55	 7.41	 C38H77N2O6P	 [SP	(18:0/14:0)]	N-(octadecanoyl)-tetradecasphing-4-enine-1-
phosphoethanolamine	
1.00	 0.86	
386.30	 5.05	 C22H42O5	 1,2-dioctanoyl-1,2,6-hexanetriol	 1.00	 0.85	
160.11	 5.40	 C8H16O3	 Ethyl	(R)-3-hydroxyhexanoate	 1.00	 0.84	
253.01	 11.70	 C10H17N6O12P3	 AMPPNP	 1.00	 0.83	
329.05	 14.44	 C10H12N5O6P	 3',5'-Cyclic	dGMP	 1.00	 0.83	
117.12	 13.16	 C6H15NO	 2-Methylcholine	 1.00	 0.83	
781.56	 7.54	 C44H80NO8P	 [PC	(16:0/20:4)]	1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-
eicosatetraenoyl)-sn-glycero-3-phosphocholine	
1.00	 0.82	
285.27	 10.03	 C17H35NO2	 [SP	methyl(16:0)]	15-methyl-hexadecasphing-4E-enine	 1.00	 0.82	
795.58	 7.52	 C45H82NO8P	 PE(18:0/22:4(7Z,10Z,13Z,16Z))	 1.00	 0.81	
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194.06	 5.58	 C10H10O4	 Ferulate	 1.00	 0.79	
87.10	 14.99	 C5H13N	 3-Methylbutanamine	 1.00	 0.77	
172.07	 5.57	 C8H12O4	 [FA	dioxo(8:0)]	4,7-dioxo-octanoic	acid	 1.00	 0.76	
138.07	 21.49	 C11H20N2O6	 N6-(L-1,3-Dicarboxypropyl)-L-lysine	 1.00	 0.76	
284.23	 5.03	 C17H32O3	 [FA	methoxy(16:1)]	2-methoxy-5Z-hexadecenoic	acid	 1.00	 0.75	
175.08	 15.26	 C7H13NO4	 alpha-aminopimelate	 1.00	 0.74	
254.08	 23.77	 C6H15N4O5P	 L-Arginine	phosphate	 1.00	 0.73	
208.15	 5.17	 C13H20O2	 4-Heptyloxyphenol	 1.00	 0.73	
369.32	 5.07	 C22H43NO3	 [SP	amino,tetramethyl(4:0/18:0/3:0)]	2S-amino-5,9,13,17-
tetramethyl-8E,16-octadecadiene-1,3R,14-triol	
1.00	 0.71	
132.04	 5.95	 C5H8O4	 2-Acetolactate	 1.00	 0.70	
453.29	 7.46	 C21H44NO7P	 [PE	(16:0)]	1-hexadecanoyl-sn-glycero-3-phosphoethanolamine	 1.00	 0.67	
240.15	 14.92	 C12H20N2O3	 Slaframine	 1.00	 0.64	
145.08	 15.28	 C5H11N3O2	 4-Guanidinobutanoate	 1.00	 0.63	
179.06	 5.72	 C9H9NO3	 Hippurate	 1.00	 0.54	
160.07	 5.64	 C7H12O4	 [FA	(7:0/2:0)]	Heptanedioic	acid	 1.00	 0.48	
146.06	 5.83	 C6H10O4	 (S)-2-Aceto-2-hydroxybutanoate	 1.00	 0.45	
174.09	 5.49	 C8H14O4	 Suberic	acid	 1.00	 0.41	
161.07	 15.97	 C6H11NO4	 L-2-Aminoadipate	 1.00	 0.41	
175.10	 18.88	 C6H13N3O3	 L-Citruline	 1.00	 0.37	
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129.15	 10.91	 C8H19N	 Octylamine	 1.00	 0.32	
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Appendix	IX:	All	metabolites	identified	in	Drosophila	melanogaster	secreted	fluid		
	
Mass	 RT	 Formula	 Putative	metabolite	 Control	 Sample	
208.08	 11.74	 C10H12N2O3	 L-Kynurenine	 0.00	 697.73	
224.08	 14.28	 C10H12N2O4	 3-Hydroxy-L-kynurenine	 0.00	 196.37	
168.03	 14.29	 C5H4N4O3	 Urate	 1.00	 156.89	
205.04	 12.73	 C10H7NO4	 Xanthurenic	acid	 0.00	 125.81	
216.12	 16.47	 C8H16N4O3	 N-acetyl-(L)-arginine	 1.00	 97.35	
136.02	 10.95	 C4H8O3S	 S-Methyl-1-thio-D-glycerate	 0.00	 83.87	
283.09	 13.95	 C10H13N5O5	 Guanosine	 0.00	 74.66	
260.03	 18.02	 C6H13O9P	 D-Glucose-6-Phosphate	 0.00	 71.29	
191.06	 11.74	 C10H9NO3	 5-Hydroxyindoleacetate	 0.00	 63.71	
129.06	 7.35	 C9H7N	 Isoquinoline	 0.00	 61.82	
398.14	 17.70	 C15H22N6O5S	 S-Adenosyl-L-methionine	 0.00	 56.43	
268.08	 12.01	 C10H12N4O5	 Inosine	 1.00	 49.25	
416.10	 12.71	 C15H20N4O8S	 O-Carbamoyl-deacetylcephalosporin	C	 0.00	 41.72	
163.10	 4.52	 C10H13NO	 (R)-2-Methylimino-1-phenylpropan-1-ol	 1.00	 36.87	
347.06	 14.52	 C10H14N5O7P	 3'-AMP	 1.00	 31.57	
145.07	 7.34	 C6H11NO3	 4-Acetamidobutanoate	 1.00	 26.63	
198.07	 9.57	 C13H24N4O8S	 Cys-Thr-Ser-Ser	 0.00	 23.01	
248.05	 16.75	 C16H26N4O8P2S	 2-Methyl-1-hydroxypropyl-ThPP	 0.00	 21.72	
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109.05	 14.38	 C6H7NO	 2-Aminophenol	 0.00	 20.77	
186.06	 11.84	 C7H10N2O4	 (S)-AMPA	 0.00	 19.58	
334.07	 18.17	 C9H19O11P	 sn-glycero-3-Phospho-1-inositol	 0.00	 19.36	
175.03	 8.68	 C9H19O12P	 nonulose	9-phosphate	 0.00	 18.73	
278.07	 12.83	 C9H15N2O6P	 Pyrimidine	5'-deoxynucleotide	 0.00	 18.39	
293.14	 15.55	 C14H19N3O4	 Phe-Ala-Gly	 0.00	 18.20	
158.04	 15.35	 C4H6N4O3	 (S)(+)-Allantoin	 0.00	 17.45	
236.08	 10.71	 C11H12N2O4	 L-Formylkynurenine	 1.00	 14.79	
79.97	 13.13	 [PO3]3-	 Phosphite	 0.00	 14.54	
143.06	 10.17	 C6H9NO3	 Vinylacetylglycine	 1.00	 14.02	
183.07	 16.85	 C5H14NO4P	 Choline	phosphate	 1.00	 13.97	
221.09	 9.16	 C9H19NOS2	 8-methylthiooctylhydroximate	 0.00	 13.39	
235.12	 4.27	 C13H17NO3	 Lophophorine	 1.00	 12.13	
113.05	 10.82	 C5H7NO2	 (S)-1-Pyrroline-5-carboxylate	 1.00	 11.96	
377.06	 11.92	 C13H18N2O7PS	 external	aldimine	 0.00	 11.49	
161.07	 16.81	 C6H11NO4	 L-2-Aminoaipate	 0.00	 10.85	
223.03	 9.49	 C10H9NO3S	 2-naphthylamine-1-sulfonate	 0.00	 10.35	
72.02	 10.86	 C3H4O2	 Methylglyoxal	 0.00	 10.24	
692.11	 17.89	 C20H26N10O14P2	 Guanosinediphosphateadenosine	 0.00	 9.68	
278.09	 13.78	 C10H18N2O5S	 Glu-Met	 0.00	 9.46	
244.05	 12.19	 C9H12N2O4S	 penem	CGP31608	 0.00	 9.46	
383.11	 16.47	 C14H17N5O8	 Succinyladenosine	 1.00	 8.61	
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249.09	 7.69	 C10H19NO2S2	 S-Acetyldihydrolipoamide-E	 0.00	 8.58	
212.08	 8.73	 C18H24N4O8	 Asp-Gln-Tyr	 1.00	 8.21	
162.09	 6.04	 C7H14O4	 beta-Cymaropyranose	 1.00	 7.81	
311.13	 8.64	 C17H17N3O3	 Imazaquin	 1.00	 7.16	
146.02	 14.96	 C4H6N2O2S	 ZAPA	 1.00	 6.42	
179.09	 13.51	 C10H13NO2	 (-)-Salsolinol	 0.00	 6.08	
117.06	 7.96	 C8H7N	 Indole	 0.00	 6.06	
205.07	 4.71	 C11H11NO3	 Gentianamine	 0.00	 6.06	
139.03	 14.59	 C6H5NO3	 6-Hydroxynicotinate	 0.00	 6.05	
276.08	 10.82	 C10H16N2O5S	 Biotinsulfone	 0.00	 5.92	
427.03	 17.25	 C10H15N5O10P2	 ADP	 0.00	 5.33	
120.06	 4.77	 C8H8O	 Phenylacetaldehyde	 1.00	 5.15	
111.98	 8.36	 CH4O4S	 Monomethyl	sulfate	 1.00	 4.89	
179.08	 8.25	 C7H9N5O	 7-Aminomethyl-7-carbaguanine	 0.00	 4.73	
243.09	 13.10	 C9H13N3O5	 Cytidine	 1.00	 4.65	
176.06	 14.26	 C9H8N2O2	 4-Hydroxyaminoquinoline	N-oxide	 0.00	 4.57	
168.04	 12.01	 C8H8O4	 Homogentisate	 0.00	 4.15	
147.07	 4.75	 C9H9NO	 3-Methyloxindole	 0.00	 3.98	
97.98	 17.96	 H3O4P	 Orthophosphate	 1.00	 3.92	
207.09	 4.81	 C11H13NO3	 Cantleyine	 1.00	 3.76	
185.11	 4.88	 C9H15NO3	 8-keto-7-aminoperlagonate	 1.00	 3.71	
202.07	 11.09	 C11H10N2O2	 alpha,beta-Didehydrotryptophan	 1.00	 3.71	
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214.10	 7.79	 C9H14N2O4	 Pyrimidine	nucleoside	 1.00	 3.52	
206.04	 19.76	 C7H10O7	 2-Hydroxybutane-1,2,4-tricarboxylate	 1.00	 3.18	
155.09	 4.84	 C8H13NO2	 Arecoline	 1.00	 3.18	
144.04	 11.11	 C6H8O4	 2,3-Dimethylmaleate	 0.00	 3.17	
363.06	 17.77	 C10H14N5O8P	 GMP	 1.00	 3.13	
165.05	 14.83	 C5H11NO3S	 L-Methionine	S-oxide	 1.00	 3.04	
138.04	 7.32	 C6H6N2O2	 Urocanate	 1.00	 3.02	
161.11	 14.79	 C7H15NO3	 L-Carnitine	 1.00	 2.96	
192.03	 20.34	 C6H8O7	 Citrate	 1.00	 2.89	
374.12	 7.37	 C16H22O10	 Secologanate	 1.00	 2.86	
173.11	 5.34	 C8H15NO3	 Hexanoylglycine	 1.00	 2.84	
125.06	 11.60	 C5H7N3O	 5-Methylcytosine	 0.00	 2.55	
	 	 	 	 	 	151.05	 13.64	 C5H5N5O	 Guanine	 1.00	 2.52	
231.11	 12.21	 C10H17NO5	 Suberylglycine	 1.00	 2.39	
184.02	 14.12	 C5H4N4O4	 5-Hydroxyisourate	 0.00	 2.38	
223.08	 8.31	 C11H13NO4	 Bendiocarb	 1.00	 2.35	
284.08	 13.75	 C10H12N4O6	 Xanthosine	 1.00	 2.20	
156.02	 11.21	 C5H4N2O4	 Orotate	 0.00	 2.19	
138.03	 4.76	 C7H6O3	 Gentisate	aldehyde	 1.00	 2.18	
170.09	 3.95	 C9H14O3	 Furfural	diethyl	acetal	 1.00	 2.07	
149.11	 9.23	 C6H15NO3	 Triethanolamine	 1.00	 2.01	
215.15	 4.24	 C11H21NO3	 N-Nonanoylglycine	 1.00	 2.01	
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257.10	 12.31	 C10H15N3O5	 5-Methylcytidine	 1.00	 1.82	
169.07	 8.06	 C8H11NO3	 Pyridoxine	 1.00	 1.81	
209.07	 7.25	 C7H15NO4S	 MOPS	 1.00	 1.74	
134.06	 9.32	 C5H10O4	 Deoxyribose	 1.00	 1.74	
160.11	 5.00	 C8H16O3	 Ethyl	(R)-3-hydroxyhexanoate	 1.00	 1.65	
243.18	 4.38	 C13H25NO3	 N-Undecanoylglycine	 1.00	 1.65	
104.01	 17.91	 C3H4O4	 Malonate	 1.00	 1.61	
200.08	 10.31	 C8H12N2O4	 Dihydroclavaminic	acid	 1.00	 1.61	
149.08	 4.65	 C9H11NO	 D-Cathinone	 1.00	 1.60	
200.18	 3.78	 C12H24O2	 Dodecanoic	acid	 1.00	 1.60	
105.08	 11.04	 C4H11NO2	 Diethanolamine	 1.00	 1.59	
123.03	 7.47	 C6H5NO2	 Nicotinate	 1.00	 1.52	
157.04	 12.91	 C6H7NO4	 2-Aminomuconate	 1.00	 1.44	
127.03	 11.86	 C5H5NO3	 2,3,6-Trihydroxypyridine	 1.00	 1.43	
166.10	 4.97	 C10H14O2	 Perillic	acid	 1.00	 1.38	
168.08	 4.84	 C9H12O3	 1,3,5-trimethoxybenzene	 1.00	 1.37	
145.04	 11.83	 C5H7NO4	 2-Oxoglutaramate	 1.00	 1.31	
229.17	 4.58	 C12H23NO3	 N-Decanoylglycine	 1.00	 1.29	
174.10	 7.87	 C7H14N2O3	 Val-Gly	 1.00	 1.27	
238.13	 6.85	 C24H36N4O6	 Ile-Phe-Thr-Pro	 1.00	 1.24	
228.21	 3.69	 C14H28O2	 Tetradecanoic	acid	 1.00	 1.24	
172.15	 4.04	 C10H20O2	 Decanoic	acid	 1.00	 1.23	
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160.04	 16.71	 C6H8O5	 2-Oxoadipate	 1.00	 1.23	
184.11	 4.05	 C10H16O3	 4,5-dihydro-5,5-dimethyl-4-(3-oxobutyl)furan-2(3H)-one	 1.00	 1.23	
376.14	 8.85	 C17H20N4O6	 Riboflavin	 1.00	 1.21	
182.08	 15.51	 C6H14O6	 D-Sorbitol	 1.00	 1.20	
236.14	 3.93	 C14H20O3	 4-Heptyloxybenzoic	acid	 1.00	 1.20	
264.17	 3.99	 C16H24O3	 Dehydrojuvabione	 1.00	 1.17	
110.05	 13.06	 C5H6N2O	 Imidazole-4-acetaldehyde	 1.00	 1.16	
215.06	 17.34	 C5H14NO6P	 sn-glycero-3-Phosphoethanolamine	 1.00	 1.15	
284.27	 3.59	 C18H36O2	 Octadecanoic	acid	 1.00	 1.14	
473.28	 7.30	 C21H39N5O7	 Gln-Leu-Leu-Thr	 1.00	 1.14	
174.06	 12.89	 C6H10N2O4	 N-Formimino-L-glutamate	 1.00	 1.13	
430.16	 4.02	 C23H26O8	 Sesartemin	 1.00	 1.12	
260.05	 12.82	 C9H12N2O5S	 2-thiouridine	 1.00	 1.09	
252.17	 3.90	 C15H24O3	 Juvenile	hormone	III	acid	 1.00	 1.09	
266.06	 12.80	 C10H10N4O5	 5'-Oxoinosine	 1.00	 1.09	
128.12	 3.97	 C8H16O	 1-Octanal	 1.00	 1.08	
100.05	 4.01	 C5H8O2	 Methyl	methacrylate	 1.00	 1.08	
197.07	 11.64	 C9H11NO4	 3,4-Dihydroxy-L-phenylalanine	 1.00	 1.08	
250.19	 3.98	 C16H26O2	 Methyl	farnesoate	 1.00	 1.06	
130.10	 4.38	 C7H14O2	 Ethyl	isovalerate	 1.00	 1.04	
162.07	 4.13	 C10H10O2	 Methyl	cinnamate	 1.00	 1.01	
208.15	 3.89	 C13H20O2	 4-Heptyloxyphenol	 1.00	 1.00	
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308.11	 4.15	 C20H12N4	 porphyrin-ring	 1.00	 1.00	
255.26	 4.02	 C16H33NO	 Palmiticamide	 1.00	 0.99	
254.22	 3.83	 C16H30O2	 (9Z)-Hexadecenoic	acid	 1.00	 0.99	
339.35	 2.62	 C22H45NO	 Docosanamide	 1.00	 0.97	
220.08	 11.73	 C11H12N2O3	 5-Hydroxy-L-tryptophan	 1.00	 0.96	
94.04	 9.73	 C6H6O	 Arene	oxide	 1.00	 0.95	
72.06	 4.53	 C4H8O	 Butanal	 1.00	 0.95	
196.06	 15.95	 C6H12O7	 D-Gluconic	acid	 1.00	 0.94	
238.10	 11.71	 C8H18N2O4S	 HEPES	 1.00	 0.93	
116.08	 4.71	 C6H12O2	 4-Hydroxyhexan-3-one	 1.00	 0.92	
201.14	 4.40	 C10H19NO3	 Capryloylglycine	 1.00	 0.86	
150.07	 4.75	 C9H10O2	 4-Coumaryl	alcohol	 1.00	 0.86	
179.08	 12.35	 C6H13NO5	 D-Galactosamine	 1.00	 0.85	
329.05	 9.38	 C10H12N5O6P	 2',3'-Cyclic	AMP	 1.00	 0.84	
236.13	 7.68	 C11H16N4O2	 CPX	 1.00	 0.82	
324.04	 16.09	 C9H13N2O9P	 UMP	 1.00	 0.81	
118.08	 4.00	 C9H10	 alpha-Methylstyrene	 1.00	 0.81	
178.11	 9.75	 C10H14N2O	 (S)-6-Hydroxynicotine	 1.00	 0.77	
150.05	 13.55	 C5H10O5	 D-Xylulose	 1.00	 0.72	
166.03	 16.02	 C8H6O4	 Phthlate	 1.00	 0.72	
194.06	 4.73	 C10H10O4	 5-Hydroxyconiferaldehyde	 1.00	 0.72	
175.08	 13.05	 C7H13NO4	 Calystegin	B2	 1.00	 0.68	
	276
206.11	 3.91	 C16H14	 trans,trans-1,4-Diphenyl-1,3-butadiene	 1.00	 0.68	
230.15	 3.89	 C12H22O4	 Diisopropyl	adipate	 1.00	 0.67	
194.08	 12.86	 C7H14O6	 1-O-Methyl-myo-inositol	 1.00	 0.63	
175.10	 17.65	 C6H13N3O3	 L-Citruline	 1.00	 0.61	
114.08	 10.71	 C5H10N2O	 L-proline	amide	 1.00	 0.61	
180.05	 15.27	 C8H8N2O3	 Nicotinurate	 1.00	 0.60	
97.97	 20.16	 H2O4S	 Sulfate	 1.00	 0.59	
397.11	 12.66	 C15H19N5O6S	 S-Adenosyl-4-methylthio-2-oxobutanoate	 1.00	 0.56	
244.11	 17.18	 C10H16N2O5	 Glu-Pro	 1.00	 0.55	
208.10	 10.13	 C17H28N4O8	 Asp-Val-Pro-Ser	 1.00	 0.55	
409.15	 10.80	 C18H23N3O8	 Glu-Asp-Phe	 1.00	 0.54	
459.26	 3.97	 C26H37NO6	 Militarinone	A	 1.00	 0.53	
384.12	 14.97	 C14H20N6O5S	 S-Adenosyl-L-homocysteine	 1.00	 0.53	
200.98	 19.20	 C3H7NO5S2	 S-Sulfo-L-cysteine	 1.00	 0.52	
187.06	 12.72	 C11H9NO2	 Indoleacrylicacid	 1.00	 0.52	
80.96	 20.15	 HO3S	 HSO3-	 1.00	 0.48	
474.13	 12.71	 C16H23N6O9P	 glutamyl-beta-ketophosphonate-adenosine	 1.00	 0.47	
308.16	 22.03	 C12H24N2O7	 Fructoselysine	 1.00	 0.44	
173.08	 15.89	 C6H11N3O3	 5-Guanidino-2-oxopentanoate	 1.00	 0.42	
204.09	 12.72	 C11H12N2O2	 L-Trypthophan	 1.00	 0.41	
128.06	 16.47	 C5H8N2O2	 5,6-Dihydrothymine	 1.00	 0.41	
381.24	 4.74	 C18H31N5O4	 Leu-Leu-His	 1.00	 0.40	
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418.34	 3.61	 C27H46O3	 7alpha,12alpha-Dihydroxy-5beta-cholestan-3-one	 1.00	 0.40	
305.04	 13.98	 C9H12N3O7P	 2',3'-Cyclic	CMP	 1.00	 0.36	
352.06	 14.13	 C12H17O10P	 Arbutin	6-phosphate	 1.00	 0.35	
264.10	 21.51	 C12H16N4OS	 Thiamin	 1.00	 0.34	
85.05	 11.37	 C4H7NO	 Acetone	cyanohydrin	 1.00	 0.34	
115.06	 14.22	 C5H9NO2	 L-Proline	 1.00	 0.33	
163.08	 12.59	 C6H13NO4	 1-deoxynojirimycin	 1.00	 0.33	
360.14	 12.54	 C12H20N6O7	 Asn-Asn-Asn	 1.00	 0.31	
122.05	 7.34	 C6H6N2O	 Picolinamide	 1.00	 0.31	
306.03	 11.98	 C9H11N2O8P	 2',3'-Cyclic	UMP	 1.00	 0.31	
178.05	 16.34	 C6H10O6	 D-Glucono-1,5-lactone	 1.00	 0.31	
256.11	 9.57	 C11H16N2O5	 1-(beta-D-Ribofuranosyl)-1,4-dihydronicotinamide	 1.00	 0.30	
159.09	 18.33	 C7H13NO3	 3-Dehydrocarnitine	 1.00	 0.30	
281.11	 7.44	 C11H15N5O4	 1-Methyladenosine	 1.00	 0.30	
202.14	 22.37	 C8H18N4O2	 NG,NG-Dimethyl-L-arginine	 1.00	 0.29	
133.02	 8.67	 C4H7NO2S	 L-thiazolidine-4-carboxylate	 1.00	 0.28	
191.03	 17.26	 C6H9NO4S	 a	Cysteine	adduct	 1.00	 0.26	
236.12	 4.75	 C12H16N2O3	 Carbetamide	 1.00	 0.26	
224.09	 12.17	 C9H12N4O3	 Temurin	 1.00	 0.25	
103.10	 20.99	 C5H13NO	 Choline	 1.00	 0.23	
210.07	 15.66	 C7H14O7	 Sedoheptulose	 1.00	 0.23	
309.11	 16.93	 C11H19NO9	 O-Acetylneuraminic	acid	 1.00	 0.23	
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132.05	 16.92	 C4H8N2O3	 L-Asparagine	 1.00	 0.23	
258.09	 11.38	 C10H14N2O6	 (1-Ribosylimidazole)-4-acetate	 1.00	 0.22	
149.05	 12.62	 C5H11NO2S	 L-Methionine	 1.00	 0.22	
136.04	 14.09	 C4H8O5	 [FA	trihydroxy(4:0)]	2,3,4-trihydroxy-butanoic	acid	 1.00	 0.21	
186.10	 15.69	 C8H14N2O3	 Ala-Pro	 1.00	 0.20	
231.13	 18.56	 C8H17N5O3	 Gly-Arg	 1.00	 0.20	
134.02	 18.19	 C4H6O5	 (S)-Malate	 1.00	 0.20	
133.04	 17.01	 C4H7NO4	 L-Aspartate	 1.00	 0.20	
165.08	 10.88	 C9H11NO2	 L-Phenylalanine	 1.00	 0.19	
135.05	 9.56	 C5H5N5	 Adenine	 1.00	 0.19	
247.07	 18.30	 C9H13NO7	 N-Succinyl-L-glutamate	 1.00	 0.18	
484.06	 17.94	 C14H22N4O9P2S	 alpha,beta-Dihydroxyethyl-TPP	 1.00	 0.18	
370.07	 9.45	 C16H20O6P2	 BPH-674	 1.00	 0.18	
267.10	 9.43	 C10H13N5O4	 Adenosine	 1.00	 0.17	
205.09	 15.40	 C8H15NO5	 N-Acetyl-D-fucosamine	 1.00	 0.17	
219.11	 9.20	 C9H17NO5	 Pantothenate	 1.00	 0.17	
155.07	 16.25	 C6H9N3O2	 L-Histidine	 1.00	 0.16	
174.11	 26.87	 C6H14N4O2	 L-Arginine	 1.00	 0.16	
131.09	 11.78	 C6H13NO2	 L-Leucine	 1.00	 0.15	
478.18	 9.42	 C17H30N6O8S	 Asn-Met-Gln-Ser	 1.00	 0.15	
158.07	 17.67	 C6H10N2O3	 5-Hydroxyectoine	 1.00	 0.15	
251.10	 8.27	 C10H13N5O3	 Deoxyadenosine	 1.00	 0.14	
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280.11	 12.77	 C13H16N2O5	 Phe-Asp	 1.00	 0.14	
144.09	 25.50	 C6H12N2O2	 L-isoglutamine	 1.00	 0.14	
87.03	 17.77	 C3H5NO2	 2-Aminoacrylate	 1.00	 0.14	
146.07	 16.72	 C5H10N2O3	 L-Glutamine	 1.00	 0.13	
147.09	 11.50	 C6H13NO3	 Fagomine	 1.00	 0.13	
148.04	 17.29	 C5H8O5	 D-Xylonolactone	 1.00	 0.13	
323.07	 16.87	 C20H34N6O12S3	 bisorganyltrisulfane	 1.00	 0.12	
229.06	 14.59	 C9H11NO6	 4-(L-Alanin-3-yl)-2-hydroxy-cis,cis-muconate	6-semialdehyde	 1.00	 0.11	
196.08	 15.52	 C18H24N4O6	 Asn-Pro-Tyr	 1.00	 0.11	
174.14	 22.17	 C8H18N2O2	 Ne,Ne	dimethyllysine	 1.00	 0.11	
112.03	 8.64	 C4H4N2O2	 Uracil	 1.00	 0.10	
105.04	 17.46	 C3H7NO3	 L-Serine	 1.00	 0.10	
188.15	 23.12	 C9H20N2O2	 N6,N6,N6-Trimethyl-L-lysine	 1.00	 0.10	
251.13	 24.41	 C24H34N6O6	 Ala-Leu-Tyr-His	 1.00	 0.10	
223.11	 15.70	 C8H17NO6	 N-acetyl	-D-	glucosaminitol	 1.00	 0.10	
219.07	 17.27	 C8H13NO6	 O-Succinyl-L-homoserine	 1.00	 0.10	
171.05	 21.22	 C7H9NO4	 2,3,4,5-Tetrahydrodipicolinate	 1.00	 0.09	
172.01	 16.17	 C3H9O6P	 sn-Glycerol	3-phosphate	 1.00	 0.09	
102.03	 17.52	 C4H6O3	 2-Oxobutanoate	 1.00	 0.09	
249.03	 21.21	 C8H11NO6S	 Norepinephrinesulfate	 1.00	 0.09	
529.09	 16.63	 C16H25N3O13P2	 dTDP-3-amino-2,3,6-trideoxy-D-threo-hexopyranos-4-ulose	 1.00	 0.09	
183.02	 17.44	 C4H9NO5S	 L-Homocysteic	acid	 1.00	 0.09	
	280
354.06	 12.56	 C15H14O10	 2-Caffeoylisocitrate	 1.00	 0.09	
75.03	 17.38	 C2H5NO2	 Glycine	 1.00	 0.09	
189.06	 16.12	 C7H11NO5	 N-Acetyl-L-glutamate	 1.00	 0.09	
89.05	 17.07	 C3H7NO2	 L-Alanine	 1.00	 0.09	
203.13	 18.37	 C8H17N3O3	 Lys-Gly	 1.00	 0.08	
181.07	 14.39	 C9H11NO3	 L-Tyrosine	 1.00	 0.08	
294.14	 19.57	 C27H40N8O5S	 Arg-Met-Trp-Pro	 1.00	 0.08	
286.08	 14.14	 C16H14O5	 (S)-DNPA	 1.00	 0.07	
147.05	 16.70	 C5H9NO4	 L-Glutamate	 1.00	 0.07	
256.14	 12.43	 C23H40N6O5S	 His-Leu-Leu-Met	 1.00	 0.07	
261.12	 12.14	 C11H19NO6	 Lotaustralin	 1.00	 0.07	
275.15	 18.69	 C11H21N3O5	 L-a-glutamyl-L-Lysine	 1.00	 0.07	
146.02	 17.67	 C5H6O5	 2-Oxoglutarate	 1.00	 0.07	
257.14	 16.93	 C11H19N3O4	 Ala-Ala-Pro	 1.00	 0.07	
504.17	 19.07	 C18H32O16	 Maltotriose	 1.00	 0.06	
119.06	 16.06	 C4H9NO3	 L-Threonine	 1.00	 0.06	
251.10	 15.82	 C9H17NO7	 Muramic	acid	 1.00	 0.06	
345.05	 14.30	 C10H12N5O7P	 3',5'-Cyclic	GMP	 1.00	 0.06	
303.15	 18.58	 C11H21N5O5	 Glu-Arg	 1.00	 0.06	
240.02	 18.00	 C6H12N2O4S2	 L-Cystine	 1.00	 0.06	
332.05	 16.66	 C16H12O8	 3,3',4',5,7-Pentahydroxy-8-methoxyflavone	 1.00	 0.06	
114.03	 16.50	 C5H6O3	 2-Hydroxy-2,4-pentadienoate	 1.00	 0.05	
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121.02	 18.01	 C3H7NO2S	 D-Cysteine	 1.00	 0.05	
324.10	 16.55	 C12H20O10	 Bis-D-fructose	2',1:2,1'-dianhydride	 1.00	 0.05	
118.03	 17.19	 C4H6O4	 Succinate	 1.00	 0.05	
257.10	 16.17	 C8H20NO6P	 sn-glycero-3-Phosphocholine	 1.00	 0.05	
100.02	 17.32	 C4H4O3	 2-oxobut-3-enanoate	 1.00	 0.05	
171.06	 18.16	 C6H9N3O3	 6-diazo-5-oxonorleucine	 1.00	 0.04	
128.09	 17.84	 C6H12N2O	 L-Lysine	1,6-lactam	 1.00	 0.04	
260.15	 18.42	 C10H20N4O4	 Lys-Asn	 1.00	 0.04	
426.09	 18.99	 C13H22N4O8S2	 S-glutathionyl-L-cysteine	 1.00	 0.04	
96.02	 17.86	 C5H4O2	 Furfural	 1.00	 0.03	
289.14	 18.86	 C10H19N5O5	 Asp-Arg	 1.00	 0.03	
353.14	 12.66	 C16H23N3O4S	 Met-Phe-Gly	 1.00	 0.03	
152.03	 12.74	 C5H4N4O2	 Xanthine	 1.00	 0.02	
291.10	 14.24	 C11H17NO8	 2,7-Anhydro-alpha-N-acetylneuraminic	acid	 1.00	 0.02	
146.11	 25.50	 C6H14N2O2	 L-Lysine	 1.00	 0.02	
335.13	 16.24	 C12H21N3O8	 N4-(Acetyl-beta-D-glucosaminyl)asparagine	 1.00	 0.02	
275.03	 18.14	 C6H15NO7P2	 Phosphophosphinate	 1.00	 0.01	
180.06	 17.87	 C6H12O6	 myo-Inositol	 1.00	 0.01	
84.02	 17.92	 C4H4O2	 3-Butynoate	 1.00	 0.01	
358.08	 16.69	 C14H18N2O7S	 Miraxanthin-I	 1.00	 0.01	
342.12	 17.85	 C12H22O11	 Maltose	 1.00	 0.01	
447.16	 17.54	 C16H25N5O10	 Ala-Asp-Asp-Gln	 1.00	 0.01	
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246.12	 14.21	 C10H18N2O5	 Glu-Val	 1.00	 0.00	
245.14	 9.30	 C10H19N3O4	 Leu-Asn	 1.00	 0.00	
498.20	 14.12	 C26H30N2O8	 strictosamide	 1.00	 0.00	
380.04	 25.52	 C10H13N4O10P	 Urate	D-ribonucleotide	 1.00	 0.00	
492.13	 26.81	 C17H24N4O13	 Glu-Asp-Asp-Asp	 1.00	 0.00	
415.28	 12.66	 C19H37N5O5	 Ala-Lys-Val-Val	 1.00	 0.00	
188.12	 7.31	 C8H16N2O3	 Glycyl-leucine	 1.00	 0.00	
217.14	 17.89	 C9H19N3O3	 gamma-L-Glutamylputrescine	 1.00	 0.00	
360.24	 14.24	 C16H32N4O5	 Leu-Lys-Thr	 1.00	 0.00	
366.06	 16.26	 C10H15N4O9P	 1-(5'-Phosphoribosyl)-5-formamido-4-imidazolecarboxamide	 1.00	 0.00	
402.14	 17.85	 C15H22N4O9	 Asp-Asp-Gly-Pro	 1.00	 0.00	
303.16	 4.88	 C16H21N3O3	 Trp-Val	 1.00	 0.00	
238.10	 13.47	 C11H14N2O4	 Gly-Tyr	 1.00	 0.00	
273.18	 15.85	 C11H23N5O3	 Val-Arg	 1.00	 0.00	
218.09	 17.04	 C8H14N2O5	 L-Ala-L-Glu	 1.00	 0.00	
520.23	 25.50	 C23H32N6O8	 His-Thr-Thr-Tyr	 1.00	 0.00	
353.07	 17.44	 C9H16N5O8P	 2,5-Diamino-6-(5'-phosphoribosylamino)-4-pyrimidineone	 1.00	 0.00	
344.22	 14.10	 C14H28N6O4	 Leu-Gly-Arg	 1.00	 0.00	
217.11	 13.88	 C8H15N3O4	 N-Acetyl-L-citrulline	 1.00	 0.00	
317.17	 4.74	 C17H23N3O3	 Leu-Trp	 1.00	 0.00	
245.15	 17.80	 C9H19N5O3	 beta-Alanyl-L-arginine	 1.00	 0.00	
289.13	 15.28	 C11H19N3O6	 Pro-Ser-Ser	 1.00	 0.00	
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243.16	 17.79	 C11H21N3O3	 Lys-Pro	 1.00	 0.00	
268.15	 8.13	 C12H20N4O3	 His-Leu	 1.00	 0.00	
219.09	 15.53	 C7H13N3O5	 Asn-Ser	 1.00	 0.00	
294.16	 4.88	 C15H22N2O4	 Leu-Tyr	 1.00	 0.00	
344.24	 12.78	 C16H32N4O4	 Lys-Val-Val	 1.00	 0.00	
358.11	 15.64	 C12H22O12	 melibionate	 1.00	 0.00	
341.23	 4.67	 C17H31N3O4	 Leu-Leu-Pro	 1.00	 0.00	
232.11	 15.49	 C9H16N2O5	 N2-Succinyl-L-ornithine	 1.00	 0.00	
276.06	 15.96	 C14H12O6	 heptaketide	pyrone	intermediate	 1.00	 0.00	
242.10	 14.23	 C9H14N4O4	 Ser-His	 1.00	 0.00	
269.11	 14.79	 C10H15N5O4	 Asn-His	 1.00	 0.00	
204.07	 17.42	 C7H12N2O5	 Glu-Gly	 1.00	 0.00	
373.21	 17.46	 C14H27N7O5	 Ala-Gln-Arg	 1.00	 0.00	
283.16	 17.83	 C12H21N5O3	 Lys-His	 1.00	 0.00	
388.24	 13.85	 C16H32N6O5	 Leu-Thr-Arg	 1.00	 0.00	
251.08	 17.42	 C12H13NO5	 N-benzoyl-L-glutamate	 1.00	 0.00	
417.26	 14.40	 C18H35N5O6	 Ala-Leu-Lys-Ser	 1.00	 0.00	
192.07	 15.21	 C6H12N2O5	 Ser-Ser	 1.00	 0.00	
260.14	 13.26	 C11H20N2O5	 Glu-Leu	 1.00	 0.00	
252.11	 7.32	 C12H16N2O4	 Ala-Tyr	 1.00	 0.00	
491.20	 11.99	 C22H29N5O8	 Ala-Thr-Trp-Asp	 1.00	 0.00	
321.18	 14.48	 C15H23N5O3	 Phe-Arg	 1.00	 0.00	
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204.11	 10.39	 C8H16N2O4	 N6-Acetyl-N6-hydroxy-L-lysine	 1.00	 0.00	
477.26	 15.29	 C20H39N5O6S	 Ile-Lys-Met-Ser	 1.00	 0.00	
422.08	 19.12	 C12H23O14P	 alpha,alpha'-Trehalose	6-phosphate	 1.00	 0.00	
287.20	 14.60	 C12H25N5O3	 Leu-Arg	 1.00	 0.00	
509.17	 16.22	 C17H31N7O7S2	 Glu-Cys-Cys-Arg	 1.00	 0.00	
430.13	 11.80	 C15H22N6O7S	 Asp-Cys-Gly-His	 1.00	 0.00	
517.21	 17.65	 C19H31N7O10	 Asp-Gln-Gln-Gln	 1.00	 0.00	
281.11	 14.87	 C25H34N6O7S	 Glu-Met-Phe-His	 1.00	 0.00	
309.17	 17.35	 C15H23N3O4	 Lys-Tyr	 1.00	 0.00	
317.16	 14.34	 C13H23N3O6	 Leu-Ala-Asp	 1.00	 0.00	
233.10	 14.35	 C8H15N3O5	 Ala-Gly-Ser	 1.00	 0.00	
316.21	 14.40	 C14H28N4O4	 Leu-Lys-Gly	 1.00	 0.00	
337.17	 17.23	 C15H23N5O4	 L-Tyrosyl-L-arginine	 1.00	 0.00	
362.19	 17.39	 C13H26N6O6	 Thr-Ser-Arg	 1.00	 0.00	
256.12	 12.95	 C10H16N4O4	 Thr-His	 1.00	 0.00	
245.17	 15.96	 C11H23N3O3	 Lys-Val	 1.00	 0.00	
293.17	 14.47	 C15H23N3O3	 Lys-Phe	 1.00	 0.00	
206.09	 14.25	 C7H14N2O5	 Thr-Ser	 1.00	 0.00	
374.19	 17.64	 C14H26N6O6	 Lys-Asn-Asn	 1.00	 0.00	
248.10	 17.04	 C9H16N2O6	 Glu-Thr	 1.00	 0.00	
632.27	 26.82	 C31H36N8O7	 Gln-Trp-Tyr-His	 1.00	 0.00	
233.14	 18.38	 C9H19N3O4	 Lys-Ser	 1.00	 0.00	
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277.15	 15.56	 C11H23N3O3S	 Lys-Met	 1.00	 0.00	
234.09	 17.43	 C8H14N2O6	 Glu-Ser	 1.00	 0.00	
176.08	 14.09	 C6H12N2O4	 Ala-Ser	 1.00	 0.00	
397.20	 13.17	 C17H27N5O6	 Ala-Asn-Pro-Pro	 1.00	 0.00	
220.11	 12.72	 C8H16N2O5	 N-Acetyl-beta-D-glucosaminylamine	 1.00	 0.00	
304.17	 17.73	 C12H24N4O5	 Lys-Ala-Ser	 1.00	 0.00	
387.25	 14.35	 C17H33N5O5	 Leu-Lys-Gln	 1.00	 0.00	
266.13	 7.32	 C13H18N2O4	 Phe-Thr	 1.00	 0.00	
331.17	 11.90	 C14H25N3O6	 Val-Val-Asp	 1.00	 0.00	
288.15	 18.35	 C10H20N6O4	 Asn-Arg	 1.00	 0.00	
275.16	 17.97	 C10H21N5O4	 Thr-Arg	 1.00	 0.00	
305.15	 15.38	 C11H23N5O3S	 Met-Arg	 1.00	 0.00	
228.11	 14.83	 C10H16N2O4	 (S)-ATPA	 1.00	 0.00	
302.20	 15.96	 C13H26N4O4	 Lys-Val-Gly	 1.00	 0.00	
247.15	 17.90	 C10H21N3O4	 Lys-Thr	 1.00	 0.00	
261.14	 18.35	 C9H19N5O4	 Ser-Arg	 1.00	 0.00	
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Appendix	X:	Purine	metabolism	metabolites	identified	in	Drosophila	melanogaster	whole	larva	and	their	mean	
signal	intensity	
Mass	 RT	 Formula	 Putative	metabolite	 17767	 18814	 18554	 CS	
175.05	 7.96	 C4H8N4O4	 Allantoate	 57728.96346	 107090.6955	 69938.86678	 83566.06908	
157.04	 18.67	 C4H6N4O3	 Allantoin	 1729723.557	 1352538.551	 515909.3323	 1168146.404	
167.02	 13.14	 C5H4N4O3	 Urate	 26209132.2	 76673121.59	 2556547.244	 18039415.34	
151.03	 12.05	 C5H4N4O2	 Xanthine	 1.38E+07	 17395936.17	 11393662.19	 18735495.37	
135.03	 9.20	 C5H4N4O	 Hypoxanthine	 1.50E+07	 18425957.35	 20254297.4	 17465088.36	
134.05	 9.57	 C5H5N5	 Adenine	 2689326.454	 3398902.548	 2752861.444	 1612219.498	
266.09	 11.61	 C10H13N5O4	 Adenosine	 18228.54369	 29087.99755	 27229.27468	 93743.668	
267.07	 11.47	 C10H12N4O5	 Inosine	 1.72E+08	 182474592.2	 201427655.8	 172103264.9	
284.10	 13.21	 C10H13N5O5	 Guanosine	 1.23E+07	 16242326.81	 24302747.72	 19443905.35	
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Appendix	XI:	Purine	metabolism	metabolites	identified	in	Drosophila	melanogaster	larval	posterior	Malpighian	
tubules	and	their	mean	signal	intensity	
	
Mass	 RT	 Formula	 Putative	metabolite	 17767	PT	 18814	PT	 18554	PT	 CS	PT	
175.05	 7.96	 C4H8N4O4	 Allantoate	 35521.33	 33719.91	 35684.46	 979334.40	
157.04	 18.67	 C4H6N4O3	 Allantoin	 711346.76	 698017.37	 693971.58	 694155.39	
167.02	 13.14	 C5H4N4O3	 Urate	 389699.12	 44200471.34	 8933683.02	 2641780.61	
151.03	 12.05	 C5H4N4O2	 Xanthine	 0.00	 0.00	 0.00	 210429.52	
135.03	 9.20	 C5H4N4O	 Hypoxanthine	 3508715.09	 3055189.67	 2525559.31	 2620326.12	
134.05	 9.57	 C5H5N5	 Adenine	 1351026.33	 1669117.89	 1255291.63	 4392923.97	
266.09	 11.61	 C10H13N5O4	 Adenosine	 6915.15	 3628.62	 2992.41	 354016.45	
267.07	 11.47	 C10H12N4O5	 Inosine	 3955298.53	 4170512.30	 2463237.70	 3159900.71	
284.10	 13.21	 C10H13N5O5	 Guanosine	 533790.66	 564416.28	 269604.53	 2222183.91	
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Appendix	XII:	Purine	metabolism	metabolites	identified	in	Drosophila	melanogaster	larval	anterior	Malpighian	
tubules	and	their	mean	signal	intensity	
	
Mass	 RT	 Formula	 Putative	metabolite	 17767	AT	 18814	AT	 18554	AT	 CS	AT	
175.05	 7.96	 C4H8N4O4	 Allantoate	 3039061.87	 32042.76	 40877.77	 174624.09	
157.04	 18.67	 C4H6N4O3	 Allantoin	 3339911.10	 704032.95	 700176.25	 712290.71	
167.02	 13.14	 C5H4N4O3	 Urate	 3630984.21	 1729150.24	 0.00	 163662.98	
151.03	 12.05	 C5H4N4O2	 Xanthine	 4084857.24	 0.00	 0.00	 312414.71	
135.03	 9.20	 C5H4N4O	 Hypoxanthine	 4668408.27	 3051599.32	 2907790.60	 2001578.03	
134.05	 9.57	 C5H5N5	 Adenine	 4841139.22	 8025804.88	 6039759.09	 9533915.79	
266.09	 11.61	 C10H13N5O4	 Adenosine	 799131.12	 3795.53	 4688.88	 191552.99	
267.07	 11.47	 C10H12N4O5	 Inosine	 1192186.75	 1947636.92	 1862475.11	 3321896.20	
284.10	 13.21	 C10H13N5O5	 Guanosine	 563465.89	 525769.80	 341711.87	 2018026.42	
